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2Abstract
Substantial evidence has implicated a role for CD8+ T cells in protective immunity against 
tuberculosis. Recombinant vaccinia (rVV) expressing Mycobacterium tuberculosis (MTB) 
proteins could be used, both as tools to  dissect CD8+ T cell responses and, in attenuated 
form, as candidate vaccines A panel of r W  expressing immunoprotective secreted proteins 
o f MTB have been constructed. An initial rVV employed the vaccinia early/late p7.5 
promoter and a gene encoding the 6 kDa early secretory antigenic target 6 protein 
(ESAT-6). Fidelity of cloning was verified by sequencing. Southern blotting and reverse- 
transcription polymerase chain reaction However, attempts to identify protein expression 
using immunoblotting were unsuccessful.
In order to overcome problems of low level expression, three further strategies were 
employed These included: (i) expressing three different MTB genes encoding the Antigen 
85 (Ag85) complex (30-32 kDa), as well as ESAT-6, (ii) comparing p7.5 with the more 
powerful T7 promoter, and (iii) use o f  a eukaryotic signal sequence belonging to human 
tissue plasminogen activator (tPA). tPA fusions were created by modifying the insertion 
plasmids, pi 108 (p7.5) and pWR510 (T7), prior to gene cloning Nineteen rVV were 
constructed Protein expression was identified for all rVV except Ag85C constructs. 
Surprisingly, the T7 hybrid system did not improve protein expression However, addition 
o f the tPA signal sequence produced a marked enhancement of expression Three higher 
molecular weight 85B glycoforms were expressed by rVV-tPA-85B, but not rVV-85B In 
vitro coupled transcription-translation, in the presence of microsomes, gave further support 
for tPA-mediated membrane translocation and glycosylation
rVV-tPA-85A was used to infect human autologous macrophage as target cells in a 6 hour 
cytotoxic T cell (CTL) assay Preliminary results suggested specific lysis of target cells using 
live BCG-stimulated T cells Thus, these rVV represent powerful tools to investigate the 
role of CD8+ T cells in immunity to tuberculosis. In addition, they offer a potential strategy 
towards designing a vaccine against tuberculosis
"Now Kalamas, Jo  not ye go by hearsay, nor by what is 
handed down by others, nor by what people say, not by what 
is stated on the authority o f  yo u r traditional teachings. "
"Hut Kalamas, when you know o f  (it) yourselves..."
Buddha's discourse lo the Kalamas of Kcsaputta Anguttara- 
Nikava. I IKK Pali Canon F L Woodward's translation, 
p 283 London: Geoffrey Cumbcrlcdgc. 1948.
In memory of my mother 
who d ie d  on October 31 st, I 0 9 5 .
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Glossary of abbreviations
1° primary
2° secondary
Ag85
Ag85
one or more of three genes encoding the Ag85 proteins (85a, 85b & 85c) 
Antigen 85 protein(s) - a complex of 3 mycobacterial secreted proteins (85A, 
85B & 85C)
APC antigen presenting cell
ATP adenosine triphosphate
ß-gal
ß2m
BCG
beta-galactosidase
beta-2-microglobulin
Mycobacterium bovis bacille Calmette-Guerin
BCL EBV-transformed B cell lines
bp
BSA
base pair
bovine serum albumin
BUdR 5-Bromo-deoxyuridine
CF culture filtrate
CFU colony forming units
CMI cell-mediated immunity
CPE cytopathic effect
CTL cytotoxic T lymphocyte(s)
DAPI 4,6-diamidino-2-phenylindole (stains cell nuclei and produces blue 
fluorescence)
DEPC diethyl pyrocarbonate
DMEM Dulbecco's Modified Eagle's Medium
DMSO dimethylsulphoxide
DN double negative
DNAse Deoxyribonuclease I
dNTPs deoxynucleotide triphosphates
DTH delayed-type hypersensitivity
EBV Epstein-Barr virus
ECL Enhanced Chemiluminescence - trademark for a signal detection system used 
in immunoblotting protocol (Life Sciences)
EDTA ethylene diamine tetraacetic acid
EGTA ethylene glycol bis (2-amino ethyl ether) - N, N, N', N'- tetraacetic acid
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EMCV encephalomyocarditis virus
ESAT-6 early secretory antigenic target protein
esal-6 gene encoding ESAT-6
FCS fetal calf serum
FITC fluorescein isothiocyanate (produces green fluorescence)
GM-CSF granulocyte-macrophage colony-stimulating factor
GMP good manufacturing practice
SPl
HBSS
guanine phosphoribosyl transferase gene 
Hanks Balanced Salt Solution
HRP horseradish peroxidase
hsp60
IFN-y
IFN-yR
IL-2
60 kDa heat shock protein 
interferon-gamma 
interferon-gamma receptor 
interleukin-2
iNOS inducible nitric oxide synthase
kb kilobase pair
kDa kilodalton
KO knockout
A. (in tables) 
L-glu
IxicZ
lamda £coRI////wdIII digest molecular weight marker 
L-glutamine
gene encoding beta-galactosidase
LAM lipoarabinomannan
LB Luria broth
LMP low melting point
mAb monoclonal antibody
MHC major histocompatibility complex
MM Mycobacterium marinum
moi multiplicity of infection
MPA mycophenolic acid
MTB Mycobacterium tuberculosis
MVA modified vaccinia virus Ankara
MW molecular weight (or molecular weight marker, in tables)
NEM N-ethlymaleimide
NO nitric oxide
NP-40 nonidet P-40
OADC oleic acid-albumin-dextrose-catalase supplement
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p/s
PBMC
penicillin/streptomycin 
peripheral blood mononuclear cells
PBS phosphate buffered saline
PCR polymerase chain reaction
pfu plaque forming units
P>
PMSF
post-infection
phenyl methyl sulphonyl fluoride
PPD tuberculin purified protein derivative
rFPV recombinant fowlpox virus
RIPA radioimmunoprécipitation buffer
rMVA recombinant modified vaccinia virus Ankara
ROI reactive oxygen intermediates
RT reverse transcriptase
RT-PCR Reverse transcriptase polymerase chain reaction
rVV vaccinia recombinant(s)
s/n supernatant
SDS sodium dodecyl sulphate
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis
SSI Statens Seruminstitut, Copenhagen
ST-CF short term culture filtrate
T25, T75 & 
T175
three different cell culture flask sizes with culture surface areas of 25, 75 and 
175 cm2 respectively
TAE Tris/acetic acid/EDTA buffer
TB tuberculosis
TK'143 a human osteosarcoma cell line with functional deletion of the thymidine 
kinase locus
TNF-cx tumour necrosis factor-alpha
tPA tissue plasminogen activator (text)
-tPA tissue plasminogen activator signal sequence (part of rVV or plasmid)
TPCK N-tosylamide-L-phenylalanine chloromethyl ketone
UV ultraviolet
vTF7-3 rVV expressing T7 polymerase
VV vaccinia
wt wild type
ZN Ziehl-Neelsen
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1.1 AIMS AT OUTSET OF PROJECT
1.1.1 Broad, long term objectives
At the outset of this study, it was proposed to utilise vaccinia recombinant DNA technology 
as a tool to assess major histocompatibility complex (MHC) class 1 antigen presentation of 
Mycobacterium tuberculosis (MTB) secreted proteins to human T cells. Recombinant 
protein expressed in this way would permit presentation of MTB antigens in a form suitable 
for recognition by CD8+ T cells. Furthermore, given that recombinant vaccinia would 
present antigen in the context of MHC class II as well as class I, this could give rise to a 
balanced CD4+ and CD8+ T cell immune response. Thus, it was also proposed to assess this 
antigen delivery system as a potential vaccine against tuberculosis (TB).
1.1.2 Specific aims
From the known available gene sequences of MTB, four genes were selected. These 
encoded the highly immunodominant secreted proteins: Antigen 85A, 85B and 85C (30-33 
kDa) and the early secretory antigenic target protein (ESAT-6) (6 kDa). These genes were 
to be obtained, as well as reagents for detection, from collaborators, Drs K Huygen and J 
Content for the genes encoding Ag85 and Dr P Andersen for the gene encoding ESAT-6.
Vaccinia recombinants (rVV) expressing these antigens were to be constructed for human 
cytotoxic T cell assays to be performed as part o f this study In addition rVV were to be 
supplied to collaborators at the Pasteur Institute, Brussels (rVV-Ag85 constructs) and the 
Statens Seruminstitut, Copenhagen (rVV-ESAT-6) for murine immunology.
1.2 BACKGROUND AND SIGNIFICANCE
1.2.1 A need for a new vaccine
Despite widespread use of Mycobacterium bovis bacille Calmette-Guerin (BCG) 
vaccination, MTB remains the single biggest infectious killer worldwide (Bloom and 
Murray, 1992). Globally, it is also the major pathogen associated with HIV disease (Bloom 
and Murray, 1992; De Cock et al 1992). The available vaccine, BCG, has been given to 
more people than any other vaccine (Bloom and Fine, 1994). Yet the vaccine offers 
protection only against disseminated childhood TB, and not the more prevalent (and 
infectious) adult pulmonary disease (Fine and Rodrigues, 1990) Indeed, in large studies in 
both southern India ("The Tuberculosis Prevention Trial", 1980) and Malawi (Ponnighaus
et al 1992), BCG was ineffective as a vaccine against pulmonary TB Alternative vaccine 
strategies are therefore urgently required
Chapter Ì Introduction 18
1.2.2 The failure and success of BCG
The reasons for the failure of BCG remain unclear Immunity to TB is poorly understood 
both at a cellular and molecular level (Bloom and Murray, 1992; Orme et al 1993). It is 
possible that BCG's ability to protect against initial infection may wane with time. 
Alternatively, BCG may be unable to prevent the establishment of dormant infection, so 
giving the potential for reactivation later in adult life (Malin and Young, 1996). One 
mechanism could be that BCG prevents blood-borne spread (the 'bacillaemia'), but not 
seeding in the lungs (Wiegeshaus and Smith, 1989). This could also explain its protective 
efficacy against childhood miliary disease and TB meningitis
These explanations, however, do not account for the enormous variation seen in different 
settings For example, in 11 controlled trials of BCG performed in four continents, vaccine 
efficacy varied between 0 and 80%. In North America and the UK, in a younger age 
population, there was a protective efficacy ranging from 60 to 80%. These studies included: 
British school children (aged 14 years), North American Indians (two studies: <3 months 
and 0-19 years), a study of infants in Chicago (< 3 months) and young adults in Haiti (<20 
years) This is in stark contrast to zero efficacy seen in two controlled trials in Chingleput, 
India (> 1 year) and Georgia, United States (6-17 years) (Rodrigues and Smith, 1990; 
Bloom and Fine, 1994), where the vaccine population tended to be older Whilst age of 
vaccination could explain some of the inter-study variation, this was not supported by 
observational studies (case-control and contact studies) which showed a similarly wide 
variation in protective efficacy, not accountable by age alone (Fine and Rodrigues, 1990). 
This overall pattern o f varying efficacy has led one researcher to comment that protection 
appears to be less effective the closer one gets to the equator (Prof P Fine, personal 
communication) Several additional factors could account for the large variation between 
the studies: (i) methodological flaws including poor randomisation of vaccine and placebo 
groups (susceptibility bias), unequal-equal follow up (surveillance and diagnostic-testing 
bias) and non-blinded evaluation of subjects i.e. knowledge of their vaccination status 
(diagnostic interpretation bias), (ii) heterogeneity between different vaccine strains; (iii) 
differences in virulence of MTB strains, (iv) variation in exposure to MTB i.e. cases may be 
predominantly exogenous (where level of exposure is high) or predominantly endogenous
(where level of exposure is low); (v) interaction with environmental mycobacteria; and (vi) 
genetic differences between subject populations. No single factor can explain both the failure 
and success of BCG. However, there is increasing evidence to support a contributory role 
for both genetic and environmental influences Elucidation of these factors will support 
rational design of a future vaccine.
1.2.2.1 Genetic influences on immunity
There is no direct evidence to suggest a genetic cause which would explain variation in 
vaccine efficacy. However, compelling evidence exists for genetic influences affecting both 
susceptibility to TB and disease severity By analogy, it would seem reasonable that these 
or other genetic factors could affect vaccine efficacy. Evidence in favour of an overall 
genetic influence is uncontested (Newport and Blackwell, 1997). The key points are 
summarised below.
1) In 1926, 251 infants from Lubeck in Germany were inadvertently immunised with 
a virulent strain of MTB instead of BCG. The responses to infection were markedly 
different; 47 developed no detectable disease, 127 developed radiologically- 
confirmed disease and 77 died ("Anonymous", 1935).
2) Several geographically remote populations not previously exposed to MTB were 
highly susceptible to TB The course of disease was often rapidly progressive and 
resulted in exceptionally high mortality rates (Stead, 1992). For example, at the turn 
of the century, the Canadian Indians o f the Qu'Appelle valley were first exposed to 
MTB resulting in a very high initial annual mortality of 10%. Following several 
generations of exposure, the annual death rate fell to 0.2%. This finding supported 
the concept of genetic selection in favour of those less susceptible to severe disease 
(Chan and Kaufmann, 1994). A confounding factor included the possibility o f MTB 
strain differences, the Indian population being exposed to less virulent strains over 
time
3) Twin studies have provided clear evidence for a genetic influence showing that a 
monozygotic twin of a TB case is much more likely to develop disease than a 
dizygotic one (Comstock, 1978).
4) There is also evidence to support a racial difference between black and white 
populations For example, one study examined infection rates, as judged by skin test 
conversion, in nursing homes across Arkansas in the US In this study, blacks were 
twice as susceptible to infection as whites However, of those infected, there were
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no racial differences in terms of progression to active disease (Stead et al. 1990). 
Whilst such a study provides suggestive data, confounding factors such as nutritional 
status and underlying disease, such as diabetes, were not addressed
Despite many studies, there is no clear evidence in favour of a strong HLA link with 
susceptibility to TB (Mehra, 1990; Pitchappan, 1990) However, the data is better for non- 
HLA gene associations and disease susceptibility. Evidence from a mouse model (Blackwell, 
1996) and some Maltese families (Levin et al. 1995; Newport et al. 1996) have shown that 
a single gene can have a strong influence on disease susceptibility. It has been difficult to 
show the same effect produced by a single gene at a population level. The strongest 
evidence comes from a population-based case-control analysis of TB in The Gambia. A 
significant number of TB cases were homozygous for a variant allele in the 3'-untranslated 
region of the vitamin D receptor gene. The same finding was not identified in a parallel study 
in India (Bellamy et al manuscript submitted)
1.2.2.2 Environmental influences on immunity
Environmental factors, such as the effects of host nutritional status (Chan et al 1996; 
Chandra, 1996) or prior infection with environmental mycobacteria (Stanford et al. 1981; 
Stanford et al 1987), could explain varying patterns of vaccine efficacy in different regions. 
In a recent study assessing disease susceptibility, mice fed on a 2% protein diet, as compared 
with littermates receiving a 20% protein diet, rapidly succumbed to infection with MTB 
(Chan et al. 1996). One could extrapolate that chronic malnutrition would also lead to a 
reduction in vaccine efficacy (Chandra, 1996).
Prior infection with environmental mycobacteria could also generate an altered immune 
response affecting subsequent BCG immunisation (Stanford et al 1981) This impact could 
be beneficial, neutral or deleterious. For example, the environmental mycobacteria might: 
(i) induce an initial immune response followed by boosting with BCG, thus conferring 
greater protection than produced by BCG alone, (ii) confer similar protection to BCG, with 
nothing further added by BCG vaccination (Wiegeshaus and Smith, 1989); or (iii) confer no 
protection and inhibit the protective efficacy of BCG (Stanford et al. 1981) Furthermore, 
it is possible that immunological interference may be dependent on the mycobacterial species 
(Stanford et al 1981, Stanford et al 1987, Wiegeshaus and Smith, 1989).
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Wiegeshaus and Smith (1989) have argued that the failure of BCG to protect against TB in 
the Chingleput trial is due to the second of these scenarios - environmental mycobacteria 
confer some protection and nothing further is contributed by BCG They have commented 
that the number o f cases in the first IV2 years o f the trial was smaller than expected ("The 
Tuberculosis Prevention Trial", 1980). Moreover, 95% of the population over the age of 10 
showed previous exposure to environmental mycobacteria. This suggested to the authors 
that the heavy environmental mycobacterial exposure would have induced protection against 
TB, such that subsequent BCG vaccination could confer little in addition
Whilst environmental mycobacteria may have contributed to the limited success of previous 
vaccination programmes, the advent of neonatal vaccination as part of the Expanded 
Programme of Immunisation would greatly limit this influence However, other 
environmental issues, such as those related to poverty and underlying disease, will still 
continue to influence variability in vaccination efficacy throughout the world.
1.2.3 An ideal TB vaccine
An ideal TB vaccine would be given at birth, confer life-long protection against disease and 
be delivered as a non-living subunit formulation (with a view to safety and quality control). 
Possible alternative profiles for new vaccines include a “booster” vaccine that could be given 
to young adults who are a high-risk age group, a “transmission-blocking” vaccine which 
would decrease sputum smear-positivity, or an “immunomodulating” or therapeutic vaccine 
(Stanford and Grange, 1993).
A sub-unit vaccine approach is attractive in terms of both quality control and safety 
However, in order to pursue a rational design strategy, it is necessary to know both the 
immune components necessary for protective immunity and the antigens required to induce 
this state (Malin and Young, 1996).
1.2.4 MTB and the macrophage - a unique intracellular niche
MTB is a facultative intracellular parasite with the capacity to survive both intra- and 
extracellularly It usually resides within mononuclear phagocytes (monocytes and 
macrophages) where replication may occur The microorganism utilises multiple receptor- 
ligand interactions to mediate attachment and phagocytic uptake For example, the MTB cell 
wall-associated lipoarabinomannan (LAM), the mycobacterial equivalent to
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lipopolysaccharide, can interact with the mannose receptor of the host cell. Additional cell 
receptors include: collectins such as protein surfactant A (Downing et al. 1995) and 
mannose-binding lectin and also the complement receptors, CR1, 3 and 4 (Chan and 
Kaufmann, 1994). Once in the mononuclear phagocyte, the bacilli may multiply slowly, with 
a generation time of only 12-24 hours or alternatively, remain quiescent for years Thus, the 
disease is characteristically chronic, with an insidious onset and slow progression 
Furthermore, an infected individual may remain latently infected and free from symptoms 
for decades until subsequent disease reactivation. MTB possesses a number of survival 
strategies to avoid destruction within what would normally be a hostile intracellular 
environment. It resides within its own phagosomal compartment (the 'TB phagosome'), 
avoids phagolysosomal fusion (Clemens and Horwitz, 1995), and prevents phagosomal 
acidification by exclusion of the vesicular proton pump ATPase (Sturgill-Koszycki et al 
1994). This latter property is thought to be a key mechanism through which MTB avoids 
intracellular destruction.
Macrophage activation and destruction o f intracellular pathogens include a variety of 
mechanisms, in particular the generation of reactive oxygen intermediates (ROI) and nitric 
oxide (NO) In the case of ROI, MTB possesses several products which either inhibit the 
respiratory burst that generates ROI or neutralise their effects These include sulphatides, 
LAM and the secreted protein, superoxide dismutase (Clemens, 1996). The protective role 
for NO production in murine antimycobacterial immunity has been established, however, its 
role in human immunity remains moot In murine models, IFN-y-mediated activation of 
macrophages led to up-regulation of inducible nitric oxide synthase (iNOS) resulting in 
control of infection The addition of iNOS inhibitors resulted in exacerbation (Kamijo et al 
1994). Furthermore, disruption of the IFN-y gene (Flynn et al 1993) or its receptor (Kamijo 
et al 1993) also resulted in more severe infection and a reduced ability to produce NO 
during infection However, iNOS has not been consistently demonstrated in human 
monocyte-derived activated macrophages, although it has been identified in alveolar 
macrophages from patients with TB (Nicholson et al 1996) Further data are required to 
elucidate its importance
Virulent mycobacterial species, such as MTB and M. leprae, possess an additional survival 
feature The terminal arabinose side-chains o f MTB LAM are capped with multiple units of 
mannose (Man-LAM) Fast-growing, avirulent mycobacterial strains lack this mannose
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capping and their LAM, unlike Man-LAM, can act as a powerful inducer of TNF-a and 
many of the mRNA molecules associated with macrophage activation such as NF-kB, KC 
and C-fos transcripts. Thus, the virulent mycobacteria could be perceived as having 
developed an inert form of LAM, permitting prolonged host cell survival (Kumararatne and 
Dockrell, 1997).
1.3 IMMUNITY TO TB
Over a third of the world's population are infected with MTB, yet of those infected, more 
than 90% will never develop overt disease (Bloom and Murray, 1992). If an individual with 
latent TB infection becomes immunosuppressed, for example with HIV infection, their 
likelihood of developing clinical TB increases from about 5% per life-time to 8% per year 
(Raviglione et al. 1992). This suggests that infection with the virulent form of the organism 
successfully induces a 'suppressive', but not sterilising, immune response in most 
immunocompetent people. Why some 5-10% of the infected population fail to develop long- 
lived protective immunity is complex and imperfectly understood What is known about the 
immune response is derived from a variety o f sources including animal models of infection 
and protection, human in vitro studies and human population-based studies of skin test 
reactivity, MTB infection and disease.
1.3.1 A pivotal role for CD4+ IFN-y secreting cells
CD4+ IFN-y-secreting T cells are pivotal in immunity against mycobacterial infection in 
murine models (Orme et al. 1993a). Key evidence comes from protection studies Orme 
(1987) showed that CD4+ T cells from MTB-infected mice could adoptively protect sub- 
lethally irradiated mice from MTB challenge Pedrazzini and colleagues (1987) offered 
further support by showing that CD4+, and not CD8+, T cell depletion in vivo resulted in 
loss of control of BCG replication in mice In addition, mycobacterial specific T cell cloning 
studies demonstrated that CD4+ Thl-type T cell clones could adoptively transfer DTH 
activity (Pedrazzini and Louis, 1986; Boom et al 1987). However, it should be noted that 
DTH activity is not synonymous with protection (Orme and Collins, 1984; Fine et al 1994) 
In humans, evidence for the importance o f  Thl-like CD4+ T cells is circumstantial Firstly, 
there is a strong correlation between CD4+ T cell responsiveness and the extent of disease 
For example, localised disease such as TB pleurisy is associated with strong CD4+ IFN-y 
responses (Barnes et al 1990), whilst disseminated disease is not (Kumararatne and 
Dockrell, 1997) Secondly, HIV infection results in progressive CD4+ lymphopenia; this
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infection represents by far the most potent risk factor for the development o f TB with a 
relative risk of 6-100 as compared with HIV-negative individuals (Nunn et al 1994). 
Furthermore, a study from Côte D'Ivoire showed a inverse correlation between CD4+ count 
and the extent of MTB dissemination and overall bacillary load (Lucas et al. 1994). A third 
piece of indirect evidence comes from a study o f Maltese children with an autosomal 
recessive immunological defect which results in fulminating non-tuberculous mycobacterial 
infection. Using microsatellite and sequence analysis, a mutation in the IFN-y receptor 1 
(IFN-yR 1) was identified (Newport et al. 1996). Previously, a study using mice with 
disruption o f the IFN-yR gene also showed a marked increase in susceptibility to disease 
(Kamijo et al 1993). In a sense, these affected children represent a human counterpart to 
the IFN-yR KO mice.
The murine adoptive transfer experiments suggest that protection could be mediated entirely 
by an interaction between CD4+ Thl-type T cells and activated macrophages Whilst the 
human data offers support for the importance o f this T cell population, their relative 
contribution remains unknown. Mice are relatively resistant to MTB and do not develop 
cavitation or caseous necrosis, the hallmark of human disease (Collins, 1984) Furthermore, 
an in vitro study comparing the effect of IFN-y when added to murine or human 
macrophages infected with MTB showed that the activated murine macrophages led to a 
marked reduction in numbers of the organism (Rook et al 1986a) In stark contrast, IFN-y 
had either no effect or a negative effect on MTB-infected human macrophages Thus, a 
CD4+ IFN-y secreting T cell population is unlikely to be the single key immune contributor 
to  protection against human disease
1.3.2 Are CD8+ T cells important?
1.3.2.1 Identification hampered by theory and methodology
There is still no satisfactory in vitro model to assess immunological correlates o f protection 
in humans. This failure may be a consequence of the limited number of immune responses 
measured, the predominance being towards CD4+ T cell proliferative and cytokine 
responses T cell cytotoxicity has been measured in mouse models of TB and researchers 
have demonstrated a role for both CD4+ T cells (Orme, 1987; Pedrazzini et al 1987) and 
CD8+ T cells (Orme and Collins, 1984; De Libero et al 1988) However, few studies have 
evaluated the human CD8+ T cell response to TB (Orme et al. 1993a).
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Until the development of knockout mouse models, there was little inclination to investigate 
CD8+ T cell immunity. This may have arisen for two historic reasons. Firstly, MTB is 
thought to be confined to a unique vacuolar compartment, there being little evidence for 
escape into the cytoplasm (Sturgill-Koszycki et al. 1994; Clemens and Horwitz, 1995; 
Moreira et al 1997). By inhibiting phagolysosomal fusion and the proton ATPase pump 
(Sturgill-Koszycki et al 1994), MTB can exist, undisturbed, within its own endocytic niche 
(Moreira et al. 1997) Because of its membrane-bound location, antigen processing was 
thought to be limited to the MHC class II pathway. Thus, the majority of the T cell 
immunity would be mediated by CD4+ T cells (Kaufmann, 1993). Secondly, this dogma was 
supported by early data which tended to identify mostly CD4+ T cell reactivity (Emmrich 
et al 1986; Kaufmann et al 1987; Oftung et al 1987; Andersen et al 1991; Manca et al. 
1991; Orme et al 1992; Orme et al. 1993). However, soluble antigen was used for in vitro 
stimulation of human or murine T cells. This would have favoured the CD4+ T cell 
phenotype (see Section 1.4.1.3). Further evidence has now accumulated to implicate a 
significant role for CD8+ T cells in protective immunity (Flynn et al 1992; Moreira et al. 
1997). In addition, alternative pathways for MHC class I antigen processing have been 
elucidated, suggesting a mechanism whereby mycobacterial protein can be recognised by 
CD8+ T cells (Kovacsovics Bankowski et al 1993; Pfeifer et al 1993; Kovacsovics 
Bankowski and Rock, 1995) These data are discussed below.
1.3.2.2 Evidence implicating human CDS t T cells in immunity
TB pleural effusions represent a useful source of human activated lymphocytes at the site 
o f disease Using this cell population, data in favour of a role for CD8+ T cells have shown 
that: (i) these cells are present at the site of infection (Rees et al 1988; Manca et al 1991); 
(ii) CD8+ T cell clones derived from these cells recognise mycobacterial antigens (Rees et 
al 1988); and (iii) that, in one study of 4 patients, they constituted the majority of T cells 
present prior to ex vivo stimulation (Manca et al 1991) Whilst this cell population offers 
easy access for laboratory manipulation, a caveat requiring consideration is that pleural TB 
represents only one manifestation of the clinical spectrum of disease (Kumararatne and 
Dockrell, 1997) Typically patients are relatively well, acid fast bacilli (AFB) are difficult to  
isolate and CMI is strong (analogous with paucibacillary disease found in leprosy) 
Therefore, one should be cautious about extrapolating these findings to other forms of TB
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Furthermore, human CD8+T cells, following 7 days of re-stimulation with live BCG in the 
absence o f  exogenous cytokines, could specifically recognise and lyse PPD-pulsed or BCG- 
infected autologous macrophage target cells in a standard 6 hour cytotoxic T lymphocyte 
(CTL) assay (Turner and Dockrell, 1996). The cells in this study were derived from BCG 
vaccinees, however, unpublished data suggests that BCG-specific CTL can also be found 
in patients with TB (Dr J. Turner, personal communication) Recent unpublished data has 
demonstrated that an ESAT-6 specific CD8+ T cell line will recognise a rVV-ESAT-6 
infected B lymphoblastic cell line in an MHC class I restricted manner (see chapter 6).
1.3.2.3 A (3r microglobulm knockout model
P2-microglobulin (P2m) constitutes the smaller of two molecules required for functional 
expression of MHC class I Thus, targeted disruption of the P2m gene in mice (P2m KO 
mice) results in paucity of CD8+ T cells due to absence of positive selection (Raulet, 1994). 
The most cited evidence for CD8+ T cell involvement comes from MTB challenge of p2m 
KO C57BL/6 mice (Flynn et al. 1992). This study demonstrated that MHC class 1-restricted 
T cells were essential for protection against a 106 colony forming units (CFU) intravenous 
challenge of MTB (Erdman strain) Within 10 weeks, all P2m KO mice died from 
overwhelming infection, in contrast to their genetically normal littermates (P2m +/+) which 
survived >20 weeks Organ histology from both groups of mice demonstrated well 
demarcated granulomas with normal architecture However, the macrophages from the P2m 
KO mice were stuffed with bacilli and, by 6 weeks post-infection, these granulomas were 
necrotic and occupied over 70% of the lung volume For the P2m +/+ mice, only 30% of the 
lung volume was occupied by granulomas and these showed no evidence of necrosis In 
contrast, BCG infection resulted in no difference in survival or organ homogenate CFU 
counts between P2m KO and control groups o f  mice
In the same study, the researchers also addressed the issue of a protective contribution from 
cytokines, particularly as CD8+ T cells may secrete a large amount o f IFN-y. Stimulation 
of splenocytes harvested 2-3 weeks post-infection did not result in a significant difference 
in either IFN-y or tumour necrosis factor-alpha (TNF-a) production between groups o f mice 
(Flynn et al 1992) This study offered strong support in favour of a contributory role for 
MHC class 1-restricted T cells However, there are two important issues concerning this 
study. Firstly, a very large, 'non-physiological', dose of virulent MTB was given to the mice 
In humans, most infective doses would occur via the respiratory route with an inoculum of
about 10l-103 bacteria. Thus, this system could be testing an immunological function not 
encountered in a typical human immune response. Secondly, the same result has not been 
reproduced, at least in the published literature, for CD8+ knockout mice. Thus, the evidence 
for a CD8+ T cell contribution remains indirect
Ladel and colleagues then examined the impact of infection with two different doses of BCG 
in p2m KO mice. Using the same 106 CFU dose as the previous study, a similar pattern was 
observed, with no deaths in the P2m -/- group. However, by increasing the dose threefold, 
half of the P2m -/- mice had died by 6 months as compared with no deaths in the P2m +/+ 
controls (Ladel et al. 1995). This study provided clear evidence for the inoculating dose 
determining the relative importance of MHC class I-restricted T cells.
1.3.2.4 Non-peptide antigens and CD ¡-restricted T cell recognition
An alternative explanation for the P2m KO study results could be that the class 1-restricted 
T cell contribution comes from a population of aP  CD4- CD8- (double negative, DN) T 
cells recognising non-peptide mycobacterial antigens presented by the non-polymorphic 
CD1 molecules The CD-I molecules are MHC class I-like molecules and would also be 
absent in P2m KO mice Porcelli and colleagues (1992) were able to demonstrate that non­
peptide mycobacterial antigen could be recognised by human DN T cells and that this 
recognition was restricted to CD lb (one of 5 allelic forms). Subsequently, both mycolic acid 
and lipoarabinomannan (components of the mycobacterial cell wall) were shown to be 
recognised by DN T cell lines, also restricted by CD lb presentation (Beckman et al 1994; 
Sieling et al 1995). Another member of this CD1 family, CDlc, was also able to present 
mycobacterial lipids T cell clones restricted to this molecule possessed a cytotoxic function 
and were MHC unrestricted (Beckman et al 1996) Whilst this non-peptide antigen 
recognition is intriguing, the biological importance has not yet been demonstrated The DN 
T cell population constitutes a relatively small proportion of T cells. Furthermore, there is 
little evidence for in vivo clonal expansion in disease models, a characteristic feature seen 
with both CD4+ and CD8+ T cells (Manca et al 1991). A knockout model would help 
resolve the issue concerning biological importance. However, such a knockout would 
require disruption of two genes in the mouse
Chaplerl Introduction 11
Chapter l Introduction 28
1.3.2.5 What is the effector mechanism fo r  CD8+ T cells?
The effector function of CD8+ T cells could be mediated by target cell lysis leading to death 
of the intracellular pathogen. This is known to be an important effector mechanism, for 
example, in the control of Listeria (Kaufmann, 1993). An alternative effector function could 
be provision of cytokines such as IFN-y in an analogous fashion to CD4+ T cell function. 
MTB is thought to down-regulate MHC class II on the surface of infected macrophages 
(Mazzaccaro et al 1996). Perhaps CD8+ T cells could provide an additional population of 
immune effectors able to recognise those infected macrophages lacking surface MHC class 
II molecules and thus provide an alternative source of IFN-y. Both cytotoxicity and cytokine 
production could potentially play a role in mediating CD8+ T cell function Direct evidence 
for murine CD8+ T cell cytotoxicity (CTL) comes from immunisation of major 
histocompatibility complex (MHC) class I congenic mice with BCG (Denis et al 1997). In 
this study, CD8+ CTL were demonstrated against BCG culture filtrate (CF) antigens using 
H-2b and H-2bxd haplotypes but not the H-2d haplotype or the MHC class I mutant mouse 
strain haplotype, B6C-H-2bml3. This suggested that these BCG-induced CTL recognized 
CF antigens exclusively in association with D(b) molecule. However, evidence from gene 
knockout experiments suggests CTL activity may not be required (see below) (Cooper et 
al. 1997; Laochumroonvorapong et al. 1997).
1.3.2.6 CTL activity does not kill mycobacteria
Mycobacteria are thought to be killed within highly activated macrophages by a variety of 
intracellular mechanisms (Section 1 2 4). The effectors which mediate successful 
macrophage activation and mycobacterial death are not fully understood and there is a clear 
variation between species (Rook et al 1986a) Theoretically, the immune control o f  MTB 
infection could be mediated entirely by an interaction between cytokine-producing a p  CD4+ 
T cells and activated macrophages, as suggested in some mice models (Orme, 1987; 
Pedrazzini et al 1987). However, other immunological immune mediators are readily 
identifiable and include: cytolytic activity, y6 T cell and ap  DN T cell responses, and 
antibody responses For example, cytolytic activity has been readily demonstrated by both 
CD4+ and CD8+ T cells (Orme and Collins, 1984; Orme, 1987; Pedrazzini et al 1987, De 
Libero et al 1988) The precise function of these CTL is unknown There is no evidence 
suggesting that they reduce mycobacterial numbers For example, human CTL lysis o f BCG- 
infected macrophages had no effect on mycobacterial growth, even if the macrophages had 
been previously co-cultured with IFN-y (Fazal et al 1995) Furthermore, perforin- or fas-
receptor gene-disrupted mice, were still able to control a challenge with MTB or BCG 
(Cooper et al 1997; Laochumroonvorapong et al 1997). It is interesting to note that in one 
of the studies, both groups of knockout (KO) mice showed a significant compensatory 
increase in cytokine levels following mycobacterial challenge (Laochumroonvorapong et al 
1997). This latter point emphasizes the fact that KO mice may develop immune 
compensatory mechanisms in response to their congenital immunological defect In principal 
this problem could be addressed using the bacteriophage-derived Cre-loxP recombination 
system where the gene deletion can be induced in the fully developed animal (Gu et al. 
1994).
Given that CTL function for both CD4+ and CD8+ T cell populations is readily observed, 
teleologically, one would imagine that these CTL would serve a useful purpose A possible 
role could be the release of mycobacteria from effete macrophages unable to destroy the 
organism. This would permit phagocytosis by macrophages better able to kill or contain 
mycobacterial growth An alternative explanation is that the observed lysis may simply 
represent redundancy in the immune response This could be likened to the strong antibody 
response also seen in many mycobacterial infections including TB, which apparently serves 
no useful function
1.3.2.7 Alternative pathways o f  MHC class I antigen processing - Tap-dependent,
Brefeldin A sensitive or peptide regurgitation 
Whole MTB organisms may not need to enter the cytoplasm for MHC class I expression of 
mycobacterial proteins There is good evidence that particulate antigen may be taken up into 
a vacuolar compartment by professional antigen presenting cells (APCs) and be processed 
and presented in the context of MHC class I (Kovacsovics Bankowski et al. 1993; Pfeifer 
et al 1993; Harding and Song, 1994). For example, chicken egg ovalbumin linked to beads 
was presented with MHC class I molecules 104-fold more efficiently than soluble ovalbumin; 
this mechanism was inhibited by cytochalasin B, an inhibitor of phagocytosis In addition, 
CD8+ CTL could be induced by immunising mice with coated beads (Kovacsovics 
Bankowski et al 1993). Subsequently, the same group showed that the mechanism was 
dependent on TAP1-TAP2 peptide transporter and inhibited by Brefeldin A (an inhibitor of 
endoplasmic reticulum/Golgi transport). They concluded that the pathway entailed egress 
of protein from its vacuolar compartment into the cytoplasm, followed by proteosome 
complex degradation and processing in a similar manner to other cytoplasmic proteins
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(Kovacsovics Bankowski and Rock, 1995). In contrast, ovalbumin-coated beads, or 
bacterial recombinants expressing an ovalbumin MHC class I restricted-epitope, showed 
evidence for a Brefeldin A resistant pathway (Pfeifer et al 1993; Harding and Song, 1994). 
These authors suggested that this was mediated by peptide regurgitation outside the APC. 
For example, degraded protein could diffuse across a 0.45 pm membrane to be presented 
by fixed macrophages of a different MHC class I haplotype (Harding and Song, 1994). The 
researchers suggested that an alternative antigen processing pathway exists which requires 
post-Golgi loading of peptide onto MHC class I molecules. It is possible that more than one 
alternative MHC class I antigen processing pathway exists.
1.3.2.8 Does MTB favour CD8+ T cell induction?
Particulate but not soluble exogenous protein can gain access to an MHC class I antigen 
processing pathway; this applies to membrane-bound intracellular bacteria such as 
Salmonella spp. and E. coli (Harding and Song, 1994). It is possible that the same would 
be true for MTB and other mycobacteria. This hypothesis was tested by Mazzaccaro and 
colleagues (1996). Using exogenous soluble ovalbumin as a reporter molecule, MTB and 
BCG were tested for their ability to permit processing of ovalbumin for presentation to 
MHC class I and/or class II hybridoma cell lines Live MTB infection was selective for 
MHC class I presentation, since MHC class II presentation was inhibited This effect was 
true only for viable organisms In addition the processing pathway was dependent on the 
TAP transporter BCG produced a similar pattern of MHC class I presentation, but to a 
lesser extent The authors suggested that mycobacterial proteins could gain access to MHC 
class I processing in a manner analogous to Listeria monocytogenes. L. monocytogenes 
produces a pore-forming haemolysin, listeriolysin, which allows protein to escape into the 
cytoplasm An MTB haemolysin has been identified and its role is under investigation (Dr 
N. Stoker, personal communication) Whilst the study by Mazzaccaro and colleagues (1996) 
demonstrated class I-restricted antigen processing of the reporter molecule, ovalbumin, it 
did not demonstrate that mycobacterial proteins are also subject to the same antigen 
processing. This issue could be addressed following the development of MHC class I and 
class II-restricted T cell clones known to recognise specific epitopes within a mycobacterial 
protein.
It was interesting to note that BCG was also able to permit some MHC class I ovalbumin 
processing, but to a lesser extent than MTB This may be important concerning the
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moderate efficacy of BCG vaccination. In part this may be due to a failure to  induce a strong 
enough CD8+ T cell response However, some MHC class I mycobacterial antigen 
processing may occur as human CD8+ T cell induction is seen with live but not killed BCG 
(Turner and Dockrell, 1996).
1.3.2.9 Animal protection models and CD8+ T cells
Vaccination with a murine transfected tumour cells expressing M. leprae hsp 65 conferred 
protective immunity to a virulent strain of MTB in mice (Silva and Lowrie, 1994). Further 
protection studies in mice used DNA vaccination. Using a variety o f  different genes 
encoding mycobacterial antigens, a similar degree of protection was conferred using DNA 
vaccination as compared with BCG immunisation (Huygen et al. 1996; Tascon et al. 1996). 
It is remarkable that expression of single antigens was able to achieve this degree o f 
protection. Due to the nature of the vaccine delivery systems, the tumour cell vaccine as 
well as the DNA vaccines induce both CD4+ and CD8+ T cells. It is possible that antigen 
delivery inducing this balanced response may be a prerequisite for successful immunity 
against MTB.
1.3.2.10 The granuloma and control o f infection - apoptosis versus CTL
No single mechanism or mechanisms have emerged to explain how the host combats MTB 
infection It could be an error to attempt understanding at a molecular and cellular level 
alone Perhaps the key resides within the granuloma, a pathophysiological 'organ' comprising 
of mycobacteria sealed-off from the rest of the host by mononuclear phagocytes in various 
states of activation surrounded by a palisade of activated lymphocytes The central zone may 
be necrotic with characteristic caseation, the result of tissue destruction and macrophage cell 
death. This environment could determine the various outcomes associated with infection: 
(i) destruction of the mycobacteria and subsequent resolution of the granuloma, (ii) 
containment of mycobacteria and persistence of the granuloma; or (iii) uncontrolled 
replication of MTB resulting in liquefaction and systemic mycobacterial spread. Accruing 
evidence has suggested that the form of macrophage cell death may determine the outcome 
of mycobacterial survival Two types of cell death are distinguishable: (i) necrosis with 
disintegration of the cytoplasm, loss of organelles and the nucleus remaining relatively intact; 
and (ii) apoptosis with nuclear fragmentation as a result of endonuclease activation 
Evidence for both types of cell death exists in TB (Kumararatne and Dockrell, 1997) There 
has been little evidence to demonstrate that cytolysis reduces mycobacterial numbers
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(discussed in Section 1.3.2.6 ). In contrast, apoptosis may result in mycobacterial death. 
However, the way in which apoptosis is triggered may be crucial. Extracellular ATP (eATP) 
can trigger macrophage apoptosis via the purinergic receptor, P2z, leading to substantial 
death of intracellular BCG, whilst apoptosis induced by fas or CD69 ligation failed to affect 
BCG viability (Molloy et al. 1994; Laochumroonvorapong et al 1996). Further work is 
required to demonstrate if eATP-mediated apoptosis represents an important mechanism in 
vivo However, whatever the mechanism(s) of cell death, one could envisage a dynamic state 
within the granuloma where repeated cycles of cell death and mycobacterial re-phagocytosis 
occur; the number of organisms, rate of cell death and degree of macrophage activation all 
resulting in an outcome of infection control or dissemination.
1.4 CANDIDATE ANTIGENS FOR A SUB-UNIT VACCINE
It has been difficult to identify antigens which induce protective immunity against TB. In 
part, this may be due to  the fact that protection requires a broad immune response with 
recognition of a large number of antigens and the induction of several crucial effector 
mechanisms. Studies have suggested that this scenario is likely in the murine TB infection 
model (Orme et al. 1993a) However, the induction of protective immunity does not have 
to mimic natural infection. Mounting evidence has identified two groups of proteins which 
have potential for use in sub-unit vaccine formulation. These include the heat shock proteins 
(hsp), particularly hsp60, and the CF proteins. Prior to describing individual vaccine 
candidates, certain methodological issues are discussed, indicating the limitations of 
ascertaining which proteins may be immunoprotective.
1.4.1 Methodological issues
Studies used to identify immunodominant proteins have been prone to methodological 
problems Three such problems are described
1.4.1.1 Protective immunity versus Tcell reactivity
In any given assay, induction of T cell responsiveness may not equate with protection 
Several studies have measured the responsiveness of murine immune T cells to antigens in 
terms of proliferation and cytokine production, usually IFN-y (Kaufmann et al. 1987; 
Andersen et al. 1991; Huygen et al. 1992). A wide variety of mycobacterial extracts (cell 
sonicates, PPD etc) and purified protein preparations have been used A T cell Western 
assay has also been employed using CF proteins resolved using SDS-PAGE (Andersen and
Heron, 1993). In different laboratories, a large number o f protein targets have been 
identified Whilst this provides screening for immunodominant proteins, it does not select 
those which are 'immunoprotective' i.e. those antigens, which upon immunisation, could 
induce long-lived immune protection. For example, T cells responding to a particular antigen 
may simply reflect a regulatory function, perhaps in response to inflammation (Orme et al 
1993a). Also, in the mouse model, it has been known for some time that delayed-type 
hypersensitivity (DTH) does not correlate with protection (Orme and Collins, 1984). This 
has been demonstrated in humans in a study in Malawi, where marked PPD skin test 
reactivity (>10 mm induration) o f healthy individuals predicted subsequent development of 
clinical disease rather than protection (Fine et al. 1994).
1.4.1.2 Kinetics o f the T  cell response
There is variation in the type of T cell response occurring at different times after infection. 
For example, in a murine model. Orme (1992) and colleagues describe the kinetics of 
emergence and loss of different populations of T cells following MTB infection. They 
provide evidence that the populations bear different phenotypic markers, recognise different 
antigens and may perform distinct functions. Thus, identification of a high level of T cell 
reactivity to a particular antigen two weeks post infection (pi) may not be true for T cells 
harvested from the same mouse 6 weeks pi.
1.4.1.3 The form o f  antigen delivery is crucial
Much of the work identifying immunodominant antigens has relied on soluble mycobacterial 
proteins and extracts. This form of antigen delivery has been used for the identification of 
MTB-specific reactive T cells (Kaufmann et al 1987; Andersen et al. 1991; Orme et al 
1992; Orme et al 1993) or the induction of T cell clones (Emmrich et al 1986; Oftung et 
al 1987; Manca et al 1991). However, the use of'exogenous' antigen would bias antigen 
processing in favour of MHC class II presentation and thus skew T cell identification in 
favour of the CD4+ phenotype This is of crucial importance as there is clear evidence for 
a protective role performed by MHC class I restricted T cells (Flynn et al 1992), yet until 
recently, in vitro assays were not designed for their identification, nor can it be assumed that 
they would recognise the same antigens
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1.4.2 Heat shock protein 60 (hsp60)
The arguments in favour of hsp60 as a candidate immunoprotective antigen are contentious 
(Kaufmann et al. 1987; Orme et al. 1993; Silva and Lowrie, 1994; Tascon et al. 1996). Early 
studies demonstrated strong immune responses against hsp60 using immunisation with heat- 
killed, MTB in adjuvants (reviewed by (Orme et al 1993 a) In one study, hsp 60 reactive-T 
cells could be readily identified following murine immunisation and limiting dilution analysis 
demonstrated a frequency of 20-25% reactive cells (Kaufmann et al 1987). Furthermore, 
human T cell clones, raised using BCG or MTB, showed strong reactivity to recombinant 
hsp60 (Emmrich et al 1986; Oftung et al. 1987).
Critics have argued that immunisation with heat-killed organism would mean that one was 
immunising with artificially high levels of the hsp60, as autoclaving would induce the protein 
just prior to cell death Moreover, they indicate that in mouse models of live MTB infection, 
the a.p T cell response to hsp60 was negligible (Huygen et al. 1992). A further argument 
relates to the kinetics of immune induction It is known, from adoptive transfer experiments 
in mice, that protective immunity is induced in the early phase o f infection (Orme, 1987), 
yet in a non-stressful environment, hsp60 is hard to detect (Orme et al 1993a).
Despite these objections, subsequent mouse protection studies using M leprae-derived 
hsp60 in a transfected tumour cell line (Silva and Lowrie, 1994) and in DNA vaccine form 
(Tascon et al 1996) demonstrated significant protection following challenge with MTB up 
to 4 weeks post-immunisation. It is intriguing that such a highly conserved molecule, with 
marked homology to human heat shock protein 65, would induce a protective effect Of 
note, the published studies did not ascertain the duration of immunological memory. It is 
possible that the effects seen might be limited to the initial immune response. Further studies 
assessing duration o f memory and adoptive protection would address this issue
1.4.3 Secreted proteins
¡.4.3.1 7' cell readivily to CFproteins
An increasing body of evidence supports an immunodominant role for MTB secreted 
proteins (also known as CF or export proteins) (Andersen et al 1991, Huygen et al 1992; 
Orme et al 1992; Orme et al. 1993; Horwitz et al 1995). Initial experiments identified 
secreted proteins as the major targets for T cell proliferation and gamma-interferon (IFN-y) 
production using cells harvested from animals immunised with live organism (Andersen et
Chapter I Introduction 35
al. 1991; Orme et al. 1992; Orme et al. 1993). One of the studies demonstrated that the T 
cells were CD4+ and MHC class II restricted and were only induced if live, but not dead, 
MTB was used (Andersen et al 1991). In another study, a strong Thl-type response (5-10 
fold increase in interleukin-2 (IL-2) and IFN-y secretion) was seen in spleen cells from 
BCG-vaccinated mice when exposed to CF proteins but not to whole BCG or BCG extract 
(Huygen et al 1992).
There is additional circumstantial evidence in support of a role for CF proteins inducing 
protection. These proteins are secreted very early in mycobacterial growth and can be 
identified as early as the third day of mycobacterial culture (Andersen et al. 1991). It is also 
known that protective immunity is induced in the early phase of infection and only with live 
organisms (Rook et al 1986; Orme, 1987; Orme, 1988). Moreover, only live organisms will 
induce a significant immune response to secreted antigens. A simple explanation would be 
that dead organisms do not secrete these proteins resulting in a significant quantitative 
difference between live and dead bacilli. This would be in contrast to the somatic antigens 
which are present in similar abundance irrespective of mycobacterial viability (Andersen et 
al 1991).
1.4.3.2 Rationale for choice o f Antigen 85 complex (Ag85)
Using fractionated CF protein, Andersen and colleagues (1992) demonstrated that a 26-35 
kDa fraction of CF proteins was one of two main targets for much of the T cell reactivity. 
Two proteins were the key targets recognised, Ag85A (also known as P32) (Huygen et al. 
1992; Huygen et al 1994) and Ag85B (Andersen et al 1992). Two groups have identified 
Ag85B as being immunodominant (Andersen et al 1992; Horwitz et al 1995), although 
others have not observed such a difference (Dr K. Huygen, personal communication) It is 
possible that the apparent disparity could result from differences in antigen preparations. The 
importance of Ag85A as a T cell target had previously been demonstrated in guinea pigs (De 
et al 1987), humans (Huygen et al 1988), and mice (Huygen et al 1992), although these 
studies did not compare Ag85A with the other Ag85 proteins or other CF proteins
Ag85A and 85B constitute two of three proteins collectively known as the Ag 85 complex 
(Wiker and Harboe, 1992), the third being called Ag85C. They are outer cell wall proteins, 
but account for a major component of CF protein (Wiker et al 1986; Wiker et al 1988, 
Wiker and Harboe, 1992) with 20-150 times higher concentrations in CF than in cell
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sonicate. They are related both at a DNA and protein level and signal sequences have been 
identified for all three proteins (Content et al 1991). They bind fibronectin to varying 
degrees, a potentially important function in macrophage uptake (Abou Zeid et al. 1988; 
Abou Zeid et al. 1991). Recently, Belisle and colleagues have indicated that Ag85B 
functions as a mycolyl transferase, suggesting that outer wall cell synthesis may be its key 
function (Belisle et al. 1995).
1.4.3.3 Ag85 proteins may be recognised by CD8+ T cells
Three studies provide evidence for recognition o f Ag85 proteins by CD8+ T cells. In a 
human pleural TB study comparing T cell immunity in peripheral blood and the pleural 
space, CD4+ T cell clones were generated using restimulation with purified protein 
derivative (PPD). Unlike PPD-generated clones from peripheral blood, the 'pleural-space' 
clones demonstrated limited clonal heterogeneity with over a third of the cells reacting to 
both a 27-35 kDa band of mycobacterial proteins and also to the purified P32 antigen (85A) 
(Manca et al. 1991). Of note, these clones could be raised very early in the disease, prior to 
PPD skin conversion; whilst peripheral blood clones could only be raised after the patient 
had become PPD skin test positive From a methodological perspective, stimulating with 
PPD would select for the CD4+T cell phenotype (exogenous antigen processing), but 
interestingly, the overall majority of T cells within the pleural space were CD8+positive.
In a another study of pleural TB, human CD8+T cell clones proliferated to a 27-45 kDa 
band of MTB fractionated protein using a T cell Western assay (Rees et al 1988). However, 
the workers did not identify the specific proteins recognised A further study used Ag 85A 
to induce human cytotoxic responses against macrophages pulsed with whole MTB (Munk 
et al 1994). In this study, T cell phenotyping was not reported although as in the first of 
these studies, the use o f soluble antigen would suggest a predominance of the 
CD4+phenotype
1.4.3.4 Why assess all three AgH5 proteins?
The Ag85 complex comprises of genomically and immunologically distinct proteins The 
gene sequences for these proteins have been derived for MTB (Borremans et al 1989; 
Content et al 1991) BCG (Matsuo et al 1988)and other mycobacterial species (Matsuo et 
al 1990; Lima et al 1991) These genes are not clustered together and sequence homology 
varies between proteins ranging from 70 8-77 5% This permits coding for unique epitopes
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(Content et al. 1991). However, of note, this sequence variation does not occur for the same 
protein across closely related species (De Wit et al 1990).
1.4.3.5 Rationale for choice o f ESA T6
An infection model o f human TB in C57BL/6 mice had previously been established which 
used a parenteral route of inoculation (Andersen et al 1991). This model was used to assess 
the memory immune T cell responses, as measured by proliferation and INF-y production, 
to fractionated short-term culture filtrate (ST-CF) proteins. This group defined short-term 
as 1 week of mycobacterial growth in Sauton's medium (Andersen et al. 1992). Very high 
degrees of reactivity were noted to the low molecular weight protein bands (4-11 kDa). A 
subsequent study in the same mouse TB model demonstrated that a resting memory cell 
population was stimulated early in secondary infection with production of large amounts of 
IFN-y. The molecular target recognised by these T cells was the 6 kDa protein (Andersen 
and Heron, 1993). Using human T cells obtained from TB patients with either minimal or 
advanced disease, marked IFN-y production in response to a <10 kDa ST-CF fraction was 
noted in 6 out of 8 patients with minimal disease, but none with advanced disease (Boesen 
et al 1995). This study did not identify discrete proteins in this low molecular weight 
fraction. These results, taken together, suggest that this protein (plus perhaps other low 
molecular weight proteins) is an important immunodominant antigen in the immune response 
to MTB.
The gene for ESAT-6 (designated esat-6) has been cloned and sequenced (Andersen and 
Heron, 1993) The protein, unlike most other CF proteins, has no signal sequence (Sorensen 
et al 1995) ESAT-6 was absent from all tested strains o f BCG, but present in virulent M  
bovis (Harboe et al 1996). In support of this finding, its gene, esat-6, was identified in a 9.5 
kb region (RD1) deleted from BCG This region is believed to be the original mutation 
leading to attenuation of M. bovis (Mahairas et al 1996). The absence of esat-6 from BCG 
makes it a potential diagnostic tool to distinguish those vaccinated from those infected with 
virulent organism
/. 4.3.6 A nimal protection studies using
Whole CF in adjuvant has induced protective immunity in mouse (Gough, 1988; Andersen, 
1994, Nicholson et al 1996) and guinea pig (Horwitz et al 1995) models o f  TB In the 
mouse studies, the protective efficacy was equivalent to vaccination with BCG In the
Chapterl Introduction 38
guinea pig study, no BCG control was performed However, this study did include 
immunising with six purified CF proteins as well as whole CF Substantial immunity using 
Ag85B but not other proteins was demonstrated (Horwitz et al. 1995). The type of adjuvant 
used was important, some adjuvants giving a protective response associated with Thl T cell 
stimulation (e g incomplete Freund's) and others giving a non-protective Th2 type response 
(e g. alum). Unfortunately, alum is the only adjuvant fully licensed for human use
In a study using DNA vaccination, an Ag85A-encoding construct induced protection to the 
same order of magnitude as BCG in both TB and BCG models of protection (Horwitz et 
al. 1995). Unpublished work has also demonstrated equivalent efficacy using an Ag85B 
construct (Dr K. Huygen, personal communication). In both cases, protection was enhanced 
by using a eukaryotic signal sequence belonging to human tissue plasminogen activator 
(tPA) (Horwitz et al 1995) (Dr K Huygen, personal communication). The presence o f this 
signal sequence had previously been shown to produce a high level o f expression using a 
transfected cell line system (Chapman et al 1991).
1.4.4 Summary - Which candidate antigen?
This section has provided evidence in favour of secreted proteins as potential candidate 
antigens, in particular, the Ag85 complex and ESAT-6 Much of the evidence suggesting 
the importance of these actively secreted proteins comes from the fact that live and not dead 
mycobacteria are required for the induction o f immunity; whole CF protein/adjuvant 
preparations are able to confer protection in murine and guinea pig models of TB. T cell 
reactivity studies provide additional data in favour of Ag85 and ESAT-6 However, somatic 
antigens, such as hsp60, have also been able to induce immunity. Even more surprising, 
mycobacterial products, such as the 36 kDa proline-rich protein, thought not to be 
'immunodominant' can also confer protection (Tascon et al 1996). Therefore, it is important 
to remain circumspect when addressing issues concerning antigen candidature
1.5 ANTIGEN DELIVERY SYSTEMS FOR SUB-UNIT VACCINATION  
AGAINST TB
A variety o f  carriers for candidate TB vaccines have been explored as described above 
These include CF proteins given with adjuvant, recombinant bacteria (Mycobacteria spp, 
Salmonella spp and Listeria spp), 'naked' DNA and recombinant virus (Malin and Young, 
1996) So far, available antigen delivery systems have failed to produce a candidate which
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consistently performs better than BCG. DNA vaccination looks very promising and clearly 
represents one useful approach. Safety aspects such as the potential genomic incorporation 
and mutagenesis have yet to be clarified Another system which has not been tested 
extensively for protective efficacy is the use of poxvirus carriers (Lyons et al. 1990; 
Baumgart et al 1996).
1.6 RECOMBINANT VACCINIA
1.6.1 Antigen delivery - a need for a sophisticated system
Ideally, an antigen delivery system should have the capacity to deliver one or more antigens 
(or epitopes) in a form that will induce a 'protective balance' of effector cells, cytokines and 
antibodies. It would also be beneficial if such a delivery system could co-express 
immunomodulatory molecules. This would 'fine tune' an immune response in order to 
maximise protective efficacy The vector or adjuvant should also be safe and able to deliver 
antigen to a wide variety of sites in order to permit induction of local as well as systemic 
immunity.
1.6.2 W hy choose a poxvirus to deliver recombinant antigen?
Poxviruses represent one such vehicle. They are cytoplasmic DNA viruses, capable of 
incorporating a large amount of foreign DNA Manipulation of the viral genome has been 
well characterised and construction is relatively straightforward (Mackett, 1995). Numerous 
vaccinia promoters have been utilised and foreign genes have been inserted in several non- 
essential loci. In this way, a single construct was able to vaccinate against multiple 
pathogens (hepatitis B, herpes simplex and influenza viruses) (Perkus et al. 1985). For ease 
of construction, a large coding region can be inserted into one site permitting the expression 
of a lengthy polyprotein or, alternatively, a tandem arrangement of multiple genes under 
different vaccinia promoters Furthermore, immunomodulatory genes can be included 
(Rolph and Ramshaw, 1997), permitting the co-expression of cytokines (Carpenter et al 
1994; Leong et al 1994) or second signal molecules (Rao et al 1996).
From an immunological perspective, poxviruses enable recombinant antigen processing in 
the context of both MHC class I and class II pathways (Smith, 1993), which is a likely pre­
requisite for effective immunity against TB Other advantages include: vaccine stability and 
freeze-drying (without need for cold storage), low manufacturing costs and ease of 
administration
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1.6.3 rVV as a tool to dissect CD8+ T cell responses
rVV represent an excellent tool to assess CD8+ CTL from human or animal origin. 
Particular features include tropism for a very wide range of cells and excellent processing 
and presentation of whole antigen in the context of MHC class I (Smith, 1993). This permits 
mapping of CD8+ T cell epitopes without relying on peptide-prediction algorithms, which 
may miss biologically important peptides (Sadovnikova et al 1994)
Factors which must be born in mind when developing constructs for the purpose of CTL 
assessment include: (i) the need to express protein under an early promoter (MHC class I 
presentation of some late viral protein is blocked) (Townsend et al 1988); (ii) CTL may fail 
to recognise some protein products which are not readily degraded in the cytoplasm (this 
can be reversed by destabilising the protein by fusing it with ubiquitin) (Townsend et al. 
1988); and (iii) recombinant protein under the control of late promoters may not be 
expressed in all CTL target cells (protein expression should be verified in the target cells 
used in a CTL assay) (Broder et al 1994).
rVV derived from wild type strains provide an excellent means for recombinant protein 
expression in CTL target cells, but are too lytic to be of use as a source of antigen for CTL 
restimulation Host-range restricted poxviruses represent an alternative vector for 
recombinant protein T cell restimulation as many of these viruses are replication-defective 
in mammalian cells (see Section 1.6.5.2).
1.6.4 Vaccinia - vaccine and vaccine vector
The prototype orthopox vims, vaccinia (VV), holds the unique position of being the only 
vaccine that has been used to eradicate a global disease In addition, it has been used as a 
vector for expressing numerous foreign genes of human, animal, bacterial and viral origin 
(Tartaglia et al 1990) Animal vaccination has protected against a large number o f  infections 
including influenza, herpes simplex, hepatitis B and rabies (Brochier et al 1990; Tartaglia 
et al 1990). Several MTB and M. leprae rVV have been made (Lyons et al 1990; 
Baumgart et al 1996) and murine immunisation with a rVV construct expressing the M. 
leprae 18 kDa protein was able to confer protection against challenge with BCG (Baumgart 
et al 1996).
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1.6.5 A need for a highly attenuated host-range restricted strain
1.6.5.1 Problems with wild-type vaccinia
The smallpox eradication campaign highlighted specific safety issues concerning the use of 
vaccinia. Rare but serious post-vaccination adverse effects were associated with some of the 
vaccine strains in otherwise healthy vaccinees. The worst o f these was encephalitis. Less 
severe, but a nuisance nevertheless, was skin involvement in those individuals suffering from 
eczema (Smith, 1993). The greatest problem of all is the possibility of severe, disseminated 
viraemia in the immunocompromised host, making the use o f a wild type (wt) recombinant 
vaccine unacceptable. This is a significant problem considering that many who would benefit 
from vaccination against TB would be infected with HIV (Bloom and Murray, 1992).
Another issue relating to wt VV is the fact that it encodes many proteins which permit 
evasion of host immunity (Smith, 1993). Theoretically, this could limit its use as a vaccine 
vehicle by down-regulating the immune response One of the key immune evasion strategies 
includes secretion of virally-encoded soluble cytokine receptor homologues. These receptors 
compete for their cognate cytokines at the expense of the cellular counterparts. Examples 
include: IL-13 receptor (B 15R) (Alcami and Smith, 1992); IFN-y receptor (B8R) (Alcami 
and Smith, 1995); INF-ot/p receptor, (B18R) (Symons et al 1995) and T N F -a  receptor. 
Given that these genes have evolved in order to evade immunity, it is not surprising that, in 
some cases, deletion results in virus attenuation (Symons et al 1995).
1.6.5.2 Non-replicating poxvirus
Non-replicating poxviruses represent an attractive alternative to wt VV They offer the 
advantage of a live virus vehicle which permits rapid cell attachment to a wide variety of 
cells, invasion and correct antigen processing; but not the disadvantage o f unwanted 
dissemination, either within the vaccinee, from the vaccinee to non-vaccinated contacts or 
to the environment. Avian poxvirus recombinants, which fail to replicate in mammalian cells, 
still correctly process and present foreign antigens to mammals For example, a canarypox 
recombinant protectively immunised cats and dogs against rabies (Cadoz et al. 1992) and 
elicited a neutralizing antibody response in humans (Taylor et al 1991) An alternative non­
replicating poxvirus is modified vaccinia vims Ankara (MVA); this is an attenuated 
derivative of one of the smallpox vaccine strains, vaccinia Ankara (Sutter and Moss, 1992). 
This particular deletion mutant represents, perhaps, the best of all the potential poxvirus 
vaccine vehicles The reasons for this are outlined below
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1.6.5.3 Recombinant MVA
During the course of the smallpox eradication campaign several highly attenuated strains of 
vaccinia were developed One of these, MVA, was derived following over 570 passages in 
chick embryo fibroblasts. This resulted in 6 major deletions with the loss of 15% o f its 
genome, which rendered it unable to grow in mammalian cell lines (Meyer et al. 1991). 
Despite this host restriction, MVA was successfully used to immunise more than 120 000 
humans against smallpox without significant side-effects. Importantly, it was also found to 
be avirulent in a wide variety of immunosuppressed animal hosts (Werner et al. 1980). 
Recombinant MVA (rMVA) expressing influenza haemagglutinin and nucleoprotein showed 
induction of specific antibody and CTL responses and protection against a lethal challenge 
from influenza virus (Sutter et al 1994). Remarkably, as low as 104 plaque-forming units 
(pfu) were able to protect the majority o f mice against a 100 LD50 challenge.
Further theoretical advantages of MVA include an ideal profile with the loss of functional 
genes encoding soluble cytokine receptors IFN-yR and IFN-a/pR but not IL-ipR 
(Blanchard et al 1997) Both IFN receptors down-regulate immune responsiveness and are 
associated with enhanced virulence and persistence of virus. Indeed, rVV expressing IFN-y 
enhances cell-mediated immunity and viral clearance Although IL-1 PR is still expressed, 
this latter cytokine receptor has been associated with a reduction in virulence in infected 
mice in an intranasal challenge model (Alcami and Smith, 1995). Consistent with this 
finding, the safer human smallpox vaccine strains, such as Lister and Wyeth, express IL -1 PR 
(Smith, 1993). By contrast, higher levels o f post-vaccinial complications were noted in those 
strains where the receptor was absent or only expressed at low levels.
1.6.6 Poxvirus recombinants and co-expression of cytokines
Several cytokines have been successfully expressed in both wt VV (Carpenter et al 1994) 
and avipoxvirus (Leong et al 1994). For example, in one study, rVV-IFN-y caused up- 
regulation of cellular IFN-y and increased viral clearance (Carpenter et al 1994) Also, the 
non-replicating fowlpox virus (FPV) has been constructed to co-express influenza virus 
haemagglutinin and IFN-y CTL activity was high for rFPV both with and without the 
cytokine, but the expression of IFN-y resulted in total abrogation of a humoral response 
(Leong et al 1994). From a safety perspective, this cytokine-encoding rFPV was non- 
pathogenic in severe combined immunodeficient (SCID) mice
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1.6.7 Use of the T7 promoter
The bacteriophage T7 promoter has been used in a variety of prokaryotic and eukaryotic 
expression systems. Due to its very high processivity and exclusive requirement for T7 RNA 
polymerase, it has been useful both for cell-free in vitro transcription/translation and 
intracellular expression using a rVV expressing T7 polymerase.
1.6.7.1 In vitro transcription/translation using the T7 system
Starting with circular plasmid DNA containing the gene of interest under the control of the 
T7 promoter, it is possible to obtain a signal from metabolically-labelled protein products 
within a short period of time using an entirely cell free system (Schenbom, 1995). 
Transcription requires T7 polymerase, the plasmid template and nucleotides plus buffer. 
Translation can then be performed, either as a separate reaction, or within the same reaction 
mix. This step requires an appropriately prepared membrane-free, cell lysate containing the 
essential translational apparatus to which amino acids are added One or more of these 
should contain a radionuclide label such as ,5S, thus permitting metabolic labelling of protein 
and autoradiographic signal detection Using a commercial kit, a coupled 
transcription/translation reaction can be performed and protein signal detected within 6 
hours. In addition, by adding microsomal membranes to the in vitro reaction, the effects of 
post-translational glycosylation can be studied (Schenborn, 1995).
1.6.7.2 The vaccinia/T7 hybrid system
This system permits very high level transient expression of foreign genes The system entails 
in vitro cellular infection using a rVV expressing T7 polymerase (vTF7-3), plus one or other 
of: (i) a second rVV coinfection; or (ii) a plasmid transfection, either of which must contain 
the foreign gene under the control of the T7 promoter (Mackett, 1995) For example, the 
rVV/plasmid system demonstrated a 400-600 fold increase in reporter gene activity as 
compared with other standard mammalian transient expression systems of the day (Fuerst 
et al 1986). Using the rVV coinfection system with a UtcT. reporter, approximately 30% of 
the total cellular RNA was T7 specified at 24 hours post-infection However, over 90% was 
uncapped and poorly translated (Fuerst and Moss, 1989) This problem was overcome by 
including a 5' untranslated leader sequence within the transcript. This was derived from 
encephalomyocarditis virus (FMCV) which, like other picornaviruses, contains an internal 
ribosomal entry site (IRFS) This region permits highly efficient cap-independent translation
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(Vennema et al 1991). In one study using the vaccinia/T7 hybrid system, the foreign gene 
product accounted for over 10% of th e  total cellular protein
1.7 SUMMARY
This chapter has argued that an alternative vaccine to BCG is urgently required, particularly 
as the current vaccine fails to protect against the transmissible adult pulmonary disease. 
From the perspective of safety and quality-control, a rationally designed sub-unit vaccine 
would be particularly desirable However, its development requires knowledge o f  what 
constitutes an effective immune response Human immunity to MTB is poorly understood, 
but there is increasing evidence in favour of a contribution from CD8+ as well as CD4+ T 
cells. The precise role for this CD8+ T  cell contribution is not known and evidence from 
knockout mice studies suggests that their importance may not be due to a cytolytic function. 
An alternative potentially important function for CD8+ T cells could be the provision of 
additional IFN-y, particularly where CD4+ T cell recognition may be compromised by 
down-regulation of MHC class II molecules in MTB-infected macrophages
MTB secreted proteins represent likely candidate antigens for a sub-unit vaccine Two 
antigenic groups, ESAT-6 (plus perhaps other low molecular weight secreted proteins) and 
the Ag85 proteins, are particularly strong candidates In terms o f the vehicle for antigen 
delivery, poxviruses show several highly desirable properties: (i) MHC class I as well as 
class II antigen presentation; (ii) vaccine potential, using host-range restricted, highly 
attenuated strains; and (iii) as a tool to  dissect human CD8+ T cell responses
In order to utilise the benefits of a vaccinia expression system in conjunction with key 
immunodominant MTB proteins, this study aimed to produce a panel of rVV expressing 
ESAT-6 and Ag85, with the intention o f  using the rVV both as tools to assess human CD8+ 
T cell function and potential vaccines in animal models of TB
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2.1 WATER AND SOLUTIONS
Distilled water was used to make up media and buffers Autoclaved double deionized water 
(Millipore, Watford, UK) was used for all molecular biology reactions. All solutions used 
in RNA work were made with autoclaved, diethyl pyrocarbonate (DEPC) treated water. All 
standard salt solutions and buffers were made up as described elsewhere (Sambrook et al 
1989).
2.2 BACTERIAL CULTURE MEDIA AND BROTHS
Media and broths were prepared according to the manufacturer's instructions or as described 
below Luria broth (LB) (Life Technologies, Paisley, UK) and LB agar containing ampicillin 
(Sigma, Poole, UK) at 50 gg/ml (stock 50 mg/ml stored at -20°C) were used for culturing 
transformed Escherichia coli. LB broth plus tetracycline (Sigma) at 50 pg/ml (stock 5 
mg/ml in 50% v/v ethanol stored at -20°C) was used for M13 bacteriophage growth
Mycobacteria broth culture was performed using either Middlebrook 7H9 (Difco, West 
Molesey, UK) supplemented with 10% w/v ADC supplement (Appendix A) or 10 % w/v 
oleic acid-albumin-dextrose-catalase supplement (OADC, Becton Dickinson, Cockeysville, 
MD, USA) or a minimal synthetic Sauton's medium (Appendix A). Mycobacteria solid phase 
media were either Lowenstein-Jenson slopes or Middlebrook 7H11 (Difco) supplemented 
with OADC.
2.3 BACTERIA
2.3.1 Escherichia coli strains
Competent E. coli strains were used for transformation and propagation of plasmids using 
Epicurian Coli supercompetent SCSI cells, (Stratagene, Cambridge, UK) and M13 
bacteriophage using Epicurian Coli supercompetent XL 1-Blue (Stratagene) All bacteria 
were stored at -80°C.
2.3.2 Bacterial transformation
Bacterial transformation was performed in accordance with the protocol from Stratagene 
In order to enhance efficiency, the system was optimized by using a range of: (i) ligation mix 
volumes (1-8 pi); (ii) concentrations of vector DNA (0.5-50 ng); and (iii) vector insert 
molar ratios ( I 5-1:90) Transformants were identified as discrete colonies grown on LB
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plates containing 50 pg/ml of ampicillin. These were picked and grown up overnight in 
LB/ampicillin broth prior to plasmid purification.
Purified plasmids were archived and stored at -20°C. In addition, 1 ml aliquots of broth 
were catalogued and stored in cryotubes (Greiner, Dursley, Glos, UK) in 30% v/v glycerol, 
at -80°C.
2.3.3 Mycobacteria culture
2.3.3.1 Preparation o f stock culture
Mycobacteria stock for subsequent culture was grown on Lowenstein-Jenson slopes and 
transferred to Middlebrook 7H9/OADC liquid medium, harvested during log phase growth 
and stored in 1 ml aliquots containing 30% v/v glycerol prior to use. Strains included: BCG 
(Glaxo strain) derived from freeze-dried stock (Evans Medical, Leatherhead, UK), M. 
marinum (MM) derived from freeze-dried stock (ATCC 11564, NCTC 10011, 16/9/69) and 
MTB H37Rv derived from the local laboratory culture which was originally provided by Dr 
M.J. Colston at NIMR, London
BCG stock was also grown for CTL work This was prepared as above but resuspended in 
RPMI. In this study, the BCG/RPMI stock was kindly donated by Dr J Turner.
2.3.3.2 Preparation o f early culture filtrate protein
Three mycobacteria strains were grown in Middlebrook 7H9/OADC for 7-14 days (MM 7 
days, BCG and MTB and 14 days) Additional experiments included growing MM in both 
Middlebrook 7H9/ADC and Sauton's medium Cells were pelleted and the supernatant 
obtained and sterile filtered using a 50 ml syringe and a 0.2 pm filter (Nalgene, Rotherwas, 
Hereford, UK). For safety reasons, 5 ml aliquots were filtered for the MTB culture
The culture filtrate was then concentrated using a Centricon 3 membrane filter which retains 
proteins greater than 3 kDa in size (Amicon, Stonehouse, Glos, UK). Filtration was 
achieved by spinning the Centricon tubes at 6000 rpm (3000 g) in a Sorvall RC-5 
Superspeed Refrigerated Centrifuge using the SS-34 fixed angle rotor The protein content 
was measured using the Bradford method (Maizels et al. 1991 )and aliquots were frozen at 
-70°C.
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2.4 PLASMIDS
2.4.1 Vaccinia insertion plasmids
Three vaccinia insertion plasmids were used for construction o f rVV: (i) pSCl 1 (Figure 
2 1 a) provided by Dr T Blanchard, LSHTM (previously obtained from Dr H Stauss, ICRF, 
London) (Chakrabarti S et al. 1985); (ii) pi 108 (Figure 2.2a) provided by Dr M Mackett, 
CRC, Manchester; and (iii) pWR510 provided by Prof J Mullins, University of Washington, 
Seattle (Figure 2.3a) (Wang and Mullins, 1995).
2.4.2 Plasmid clones containing mycobacterial genes
Clones containing the genes that encode MTB Ag85 complex and the 6 kDa secreted 
protein, ESAT-6 had been previously cloned into bacterial plasmids (Borremans et al 1989; 
Content et al 1991; Sorensen et al. 1995) The clones were donated by other laboratories 
and were used as PCR templates for the construction of the vaccinia insertion plasmids 
required for rVV development. The genes encoding proteins of the Ag85 complex, 85a, 85b 
and 85c, were provided by J Content, Pasteur Institute, Brussels. The genes had been 
subcloned into the BlueScribe-M13+ vector (Stratagene) and were designated: pBS-85A, 
pBS-85B and pBS-85C The esat-6 gene had been subcloned into pBlueScript II SK+ 
(Stratagene) to make the clone, pAA249. Genes 85a, 85c and esat-6) were originally derived 
from the Rick Young Àgtl 1 gene library (Young et al. 1985). 85b was derived from BCG 
genome (Dr J Content, personal communication) However, it has identical sequence 
homology to MTB at the amino acid level (Content et al 1991). Both the plasmids with 85a 
and 85c are the property o f Innogenetics, Ghent, Belgium A Memorandum of Agreement 
concerning commercial application of the derivatives was signed prior to their release
2.4.3 Additional vectors
Sequencing vectors, M13-mpl8 and -mpl9, were obtained from Sigma
2.5 PRIMERS AND OLIGONUCLEOTIDES
Primers were obtained from three sources: (i) Oswel DNA Service, Edinburgh, UK (pSCl 1- 
ESAT-6 cloning primers and tPA oligonucleotides); (ii) MWG Biotech, Ebersberg, 
Germany (primers 1 to 20); and (iii) Life Technologies (all other primers unless otherwise 
stated). The oligonucleotides were HPLC purified However, none of the primers were 
HPLC purified Individual primers were stored as 20 pM stock solutions at -20°C.

Nhe\ BamH\ Sma I EcoRI
c
Nhe I 
SamHI 
Smal 
EcoRI
Figure 2.2 Cloning the tPA signal sequence into p i 108
a) p i 108 is derived from pBR328 and includes the essential elements for vaccinia ho­
mologous recombination: flanking thymidine kinase sequences (tkL and tkR), a multiple 
cloning site (MCS) downstream from the early/late p7.5 promoter for insertion of foreign 
DNA, and the selectable marker, guanine phosphoribosyl transferase gene (gpt), under 
control of the 19 kDa promoter. AmpK=ampicillin resistance, b) tPA sense strand (antisense 
includes an additional 4 nucleotide EcoRI overhang). The hybridised oligonucleotide pair 
encodes the 21 amino acid tPA signal sequence and a MCS. c) pi 108-tPA was constructed 
by cloning the tPA blunt/EcoRI fragment into the BatnH\ cut, Klenow-filled, EcoRI cut 
vector.
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tkL SV40
Swal
Nhe I
S ad i
Xba\
EcoRI
SamHI
Sival Nhe I Sadi
5’-CCTTTGAAAAACACGATTTAAATATGGCTATGCATATGTACGTACCGCGGGCCC 
Xba\ EcoRI His6 SamHI
TCTAGAATTC CATCACCATCACCATCACGGGGCGCCCGCATAGGGATCC-3’
Figure 2.3 Cloning the tPA signal sequence into p\VR510
a) Map of pWR51() showing the essential elements for construction of rVV: the compo­
nents required for cloning and propogation in E. coli (fl ori. AmpR and P15A ori) and an 
expression cassette required for homologous recombination with VV (SRallT l promoter, 
EMC element, poly(A) and T7 terminator (ter), the selectable marker gene gpt, and r£L 
and ikR sequences), b) The nucleotide sequence of pWR510 surrounding the start codon, 
unique cloning sites and His6 tag. c) pWR510-tPA was constructed by cloning the tPA 
blunt/EcoRI fragment into the Swal/EcoR\ cut vector.
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2.5.1 Primer nomenclature
This was defined according to an 8 character code (see Figure 2.4). Primer pairs were coded 
by the 2 digit unique identifier e g. 01/02.
PR II *** II CD CD F o r R
t A t t
primer 3 character 2 digit Forward or
description of 
amplification 
product
unique Reverse
identifier primer
Figure 2.4 Primer nomenclature
2.5.2 Primer design
Primers were designed using a genetic software package (Lasergene, DNASTAR Inc. 
USA) Optimal primers were identified by using the primer select programme The software 
permitted subsequent manual manipulation in order to allow addition and/or substitution of 
non-complementary nucleotides required for cloning (see below).
2.5.3 Cloning primers
Cloning primers were selected to amplify only the region encoding the mature secreted 
protein (entire open reading frame (ORF) for esat-6 which lacks a signal sequence) or as 
close as possible to this Thus, in the case of the Ag85 proteins, primers were designed to 
include a start codon just before the first residue of the mature protein, phenylalanine (Phe) 
All cloning primers are listed in Table 2.1 The table does not include the first primer pair 
used for cloning esat-6 into pSC 11 (see Section 2.7.3.1).
The computer programme-generated primers were manipulated to include (from the 5' end): 
(i) two nucleotides of either dGTP or dCTP for both strong 5' binding and the requirement 
of an overhang required for endonuclease digestion, (ii) a selected restriction site (either 
NheI, Xba\ or BamYW in the upper primer and £coRI in lower primer) in accordance with 
the cloning site of the plasmid, (iii) an ATG translation initiation codon (if absent in the 
vector or amplified coding sequence), and (iv) at least 11 nucleotides of template sequence 
homology The programme gave a ranking for each primer pair including the primers 
modified for cloning purposes Where a selected primer was predicted to perform badly, an 
alternative primer, upstream from the
■ Ml H I ■
Nam e S e quence Size Tm  (-C) Gene P lasm id S ite N otes*
PR85A01R 5-C G T  C TAG ATTTT CCCGG CCGG GCTT-3' 25 57.5 85a pW R510 X 6al start codon at Phe
PR85A02R 5'-CG GAATTCG GCGCCCTG GGG CG CG G-3' 25 65.7 85a pW R510 EcoRI no stop codon
PR85A03F 5'-G CG G ATCCATG G CG G G G G CATTTTC-3' 25 59.1 85a* p1 108 BamHI Phe preceded by Ala Gly Ala
PR85A04R 5'-G CG AATTCAG CTAG G G ACG G G ATT T-3' 25 54.2 85a* p1 108 EcoRI 55 bp downstream from the stop codon
PR85B05F 5'-CG TCTAGATTCTCCCGG CCGG GGCT-3' 25 60.8 856* pW R510 Xbal start codon at Phe
PR85B06R 5'-CCG AATTCCG G CG CCTAACG AACTC-3' 25 57.5 856* pW R510 EcoRI error in primer - need EcoRI to be in frame for His tag
PR85B07F 5'-CCGG ATCCATGTTCTCCCG GCCG -3' 23 5 91 856* p1 108 BamHI start codon at Phe
PR85B08R 5'-GGG AATT CTCGGTT G AT CCCG T C AG-3' 25 55.9 856* p 1 108 EcoRI native stop codon and 4 codons
PR85C09F 5'-CG TCT AG ATT CTCT AG G CC C G G T CT-3' 25 55.9 85c PW R510 X6a l start codon at Phe
PR85C10R 5'-GGG AATT C ACAG GCGGCCGGCGCA-3' 24 60.8 85c pW R510 EcoRI mutates stop codon only TG A to TG T
PR85C11F 5'-CCGG ATCCATGTTCTCTAGGCCCG -3' 24 57.4 85c* p 1 108 BamHI start codon at Phe
PR85C12R 5'-G CG AATTCG CT GG CT C AGGCGG -3' 22 57.2 85c* both EcoRI pW R 510 and 1108, stop codon present +3 bp
PR85A13F 5-G C G C T  AG C AC CG CG G G G G C ATTTT C-3' 25 6 0 8 85a pW R510 N he\ Phe preceded by T h r Ala Gly Ala
PR85A14F 5'-CCGG ATCCATGTTTTCCCGG CCGG G-3' 25 60.8 85 a p1 108 BamHI start codon at Phe
PR85A15R 5'-G GG AATTCCTAGG CG CCCTGG GGC-3' 24 60.8 85a pW R510 EcoRI stop codon only
PR85B16F 5'-CG G CTAG CTTCTCCCG G CCG G G G CT-3' 25 6 41 856 pW R510 N hel start codon at Phe
PRESA17F 5'-CG GCTAGCGACAGAG CAG CAG TGG -3' 24 59.1 esat-6 PW R510 N he\ error in primer - extra G at position 9
PRESA18R 5'-G CG AATTCATATG CG AACATCCCAG -3' 25 52.6 esaf-6 pW R510 EcoRI mutates stop codon to Tyr, in frame
PRESA19F 5'-GCGGAT C CAT G AC AGAG CAG C AG T G-3' 25 57.5 e sa t-6 p1 108 BamHI amplifies ORF (no signal sequence for ESAT-6)
PRESA20R 5'-G CG AATTCCTATG CG AACATCCCAG -3' 25 54.2 e sa t-6 p 1 108 EcoRI amplifies ORF
PR85C21F 5'-CG GCTAGCTT CTCTAG G CCCG G TCT-3' 25 5 9 1 85c pW R510 Nhel start codon at Phe
PR85B22R 5'-CG GAATTCCCAGCCG GCGCCTAACG -3' 25 6 0 8 856 pW R510 EcoRI mutates stop codon to Tyr, in frame
Table 2.1 Cloning primers
description of primers with respect to: translational initiation (Phe residue at start of mature protein, upstream from mature protein or at ORF), termination 
of translation and errors in primer design (see Section 2.5.3), §=Taq polymerase used for this pair, *=PCR annealing temperature of 55°C.
;.....  j = primers used in p 1108 and pWR510 constructs.
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start of the mature protein coding sequence (starting with Phe) was also purchased (see 
notes section in Table 2.1).
2.5.3.1 pSC 11-ESA T-6 primer pair
The initial cloning experiment included two 20 nucleotide-length (mer) sequences. The 
primers were designed to amplify esat-6 prior to T:A cloning into pSCl 1 - see Figure 2.5 
and Section 2.10). The forward primer amplified from the start of the native start codon of 
the ORF (5'-ATGACAGAGCAGCAGTGGAA-3'). The reverse primer included the stop 
codon and an additional four non-complementary nucleotides encoding part of a Bsu36\ site 
(5'-AAGGCTATGCGAACATCCCA-3'); the remaining T-vector sequence completing the 
site following successful cloning.
2.5.3.2 p i  108 and pWR510primers
Each primer pair was designed to amplify the coding sequence for the mature protein only 
with exclusion of the mycobacterial signal sequence (Content et al. 1991) (not applicable 
for esat-6 which has no signal sequence). Forward primers included a BttmHl site and a start 
codon for pi 108 and either a Nhel or Xba\ site, but no start codon, for pWR510 (Table
2.1) The reverse primer included an IicoRX site for all amplification products For pWR510 
reverse primers, the stop codon was removed to allow a C-terminus six residue histidine 
fusion (His6 tag) (Figure 2.3) for recombinant protein purification using nickel affinity 
chromatography (Wang and Mullins, 1995). Thus, directional cloning could be performed 
using PCR restriction enzyme cut products into fla/wHI/AcoRI cut pi 108 (Figure 2.2) and 
NheVEcoRl cut pWR510 (Figure 2.3).
2.5.4 Additional primers used for sequencing and PCR verification
2.5.4.1 Primers for sequencing pSC l J-ESA T-6 and M l 3 subclones
External primers flanking the pSC 11 cloning site were used in double stranded sequencing
of recombinant pSCl l-ESAT-6 These were kindly provided by Dr T Blanchard (see Table
2.2) . The Ml 3 forward primer (Sigma) was used for single stranded sequencing of Ml 3- 
ESAT-6 recombinants (mpl8 and mp!9).
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c
( pAA249 \
Pfu or Taq 
polymerase
esat-6
PCR
d
Taq
pol
► ^ dATP
A
A
^ p sc ii^ y _ Smal
cloning
site
Smal
cut
5’ 5 ’
Taq _ 
pol
T
dTTP
T
7.6 kb
T4 ligase
pSC11-ESAT-6
Figure 2.5 T:A cloning of e sa t-6  into pSCll
a) An insert carrying esat-6, suitable for cloning into the vaccinia insertion plasmid, pSCl 1, 
was obtained by PCR amplification from the plasmid pAA249 using primers PI and P2.
b) pSCll was linearised using S m a l restriction digestion, c) The esa t-6  amplification 
product was gel-purified. The Pfu product was tailed with a single dATP (A’ tailing was 
not required for 7<«y-gencrated products), d) The S m a l  cut pSC 11 was tailed with a single 
dTTP. e) A’-tailcd esat-6  and T’-tailcd pSCl 1 were ligated to form pSCl l-ESAT-6
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N a m e S e q u e n c e
S iz e
(m e r)
R e g io n
re c o g n iz e d
P C R
p ro d u c t
s iz e
(b p )
P R 5 1 0 2 3 F * 5 -C A T  G C T T T  A C A T  G T  G T T T A G T C G -3 ' 23
p W R 5 1 0
se nse
184
P R 5 1 0 2 4 R * 5 '-G T  A A C C G T T  A A C G G A T  C C C T  A T G C -3 ' 24
P W R 5 1 0
se nse
P R tP A 2 5 F * 5 -A A A T  A T  G G A T  G C A A T  G A A G A G A -3 ' 22 tP A  s e n s e
7 9
P R tP A 2 6 R * 5 '-G G A T C C G C T A G C C G A A A C G A A -3 ' 21 tP A  a n tise n se
P R 1 0 8 2 7 F * 5 '-T  A T T  C T  A A T T T  A T T  G C  A C  G G T  A A G -3 ' 24 p 1 1 0 8  se n s e
63
P R 1 0 8 4 0 R * 5 -C G C G G G C C C G A G A T  C T T  A G T T A G -3 ' 2 3
p 1 108
a n tise n se
P R T K 3 2 8 F 5 '-A A T T  A G A C G A G T T  A G A C G -3 ' 18 tk  L n o t
kn o w nP R T K 4 2 9 4 5 '-A T C T C G G T T T C C T C A C C C -3 ' 18 tkR
P R 8 5 B 3 0 F 5 '-A T C A A C A C C C C G G C G T T C G A G T G -3 ' 23 85A  a n d  8 5 8 n/a
P R 8 5 C 3 1 R 5 -C G G C A G C T C G C T G G T C A G G A -3 ' 20 85A  a n d  8 5 8 n/a
P R 8 5 C 3 4 R 5 -C C G C G T T  G C C T  G T C G G G G -3 ' 19 8 5C n/a
P R 8 5 C 3 5 F 5 '-C T  G G A A G C G C A A C G A C C -3 ' 17 85C n/a
P R P S C 4 2 F * 5 '-A A A C T  G A T  C A C T  A A T T  C  C A A A C  C -3 ' 2 3 pS C 11 se n se n/a
P R P S C 4 3 R * 5 '-G T T T G C C A T  A C G C T  C A C -3 ' 17
pS C 11
a ntise n se
n/a
Table 2.2 Primers used for PCR verification of rVV and sequencing of plasmids
*=primer pairs used for verification of rVV gene integration All primers were used for 
sequencing except for PR51024R and PRtPA26R
2 .5 .4 .2  P r im e rs  f o r  p j  108, p W R 5 1 0  a n d  th e ir  tPA d eriva tive s
A variety of primers were designed for both sequencing of recombinant insertion plasmids 
to confirm fidelity of cloning and to provide verification for successful rVV construction. 
These are listed in Table 2 2 Primer pair 28/29 (TK primers) was given by T Blanchard, 
Oxford Primers 30-33 were given by Dr J. Content, Brussels
2.6 ENZYMES, KITS, RADIONUCLIDES AND MISCELLANEOUS 
REAGENTS
All reactions were carried out according to the manufacturer's instructions and reagents 
were stored at -20°C unless otherwise stated
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2.6.1 DNA restriction enzymes
Enzymes and buffers were purchased from Promega, Southampton, UK unless otherwise 
stated The following restriction enzymes were used: BamHl, Bsu36l, EcoRl, Hindi, 
Hindill, Nhe\ (Stratagene), Pstl, Pvttl (Stratagene), Sacll, Smal, Swal (Boehringer 
Mannheim, Lewes, UK) and Xbal.
2.6.2 DNA modifying enzymes and related reagents
Individual modification enzymes included: (i) T4 ligase (Promega); (ii) DNA polymerase 
I Large (Klenow) Fragment (Promega); PCR DNA polymerases - Taq (with storage buffer 
B, Promega) and cloned Pfu (Stratagene); (iii) RNAse-free DNAse (Deoxyribonuclease I, 
Amplification Grade, Life Technologies); (iv) RNasin ribonucléase inhibitor (Promega); and 
(v) 100 mM deoxynucleotide triphosphates (dNTPs) (Promega).
2.6.3 Molecular biology kits
1) Manual sequencing was performed using the Sequenase Version 2.0 DNA 
Sequencing Kit (USB, Life Science).
2) Cycle sequencing was performed using the ABI PRISM Dye Terminator Cycle 
Sequencing Ready Reaction Kit with AmpliTaq DNA Polymerase FS (Perkin Elmer, 
Foster City, CA, USA).
3) Reverse transcriptase PCR (RT-PCR) reagents were obtained from Gibco BRL 
Superscript Preamplification System for First Strand cDNA Synthesis kit (Life 
Technologies).
4) \n vitro coupled transcription/translation was performed using the TNT T7 Coupled 
Reticulocyte Lysate kit (Promega) and stored at -70°C.
5) Immunoblotting was performed using the Enhanced Chemiluminescence (ECL) 
Western blotting Detection system (Life Sciences, Little Chalfont, Bucks , UK) and 
stored at 4°C.
2.6.4 Radionuclides
Three radionuclides were used in this study: (i) ,5S-dATP stored in a 100 pi volume, at 4°C, 
with an activity 10 mCi/ml on day 0, (ii) ” S-methionine stored in 5 pi aliquots, at -80°C, 
with an activity 15 mCi/ml on day 0; and (iii) 5lCr stored in a 1 ml volume, at 4°C, with an
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activity range of 1-5 gCi/ml depending on usage Radionuclides were purchased from Life 
Sciences, Little Chalfont, UK and ICN, Thame, UK.
2.7 AGAROSE GEL ELECTROPHORESIS AND DOCUMENTATION
2.7.1 Agarose, running and loading buffers
Electrophoresis grade Ultrapure Agarose was obtained from Life Technologies For most 
purposes, 1% w/v gels were poured shortly before use and included 0.02% w/v ethidium 
bromide (BDH Electran, Merck, Poole, UK). Occasionally, 0.7-3% w/v gels were poured 
to improve size resolution. Initially, Ultrapure LM P (low melting point) agarose (Life 
Technologies) was used in DNA purification (pSCl l-ESAT-6 cloning only). TAE 
(Sambrook et al. 1989) was used as the gel tank buffer. When a longer electrophoresis 
running time was required, ethidium bromide was added to the buffer in order to maintain 
uniform gel staining. A commercial loading buffer (Promega) containing three colour dyes 
was initially used, but it was noted that the presence of the dye could obscure a band 
running at the same speed. As alternatives, 0.25% w/v xylene or 0.25% w/v bromophenol 
blue in 30% v/v glycerol were prepared (Sambrook et al 1989); xylene loading buffer for 
DNA of low molecular weight and bromophenol blue for DNA of high molecular weight, 
thus avoiding band obscuration.
2.7.2 Molecular weight markers
Two molecular weight markers were used: (i) lamda phage Ht/tdlWX'coRl digest (Promega) 
designated as 'X' in figures, and (ii) a 100 base pair ladder (Pharmacia Biotech, Uppsala, 
Sweden) designated as 'MW' in figures As well as molecular weight sizing of bands, X was 
also used to approximate DNA quantity
2.7.3 Gel documentation
Ethidium bromide stained DNA bands were visualized using ultraviolet (UV) light The 
results were recorded using gel documentation apparatus (Chromato-Vue, UV 
Transilluminator TM-20, UVP Inc , San Gabriel, CA, USA and Mitsubishi Video Copy 
Processor P65B, Tokyo, Japan) and relevant results were subsequently scanned using 
Adobe Photoshop 3.0 software (Macintosh) and a UMAX UC840 Max Vision Scanner at 
a resolution o f400 dots per inch Image reproduction was enabled by pasting encapsulated 
postscript files into a desktop publishing file (PageMaker 6.5, Macintosh) for final
production of figures. Black and white print film (Polaroid, type 57) was also used for some 
agarose gels
2.8 DNA PURIFICATION
2.8.1 Plasmid preparations
Small scale preparations of plasmid from 5 ml overnight LB cultures were prepared using 
the Wizard Minipreps DNA Purification System (Promega) Larger scale plasmid 
preparations used either Wizard Midiprep or Maxiprep (Promega) or Plasmid Maxi Kit 
(Qiagen, Hilden, Germany) In order to increase purity, as required for vaccinia homologous 
recombination, an additional phenol/chloroform extraction and ethanol precipitation 
(Sambrook et al. 1989) step was included In later experiments, a desalting step was also 
added using membrane filtration (Microcon 50 or 100, Amicon) - see Figure 4 8
2.8.2 Insert and vector purification prior to ligation
Inserts and vectors were purified using a variety of techniques
1) Resin purification with the Wizard PCR Preps DNA Purification System (Promega) 
(for pSCl l-ESAT-6 only).
2) Gel purification as described elsewhere (Sambrook et al 1989). Briefly, 1% w/v 
agarose gel electrophoresis was performed and the appropriate band excised. 
Extraction from the agarose was achieved using either: (i) low melting point agarose 
(for pSCl l-ESAT-6 cloning); or (ii) electroelution (all other cloning). This latter 
technique utilised Va" dialysis tubing (Sigma) containing the gel fragment and 
approximately 500 p i o f  1 % w/v TAE; the tubing was sealed by two freezer bag 
clips This was then placed into the buffer in the gel tank and eluted from the 
agarose Micropure spin columns (Amicon) were also tried but this technique was 
abandoned (see Figure 4 8b and Section 4 2.3.2 for details).
3) Phenol chloroform extraction and ethanol precipitation (Sambrook et al 1989).
4) Sephadex G-50 Fine columns (Pharmacia Biotech) were used for removal of the 
intervening oligonucleotide fragment following double digest of M 13 bacteriophage 
cloning (Sambrook et al 1989).
5) Spin column membrane filtration using Microcon 50 or 100 (Amicon) were used 
for: (i) enzyme removal (Micropure EZ insert); (ii) buffer exchange; (iii) DNA 
concentration, and (iv) removal of oligonucleotide fragment following double digest 
of vector (Figure 4 8a).
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2.8.3 Nucleic acid quantification by spectroscopy
Spectroscopy was performed using a GeneQuant II spectrophotometer, Pharmacia Biotech, 
LKB Biochrom, Cambridge, UK for DNA and RNA samples where an assessment of purity 
and a more accurate estimate of quantity was required (first strand cDNA synthesis and 
plasmid preparation prior to transfection, in vitro transcription/translation and sequencing). 
Optical densities at 260 and 280 nm (OD260 and OD280 respectively) and the ratio 
OD260/OD280 were recorded for a given dilution of sample. The quantity was calculated and 
purity assessed as described elsewhere (Sambrook et al. 1989).
2.9 PCR
2.9.1 Equipment and reagents
Thermal cycling was performed using a PHC-3 Techne thermal cycler Working solutions 
of individual dNTPs (10 mM) and mixed dNTPs (2 mM) were stored at -20°C. The PCR 
mix consisted of: dNTPs (final concentration of 0.2 mM each); primers (final concentration 
of 0.2 mM each); template (usually 250 ng for cloning purposes and variable for diagnostic 
purposes); DNA polymerase (2.5 U of Pfu or Taq) plus xlO reaction buffer; plus 2 mM 
magnesium (for Taq only); and nanopure water up to a final volume of 100 pi for cloning 
purposes and 20-50 pi for diagnostic purposes. Reactions were performed using thin-walled 
250 pi microfiige tubes.
2.9.2 Hot start PCR
A 'hot start' was used in most reactions by pre-sealing the primer pair under a wax pellet. 
This was achieved by adding the primer pair to the PCR tubes followed by the pellet The 
tubes were then heated to 80°C for 5m then placed on ice Initially, stock tubes containing 
pre-mixed primers under wax were stored at -20°C. Later, all reagents including primers 
were freshly made up and kept on ice to improve PCR yield
2.9.3 Amplification of esat-6 for cloning into pSCl I
Plasmid pAA249, containing esat-6, was used as the template. For Pfu Polymerase, the 
cycle conditions were: initial temperature 95°C 5m, 40°C 5m, 74°C 30s; then 25 cycles of 
95°C 20s, 45°C lm, 74°C 30s; and extension of 75°C 5m For Taq Polymerase, cycle 
conditions were similar except the annealing temperature was 45°C for the first cycle and 
50°C for subsequent cycles and the extension temperature was 72°C throughout.
Chapter 2 Materials, Methods and Optimising Systems 64
2.9.4 Amplification of genes encoding the Ag85 com plex and ESAT-6
PCR amplification of cloning inserts was enabled using the appropriate plasmid template 
(Section 2.4.2) and primer pair (Table 2.1 and Section 2.5.3.2). Where problems with 
amplification were encountered, a variety of conditions w ere assessed in order to optimise 
both quantity and sequence fidelity. These included:
(i) varying template and/or primer quantity;
(ii) hot versus cold start;
(iii) increasing melting temperature from 95 to 98 °C in order to reduce potential 
secondary structural problems;
(iv) addition of 2% v/v glycerol or 10% w/v dimethylsulphoxide (DMSO) (Hybri-Max, 
Sigma) also in order to reduce potential secondary structural problems;
(v) varying annealing temperature (range assessed 45-55°C); and
(vi) a switch from Pfit to Taq polymerase
Following optimisation, reactions using Pfit polymerase w ere performed using the PCR mix 
as described in Section 2.9.1, a hot start and the following cycle protocol: melting 
temperature 95°C 5m; 25 cycles of 95°C 30s, annealing 50°C  lm (except 55°C for primer 
pairs 05/06, 07/08 and 11/12), extension 75°C 30s followed by 75°C for 5m. Reactions 
using 7'aq polymerase (primer pairs 01/02 and 03/04) w ere as described for Pfit with an 
annealing temperature of 50°C and an extension temperature of 72°C.
2.9.5 Making a digoxigenin-labelled csa t-6  probe
esat-6 was amplified using the same protocol described in Section 2.9.3 using Taq 
Polymerase. However, in this case 25% of the dTTP was replaced by digoxigenin-labelled-
1 l-dUTP(Boehringer-Mannheim). The PCR product w as run on a 1% w/v LMP agarose 
gel, the corresponding band cut was out and stored in 100 pi aliquots at -20°C. In order to 
demonstrate successful digoxigenin-labelled probe, 10 pi aliquots of neat and three 10 fold 
dilutions of probe were blotted onto nylon membrane (Hybond-N, Life Science), baked for 
2h at 80°C and then subjected to a chemiluminescent protocol (described in Section
2 16 1 4) Successful digoxigenin-labelling of the probe is shown in Chapter 3, Figure 3.7
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2.10 T:A CLONING
The coding region, esat-6 was inserted into pSC ll using T:A cloning as described by 
Marchuk and colleagues (Marchuk D et al 1991). Figure 2.5 summarises the technique 
which takes advantage of the 3' terminal transferase activity of Taq Polymerase as over 90% 
of PCR product strands have a single 3' protruding dATP (A-tail). This overhang can be 
ligated to a cut vector with a complementary 3' dTTP overhang (T-tail). Ligation is more 
efficient than blunt-ended ligation and the risks of vector religation and insert 
concatamerisation are reduced.
2.10.1 T-tailing o f  the Smal cut p S C ll
pSC 11 was Smal digested, gel and resin-purified and then incubated with Taq polymerase, 
xlO reaction buffer, 4 mM Mg and 6 mM dTTP at 72°C for 2h to produce T-pSCl 1. This 
was followed by further resin purification and estimation of DNA concentration using gel 
electrophoresis.
2.10.2 A-tailing o f  esat-6
The PJu polymerase product was A-tailed as described for T-tailing but dTTP was 
substituted with dATP, thus producing A-esat-6. Amplification of esat-6 using Taq 
polymerase resulted in an A-tailed product, which was used directly in the ligation reaction 
following purification.
2.10.3 Ligation o f  A-esat-6 and T-pSCl 1, transformation and plasmid identification
Ligations were performed using T4 ligase, the appropriate reaction buffer and the addition 
of 1 pi of 1 mM ATP (stored in small aliquots at -70°C) (Sigma) in a 10 pi final volume at 
15°C overnight In the final experiment, the ligation mix was cut with Smal, in order to 
reduce the background from vector religation Following transformation (Section 2.3.1) and 
plasmid purification, pSCl 1-ESAT-6 could be identified using £coRI digestion to identify 
recombinants and Hsu36l (or double digestion with £ c o R I /M )  to identify orientation (see 
restriction map Figure 2.1).
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2 .11 DIRECTIONAL CLONING
Following T:A cloning o f pSCl l-ESAT-6, all subsequent cloning was directional, using 
non-complementary restriction sites at each end, thus permitting correct insert orientation 
and reducing the background vector religation.
2.11.1 Construction o f  p ll08-tP A  and p\VR510-tPA
In half the constructs, coding sequences were placed downstream from a 90 bp region 
encoding the 21 amino acid signal sequence of tPA (Ny et al. 1984) and a multiple cloning 
site This would permit expression of a target foreign protein with the tPA signal sequence 
leader (see Figure 2.2b). Two additional insertion plasmids, pi 108-tPA (Figure 2.2c) and 
pWR510-tPA (Figure 2.3c) were therefore constructed
2.11.1.1 Designing the tPA insert
In order to utilize the same oligonucleotide pair, the sense and antisense strands were 
designed to include: (i) the native start codon (and maintaining the same oligopyrimidine 
tract length to the ATG for pWR510 (Wang and Mullins, 1995)); (ii) a blunt 5' end suitable 
for cloning at pWR510 .Viral site and pi 108 Klenow-filled PamHl site; (iii) a multiple 
cloning site; and (iv) an EcoRX 4 bp 5' overhang for directional cloning and facilitating in 
frame fusion for the pWR510 His6 tag The sense strand is shown in Figure 2 2b The 
antisense strand included an additional GAAT overhang at the 5' end creating the 'cut' 
EcoRX sticky tail
2.11.1.2 ( 'toning the tPA insert
1) The oligonucleotide pair consisted of an 86mer sense strand (tPA-OLI-1) and a 
90mer antisense strand (tPA-OLI-2). These freeze dried preparations were dissolved 
in nanopure water to a concentration o f 500 ng/ml
2) 20 pi o f each were mixed in a microfuge tube, heated to 80°C in a water bath and 
allowed to cool slowly
3) The hybridised product was gel and phenol/chloroform purified prior to cloning
4) pWR510 was prepared by .Viral (3h at 25°C ) followed by ficoRl digestion (2h at 
37°C ) using buffer H (Boehringer Mannheim ) (see map, Figure 2.3).
5) pi 108 was prepared by: (i) HamHX digestion; (ii) Micropure EZ/Microcon step, (iii) 
Klenow fill (reaction consisting of: HttmXXX cut vector, 2.5 pi reaction buffer, 1 pi
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(—5-10 units) Klenow enzyme, 1 pi dNTPs (2 mM stock) in final volume o f 25 pi), 
(iv) phenol/chloroform step; (v) £coRI digestion (see map. Figure 2.2); and (vi) 
Micropure EZ/Microcon step spun to a final volume of 10 pi
6) The ligation, transformation and plasmid preparation steps were performed using 
the optimised protocol (Section 2.11.2.3).
7) In a repeat pi 108-tPA ligation experiment, after the ligase reaction, the mix was cut 
with Hitt dill to reduce the religation background (this restriction site was present 
in vector but absent in recombinant).
2.11.2 Generation of PCR clones
2.11.2.1 Preparation o f PCR-generated inserts prior to cloning
Between 300-500 pi of amplified PCR product (3-5 reaction tubes pooled) was prepared 
as follows: (i) gel purified using electroelution; (ii) phenol/chloroform extracted and ethanol 
precipitated; (iii) double digested using appropriate restriction enzymes and universal buffer; 
(iv) enzymes were either heat inactivated, phenol/chloroform extraction step or removed 
with Micropure EZ (Amicon); and (v) membrane filtered using Microcon 50 or 100 (Figure 
4.8a).
2.11.2.2 Preparation o f vector prior to cloning
Approximately 1 pg of plasmid vector was manipulated as described for steps (iii) to (v) for 
insert preparation (Section 2.11.1).
2.11.2.3 Development and identification o f  recombinants - the optimised protocol 
The ligation, transformation and plasmid purification steps were carried out as described 
above (Sections 2.10.3, 2 3 2 and 2.8 1 respectively) However, at this stage, the protocol 
was standardised to include: (i) an insert to vector ligation ratio of 5:1 (weight ratio); (ii) 
adding 1-2 pi of ligation mix containing 10 ng of vector DNA to SCSI supercompetent 
cells; and (iii) plating out 200 pi of transformed cells both neat and diluted 1 in 10. 
Successful recombinants were identified as described below.
1) Initially, screening was performed using PCR. The primer pair which had generated 
the insert was used with whole bacteria as the template and the /«i/ PCR protocol 
as described in Section 2.9.4, using 30 pi reaction volumes. The bacteria were
picked from a discrete colony using a sterile toothpick. PCR positive clones were 
then subjected to plasmid purification and double enzyme digestion.
2) When cloning efficiency was reaching >80% (recombinants versus religations), the 
PCR step was omitted and 3-4 colonies were picked per ligation. Plasmid 
recombination was verified using double enzyme digestion.
2.11.3 Subcloning
Two subcloning experiments were performed. These included the transfer of: (i) esal-6 from 
pSCl l-ESAT-6 to M l3 mpl8 and mpl9; and (ii) 85a and esat-6 from the pi 108-tPA 
constructs to pWR510 and pWR510-tPA.
2.11.3.1 Preparation o f  plasmid-derived insert prior to cloning
Inserts were moved from recombinant plasmid to the target vector using the following 
steps: (i) approximately 2-5 pg of plasmid were double enzyme digested to cut out the 
relevant insert; (ii) the insert was gel purified and electroeluted; and (iii) further purification 
was performed using either phenol/chloroform extraction (M l3 cloning) or Micropure 
EZ/Microcon membrane filtration (pWR510 cloning).
2.11.3.2 Construction o f M13-ESA T-6
An EcoRMHamHX fragment containing the esat-6 gene was cut from pSC 11 -ESAT-6 and 
cloned into M13 mpl8 and mpl9 In order to enhance the efficiency of recombination, a 
Sephadex G-50 Fine column was used to remove the sticky-ended 20mer from the cloning 
site of the double-digested vector The EcoRl/PamHl cut vectors and cut insert (see 2.13.1) 
were cloned using standard techniques White plaques were picked and transferred to LB/ 
tetracycline (50 pg/ml), recombinant phage grown overnight in XL-1 Blue E. coli and single 
stranded DNA prepared (Sambrook et al 1989). Despite gel purification, there was some 
risk of contamination with a similarly sized fragment, the p7.5 promoter region (400 bp). 
Therefore, DNA preparations were subjected to PCR using the esat-6 primers and the 
clones with strong PCR signals were selected for sequencing
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2 .1 1 .3 .3  C o n s tru c tio n  o f  p W R S IO  a n d  p W R 5 1 0 - tP A  c lo n e s  e x p re ss in g  8 5 A  a n d  
E S A T -6
pWR510-85A, -tPA-85A, -ESAT-6 and tPA-ESAT-6 were generated using inserts (Section 
2.13.1), cut vector (Section 2.12.2) and ligation/transformation (Section 2.12.3). Five 
transformants per ligation were screened using NheVEcoRl digestion.
2.12 SEQUENCING
2.12.1 Manual sequencing of pSC ll-ESA T-6 and M13 m pl9-ESAT-6
2 .1 2 .1 .1  P re p a ra tio n  o f  s in g le  s tr a n d e d  se q u e n c e
Two strategies for denaturing the double stranded pSCl 1 plasmid were utilised (1) Plasmid 
DNA(3-5 pg in 18 pi volume) was added to 2 pi of 2M NaOH/50 mM EDTA and left at 
room temperature for 20m. 8 pi of 5M sodium acetate, pH 5.2 were added and this volume 
was ethanol precipitated. (2) Plasmid DNA (3-5 pg in 8 pi volume) was added to 16 pi of 
water, 8 pi of 2M NaOH, and 8 pi of 10 mM EDTA. The mix was then heated to 65°C for 
5m. A pre-cooled mix of 12 pi of sodium acetate, 28 pi of water and 240 pi of ethanol was 
prepared, added to the denatured template and immediately transferred to dry ice in order 
to reduce renaturation The mix was ethanol precipitated and resuspended in 14 5 pi of 
water providing enough for two sequencing reactions just prior to the annealing reaction 
In the case of the Ml 3 constructs, DNA was prepared according to a standard protocol 
(Sambrook et al. 1989).
2 .1 2 .1 .2  V a ria tio n s  in  th e  se q u e n c in g  p r o to c o l
The Sequenase Version 2 0 DNA Sequencing Kit (USB/ Life Sciences) was used for 
sequencing The protocols for annealing, labelling, and termination reactions were as 
described by the manufacturer Variations in reactions included (i) two labelling mix 
dilutions (1 in 5 and 1 in 15); and (ii) parallel use of the dITP labelling mix (1 in 5 dilution) 
to resolve compressions In order to read close to the primer, manganese buffer was added 
and the labelling period shortened from 5 to 2m
2.12.2 Cycle sequencing of p i 108 and pWRSIO constructs
PCR clones containing a mycobacterial gene were subjected to cycle sequencing using AB1 
PRISM Dye Terminator Cycle Sequencing (Perkin Elmer) The sequencing primers are 
listed in Table 2.2 Plasmid templates were purified, desalted and concentrated using 
Microcon membrane filtration (Amicon) Before an automated sequencer was available at
the London School o f Hygiene & Tropical Medicine (LSHTM), an initial 15 reactions were 
performed at the School of Biological Sciences, University of Surrey, Guildford, UK. All 
subsequent reactions were performed at LSHTM The manufacturer's protocol was 
followed, with the exception of two modifications based on 'in house' experience These 
changes included: (i) a 50% reduction of terminator ready reaction mix (4 pi used), 200 ng 
plasmid, 1.6 pmol o f primer and water to a final reaction volume of 10 pi; and (ii) a cycle 
protocol of94°C 30s, 50°C 30s, 60°C 4m for 25 cycles. The 50°C annealing temperature 
was altered for some reactions, with the aim of setting this figure at approximately 5°C 
below the primer melting temperature.
2.13 CELL CULTURE
2.13.1 Plastics
Most tissue culture plastics were obtained from Greiner These included: standardised 
culture flasks (T25, T75 and T175 representing 25, 75 and 175 cm2 respectively), 60 x 15 
mm individual Petri dishes and 6 well plates. The 24 and 96 well plates were obtained from 
Falcon, Becton Dickinson, Franklyn Lakes, US Nunc Lab-Tek Tissue Culture Chamber 
Slides (glass) were obtained from Life Technologies
2.13.2 Cell culture media, serum and other additives
2 .1 3 .2 .1  M e d ia
All media were purchased from Life Technologies Several types of medium were used in 
accordance with the cell culture requirements: (i) RPM1 1640 for human peripheral blood 
mononuclear cells (PBMC) and primary macrophage culture, and (ii) Dulbecco's Modified 
Eagle's Medium (DMEM), DMEM plus Glutamax 1 and Optimem 1 for TK' 143 cell culture 
Hanks Balanced Salt Solution (HBSS) was used for cell washes and as a diluent for virus.
2 .1 3 .2 .2  S e ru m /p la sm a
Serum and plasma were sterile-filtered and stored at -20°C. Concentrations used in cell 
culture consisted of either: (i) 10% v/v autologous or human AB+ plasma for 
PBMC/macrophage culture; or (ii) 5% v/v heat-inactivated fetal calf serum (FCS, Sigma) 
for TK' 143 culture.
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2 .1 3 .2 .3  A n tib io tic s  a n d  L -g lu ta m in e
Antibiotics were added unless otherwise specified: 0.5% v/v ampicillin (stock concentration 
of 10 mg/ml, Sigma) for PBMC/macrophage culture and 1% v/v penicillin/streptomycin mix 
(p/s) (stock penicillin concentration 1000 IU/ml, streptomycin concentration 1000 pg/ml, 
Life Technologies) for TK' 143 culture. L-glutamine 1% v/v (L-glu) (Life Technologies) 
was added to RPMI and DMEM This was not required for DMEM plus Glutamax I.
2 .1 3 .2 .4  C o m p le te  m e d ia
For most cell culture work, complete medium for: (i) PBMC/macrophage culture included 
RPMI, ampicillin, L-glu and 10% v/v autologous plasma; and (ii) TK' 143 cell culture 
included DMEM (or DMEM glutamax II), L-glu (DMEM only), p/s and 5% v/v FCS.
2 .1 3 .2 .5  A d d itio n a l r e a g e n ts
5-Bromo-deoxyuridine (BUdR) was obtained from Sigma. Stock was made up to 2.5 mg/ml 
in PBS, warmed for 2m until dissolved, filter sterilised and stored at 4°C wrapped in silver 
foil. X-gal (Life Technologies) was freshly made up on each occasion by dissolving the 
powder in DMSO in a glass bijoux to make a stock concentration of 50 mg/ml. Two percent 
agarose (Type VII: Low Gelling; Sigma) was made up in serum-free antibiotic-free RPMI 
medium (Life Technologies), autoclaved and stored at 4°C Mycophenolic acid (MPA) 
(Sigma), xanthine (Sigma) and hypoxanthine (Sigma) were each dissolved in 0 .1M NaOH 
at stock concentrations of 10 mg/ml The solutions were filter sterilised, aliquoted and 
stored at -20°C.
2.13.3 TK 143 tissue culture
The TK' 143 cell line (ATCC CRL 8303), a human osteosarcoma cell line with a functional 
deletion of the thymidine kinase locus, was used to both construct rVV and propagate virus. 
The cell line was obtained from two sources: firstly from Dr T Blanchard, who had initially 
received it from Dr H Stauss, ICRF and secondly, also through Dr Blanchard, from Prof 
G Smith, Sir William Dunn School of Pathology, Oxford Cells were stored in the gaseous 
phase of liquid nitrogen When required, cells were thawed rapidly in a water bath, washed 
and seeded into complete medium On occasions, rapidly dividing cells were frozen down 
in complete medium containing 20% v/v FCS and 9% w/v DMSO
Cell culture was maintained in T75 culture flasks in a humidified incubator at 37°C in the 
presence o f 5% carbon dioxide Passage was performed when the monolayer reached near 
confluence with a 1 in 5 (range 4-8) division of cells Sub-culture entailed: (i) discarding the 
medium; (ii) washing the monolayer once with phosphate buffered saline (PBS) (Sigma); 
(iii) addition o f 2 ml of trypsin/EDTA (Sigma) and incubating at 37°C until the cells were 
just non-adherent; (iv) addition of 6-8 ml of complete medium to inactivate the trypsin; (v) 
washing the cells twice in a 14 ml tube at 1350 revolutions per minute (rpm) (410 g) for 
10m using a Mistral 3000 bench centrifuge (MSE, Crawley, UK); (vi) resuspending the cells 
in 2.5 ml (range 2-4 ml) and seeding a 0.5 ml aliquot into a new T75 flask containing 11.5 
ml of warmed complete medium.
2.13.4 Human PBMC and primary macrophage culture
Ethical permission was obtained in order to venesect up to 50 ml of blood from consenting 
laboratory donors.
2 .1 3 .4 .1  I s o la tio n  o f  P B M C
1) Venous blood was collected into 50 ml sterile conical tubes containing preservative 
free heparin (20 units/ml of blood). This was processed within l-2h
2) Heparinised blood was diluted 1:1 with warm RPMI
3) For each 20-25 ml of diluted blood, 12 ml of ficoll (Histopaque - 1077, Sigma), at 
room temperature, was placed in a 50 ml tube and overlaid with the diluted blood 
The ficoll gradients were then centrifuged at 1350 rpm (410 g) for 30m at room 
temperature and no brake
4) Following centrifugation, 10 ml of 50% v/v plasma (per 50 ml tube) were collected 
to be used for complete medium
5) PBMC were collected from the interface using a plastic Pasteur pipette (Alpha 
laboratories, Eastleigh, UK). Approximately 4 ml from each ficoll gradient were 
transferred and pooled into a 50 ml tube This was then topped up with warmed 
HBSS and washed three times, spinning at 1350 rpm (410 g) for 10m and full brake
6) The final pellet was then carefully resuspended in 1 ml of sterile-filtered complete 
medium and the cells counted using a counting chamber and 0 4% trypan blue 
(Sigma) The cells were finally resuspended at I x 10h cells/ml in complete medium 
ready for use either in a cytotoxic T lymphocyte (CTL) assay or macrophage 
experiments
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2 .1 3 .4 .2  I s o la t io n  o f  p r im a r y  h u m a n  m a c ro p h a g e s
Seven day primary human macrophage cultures were used for: (i) target cells in CTL assays, 
(ii) immunofluorescence of recombinant protein following rVV infection; (iii) 
immunocytochemistry of antigen-coated phagocytosed beads; and (iv) Ziehl-Neelsen (ZN) 
staining of BCG-infected macrophages
For experiments (ii)-(iv), 400 pi of 1 x 106/ml PBMC were plated out into 8 well tissue 
culture glass chamber slides (Life Technologies). Non-adherent cells were gently washed 
away the following day. The remaining adherent cells were cultured for a total o f  7 days. 
Given that the macrophage population accounts for approximately 10% of PBMC, it was 
estimated that each well contained ~4 x 104 macrophages. Culture for CTL target cells is 
described below.
2.14 VACCINIA PROPAGATION AND QUANTIFICATION
Permission for genetic manipulation of the vaccinia genome was obtained both from the 
Health Safety Executive, Ministry of Health (HSE) and the Genetic Manipulation Advisory 
Group (GMAG) of LSHTM
2.14.1 Viral preparation - crude stock
Crude viral stock was prepared for biochemical analysis and storage Both wild-type (wt) 
vaccinia (VV) (strain WR) and recombinant vaccinia (rVV) were propagated by infecting 
a near confluent TK‘ 143 cell monolayer Typically, infection of a T175 flask was performed 
on a near-confluent monolayer as described below (volumes scaled down appropriately for 
T75 and T25 flasks).
1) The media was discarded
2) The monolayer was washed with 6 ml of warmed PBS
3) The virus was added at a multiplicity of infection (moi) of 0.05 in 2 ml HBSS and 
incubated for l-2h at 37°C.
4) The vims inoculum was discarded and replaced with 28 ml of complete medium and 
incubated for 48-72h until a cytopathic effect (CPE) was clearly developed
5) The virally-infected cells were scraped into the medium, transferred to a centrifuge 
tube and pelleted at 1350 rpm (410 g) for 10m.
6) The cells were resuspended in 2 ml of cold HBSS containing 0.1% w/v bovine 
serum albumin (BSA) or 10 mM Tris-HCl pH 9.0
7) Virus was released by three freeze/thaw cycles using liquid nitrogen and a water 
bath. This was followed by 30s o f water bath sonication.
8) Released virus was stored in 5-10 aliquots at -70°C.
2.14.2 Viral preparation - sucrose cushion-purified stock
Sucrose cushion-purified virus was used for animal immunisation and human in vitro assays.
Preparation involved infection of eight T175 monolayers per rVV as described in Section
2.14 1 steps 1) to 4). The remaining procedure was carried out on ice.
1) Cells were pelleted at 1350 rpm (410 g) for 10m and resuspended in 2 ml of cold 
10 mM Tris-HCl pH 9.0.
2) This suspension was homogenised with 20 strokes of a tight fitting Dounce 
homogeniser.
3) The nuclei were pelleted by centrifugation at 750 g for 5m.
4) The supernatant was recovered and kept on ice.
5) The pellet was resuspended in 10 mM Tris-HCl pH 9.0 and steps 2) to 4) were 
repeated The supernatants were pooled
6) 8 ml of supernatant were layered on 7 ml of autoclaved 36% w/v sucrose dissolved 
in 10 mM Tris-HCl pH 9.0. These sucrose cushions were prepared in U-bottomed 
centrifuge tubes suitable for a SW40 Ti swing bucket rotor (Beckman, High 
Wycombe, UK).
7) Centrifugation was performed at 14,400 rpm (25000 g) for 80m at 4°C in a 
Beckman L8-80 Ultracentrifuge.
8) The pellet was resuspended in a small volume of 1 mM Tris-HCl pH 9.0 (1-2 ml) 
and pooled with other pellets from the same preparation
9) Sonication for 30s was performed using a cup sonicator (Sonicator, Ultrasonic 
Processor XL, Heat Systems, Farmingdale, NY, USA)
2.14.3 Viral titration - calculation o f  pfu/ml
The number of pfu/ml of viral stock was measured by sampling from one cryotube
1) Six well plates were seeded with 8 x 105 TK' 143 cells/well in 2 ml complete 
medium and allowed to grow overnight
2) Monolayers were washed once with PBS and infected with five tenfold dilutions of 
stock virus in 0.5 ml of HBSS containing 0 1% w/v BSA (normal range lO'MO"6, 
but higher dilutions were performed with high titre stock).
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3) The virus inoculum was replaced with 2 ml of complete medium and incubated for 
48h.
4) The monolayers were washed with PBS This was followed by adding 0.5 ml 0.2% 
w/v crystal violet stain per well and left to stand for 2m. The residual stain was 
removed and the plates allowed to dry.
5) The number o f plaques per well for a given dilution was counted and the pfu/ml of 
stock virus was determined (Figure 2.6, see figure legend for details).
2.15 CONSTRUCTION OF rVV
This study utilised two similar techniques to construct rVV, both requiring lipid cationic 
transfection and recombinant virus selection The transfection step was achieved using one 
of two cationic lipid transfection reagents: (i) lipofectin (Life Technologies) for construction 
of rVV-ESAT-6 using the pSCl 1 construct; and (ii) DOTAP (Boehringer Mannheim) for 
all other rVV. The methodology for cell transfection and virus homologous recombination 
was derived from the manufacturer's instructions and from Mackett (1995). Recombinant 
selection for the pSCl 1-derived rVV utilised lacZ expression and negative selection due to 
the tk' phenotype pi 108 and pWR510-derived constructs were positively selected using 
guanine phosphoribosyl transferase gene (gpt) expression.
2.15.1 Construction o f  pSCl 1-derived rVV-ESAT-6
2.15.1.1 Transfection using lipofectin
A recombination mix containing rVV-ESAT-6 was obtained using the following protocol
1) A near confluent TK" 143 cell monolayer in a T25 flask, seeded the previous night, 
was infected with wt VV at a moi of 0.1.
2) The virus inoculum was discarded and the monolayer washed twice prior to adding 
the lipid-DNA complex.
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Figure 2.6 Vaccinia plaque assay
Measurement of viral titre was performed by seeding a 6 well plate withTK 143 cells the 
previous night and infecting 5 wells with a series of tenfold dilutions, according to the 
suspected titre of the virus. In this case, an initial dilution of 1 in 100 was made (the well 
infected with this concentration is labelled -2) with increasing dilutions to well -6. The 
remaining well (labelled 0) was mock infected with virus diluent alone. Plaques were 
counted after 48 hours of culture, using crystal violet to stain the monolayers.
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3) In one tube, 1 pg of pS C l l-ESAT-6 was added to serum-free and antibiotic-free 
medium, with a final volume o f260 pi. In a second tube, 26 pi o f lipofectin reagent 
(Life Technologies) was made up to the same volume with the same diluent The 
contents of the two tubes were mixed and left for 10m at room temperature
4) Two millilitres of antibiotic-free, serum-free medium was added to the lipid-DNA 
complex. This was then added to the freshly washed T25 monolayer.
5) The flask was incubated for 5h and then topped up with 2 ml medium containing 5% 
v/v FCS.
6) The flask was incubated for a further 36h and virus harvested as described above.
As a positive control, the same experiment was repeated using pSC 11 -MOMP, containing
a chlamydial gene insert (Blanchard et al. 1993).
2 .1 5 .1 .2  P u r if ic a tio n  o f  r W - E S A T  (Ik' a n d L a c Z  se le c tio n )
Two rounds of plaque purification were performed in order to achieve clonality and to
separate rVV from contaminating wt VV. This was achieved as described below.
1) Six Petri dishes (60 x 15 mm) per recombination mix were seeded and cells were 
grown overnight in the presence of BUdR (25 pg/ml).
2) Monolayers were infected with three tenfold dilutions (10‘2-10‘4) of the 
recombination mix and this was performed in duplicate
3) After 2h, a 4 ml agarose overlay containing 1% w/v type VII agarose (Sigma) 25 
pg/ml BUdR and 2.5% v/v FCS in medium was added.
4) The overlay was cooled to  room temperature under foil (approximately 10m) and 
then incubated at 37°C fo r 48h.
5) A second agarose overlay containing 200 pg/ml X-gal was added and this was 
incubated for a further 2-6h, until blue plaques were visible
6) A blue plaque was picked using a plastic Pasteur pipette and transferred to 1 ml of 
medium for subsequent virus release as described in Section 2 14 1 step 7).
7) Half of the released virus derived from the plaque was used to infect a further 
monolayer (2nd plaque purification) and steps 3) to 6) were repeated
8) rVV derived from the second plaque was then grown up in the presence of BUdR 
(typically one T25 flask followed by one T75 flask). Viral titration was then 
performed prior to making stock
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2.15.2 Construction of rVV derived from pi 108 and p\VR510
2 .1 5 .2 .1  T ra n sfec tio n  u s in g  D O T A P
The recombination mix for 18 rVV was prepared as described below.
1) T25 monolayers, 90% confluent, seeded the previous night, were infected with 
wt VV at a moi of 0.1.
2) DOTAP (22 pi) was added to a 15 ml polystyrene tube for each of the rVV 
recombination experiments and a 25 pi volume containing 4 pg of the appropriate 
recombinant plasmid was added to the DOTAP and gently mixed. Tubes were then 
left for 15m at room temperature
3) Three millilitres of DMEM containing 5% v/v FCS (no antibiotics) were added to 
each of the lipid-DNA mixes.
4) The virus inocula were discarded from the T25 flasks lh post-infection (pi). 
Following this, the lipid-DNA/medium mix samples were added to the appropriately 
labelled infected-cell monolayers.
5) The following morning the medium was replaced with complete medium and 
transfected cells were incubated for a further 24h.
6) The virus was harvested as described in Section 2.14.1 steps 7) to 8).
2 .1 5 .2 .2  P u r if ic a tio n  o f  rV V  (g p t s e le c tio n )
Purification of rVV was achieved as described below.
1) Six well plate cell culture monolayers were prepared
2) The complete medium was changed to DMEM containing 2.5% v/v FCS, 250 pg/ml 
xanthine, 15 pg/ml hypoxanthine and 5 pg/ml MPA (MPA selection medium) and 
the cells incubated overnight.
3) Monolayers were infected with three tenfold dilutions (10"2- 1 O'4) of the 
recombination mix and this was performed in duplicate
4) The inocula were discarded after 2h and MPA selection medium was added The 
monolayers were cultured for a further 48h (an agarose overlay was not used)
5) The medium was replaced with DMEM containing 0.01% w/v neutral red and 
incubated for 2h
6) Two plaques were picked per recombinant using a plastic Pasteur pipette Each was 
transferred to I ml o f HBSS 1% w/v BSA for virus release as described in Section
2.14.1 step 7).
7) Half o f the plaque-derived released virus was used to infect a further monolayer 
(2nd plaque purification) and steps 4) to 6) were repeated
8) The rVV was then grown up in MPA selection medium in a similar manner to 
Section 2.15.1.2 step 8).
2.16 CONFIRMATION OF rVV
2.16.1 Southern blotting of rVV-ESAT-6 genomic DNA using the digoxigenin- 
labelled e s a t - 6  probe
2 .1 6 .1 .1  E x tra c tio n  o f  g e n o m ic  D N A  fro m  v ir a lly - in fe c te d  TK~ 1 4 3  c e lls
A near confluent T75 monolayer was infected with rVV-ESAT-6 at a moi o f 10:1 and cells 
were harvested after 24h. The cell pellet was resuspended in 0.8 ml o f TE buffer and 
digested with the addition of 20 pi proteinase K (5 mg/ml stock stored at -20°C) (Sigma) 
and 40 pi 10% w/v sodium dodecyl sulphate (SDS) (BDH Electran). This was mixed and 
digested overnight at 37°C. To prevent SDS precipitation at low temperature, 40 pi o f 5M 
NaCl were added prior to a phenol/chloroform extraction purification step The genomic 
preparation was then dissolved in 50 ml of water.
2 .1 6 .1 .2  E c o R I  d ig e s tio n  o  f  g e n o m ic  r W  a n d  p la s m id  D N A
A 20 pi aliquot o f  purified genomic DNA (~ 1 pg/pl) was added to 67 pi o f water, 3 pi of 
E c o K \  and 10 pi o f enzyme reaction buffer and incubated for 3h at 37°C. The digest was 
then ethanol precipitated and resuspended in 10 pi. A rVV-P gal DNA preparation, kindly 
provided by Dr D Conway, was used as a negative control £coRI digests of plasmids 
pSCl l-ESAT-6 (positive control) and pSCl 1 were also included
2 .1 6 .1 .3  G e l  e le c tr o p h o r e s is  a n d  c a p il la r y  tra n s fe r  to  a  n y lo n  m e m b ra n e
The digests were run on a 1% w/v agarose gel and the image recorded with a UV 
fluorescing ruler in  situ. DNA was then transferred by capillary action onto N-Hybond nylon 
membrane (Life Sciences) following a standard protocol The membrane was then baked 
for 2h at 80°C.
2 .1 6 .1 .4  C C h em ilum inescen t h y b r id isa tio n
Hybridisation was performed using the digoxigenin-UTP labelled e s a t - 6  probe (Section 
2.9.5), anti-digoxigenin alkaline phosphate conjugate and Lumigen PPD (Boehringer
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Mannheim). The chemiluminescent protocol was followed as per manufacturer's instructions 
and the signal was detected using ECL Hyperfilm (Life Sciences).
2.16.2 RT-PCR for recombinant esa t-6  transcripts
2 .1 6 .2 .1  I s o la t io n  o f  RN A
The following protocol was adapted from Gough (1988) and required two solutions: (i) 
Solution 1 (final concentration) = 10 mM Tris-HCl, pH 7.5, 0.15M NaCl, 1.5 mM MgCl2, 
0.65% w/v nonidet P-40 (NP-40, Sigma) (stored as xlO solution at 4°C ); and (ii) Solution 
2 = 7M urea, 1% w/v SDS, 0.36M NaCl, 10 mM EDTA, 10 mM Tris-HCl pH 7.5 (stored 
at room temperature).
1) A near confluent T25 monolayer was infected with rVV-ESAT-6 at a moi of 20:1 
and cells were harvested after 24h as described above
2) mRNA was isolated by resuspending the pellet in 200 pi of ice cold Solution 1 and 
1 ml of RNasin (Promega). This was vortexed vigorously and centrifuged at 6,500 
rpm (3300 g) for 5m to pellet the nuclei
3) The supernatant was added to 200 pi of Solution 2.
4) A standard phenol/chloroform extraction step was carried out and the ethanol- 
precipitated RNA was dissolved in 50 pi of DEPC-treated water and assessed using 
agarose electrophoresis and spectroscopy.
2 .1 6 .2 .2  l ' i r s t  s t r a n d  cD N A  sy n th e s is  a n d  PC '.R o f  cD N A
Reverse transcription of mRNA was performed using the Superscript Preamplification 
System (Life Technologies) in accordance with the manufacturer’s instructions. In this case, 
oligo(dT) was used for first strand cDNA synthesis. This was followed by PCR of cDNA 
using the ESAT-6 cloning primers (Section 2.5.3 1) and the T aq  PCR protocol (Section
2.9 3), thus amplifying a predicted 292 bp product
2 .1 6 .2 .3  A p p r o p r ia te  c o n tro ls
Given that the mRNA preparation would be contaminated with viral genomic DNA (VV is 
a cytoplasmic virus), the test samples were treated with deoxyribonuclease I, amplification 
grade (DNAse) (Life Technologies) prior to the RT step The relevant controls included: 
(i) no RT step without DNAse treatment (contaminating rVV genome); (ii) no RT step with 
DNAse treatment (efficacy of DNAse treatment); (iii) RT step included and no DNAse
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treatment (combined signal from genomic and cDNA template); (iv) a plasmid incorporating 
e s a t -6  (positive control); and (v) cDNA from rVV lacking e s a l-6  (negative control).
2.16.3 Immunoblotting
Both dot blots and Western blots were performed to detect mycobacterial proteins (and 
P-gal) derived from rVV and mycobacterial culture filtrate. Dot blotting was used to screen 
for efficacy of donated antibodies and permit their titration prior to Western blotting. It also 
provided a comparison between relative levels of expression of recombinant proteins A 
chemiluminescent protocol, the ECL Western blotting Detection system (Life Sciences), 
was used for all immunoblotting
2.16.3.1 A Mi bodies
Antibodies used in the detection of protein are listed in Table 2.3. Antibodies against 
mycobacterial proteins of the Ag85 complex and ESAT-6 were kindly donated by 
collaborating laboratories; the monoclonal antibody (mAb) against P-gal was purchased (see 
Table 2.3). Where data were unavailable, dot blots using different primary (1 °) antibody 
dilutions were assessed in order to optimise antibody concentration for subsequent 
immunoblots (see example. Figure 2.7) Antibody dilution details for immunofluorescence 
and immunocytochemistry are also listed in Table 2.3.
2 .1 6 .3 .2  P r o te a s e  in h ib ito r  m ix
In order to prevent protein degradation, a mix of different protease inhibitors was used 
when harvesting virally-infected cell lysates This included two x200 stock solutions, PI-A 
and PI-B Individual reagents were made up, as described in Appendix A, Table A 3 PI-A 
(aqueous) was made by mixing 1 volume (vol.) each of EDTA, EGTA and NEM plus 2 vol. 
of water PI-B (organic) was made by mixing 3 vol of PMSF with 1 vol each of Pepstatin 
and TPCK and warming in a water bath at 65°C until dissolved These solutions were 
stored in 1 ml aliquots at -20°C.
2 .1 6 .3 .3  rV V  re c o m b in a n t p r o te in  e x p re ss io n  tin d e r  p 7 .5  c o n tr o l
Protein extraction was performed using lysis buffer and the protease inhibitor mix (see 
Appendix A) The lysis buffer consisted of: 50 mM Tris-HCl (pH 8 0), 150 mM NaCl,
0.02% w/v sodium azide and 1% w/v NP-40 Five microlitres each of PI-A and PI-B were
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added to 990 pi of lysis buffer just prior to use
A n t ib o d y
n a m e
P ro te in
r e c o g n is e d
A n t ib o d y  type  
(o rig in )
O p t im a l
d ilu tio n *
2 "
a n tib o d y
(d ilu t io n )
S o u r c e  of 
1° a n tib o d y
H Y B 7 6 -8 E S A T -6
m o u se  m Ab 
(p ro te in  A  purified)
1 in  1 0 0 0
P 2 6 0 5 
(1 in 1 000)
P  A n d e rs e n ,
C o p e n h a g e n ,
D e n m a rk
T D -1 7 A g 8 5  co m ple x
m o u se  m Ab 
(superna tant)
1 in  2 0
P 2 6 0 §
(1 in 1 00 0 ) K  H uyg e n ,
B russe ls ,
B e lg iu m
im m u n o ­
flu o re s c e n c e  
1 in  2
a n ti-m o u se
F IT C *
(1 in  5 0 0 )
T D -3 2 A g 8 5  co m p le x
m o u se  m Ab 
(superna tant)
1 in  2 0
P 2 6 0 5 
(1 in 1 000)
K  H uyg e n ,
B russe ls ,
B e lg iu m
S e ra  fro m  
A g 8 5 D N A  
v a c c in a te d  
m ice
A g 8 5  co m ple x
4 m o u se  
p o lyc lona l sera 1) 
85A , 2 ) 85B , 3) 
8 5C  & 4) 85A /B /C  
trip le  vaccinated 
(n e a t sera)
1 in  1 0 0 0
P 2 6 0 §
(1 in 1 000)
K  H uyg e n ,
B russe ls ,
B e lg iu m
K 9 2 A g 8 5  co m ple x ra bb it polyclonal
1 in  1 0 0 0
P 2 1 7 s 
(1 in  1 000)
M  H arboe , 
O s lo , Nonwayim m u n o -  
c y to c h e m is try  
1 in  1 0 0
P 2 1 7 §
(1 in  100)
K 9 3 A g 8 5  co m p le x ra bb it polyclonal 1 in  1 0 0 0
P 2 1 7 §
(1 in  1000)
M  H arboe , 
O s lo , N orw ay
A n ti-|t-g a l l'-g a i
m A b
(P ro te in  A  purified)
1 in  5 0 0 0
P 2 6 0 §
(1 in  1000)
B o e h rin g e r
M a n n h e im
Table 2.3 Details of antibodies used
2°=secondary, P260=horse radish peroxidase conjugated to rabbit anti-mouse IgG, 
P 217=horse radish peroxidase conjugated to goat anti-rabbit IgG, *=dilutions refer to 
immunoblotting unless otherwise stated, §=antibodies purchased from Dako, Glostrup, 
Denmark; #=gift o f Dr P Kaye, LSHTM, London FITC=fluorescein isothiocyanate
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Figure 2.7 Assessment of two polyclonal antibodies raised against Ag85
Two rabbit polyclonal antibodies, K92 and K93 were assessed for their reactivity against 
rVV-Ag85 infected cell lysates and MTB CF (positive control). Undiluted 1 pi aliquots 
were dotted onto nitrocellulose membranes and these were probed with the two antibodies 
using two different dilutions: a) & c) 1 in 100; and b) & d) 1 in 1000.
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Near confluent T75 monolayers were infected with r W  at a moi of between 10:1 and 30:1. 
Mostly, these were incubated overnight. However, a time course pi (0, 1, 3, 5, 7, 18h) was 
also assessed for both rVV-ESAT-6 and rW -P-gal. At harvesting, all reagents and the cell 
monolayer were kept on ice. Initially, the medium was discarded and the monolayer washed 
twice with PBS. The cells were then lysed using 550 pi o f  lysis buffer plus protease 
inhibitors, scraped from the flask and transferred to a microfuge tube This was then spun 
at 12000 rpm (11600 g) for 2m and the supernatant stored at -70°C. Subsequently, protein 
concentration was measured using the Bradford method (Maizels et al. 1991).
2 .1 6 .3 .4  r W  r e c o m b in a n t  p r o te in  e x p re s s io n  u n d er  T7 c o n t r o l
Expression of the pW R510-derived rVV required co-infection with a rVV construct 
expressing T7 polymerase (vTF7-3, ATCC VR-2153). Thus, monolayers were co-infected 
with an equal titre (moi 10:1 each) of pWR510-derived rVV (foreign insert under the 
control of the T7 promoter; designated rVVpT7) and vTF7-3. Protein extraction was 
performed in a similar manner to 2 .1 6 .3 .3
2 .1 6 .3 .5  SIJS p r o te in  g e l  e le c tr o p h o r e s is  (S D S -P A  G E )
Protein gel electrophoresis was performed on a minigel system (Hoefer Mighty Small, 
Hoefer Pharmacia Biotech, San Francisco, USA) using standard SDS-PAGE (Sambrook 
et al 1989). Polyacrylamide gels (12% w/v) were made using bis acrylamideacrylamide 
(1 37 5) (Sigma) Gel preparation and electrophoresis solutions are described elsewhere 
(Sambrook et al 1989). In some circumstances, a large gel system (Hoefer SE400) was 
employed to enhance resolution or to identify weak signals
In most cases, 5-10 pi o f  protein (rVV cell lysate, mycobacteria culture filtrate or in  v itro  
transcription/translation product) were run under reducing conditions with the addition of 
5% w/v 2-mercaptoethanol (Sigma) just prior to 5m boiling in SDS loading buffer Size was 
recorded using a colour Low Range Molecular Weight (MW) marker (45 kDa, 29 kDa, 20 
kDa, 14 kDa and 6 5 kDa) (Sigma) Where appropriate, replicate gels were run, one for 
Coomassic Blue (BDH) staining and the other, for immunoblotting
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2 .1 6 .3 .6  P ro te in  tra n s fe r  a n d  d o t  b lo ttin g
For SDS-PAGE, protein transfer to a nitrocellulose membrane (Schleicher and Schuell, 
Dassel, Germany) was performed using a semi-dry immunoblotter (the Semi-Phor, Hoefer 
Pharmacia Biotech) (Sambrook et al 1989). A stack was made to permit electrophoretic 
transfer of proteins from the gel to 0.45 micron nitrocellulose membrane The stack was 
composed of a Mylar mask, just smaller than the gel. This was placed on the anode and 
covered by three pieces of blotting paper soaked in transfer buffer The blotting paper was 
then covered with a piece of nitrocellulose membrane, wetted with water (30s) then pre­
soaked in transfer buffer (5m), followed by the gel and three further pieces o f soaked 
blotting paper. The electricity supply was set at a current of 0.8 mA per cm2 for 2h. Transfer 
was confirmed by visualising the colour MW marker bands on the nitrocellulose membrane 
In addition, some experiments included the direct transfer of protein by dotting 1 pi volumes 
onto nitrocellulose membrane, usually with twofold protein dilutions. The membrane was 
left to dry (30m at room temperature) and then subjected to the same protocol as the 
Western immunoblot.
2 .1 6 .3 .7  S ig n a l d e te c t io n
The ECL Western blotting Detection system (Life Sciences) was used in accordance with 
the manufacturer's instructions. Following initial optimisation three modifications were 
made These included: (i) overnight incubation with Io antibody in most cases (or 
occasionally for 2h at room temperature); (ii) use of 5% w/v milk powder (Marvel, Tesco's 
Supermarket) as a blocking agent; and (iii) inclusion o f  the blocking agent with both 1 ° and 
2° antibody incubations A series of steps were followed, using gentle rocking, as described 
below.
1) The nitrocellulose membrane was blocked for 2h using 5% w/v milk powder 
dissolved in PBS-T (PBS and 0.1% v/v Tween 20).
2) Five washes with PBS-T were performed (2 rinses followed by x3 10m washes)
3) I o antibody diluted in blocking agent was incubated overnight at 4°C (or 2h at 
room temperature)
4) Five washes, as for step 2.
5) 2° antibody diluted in blocking agent was incubated for lh at room temperature
6) Five washes, as for step 2.
7) In the darkroom, the substrate reagents 1 and 2 were mixed (1 ml o f each per 
minigel membrane) and then overlaid on the membranes for lm The membranes
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were then briefly drip dried (10s) and quickly sandwiched between two clear plastic 
sheets (overhead projection sheets). Bubbles were carefully pushed to the edges of 
the membrane.
8) The membrane/plastic sheet sandwich was then placed in a film cassette and an 
initial exposure of 30s was performed using ECL Hyperfilm Repeat exposures were 
taken according to the intensity of the signal. No increase in signal was noted for 
exposures greater than 30m.
2 .1 6 .3 .8  P e p t id e  N -g ly c o s id a s e  tre a tm e n t o f  r e c o m b in a n t A g 8 5 B
Deglycosylation of rVV-derived recombinant Ag85B was performed using peptide N- 
glycosidase (N-Glyconase, Genzyme, Cambridge, MA, USA). The protocol was based on 
the example described by manufacturer
1) The sample (20 pi) was boiled with 0.5% w/v SDS and 50 mM 2-mercaptoethanol 
in Tris-HCl pH 8.0
2) T o a 10 pi aliquot, the following reagents were added: 5 pi of 7.5% w/v NP-40, 1.2 
pi (0.3 U) N-Glyconase and water to a final volume of 30 pi
3) The reaction mix was incubated overnight at 37°C.
4) The following day, the reaction was stopped by boiling for 5m Samples were then 
run on SDS-PAGE or stored at -70°C.
2.16.4 Immunofluorescence
In order to  confirm rVV expression in the target cells (primary cultured macrophages) used 
in the CTL assay, immunofluorescence was performed using an 'in house' protocol from the 
laboratory of Dr P Kaye Seven day cultured macrophages were prepared in an eight well 
tissue culture chamber slide as described in Section 2.13.4 2. The macrophages were 
infected with rVV-tPA-85A, rVV-85A and rVV-tPA alone at two moi (25:1 and 5:1) i.e 
6 wells plus 2 wells left uninfected Eighteen hours pi the macrophages were then treated 
according to the following protocol
1) The adherent cells were washed three times with PBS and very briefly rinsed with 
water.
2) Cells were fixed for 30m in freshly made-up 4% w/v paraformaldehyde in PBS pH 
7.2.
3) Three washes were performed with PBS.
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4) Quenching was performed with 50mM NH4C1 in PBS for 10m.
5) The cells were rendered permeable with 0.01% w/v saponin in PBS 0.1% w/v BSA 
for 30m.
6) A further three washes were performed with PBS containing 0.01% w/v saponin
8) Step 6 was repeated
9) The cells were then incubated with 1° antibody in PBS (Table 2.3) for lh (1° 
antibody omitted from one of the uninfected wells).
10) Step 6 was repeated.
11) The cells were then incubated with 2° antibody in PBS (Table 2.3) for 45m
12) Two washes were performed followed by rinsing with water.
13) The cells were covered with Vectashield mounting medium containing 4,6- 
diamidino-2-phenylindole (DAPI) (Vector Laboratories, Inc., Burlingame, CA, US) 
and a glass coverslip.
14) Photographed was carried out using fluorescence microscopy (Zeiss Axioplan and 
M CI00 camera, Zeiss, Oberkochen, Germany) with appropriate filters for both 
nuclear (DAPI) blue staining and recombinant protein (FITC-conjugated antibody) 
green staining.
2.17 T7 COUPLED TRANSCRIPTION/TRANSLATION
In vitro transcription and translation was performed in a single step using the TNT T7 
Coupled Reticulocyte Lysate kit (Promega) The vaccinia insertion plasmid, pWR510, 
contained the appropriate elements for cell-free protein expression of Ag85 genes and esat-6 
cloned downstream from the T7 promoter (Figure 2.3). The system was manipulated to 
compare products of the genes, both with and without the tPA coding sequence and also 
with and without the presence of microsomes
2.17.1 Transcription/translation in the absence of microsomes
1) Eight pWR510 constructs were assessed (85A, 85B, 85C and ESAT-6 both with 
and without the tPA signal sequence) The reaction was carried out in accordance 
with the manufacturer's instructions, although the mix was scaled down by 50%
7) Blocking was carried out using 50% v/v horse serum for 15m
TNT rabbit reticulocyte lysate 
TNT reaction buffer 
TNT T7 RNA polymerase
12.5 pi 
1 Pi
0.5 pi
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amino acid mixture minus methionine, 1 mM 
35S-methionine (between 1 -3 pi depending on activity) 
RNasin ribonuclease inhibitor, 40 u/pl 
DNA template 
DEPC-treated water
0.3 »8
final vol. 25 pi
0.5 pi 
20 pCi 
0.5 pi
2) Following a 90m incubation at 30°C, samples w ere heated at 80°C for 5m to stop 
the reaction.
3) A 5-10 pi sample from each reaction was subjected to 12% w/v SDS-PAGE. The 
remainder of the samples were stored at -70°C.
4) Following electrophoresis, the gel was dried and autoradiography performed with 
4-48h exposures, depending on the strength of the signal
2.17.2 Transcription/translation in the presence of microsomes
1) Six pWR.510 constructs were assessed (85A, 85B, and ESAT-6 both with and 
without the tPA signal sequence) Ultracentrifugation of the products permitted 
comparison between membrane and non-membrane associated fractions The 
reaction was carried out in accordance with the manufacturer's instructions in a 
manner similar to  when there were no microsomes The mix used in these 
experiments was as for 2.17.1, except 2.5 pi o f  canine pancreatic microsomal 
membranes was included in the reaction mix
2) Following a 90m incubation at 30°C, samples were cooled on ice.
3) Samples were then transferred to U-bottomed centrifuge tubes suitable for the 
Beckman TL 100.1 fixed angle rotor and spun at 50 000 rpm (88760 g) for lh in a 
Beckman Optima TL Ultracentrifuge The supernatant was recovered and the pellet 
resuspended in 25 pi of RIPA buffer (Mackett, 1995). Samples were stored at 
-70°C until SDS-PAGE and autoradiography (2.17.1, step 4).
2.18 T CELL AND MACROPHAGE STUDIES
rVV expressing the mycobacterial secreted proteins were used to infect human macrophage 
target cells in a 6 hour CTL assay. Live BCG was used to obtain a restimulated CTL 
population (the effectors) (Turner and Dockrell, 1996) However, as this allows only 
restimulation of CTL recognising Ag85 epitopes, alternative strategies were considered 
One of these strategies included the use of latex beads coated with mycobacterial culture
filtrate for macrophage phagocytosis and MHC class 1 antigen presentation. Preliminary 
CTL assays and a study with culture-filtrate coated latex beads were performed.
2.18.1 CTL assay
A 51Cr release assay was performed as developed within our laboratory (Turner and 
Dockrell, 1996). The protocol included: (i) 7 days restimulation o f PBMC CTL with live 
BCG; and (ii) 7 days culture of autologous macrophages with addition of antigen (BCG or 
rW ) the evening before the 6h release assay The protocol is described below. An example 
of the target plate plan is also given (Figure 2 8)
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Figure 2.8 Example of plate plan
Shaded area = medium alone to prevent drying. tPA-85A and tPA alone=rVV 
infected target cells (moi 25:1).
day 0 Target and effector cells
1) PBMC were prepared at a dilution of 1 x 106 cells/ml as described in Section
2.13.4.1.
2) For use as target cells 150 pi aliquots of PBMC were pipetted into a 96 well U- 
bottomed plate in accordance with the plate plan A 'hedge' of medium alone was 
placed around the PBMC wells to limit drying
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3) For use as effector cells 2 ml aliquots of PBMC were pipetted into 24 well plates 
and antigen (BCG) was added at a variety of moi (25:1, 5:1, 1:1 and 0.2:1). 
Subsequent experiments used a moi of 1:1.
day 1 Target cells
4) Non-adherent cells were removed by gentle pipetting up and down 5 times, removal 
of 100 pi from each well and replacement with complete medium.
day 6 Target cells
5) A 100 pi sample of medium was removed from each well and discarded.
6) Aliquots of 25 pi of complete medium containing either rVV-tPA-85A, rVV-tPA 
alone (negative control), BCG (positive control), or complete medium alone 
(negative control) were added to each well according to the plate plan Early studies 
used a variety of moi: (i) rVV - 25:1 and 5:1; and (ii) BCG - 25:1, 5:1, 1:1 and 
0.2:1. Subsequent studies used BCG at 5:1.
7) An aliquot of 25 pi of 2 pCi 51Cr in complete medium was added to each well. The 
plate was then incubated overnight.
day 7
8) Effectors cells The effector cells were harvested, pelleted and resuspended in 1 ml 
for counting. Depending on the experiment, cell counts were adjusted to obtain a 
variety of effector target ratios; typically 25:1, 5:1 and 1:1.
9) Target cells The target cells were washed 4 times very gently by discarding all the 
medium and replacing with warm RPMI An aliquot of 50 pi of complete medium 
was added to each experimental well followed by 100 pi of either effectors or 
complete medium alone to measure spontaneous release from infected target cells 
The plate was then incubated for 6h
10) The plate was spun at low speed (1100 rpm, 270 g) in a Mistral 3000 centrifuge for 
4m.
11) The entire supernatant from each well was transferred to an LP2 tube (Alpha 
Laboratories), taking great care not to disturb the pellet This enabled both the 
supernatant and pellet count to be assessed The pellets were then lysed with 150 
pi 5% w/v SDS for 2h and the contents were transferred to LP2 tubes Each tube 
was sealed with wax and the activity of the supernatant and pellet measured on a 
gamma counter (1480 Wizard 3", Wallac).
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12) The percentage isotope release (IR) and the cytotoxicity (C) was calculated as:
CPM supernatant
IR = -------------------------------------------------------  x 100
CPM supernatant + CPM pellet
and:
C = %IR effector well - %IR for target+Ag alone well
where the target+Ag alone wells were manipulated in an identical way (using the 
same antigen) except for the omission of effector cells.
2.18.2 BCG infection of macrophages - assessing moi
2 .1 8 .2 .1  C a lc u la tio n  o f  C F U  p e r  m l
1) BCG suspended in RPM1 was prepared as described in Section 2.3.2.1.
2) An aliquot was thawed, briefly vortexed and spun for 15s at low speed (1000 rpm, 
80g) to pellet any grossly clumped organisms.
3) The supernatant was obtained and water-bath sonicated for 10s.
4) Four tenfold dilutions (1 O'4-10"8) o f the supernatant were performed and plated in 
replicate Plates were then incubated for 4-6 weeks
5) Colonies were counted and the CFU/ml of stock calculated.
6) At a later date, steps 2 to 5 were repeated for another aliquot and the average taken
2 .1 8 .2 .2  D ir e c t  a s se s sm e n t o f  m o i
1) A seven day macrophage culture, in an 8 well tissue culture chamber slide, was 
prepared as described in 2.13.4.2.
2) BCG was prepared as described in Section 2.18 2.1 steps 2 to 3.
3) Macrophages were infected with BCG at four moi (25:1, 5:1, 1:1 and 0.2:1) based 
on the estimated number of macrophages per well (4 x 104) and the calculated 
CFU/ml (Section 2 18 2 1). Two separate batches of BCG were assessed
4) The following day, infected cells were washed three times with PBS and then briefly 
rinsed with water, to wash away precipitated salt which might have taken up stain 
non-specifically
Cells were fixed for 15m with acetone and the washing step repeated5)
6) A modified ZN stain was performed (cold staining) and the cells were 
counterstained with TB Brilliant Green K (Difco).
7) The percentage of infected macrophages for each moi was assessed. A photographic 
record was taken.
2.18.3 Mycobacterial culture filtrate coated beads
2 .1 8 .3 .1  C o v a le n t c o a tin g  o f  c a rb o x y la te d  la te x  b e a d s
The method had been previously established in this laboratory and had been adapted from
the 'carbodiimide method' as recommended by Polysciences, Northampton, UK
1) Aliquots of 100 pi of 10% w/v latex solution (carboxylated polystyrene 
microparticles, 0 9 (am in size) (Sigma) were added to two microfiige tubes. A wash 
step was performed by mixing the beads with 800 pi of carbonate buffer (pH 9.6), 
centrifuging for 5m at 12 000 rpm (11600 g), and discarding the supernatant (the 
beads float at this pH). The washing step was repeated twice.
2) Three washes were then performed with 0.02M phosphate buffer pH 4.5. The beads 
were resuspended in 500 pi of this buffer.
3) A 500 pi volume o f carbodiimide (cyanamide, Sigma) was added slowly, the tube 
mixed by inversion and left at room temperature for 4h with gentle agitation.
4) Three washes were performed using 0.02M phosphate buffer pH 7.4 to remove 
unreacted carbodiimide.
5) The bead pellets were resuspended in 200 pg o f either MTB ST-CF (from SSI) or 
BSA. They were incubated at room temperature with gentle agitation overnight.
6) A 20 pi volume of ethanolamine (Sigma) were added for lh to block any unreacted 
sites.
7) Three washes were performed with 0.02M phosphate buffer pH 7.4 to remove 
unbound antigen and ethanolamine.
8) The beads were then incubated with 1 ml of 0.25% w/v BSA in 0.02M phosphate 
buffer pH 7.4
9) Three washes were performed with 0.02M phosphate buffer pH 7.4.
10) The pellets were finally resuspended in 1 ml o f 0.02M phosphate buffer pH 7.4 
containing 8 mg/ml NaCl, 10 mg/ml BSA and 5% v/v glycerol and stored at 4°C for 
up to 1 month. This constituted a final concentration of 1% w/v beads
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2.18.3.2 lmmunocytochemistry o f culture filtrate-coated beads
In order to assess successful antigen coating (and have an indication as to an appropriate
quantity of beads per macrophage), immunocytochemistry of beads phagocytosed by
macrophages was performed.
1) A seven day macrophage culture on an 8 well tissue culture chamber slide was 
prepared as described in 2.13.4.2.
2) On day 6, 40 pi, 4 pi and 0.4 pi o f 1% w/v culture filtrate-coated beads were added 
each to a well containing 4 x 104 macrophages This was repeated for BSA-coated 
beads. Two wells were left without beads.
3) On day 7, macrophages were fixed with acetone and washed as described in Section
2.18.2.2 steps 2 and 3.
4) The cells were then blocked with 1% w/v BSA PBS for lh.
5) A lh incubation with 1 ° antibody (K92 at 1 in 100 - see Table 2.3) in 1% w/v BSA 
PBS was performed. In one of the bead-free wells, no antibody was added.
6) Three washes with PBS were performed.
7) A lh incubation with 2° antibody (P217 at 1 in 200) in 1% w/v BSA PBS was 
performed
8) A further three washes with PBS were performed
9) A freshly prepared solution of diaminobenzidine (Sigma) was added for 15m. The 
slide was then washed and mounted.
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3.1 INTRODUCTION
The gene encoding the mycobacterial protein, ESAT-6, represented an attractive first choice 
for r W  construction. This protein is a key target recognised by immune T cells in a mouse 
TB infection model (Andersen and Heron, 1993) and there is indirect evidence that the same 
is true in humans (Boesen et al 1995), as discussed in Section 1 4 3.5. The gene is absent 
from known strains of BCG and most environmental mycobacteria (Mahairas et al. 1996), 
thus a potential rVV-ESAT-6 construct would represent a useful tool which would be 
specific for immune responses to the M. tuberculosis complex.
The gene was provided as part o f a cloning vector, pAA249, through a collaboration with 
Dr P. Andersen, Statens Seruminstitut (SSI), along with a mAb for detection of recombinant 
ESAT-6 and ST-CF containing the native protein as a positive control in immunoblotting. 
In return, the construct was to be made available to SSI for mouse immunology studies 
including protective efficacy.
The cloning strategy was selected on the basis of the laboratory expertise available at the 
time Several rVV constructs expressing chlamydia proteins had recently been constructed 
(Dr T Blanchard) using the vaccinia insertion plasmid, pSC ll. At that time, plasmid 
recombinants had been generated using a T:A cloning strategy (Section 2.10) of PCR- 
generated foreign gene inserts. In addition, rVV were constructed using TK" 143 cells, 
lipofectin transfection, and BUdR negative selection with the addition o f colour selection 
to exclude tk- spontaneous mutants (Section 2.15.1).
The construction of pSCl 1-ESAT-6 was performed using much the same strategy as that 
used for the chlamydia constructs. Chapter 2 details the methods used in the construction 
of rVV-ESAT-6. The methodology included (i) PCR generation of the insert (Section 
2 5.3.1 and 2.9.3); (ii) T:A cloning into pSCll (Section 2 10); (iii) homologous 
recombination of the insert and selectable marker into the tk locus of the vaccinia genome 
(Section 2.15.1); (iv) selection and purification of rVV; (v) identification of gene insertion 
and transcription; and (vi) identification o f gene expression
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3.2 RESULTS
3.2.1 Construction of pSCll-ESAT-6
After initial attempts at cloning P fu  polymerase-generated e s a t-6 , pSCll-ESAT-6 was 
finally constructed using Tatf polymerase The protocol steps are summarised in Figure 2.5, 
with the omission of A-tailing for the '/a<y-generated products.
3 .2 .1 .1 P C R  o f  e s a t-6
Strong single bands of predicted size (292 bp) were visible for all reaction conditions, 
whether using Taq  or P fu  DNA polymerases. Figure 2.5a shows a preparatory gel prior to 
gel purification; in this case, all bands came from the same PCR reaction.
3 .2 .1 .2  Y ie ld s  o f  ta i le d  in se r t a n d  v e c to r  p r i o r  to  l ig a tio n
Initially, yields of purified A-ESAT-6 and T-pSCl 1 prior to ligation were unacceptably low 
(<10 ng/pl). This yield was increased to 10-200 ng/pl by changing the methodology as 
follows. In the case of T-pSCll, the concentration and overall yield were improved by 
omitting the gel purification step and switching from resin purification (Promega) to a 
phenol/chloroform extraction step, with final resuspension of the pellet in a small volume 
of water (10 pi) In the case of A-ESAT-6, the yield was improved by switching from P fu  
to T aq  amplification, thus dispensing with the additional A-tailing Figure 2.5e shows faint 
bands of the tailed insert and vector used in the final construction of pSCl 1-ESAT-6.
3 .2 .1 .3  T ra n sfo rm a tio n  e ffic ie n c y
Ten transformations, designated T1-T10, were performed prior to obtaining the recombinant 
pSCl 1-ESAT-6 The initial transformation (Tl) produced numerous colonies (>400 on each 
plate) Plasmid miniprep purification and restriction enzyme digestion showed that most of 
these were due to contamination with the PCR template plasmid (the first PCR product 
preparations were not gel-purified prior to ligation). Subsequent transformations (T2-T8) 
produced much lower transformation efficiencies with 0-24 colonies, although a plasmid 
control (pUC18) consistently produced >200 transformants per plate After optimising the 
system as previously described, two further transformations, T9 and T10, resulted in high 
efficiencies (>400 colonies per plate). T-pSCl 1 was also added to the ligation mix without 
insert and a high religation background was noted This background was greatly reduced 
by cutting the ligation mix with S m a l prior to transformation, this site is present in uncut 
vector (or religated untailed vector) but absent in recombinants
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3 .2 .1 .4  C lo n in g  a tte m p ts
One hundred and sixteen plasmid preparations from transformations T1-T9 resulted in 
pSCl 1 alone or the contaminating PCR template, pAA249. Gel purification o f A-ESAT-6 
resulted in a reduction but not elimination of pAA249. In one cloning experiment, 25% of 
transformants contained this plasmid, despite gel purification of the insert In transformation 
T 10 (which used the S m a l cut ligation mix), three recombinants were identified from 24 
minipreps This is demonstrated in Figure 3.1a which shows an E c o R l digest cutting a 700 
bp band from putative pSCl l-ESAT-6 recombinants (see also plasmid map, Figure 2.1). 
The recombination event was confirmed using B s u 3 6 l ,  E c o R V P s tl and S m a l digestion. The 
S m a l digest showed loss of the this site in the recombinants The other digests indicated that 
the orientation was correct in clones 15 and 19 and incorrect in clone 18 (Figure 2.1b and 
Figure 3 1b).
3.2.2 Sequencing of pSCl l-ESAT-6 and M 13 subclones
3 .2 .2 .1  D o u b le  s tr a n d e d  se q u e n c in g  o f  p S C  1 1-ESA T -6
Double stranded sequencing produced incomplete sequencing data covering only the first 
225 bp of the 292 bp insert (see Figure 3.2a, reactions: 'PSCI1F.SEQ', 'PCRF.SEQ' and 
'PCR R.SEQ'). Four further attempts to complete the sequence, using a reverse external 
primer with viral tk  homology (Section 2.12.1 and Table 2.4), were unsuccessful The 
function of the sequencing primers had been previously confirmed using other pSCll 
recombinants (Dr T Blanchard, personal communication)
3 .2 .2 .2  ( C onstruction  o f  M l  3  m p  1 8 - a n d  m p  19-E SA  T -6
Further analysis was permitted by sub-cloning into two M 13 single stranded sequencing 
vectors, mpl8 and mpl9 Directional sticky-ended cloning was achieved by E c o K l/B a m H l  
double digestion of pSCl l-ESAT-6 with gel-purification of a band slightly greater than 292 
bp Ligation with the cut M13 vectors was performed, followed by transformation (XL- 
lBlue strain) and screening of white plaques (Section 2 11 3.2). There was the potential for 
ligating a contaminating -400 bp insert containing the p7 5 promoter (see Figures 2 1 and 
3 3a) Recombinant clones with e s a t-6  were therefore identified using PCR A plaque was 
picked for the PCR template and the original insert primers were used to generate products
a 98
b Bsu36\ EcoRUPstt Smal
MW P 15 18 19 P 15 18 19 2 P 15 18 19
Figure 3.1 Identification or pSCll-K SAT-6 recombinants
a) Following ligation and transformation, 22 transformants were picked, plasmid ‘minipreps' 
performed and the purified DNA digested with EcoR\ and run on a gel. Three clones were 
consistent with recombination (15, 18 and 19), as suggested by the increase in fragment 
size from 4(X) to 7(X) bp. b) The 3 clones and a pSCl I control (P) were further digested 
with /¿.vm36I, EcoRMPstX, and Smal. Successful recombination and orientation of insertion 
was verified. The detail of the Hsu361 digest shows a 900 bp band for clones 15 and 19 
(correct orientation) and a 600 bp band for clone 18 (incorrect orientation). See restriction 
map in Figure 2 .1 for details.
E S A T - 6 .S E Q ( 1 > 3 2 7 ) 
M 1 3 _ 1 9 _ 6 . S E Q ( 1 > 1 2 4 )  
M l3 _ 1 8 _ 3 . S E Q ( 1 > 1 2 4 ) 
P S C 1 I F .S B Q ( 1 > 1 0 2 ) 
N 1 3 _ 1 8 _ 4 . S E Q ( 1 > 2 9 1 ) 
M 1 3 _ 1 8 _ 2 . S B O ( 1>  2 6 1 >  
M 1 3 _ 1 8 _ 1 . SBQ ( 1 > 1 5 6 )  
H 1 3 _ l t  7 . S B Q ( 1 > 9 8 ) 
P C R _ F .S E Q ( 1 > 8 6 )
H i 3 _ 1 8 _ 5 . S B Q ( 1 > 1 6 4  ) 
P C R _ R .S B Q ( 1 > 9 4 >
H I 3 _ 1 9 _ 4  . SEQ  ( 1 >  1 1 1 )  
H 1 3  1 9 _ 3 .S B Q ( 1 » 7 1 )  
H 1 3 _ 1 9  2 .S B Q ( 1 > 9 6 )
SO  1 0 0  1 5 0  2 0 0  2 5 0  3 0 0  3 5 0 99
Vr
-6 .S E Q (  1 > 3 2 7 ) 
9 _ 6 . S B Q (1 > 1 2 4 )
*JUl
4 0
iJ-i 5 0i_U 6 0
B S A T - 6 .  
H 1 3 _ 1
H 13 18  3 .5 B Q ( 1 > 1 2 4 ) 
P S C T lF .S E O ( 1 > 1 0 2 ) 
M 1 3 _ 1 8 _ 4 . SEQ ( 1 * 2 9 1 )  
M 1 3 _ 1 8 _ 2 .S E Q ( 1 > 2 6 1 )
- GTCGA -C T C T  AGA -  OG ATCCCCTATGAC AGAGC AGC AGTGGAATTTCGCGCCT ATCC AG
* CGA-CTCTAGA-GGATCCCCTATOACAGAOCAGCAGTGGAATTTCGCGGGTATCGAG
* GAACAGT-GACGGATCCCCTATGACAGAGCAGCAGTGGAATTTCCCCCCTATCGAC
► TCCCCTATGAC-GAGCAGC AGTGG— TTTCGC -GGTATCGAG
* ATCGAG
T BWHCAaPWBTagAcgGATg g g g TATCAgACAggAGgAgTggXATTTtlggUggTATgCAC
7 0 8 0 9 0 100 ' 110 120
E S A T - 6 .S E Q < 1 > 3 2 7 )
M l 3 19  6 . S E Q ( 1 > 1 2 4  ) 
M13 1 8 _ 3 . S E Q ( 1 > 1 2 4  ) 
P S C 1 I F . S E Q ( 1 > 1 0 2  )
M l3 _ 1 8 _ 4 . S E Q ( 1> 2 91>  
M l3 _ 1 8  2 .S E Q ( 1 > 2 6 1 ) 
Ml 3 _18~*1. S E Q ( 1 > 1 5 6  ) 
M 1 3 _ 1 9 _ 7 . S E O ( 1 > 9 8 ) 
P C R _ F .S E Q (1 > 8 6 )
- >  g c c g c g g c a a g c g c a a t c c a g g g a a a t g t c a c o t c c a t t c a t t c c c t c c t t g a c g a g g c c
- >  GCCGCGGCA— g c a a t c c a g g g a a a t c t c a c g t c c a t t c a t t t c c t c c t t g a c g a g g g g  
- >  g c c g c g g c a a c c g c a a t c c a g g g a a a t g t c a c g t c c a t t c a t t - c - t - c t
- >  GCCGCGGCAG-CGCAATCCAGGGAAATGTCACGTCCATTCATTTCCTCCTTGACGAGGGG 
- >  GCCGCGGCAA— GCAATCCAGGGAAATGTCACGTCCATTCATTTCCTCCTTGACGAGGGG 
- >  AA -  CO -  AATC C AGGG AAATGTC ACGTCC ATTC A TTTC CTCCTTGAC G AGGGG
< -  AAGCGCAATCCAGGGAAATGTC ACGTCC ATTCATTCCCTCCTTGACGAGGGG
- >  CCCTCCTTGACGAGGGG
OPCCCgCPAAqCeeAATCeACegAAATCTCACCTCCATTCATTVeeTCCrrCACCACCCC
1 3 0  1 4 0  IS O  1 6 0  1 7 0  1 8 0
E S A T - 6 .S B Q ( 1 > 3 2 7 )  
M 1 3 _ 1 9 _ 6 . S E Q ( 1 > 1 2 4 )  
M 1 3 _ 1 8 _ 3 .S E Q < 1 > 1 2 4 > 
M 1 3 _ 1 I _ 4 .S E Q ( 1 > 2 9 1 >  
M 1 3 _ 1 8 _ 2 .S E Q ( 1 > 2 6 1 >  
M13 18 1 . S E Q ( 1 > 1 5 6 )  
M 1 3 _ 1 9 _ 7 .S E 0 ( 1 > 9 8 )  
P C R _ P .S E Q < 1 > 8 6 )
M l3 _ 1 8  5 .S B Q ( 1 > 1 6 4 )  
P C R _ R .S E Q < 1 > 9 4 )
i-l
E S A T - 6 .S E Q ( 1 > 3 2 7 ) 
M 1 3 _ 1 8 _ 4 .S * Q ( 1 > 2 9 1 )  
M13 I I  2 . S E Q ( 1 > 2 6 1)
Ml 3_18 1 . S E Q ( 1> 1 5 6 )
P C R _ F .5 e Q ( 1 > 8 6 )  .
M13 I I  5 . S E Q ( 1 > 1 6 4 )  
P C R _ R .5 B Q ( l> 9 4 )  
M 1 3 ~ 1 9 _ 4 .S E Q ( 1 > 1 1 1 )  
M 1 3_19  3 . S B Q (1 > 7 1 )  
M 1 3 " 1 9 “ 2 .S E Q ( 1 > 9 6 )
- >  AAGCAGTCCCTGACCAAGCTCGCAGCGGCCTGGGGC-GGTAGC— GGTTCGGAGGCGTAC 
< -  AAGCAGT 
- >  AAGCAGTCC-TGA
- >  AAGCAGTCCCTGACCAAGCTCGCAGCGGCCTGGGGCTGGTAGCT-GGTTCGGAGGCGTAC 
- >  AAGCAGTCCCTGACCAAGCTCGCAGCG-AATGGG-CGGGTAC— -GGTTCGGAGGCGTAC 
- >  AAGCAGTCCCTGACCAAGCTCGCAGCG-CCTGGGGC-GGTAC------ GGTTCGGAGGCGTAC
- >  AAGCAGTCCCTGACCAAOCTCGCAGCGGCCTGGCGC-CGTA-C — GGTTCGGACGCCTAC 
- >  AC— OGTTCOOAOOCGTAC
< -  TCACCGTTC -G A -O C  GT ACAAegACTCCCTCAeeAAccTeegAgccqeewcecekeeTAxe—ecTTeecAeccerAe—
1 9 0  2 0 0  2 1 0  2 2 0  2 3 0  2 4 0
- >  CAi^GTCTCCAO-CAAAAA-TGGGACG-CCACGCCTACCGAGCTGAACAA^CO-CGCTGC 
- >  CAGGGTGTCCAG-CAAAAA-TGGGACCTCCACGGCTACCGAGCTGAAC-AACGTCGCTGC 
- >  CAGGGTGTC CAG-TAAAAA-TGGGACG-CCACOGCTACCGAGCTGAAC-A-CC-CCCTGC 
- >  -A G O -TO T C  -AG -CA A A — -TGG G CAG-CCACGCC-ACCGAGCTGAAC-A-CG-CGCTGC 
- >  CAGGGTGTCCAG-C
- >  CAGGGTGTC-AG-CAAAAA-TGGGACG-CCACGGCTACCGAGCTGAAC-A-CG-CGCTGC
<  -  CAGGGTGTC CAGTCAAAAAATC-------------CCACGGCTACCGAGCTGAACAA-CG-COCTGC
< -  AAC-GCTACCGAGCTGAACAACCG-CGCTGC
< -  ACCGCTACCGAGCTCAACAA-CG-CGCTGC
< -  CAA-CG-CGCTCCTXflccTeTPcXg-ejuuuui-Teccxcg-ggjigccgTxeecjiflgTCAAeAA-cc-gcCTcc—
2 5 0 2 6 0 2 7 0 2 8 0 2 9 0 3 0 0
- >  AGAACCTGCCGCGGACGATCAGCGAAGC-CGGTCAG-GCAATGGCTTCGACCGAAGGCAA 
- >  AGAACCTGCCOCOGACGATCAGCOAATC -CGOTCAG -GCAATOGCTTCOAC-GA-GTCAA 
- >  AGAACCTGGCGCGGACGATCAGCGAA-CGCGGTCAGCG-AATCOCTTCOACCGAAG-CAA 
- >  AGA
G-AATGGCTTCGACCGAAG-CAA
x g x x g g T e e g c g e e x g e x T g x e g q x A q g g g g a T g x a c a c X X T c a g T T g g x g g g x x e q C x x
E S A T - 6 .S E Q (1 > 3 2 7 )  
M l3 _ 1 9 _ 4 . S E Q ( 1 > 2 9 1 ) 
M13 I I  2 . 8 B 0 ( 1 > 2 6 1> 
M 1 3 _ 1 8 ~ 1 . S E Q ( 1 > 1 5 6 ) 
M l3 18 5 . S E Q ( 1 > 1 6 4 ) 
P C R ~ R .? B Q ( 1 > 9 4 ) 
M 13_19  4 . SB Q ( 1 > 1 1 1 )  
M 1 3 ~ 1 9 _ 3 . SB Q ( 1 >  7 1 )  
M 1 3 ~ 1 9 _ 2 . S B Q ( 1 > 9 6 )
3 1 0 3 2 0 3 3 0
E S A T - 6 .S B Q ( 1 > 3 2 7 ) 
M 1 3_18  4 . S E Q ( 1 > 2 9 1) 
N 13—18—2 . S E Q ( 1 >  2 6 1 )  
M l3 _ 1 8 _ 5 . S E Q ( 1 > 1 6 4 )  
M13” 1 9 " 4 .S B Q ( 1 > 1 1 1 )  
M13” 1 9 ~ 2 .S E Q < 1 > 9 6 )
- >  c g t c a c t g g g a t c t t c o c a t a g c c t t a g g g a a t t c t g t
- >  CCTCACTGCGATGTTCGCA-A-TG 
- >  CGTCACTGG—A TQ T -C G C A T A -G C TT A G O -A -T TC -C  
- >  CCTCACTGCCATGTTCGCATAGCCTTAGCCAATTC-GT 
< -  CGTCACTOGCATGTTCGCA-ATGCC 
< -  CGTCACTOGGATGTTCGCA-ATGCCTAT
ggTCXg TCLUATUITL'U. A t Ak BP Y TAgCq AaTTP l gT
A
Figure 3.2 pSCll-KSAT-6 sequence dala.
All sequences were entered into a computer alignment programme (Lasergene, Seqman) 
and the data was expressed both as: a) a strategy view, and b) an alignment view. The left 
hand list indicates names of the sequence runs and the arrow indicates the direction of the 
run. The first sequence, labelled ‘ ESAT-6.SEQ’ represents the published sequence data 
(Sorensen ct al. 1995). Other names refer to single-stranded runs (prefixed M 13) or dou­
ble stranded runs (all others), y = T-tail, 1 = A-tail from AT cloning. = C to T substitution 
in four runs from one MI3_mpl8 clone.
of 292 bp in size (Section 2.5.4). Figure 3.3c shows that 6 out of 10 white plaques contained 
the insert for these M13 mpl8 clones M13 mpl9-ESAT-6 clones were also generated (data 
not shown). Together, these recombinants permitted single stranded sequencing in both 
directions
3 .2 .2 .3  S in g le  s t r a n d e d  se q u e n c e  d a t a
M13 mpl8- and mpl9-ESAT-6 sequencing was performed Figure 3.2 shows the computer 
generated sequence strategy view and alignment. Figure 3.4 shows 4 examples of 13 runs. 
Of interest, an unequivocal substitution w as present in one of M 13 mp 18 clones (C to T, 
position 104, Figure 3.2b). However, this was absent in sequence data from two other M l3 
clones (one mpl8, the other mpl9) and the double stranded sequencing, thus indicating a 
mutation in that M 13 clone.
Several sequence conflicts in GC rich regions were identified following sequencing of 
M l3 mpl8-ESAT-6. These were all resolved by sequencing in the reverse direction using 
an M l3 mpl9-ESAT-6 clone The sequencing data demonstrated successful T:A cloning 
at the Sma I site, with T and A residues flanking the amplified product at positions 24 and 
327 respectively (Figure 3.2b).
3.2.3 Construction of rVV-ESAT-6
3 .2 .3 .1  I  r a n s fe c tio n  a n d  r  W  p u r if i c a t io n
The first attempt at transfection was successful for both rVV-ESAT-6 and the rVV-MOMP 
control (chlamydia gene encoding the major outer membrane protein) (Blanchard et al 
1993). Five plaques were picked from the rVV-ESAT plaque purification plates (two from 
the 10‘2 plate and three from the 10"’ plate) and subjected to further plaque purification steps 
(Section 2 15.1.2). Following two rounds o f  plaque purification, one virus plaque was then 
used to infect a T25 monolayer which yielded ten aliquots of 1.5 x 106 pfu/ml This was then 
used as a source for growing up stock virus.
3 .2 .3 .2  A c h ie v in g  h ig h  p fu /m l  s t o c k
In the early stages o f this study, our laboratory had achieved relatively poor viral yields In 
an attempt to optimise viral growth, probe sonication was compared with water bath 
sonication A 2.7 fold increase in pfu was achieved using probe sonication (7 x 107 versus
2.6 x 107 pfu/T175 monolayer) However, the probe sonicator introduced the potential for
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Figure 3.3 Cloning esal-6  into the bacteriophage M13
a) pSCll-ESAT-6 was double digested withEcoRI and BamH\ and the digest run on a 
preparatory gel (lanes 1-6). The lowest molecular weight bands (slightly larger than the 
292 bp marker) corresponded to the fragment containing esat-6. These were cut from the 
gel, pooled and purified prior to cloning, b) The purified EcoRl/BamHl cut esat-6 insert 
and the EcoRl/BamHl M13mpl8 cut vector were subjected to agarose electrophoresis 
(lanes ‘E’ and ‘M 13’ respectively). X=lamda£cY>RI////>idIII digest molecular weight marker, 
c) The ligation reaction was performed and 10 recombinant phage (white plaques) were 
picked for PCR verification of esat-6 insertion and the PCR products electrophoresed 
(Lanes labelled 1-10). A blue plaque was included as a negative control (lane ‘Bl’) and 
and the esat-6 cloning vector, pAA249, was used as a positive control (lane ‘P’). MW=100 
bp molecular weight marker.
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M13_18_2.SEQ pSC11 F.SEQ M13_18_1.SEQ
Figure 3.4 pSCll-ESAT-6 sequencing gels
Three sequence runs are shown demonstrating data derived from double-stranded 
(pSCl lF.SEQ) and single-stranded sequencing (M 13_18_1.SEQ and M 13_l8_2.SEQ) - 
see Figure 3.2 for details of the runs. A ‘C to T’ substitution is shown in two runs from the 
same M13mpl8 clone (upward arrows). The correct sequence is indicated in the double- 
stranded sequence data (downward arrow, middle image) and was confirmed in 2 other 
M l3 clones. One of several GC-rich compressions is shown in the left hund image 
(downward arrow) where ‘gc’ should read ‘gege’ (positions 71-74). All of these were 
resolved by sequencing in the other direction, using an M13mpl9-ESAT-6 clone.
contamination and was not used in further experiments Further optimisation was achieved 
by infecting near confluent monolayers rather than 80% confluent monolayers, using low 
passage TK‘ 143 cells obtained from Oxford (Dr T. Blanchard) and more powerful cup 
sonication (Section 2 .14.2). With these methods, a viral yield of between 5 x 107and 10® 
pfu/T175 monolayer was obtained.
3.2.4 Verification of rVV-ESAT-6 at the genome level
3 .2 .4 .1  P C R  v e r if ic a t io n
Viral genomic preparations were made as described in Section 2.16.1.1. These were used 
as template in the standardised e sa t-6  PCR protocol (Section 2.9.3). Both purified MTB 
genome and the e s a t-6  cloning vector, pAA249, were used as positive controls (Figure 
3.5a). A clear band of the predicted size (292 bp) was seen with the rVV whether the 
template was used neat or diluted 1 in 10. A signal of the correct size was present with the 
undiluted MTB genome preparation, but disappeared when the template was diluted 1 in 10. 
A similar PCR reaction was carried out using BCG genome, and, as predicted from the 
known deletion of the e s a t - 6  gene (Mahairas et al. 1996), a signal was not seen (data not 
shown).
3 .2 .4 .2  V e r if ic a tio n  u s in g  S o u th ern  b lo ttin g
A whole gene digoxigenin-labelled probe and chemiluminescent protocol was employed 
(Section 2.16.1). In order to check uptake of the label, the probe was dotted onto nylon 
membrane and the labelling checked as described in Section 2.16.1.4. Figure 3.5b shows 
successful labelling with a signal readily identified at 1 in 1000 dilution. Figure 3.6 
demonstrates that e s a t - 6  was integrated into the VV genome, showing agarose gel 
electrophoresis of AcoRI-digested plasmids and rVV with and without the e s a t-6  gene insert 
and the corresponding Southern blot probed with the digoxigenin-labelled e s a t-6  probe The 
gel electrophoresis shows 400 bp and 700 bands of the AcoRI-digested plasmids in lanes 1 
and 2 (Figure 3.6a), consistent with the respective predicted fragments for pSCl 1-ESAT-6 
and pSC ll alone (see map, Figure 2.1b). In the Southern blot, the autoradiograph 
demonstrated strong signals for both the digested rVV-ESAT-6 genome and the positive 
control, pSCl 1-ESAT-6 (lanes 2 and 4) These bands are approximately 700 bp in size. The 
AcoRI-generated 700 bp band in the pSCl l-ESAT-6 lane corresponds to the signal in the 
equivalent lane of the Southern blot This corresponds to  the predicted fragment size (see 
map, Figure 2.1b) The same map indicates that an £coRI digest of whole rVV genome
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Figure 3 .5  PCR verification of rVV-ESAT-6 and assessment of an esa t-6  probe
a) Integration of esat-6 into VV was assessed using PCR amplification in conjunction 
with the esat-6 cloning primers, giving a predicted product size of 292 bp. A genomic 
preparation of a twice plaque-purified rVV-ESAT-6 preparation was used as template at 2 
concentrations (neat and 1 in 10) and the products were run in the 2nd and 3rd lanes 
respectively. In addition, an MTB genomic preparation, at 2 concentrations, and a plasmid 
carrying esat-6 were used as PCR template positive controls (4th to 6th lanes from left), b) 
In order to verify adequate labelling of a digoxigenin-labclled esat-6 whole gene probe, 
the PCR-generated probe was dotted onto a nylon membrane in a non-purified form (left 
dot) and in a gel and resin-purified form (neat and in 3 tenfold dilutions). The membrane 
was subjected to a chemiluminescence protocol (Boehringer Mannheim) and the signal 
recorded on ECL hyperfilm.
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Figure 3.6 Southern blot of rVV-ESAT-6 derived e sa t-6  DNA
a) FcoRI-digcsted plasmids, pSCl 1 and pSCl l-ESAT-6 (left hand lanes), and genomic 
preparations from rVV-infected TK 143 cells (rVV-(J-gal and rVV-ESAT-6 - right hand 
lanes) were run on an agarose gel. b) The DNA from this gel was transferred to a nylon 
membrane and subjected to Southern blotting using a digoxigenin-labelled whole gene 
esat-6 probe and a chemiluminescence protocol (Boehringer Mannheim). The signal 
was recorded using ECL Hyperfilm (Amersham).
would also produce a 700 bp fragment, as the same cutting sites are transferred following 
recombination of the insert, the selectable marker and their promoters rVV-0 gal and 
pSCl 1 alone, used as negative controls, gave no signal The faint band in the first lane 
(pSCl l-ESAT-6) represents background signal from the strong 4 kb band (see agarose gel). 
It was noted that the band from the whole genome digest was slightly advanced and 
narrower than the plasmid positive control. A likely cause is a gel artifact created by running 
more DNA in the whole genome lane (cellular and viral genome) compared with the plasmid 
lane.
3.2.5 rVV-ESAT-6 expression
3.2.5.1 Immunoblotting
Protein was extracted from rVV-infected TK' 143 cells and quantified as described in 
Section 2.16.3.3. The rVV-ESAT-6 cell lysate yielded a protein concentration of 1.9 mg/ml 
and the ST-CF positive control was supplied at a concentration o f 2 mg/ml. A minigel 
system was used, which permitted the loading of a maximum of 30 pi per lane (22.5 pi of 
cell lysate plus 7.5 pi of x4 loading buffer). Following protein transfer and probing with the 
mAb, HYB76-8, no signal could be detected from rVV-infected cell lysates, whilst there 
was a strong signal from the ST-CF as demonstrated in Figure 3.7a In an attempt to 
improve sensitivity, a much larger volume o f lysate was loaded (150 pi per lane) using a 
larger gel system and a 3 mm thick 18% polyacrylamide gel rVV-ESAT-6 lysate was loaded 
neat (lane 1) and at I in 5 and 1 in 10 dilutions (lanes 2 and 3 respectively). Given the strong 
signal from the previous Western blot, the ST-CF was diluted and 3, 0.3 and 0.03 pg total 
protein used for lanes 4, 5 and 6 respectively After a 15s film exposure, no signal was 
present from the rVV cell lysate lanes and a strong signal was seen from the positive control 
(lowest dilution) Deliberate over-exposure (5m) produced a very high background, but also 
a signal from the second ST-CF dilution lane (0 3 pg), marked by an arrow on Figure 
3 7b(ii). Again, no signal was obtained from the rVV-ESAT-6 sample The background in 
these experiments was very high This may have resulted from not including the blocking 
agent as part of the antibody diluent, a protocol step recommended by the manufacturer 
(Life Sciences)
3.2.5.2 RT-PCR
mRNA was harvested from three separate preparations of rVV-ESAT-6 infected cells and 
one preparation of rVV-P gal as described in Section 2 16.2.1 Aliquots of 2 pi were
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Figure 3.7 Western blots of rVV-ESAT-6 infected cell lysate
rVV-ESAT-6 infected cell lysate and MTB CF (positive control) were subjected to SDS- 
PAGE using small and large gel formats. These were immunoblotted and the signal detected 
using a chemiluminescence technique (ECL, Life Sciences). a)i A Coomassie blue stain of 
an SDS-PAGE gel is shown, which included two concentrations of rVV-ESAT-6 cell lysate 
(rVV-E), loaded in lOpl volumes per lane (neat and diluted 1 in 2). ii A Western blot of a 
replicate gel to a)i. The blot was probed using the ESAT-6 specific mAb HYB76-8. b)i A 
larger scale Western blot was performed using the same rVV-ESAT-6 cell lysate, but the 
lanes were loaded with 150 pi, in 3 tenfold dilutions, equivalent to 285, 57 and 29pg of 
total protein respectively. Lanes 4 to 6 show the MTB CF with 3, 0.3 and 0.03 pg.of total 
protein loaded in each lane respectively, ii This image shows an overexposed version of 
b)i. The arrow denotes presence of signal consistent with ESAT-6 (lane 5).
electrophoresed to exclude degradation (Figure 3.8a). Spectroscopy was also performed 
which identified preparation 3 as the most pure (OD260/OD2go = 1.92). This preparation had 
a calculated mRNA concentration of 129 ng/pl The rVV-P gal preparation had an 
OD260/OD2g0 = 2.01 and a concentration of 3.04 gig/pil. Generation of cDNA and PCR 
amplification was performed as described in Section 2.16.2.2. ESAT-6 specific mRNA 
transcription was readily identified using RT-PCR (Figure 3.8b). This figure also shows the 
relevant controls: with and without DNase treatment of mRNA preparations and with and 
without an RT step. These controls were used to exclude the possibility of amplification of 
the esat-6 gene from contaminating viral genome in the mRNA preparations. This would 
have occurred if DNase treatment had not been used, as demonstrated by the faint signal 
seen in lane 5 where the mRNA preparation was not treated with DNase (potential for 
contaminating DNA) and no RT step performed (no cDNA generated). In order to exclude 
the possibility of a similar sized band being amplified from a rVV lacking the esat-6 insert, 
PCR was also performed using four tenfold dilutions of cDNA template each derived from 
rVV-ESAT-6 and rVV-P gal Figure 3.8c shows a single discrete band, visible in the first 
two template dilutions of rVV-ESAT-6 Only multiple bands were visible for rVV-P gal
3.2.5.3 Optimising the immunoblotting conditions
High backgrounds were seen in the early immunoblots (Figure 3.7). Therefore, 5% milk 
powder in PBS-T was added to the primary and secondary antibody incubations (an 
accepted deviation from the recommended protocol from Life Sciences) Dot blots were 
performed to compare the presence or absence of blocking agent in the antibody diluent 
The addition o f blocking agent produced no loss o f sensitivity and a greatly reduced 
background (data not shown) This modified protocol was then performed for Western 
blotting of ESAT-6 using protein samples from eight twofold dilutions of M  marinum 
culture filtrate (CF) (Figure 3.9b) This figure shows a clear signal of correct size for 
ESAT-6, down to lane 6(1 in 32 dilution) This lane contained 0.16 pg of CF protein of 
which <1% would contain ESAT-6 (Dr P Andersen, personal communication) indicating 
that this assay had a sensitivity of s 1.6 ng In a separate experiment, a direct comparison 
using dot blots showed that, if anything, the signal to noise ratio was slightly improved by 
the addition o f blocking reagent to antibody incubations (data not shown) Of note, the 
addition of blocking reagent did prolong the exposure time from about 30s to several 
minutes, with the optimum exposure for weak signals being about 15-30m
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Figure 3.8 RT-PCR o f rVV-ESAT-6
a) Agarose gel electrophoresis of three RNA preparations of rVV-ESAT-6 and one of rVV- 
(i gal infected cell lysates is shown, b) Following reverse transcription of ‘rVV-E prep. 3’, 
PCR was performed using the esut-6 cloning primers (predicted product size of 292 bp) 
and the products run as shown: lane 1 - 10O bp molecular weight marker; lane 2 - test 
sample (RNA sample pre-treated with DNAse prior to the RT step); lanes 3 to 5 - the 
relevant controls (with/without DNAse treatment and with/without the RT step); lane 6 - 
the positive control (pAA249 plasmid template which carries esat-6) c) RT-PCR was 
performed as for b), but included rVV-(3-gal (rVV-P) as an additional negative control. 
Reactions were replicated to include 4 tenfold dilutions of the cDNA templates.
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Figure 3.9 Western blots of rVV-ESAT-6 and rVV-P-gal cell lysates and M . 
m a r in u m  culture filtrate
Additional Western blots were performed in order to address possible explanations for 
failure to elicit a signal when probing for rVV-generated ESAT-6. a) A rVV-ESAT-6 time 
course was performed, where cell lysates were harvested between 0 and 18 hours pi and a 
Western blot was performed using the ESAT-6-specific mAh, HYB76-8. b) M. marinum 
culture filtrate (CF) was subjected to Western blotting using neat CF protein (5 pg) and a 
series of twofold dilutions, c) A rVV-P-gal time course was performed as for a), but was 
probed with an anti-P-galactosidase antibody (Boehringer Mannheim), d) Four rVV-ESAT- 
6 plaques were selected from the initial recombination mix and rVV-infected cell lysates 
were prepared and Western blotted (labelled l-4). The 2 left hand lanes show M. marinum 
C F in two concentrations (Cl = neat and C2 = l in 10). The right hand lane (labelled PG) 
shows an rVV-P-gal negative control.
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3.2.5.4 Excluding methodological reasons fo r  lack o f signal
1) To exclude the possibility that ECL immunoblotting might be inhibited by rVV- 
infected cell lysates, the rVV-P-gal lysate was probed with a specific anti-P gal mAb. 
Lysates were collected at six time points over 18h (see Figure 3.9c), proteins were 
resolved and blotted as described in Section 2.16.3. Figure 3.9c shows that P-gal 
specific bands were visible from 3h post infection. Thus, the system was easily able 
to detect a rVV-encoded recombinant protein
2) To exclude the possibility of transient expression, a rVV-ESAT-6 time course 
similar to rVV-P-gal was performed. No ESAT-6 specific signal was identified at 
any time point, showing that expression was not transiently detectable and missed 
because of the previous time-point selected for sampling (Figure 3.9a).
3) To exclude the possibility of having selected an aberrant plaque during the 
purification steps, four additional plaques from the original recombination mix were 
picked and grown up No signal was seen when probing these cell lysates for 
ESAT-6 (see Figure 3.9d) This confirmed that the lack o f signal was not due to an 
error in the rVV clone selected at the outset.
3.3 DISCUSSION
rVV-ESAT-6 was successfully constructed using the pSCl 1 insertion plasmid and standard 
techniques This represented the first known rVV to incorporate the esat-6 gene Fidelity 
o f cloning was verified by gene sequencing, PCR, Southern blotting and RT-PCR However, 
repeated immunoblotting with alteration of several parameters failed to identify protein 
expression. Eighteen months later, following the development of a capture ELISA by Prof 
M Harboe, rVV-ESAT-6 protein expression was identified (Figure 5.7) (Harboe et al 
1997) This will be discussed in chapter 5.
3.3.1 Why was protein expression not identified?
Following rVV-ESAT-6 construction both Southern and Western blotting were performed 
These data showed viral incorporation of the gene but no gene expression using the only 
available antibody (at that time, no polyclonal sera or alternative mAbs existed). Two 
explanations amenable to investigation were addressed
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3 .3 .1 .1  P o te n t ia l  m is in c o rp o ra tio n  d u r in g  P C R  in se r t g e n e ra tio n
In the early stages of the study, plasmid cloning had not been optimised and the results of 
T:A cloning were poor. Ten ligation/transformation experiments and over a hundred 
minipreps were required to obtain one successful clone This was in marked contrast to the 
optimised cloning subsequently developed and described in chapter 4. In later experiments, 
T a q  rather than P fu  polymerase was used. This enzyme permitted the omission of the A- 
tailing step (Figure 3.1c) and resulted in a higher insert yield However, T a q  polymerase 
does not possess 3' proof reading activity and the potential for PCR misincorporation is 
approximately 10 fold greater than with some of the high fidelity DNA polymerases such 
as P fu  (Lundberg et al 1991). The error rate (ER) for T aq  has been calculated at 2 x 105 
per base pair per cycle (Eckert and Kunkel, 1990), whilst for P fu  the rate is 1.6 x 106 
(Lundberg et al 1991). Thus, using the equation:
no of cycles
% error free amplification = (  (1- ER) no ofbp )  x 100
For T a q , the % error free amplification is 86 4%
For P fu , the % error free amplification is 98 8%
(where the number of base pairs = 292 and the number of cycles = 25)
It should be noted that these error rates have been obtained empirically and may vary 
according to a number of factors including: the template, primer pair, dNTP and Mg 
concentration, and pH (Lundberg et al 1991). However, despite the relatively high chance 
of misincorporation using Taq polymerase, PCR fidelity was confirmed by sequencing e sa t-6  
forwards in pSCl l-ESAT-6 and in both directions in M13 subclones (Figure 3.2).
3 .3 .1 .2  P o te n t ia l  f a i lu r e  o f  f o r e ig n  g e n e  tr a n s c r ip t io n
A vaccinia promoter is necessary for viral transcription of foreign gene inserts The virus 
uses its own multisubunit RNA polymerase, an exception being the T7 hybrid system where 
the foreign insert is under the control of the T7 polymerase promoter A motif encoding 
transcriptional termination for vaccinia early genes has been recognized (5'-TTTTTNT-3') 
(Mackett, 1995) but this was not present in e sa t-6 .
As with other vaccinia promoters, it is believed that transcriptional initiation occurs within 
the p7.5 promoter region It is recommended that the ORF o f the foreign insert is cloned as 
close as possible to the viral promoter (Mackett et al. 1982; Mackett et al. 1984). The 
cloning of this construct used a PCR-generated insert of the ORF without the addition of 
5' untranslated sequence Despite these measures, it was still possible that for some 
idiosyncratic reason, the gene was not transcribed Therefore, RT-PCR was carried out. 
This demonstrated that failure of transcription was not the cause of absent gene expression 
(Figure 3.8).
3 .3 .1 .3  R a p id  d e g r a d a t io n  o f  n a s c e n t  re c o m b in a n t p r o te in
ESAT-6 is a small protein o f prokaryotic origin In its native state, it is actively secreted by 
some strains o f  mycobacteria by a signal peptide independent process (Harboe et al 1996). 
Whatever mechanisms permit protein stability and secretion would not necessarily apply in 
a mammalian cell Indeed, it is possible that its presence in the eukaryotic cytoplasm could 
give rise to rapid proteolysis, thus preventing identification o f the whole protein However, 
one could assume that protein degradation would give rise to MHC class I antigen 
processing and presentation o f ESAT-6 peptides to CD8+ T cells Thus, a CTL assay could 
be used as a readout for protein expression, providing there was an adequate system for 
restimulating low precursor frequency ESAT-6 specific CD8+ CTL. However, the 
methodology available in our laboratory used live BCG for T cell restimulation, which lacks 
ESAT-6. Eighteen months later, collaborators in Oxford (Prof A. Hill's group) demonstrated 
class I restricted, CD8+ T cell recognition of this rVV-ESAT-6 using peptide restimulation 
of human CTL (see chapter 6) (Lalvani et al 1997)
3 .3 .1 .4  F u rth er p o te n t ia l  e x p e r im e n ts  n o t p e r fo r m e d  in  th is  s tu d y  
Immunoblotting was limited, owing to the fact that only a single mAb, specific for ESAT-6, 
existed at the time of experiments Alternative strategies to identify protein production could 
have included direct identification using immunoprécipitation or immunofluorescence 
(offering the potential of increased sensitivity) (Mackett, 1995) In addition, indirect 
identification may have been possible using: (i) IFN-y production or T cell proliferation to 
rVV-infected cell lysate using mouse immune splenocytes (Andersen et al 1991); (ii) animal 
immunisation with rVV-ESAT-6 and testing for a recall response with ESAT-6 from a 
source different from rVV; and (iii) immunoblotting the rVV-ESAT-6 cell lysate using sera 
from animals immunised with ESAT-6 protein
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3.3.2 Which way forward? Pitfalls of CTL
Performing CTL experiments to recognise MHC class I associated ESAT-6 peptide 
represented the most likely chance of obtaining a positive signal from the ESAT-6 construct. 
At this stage in the study, it was felt that there were significant problems in pursuing this 
approach These are discussed below
3 .3 .2 .1  A w h o le  a n t ig e n  a p p r o a c h
As stated previously, no immediate means for CTL restimulation were available. Whilst 
BCG did restimulate CD8+ T cells, the organism does not include ESAT-6. As an 
alternative, virulent MTB could have been used, but we had little experience of working 
with this Category III organism in tissue culture. M y c o b a c te r iu m  m a rin u m  represented a 
source of ESAT-6 (the only Category II M y c o b a c te r iu m  spp expressing this protein), but 
it was not known whether this would reproduce the CD8+ CTL restimulation property 
identified using live BCG (Turner and Dockrell, 1996).
3 .3 .2 .2  A p e p t id e  a p p r o a c h
Using peptides to restimulate CTL represented an attractive approach, but not without 
drawbacks The main problem would have been identifying which peptides to use 
Overlapping peptides could miss important peptides, with the potential for missing a key 
peptide straddling a region represented by two peptides Alternately, predicted peptides 
based on HLA class I specific motifs, could have been used in conjunction with knowledge 
of HLA resistance alleles Hill and colleagues (1992) successfully used this technique for the 
identification of malaria CTL peptides and HLA B53. However, this 'reverse 
immunogenetics' requires knowledge o f an HLA resistance allele, and these data are not 
available for TB (Pitchappan, 1990). Another option was to scan for predicted peptides for 
common HLA alleles within the sequence o f e s a t - 6  and screen using a class I binding assay 
or assess for CTL restimulation using pools of peptides This represents a useful approach 
However, problems can arise whereby peptide-restimulated CTL can be generated to kill 
peptide-pulsed target cells, but not target cells expressing endogenously processed whole 
antigen (Stauss et al 1992) This may be a consequence of differential processing by antigen 
presenting cells (Eisenlohr et al 1992) Furthermore, alternative peptides not predicted by 
known algorithms can also induce CTL (Sadovnikova et al 1994) From a logistic 
perspective, the number o f  donors would be restricted Each donor would require HLA
typing with selection of only those with an HLA type corresponding to  the available panel 
of peptides.
3.4 CONCLUSION
A strategic decision was made to pursue construction of further rVV rather than look for 
CTL using the available rVV-ESAT-6. The pursuit of CTL at this stage was felt to be high 
risk given the difficulties in restimulating biologically-relevant ESAT-6 specific CTL. In 
addition, whilst identification of ESAT-6 specific CTL would have been beneficial, failure 
to find CTL would have begged the question of a problem with the construct rather than 
absence of significant CTL in the subject population Therefore, several strategies were 
pursued in order to maximise the chances of obtaining rVV with identifiable expression of 
MTB secreted proteins
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4.1 INTRODUCTION
Failure to identify protein expression from rVV-ESAT-6 led to three alternative strategies: 
(i) the use of genes for three further M  tuberculosis secretory proteins; (ii) the addition of 
a signal sequence; and (iii) the application o f the vaccinia/T7 hybrid system This chapter 
describes construction of two vaccinia insertion plasmids containing a signal sequence 
derived from tPA (pi 108-tPA and pWR510-tPA), PCR generation of the required genes 
prior to cloning, development of rVV and verification of homologous recombination at a 
DNA level Studies of rVV protein expression are included in chapter 5.
4.1.1 Genes encoding additional MTB secreted proteins
4.1.1.1 The choice o f available genes
It was decided to use additional secreted proteins for M. tuberculosis. However, the number 
of candidates was limited to the known available sequences At that time, potential 
candidates could have included genesencoding: the Ag85 complex (Borremans et al 1989; 
Content et al 1991), the 23 kDa superoxide dismutase protein (Zhang et al 1991); the 38 
kDa phosphate binding protein (Andersen and Hansen, 1989); and the 10 kDa heat shock 
protein (Baird et al 1989). As discussed in Section 1 4 3.2, the Ag85 complex represented 
the most attractive group of immunodominant secreted proteins Furthermore, data 
presented at a Keystone meeting on Mycobacterial Disease held at Tamron, Colorado, 1995
suggested that these antigens offered protection when vaccinated as DNA constructs (Drs 
K. Huygen and J. Content, personal communication). Similar to rVV, DNA vaccination is 
known to induce CD4+ and CD8+ immunity (Huygen et al 1996). A collaborative link was 
established with this group and an agreement was made to exchange reagents. I f  rVV were 
produced, these would then be used for mouse immunology studies in Brussels and human 
immunology studies in our laboratory.
4 .1 .1 .2  The a d d i t io n  o f  a  s ig n a l  se q u e n c e  to  e n h a n ce  e x p re ss io n
Whilst rapid degradation of protein in the cytoplasm would be beneficial for inducing MHC 
class I restricted immune responses, complete absence of identifiable expression would make 
the interpretation of such a negative result difficult. If a CD8+ CTL clone against a 
commonly recognised MTB secreted protein epitope was available, this could be used as a 
yardstick to assess putative CTL precursor frequency in TB patients or BCG vaccinees. 
Unfortunately, such CD8+ clones were not available Therefore, one of the strategies 
employed was to improve the potential for protein expression by including a eukaryotic 
signal sequence.
Previous work had identified the value of the human tissue plasminogen activator signal 
sequence in a mammalian cell expression system (Chapman et al 1991) and this had been 
used successfully with rVV (Wang and Mullins, 1995). Moreover, the DNA vaccine studies 
using Ag85 genes demonstrated enhanced immunogenicity with tPA, as compared with 
either no signal sequence or the mycobacterial native signal sequence (Dr J Content, 
personal communication). These data led to the decision to generate rVV using Ag85 
coding sequences without the native signal sequence In addition, half the constructs would 
also include tPA This would enable direct comparison of rVV both with and without this 
eukaryotic signal sequence
4 .1 .1 .3  T 7  c o n s tr u c ts
It was possible that failure to observe protein expression in rVV-ESAT-6 was a quantitative 
problem in that expression may have occurred, but at a level below the sensitivity of the 
immunoblotting Encoding foreign genes under a late vaccinia promoter could potentially 
resolve this problem, where expression levels may be increased tenfold or greater (Mackett, 
1995). However, during late vaccinia infection, some of the MHC class I peptide complex 
sites may be blocked; this is an idiosyncratic finding not seen for early antigen class I
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processing and CD8+ CTL recognition (Browne et al. 1988). Furthermore, Broder and 
colleagues (1994) provide data showing that vaccinia late proteins are not expressed in 
cultured human macrophages. In contrast, proteins expressed using the T7 hybrid system 
to infect macrophages resulted in very high recombinant protein expression. Therefore, it 
was decided to construct rW T7, expressing each o f the genes, both with and without tPA. 
These constructs could be used for transient expression for use of identification of CTL, but 
they would not be suitable for animal vaccination (recombinant protein expression requires 
co-infection with two vaccinia constructs, see Section 1.6.7.2). In addition, the T7 insertion 
plasmids required for rVV construction would permit in  v itro  transcription/translation 
studies and provide further data concerning the effect of the signal sequence (chapter 5).
4.2 RESULTS
4.2.1 Generation of Ag85 and ESAT-6 gene inserts
4 .2 .1 .1  R e s tr ic tio n  d ig e s t  v e r if ic a tio n  o f  c lo n in g  p la s m id s  c o n ta in in g  A g 8 5  g e n e s  
The three genes were obtained in plasmid form from the Pasteur Institute, Brussels (Section 
2.4.2). In order to confirm their identity, restriction digests were performed based on maps 
from the literature (Borremans et al. 1989; Content et al 1991). Figure 4 1a shows four 
enzyme digests (fia/wHI, ///«dill, E c o K \  and P s t l )  for each of the three BlueScribe (pBS) 
clones. The banding pattern was consistent with the restriction digest maps, thus confirming 
their identity.
4 .2 .1 .2  O p tim is in g  P C R  a n d  p o te n tia l  p i t f a l l s
Primer pairs were selected according to the criteria laid out in Section 2.5.3. The computer 
predicted primer pair efficacy gave very low scores for 8 5 a  products when the upper 
primers were selected to encode the recombinant protein from the start of the mature 85A 
protein, where the first residue is Phe (Content et al 1991). Examples of these upper 
primers include PR85A14F (includes a B a m \\\ site) and PR85A01F (includes an X b a \  site) - 
see notes section in Table 2.3. When paired with an otherwise effective lower primer, 
PR85A15R, PR85A14F gave no signal (Figure 4 2a, lane 8) The upper primer, PR85A01F, 
was able to generate a product when paired with PR85A02R, but the signal was poor and 
a double band was generated when using P fu  polymerase (Figure 4 3a) The 8 5 a  gene could 
be amplified using an upper primer which included an additional three or four codons 
upstream from the first residue o f the mature protein e g PR85A13F, see Figure 4 2a, 
lane 4; and PR85A03F, see Figure 4 4b(ii).
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Figure 4.1 Restriction digest verification of plasmids
a) Bluescribe clones carrying one of the Ag85 genes (85a, 85b and 85c) were subjected to 
single enzyme digestion with four different restriction enzymes. B=B«wHI, E=£cr>RI, 
H=HinA\\\ and P=P.vrI. b)The vaccinia insertion plasmids, pWR510, pSI, pSII, pi 107 and 
pi 108 were digested with either £ cy.»R1 (E cut) or Bam\\\ (B cut). All banding patterns 
were consistent with known restriction maps. MW=100 bp molecular weight marker. 
A.=lamda £c«RI////>idin digest molecular weight marker.
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Figure 4.2 Assessment and optim isation of PCR cloning primers
a) Agarose gel electrophoresis of P fu  polymerase PCR products using several primer pair 
combinations: lane 2 17/18 (e sa t-6  with N h e l) , lane 3 19/20 (esa t-6  with B h a m W l), lane 4 
13/02 (85a  with N h e l) , lane 5 14/04 (8 5 a  with B h a m H l), lane 6 13/04 (8 5 a  with N h el), 
lane 7 14/15 (8 5 a  with B h a m H l) , lane 8 13/15 (85a  with N h el), lane 9 16/22 (8 5 b  with 
N h e l) , lane 10 21/10 («5c with N h e l) , lane 11 03/04 (85a  with B ham H l). b)i A range of 
template quantities (100, 10 and 1 ng) was assessed to identify which gave the maximum 
yield using primer pair 01/02, pBS-85A as template and a P fu  polymerase PCR protocol.
b) ii Hot and cold start PCR protocols were assessed using otherwise identical parameters. 
MW=100 bp molecular weight marker.
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Figure 4.3 Differences in PCR amplification using P fu  and Taq polymerase
a) A variety of reaction conditions were used in order to identify the optimum means to 
obtain the difficult-to-amplify S5a product when using Pfu polymerase and the primer 
pair 01/02. Lanes 2-4 represent products using the PCR cycle protocol: 98, 50, 75 (melt­
ing, annealing, extension temperatures in degrees centigrade - see text for further details). 
Lane 2 includes no additive, lane 3 10% DMSO, and lane 4 2% glycerol. Lanes 5-7 in­
clude products after varying the annealing temperature. Lane 5 cycle protocol = 95, 75, 
55, lane 6 = 95, 75, 50 and lane 7 = 95, 75, 45. Lane 8 is the Taq polymerase product 
showing a single band (annealing temp. 50). b) The Taq polymerase product was diluted 
to assess if a double band was hidden within the strong signal. Lanes 2-4 represent the Taq 
polymerase product diluted 1 in 2, 1 in 5 and 1 in 10. Lanes 5-8 represent Pfu polymerase 
products showing double bands despite varying the annealing temperatures: 55, 50 and 45 
for lanes 5-6 respectively and lane 8 includes the addition of 10% DMSO (annealing 
temp. 50). MW=100 bp molecular weight marker.
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Figure 4.4 Ag85 PCR products used in cloning experiments
a) Pre-prepared primer pairs were initially stored at -20 degrees centigrade under wax 
pellets for bulk use. A comparison of PCR product yield was made for primers: stored 
(0=old), stored but reheated just prior to use (OR=old/reheated), and primers diluted and 
mixed just prior to use (F=fresh). b) Gel showing Ag85 gene inserts generated by PCR, 
using the cloning primers which performed the best. Primer pairs incorporated 5’ restric­
tion sites suitable for cloning into either pWR510 (Nhel) or pi 108 (BamHY). i Pfu polymer­
ase products for 85b (B) and 85c (C) genes, ii Taq polymerase products for 85a (A). 
MW=100 bp molecular weight marker.
The three other genes, esal-6, 85b and 85c, were readily amplified using Pfu polymerase 
(see Figure 4.2a).
In an attempt to optimise primer efficacy for 'difficult-to-amplify' products, a number of 
strategies were pursued, as listed in Section 2.9.4 In the case of primer pair 01/02, a switch 
to Taq polymerase resulted in a clear signal; the intensity of the signal was proportional to 
the amount of template (Figure 4.2b). A signal of the same molecular weight was also 
produced using Pfu polymerase with a 'hot start', but not 'cold start' (Figure 4.2c and 
Section 2.9.2 for methodology) However, use of this enzyme produced a clear double band.
This may have arisen as a consequence of secondary structure within the template, although 
mispriming could also have occurred Several attempts were made to manipulate the 
reaction conditions to allow the high fidelity DNA polymerase, Pfu, to be used in preference 
to Taq These were based on the prevention of secondary structure formation using a higher 
melting temperature (98°C), with or without the addition of 2% glycerol or 10% DMSO. 
Figure 4 3a shows that none of these methods were successful. In another experiment, in 
order to reduce the chance of mispriming, the annealing temperature was altered, but this 
also failed to remove the second band (Figure 4.3b, lanes 5-7). In order to confirm that the 
Taq PCR protocol did not also produce a double band, perhaps hidden by the strong signal 
seen in Figure 4 2b, the Taq PCR product was diluted 1 in 2, 1 in 5 and 1 in 10 and the 
electrophoresis run time was prolonged. Figure 4 3b, lanes 2-4 confirmed the presence of 
a single /¿/¿/-generated band with an obvious double band from Pfu PCR for comparison
In order to streamline the hot start PCR, batches of primer pair aliquots were stored in thin- 
walled PCR tubes under wax at -20°C; a standard practice carried out for MTB diagnostic 
work in the same department (Dr Stuart Wilson, personal communication) However, the 
use of these stored tubes resulted in an unacceptably low yield of PCR products Figure 4.4a 
shows a comparison between stored primer pairs (O), stored but reheated to 80°C primer 
pairs (OR) or freshly made reaction tubes (F) for two sets of primers. It is clear that under 
these reaction conditions, freshly made up primers were essential for production of an 
adequate PCR product yield
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4.2.1.3 Inserts used in cloning
The shaded boxes in Table 2.3 indicate the primer pairs used to generate each insert used 
in cloning and the plasmids generated using these inserts are listed in Table 4.1 below. The 
optimised PCR protocol (Section 2.9.4) employed the high fidelity Pfu polymerase to 
generate all of the inserts except for the 85a products which required Taq polymerase. The 
annealing temperature was set at 50°C for all primers, except 07/08 and 11/12, which 
required a temperature o f 55 °C. On the basis of the above experiments, PCR protocols were 
selected to generate inserts for cloning Examples of the optimised reactions are shown in 
Figure 4 4b for Ag85 products and Figure 4.2a (lanes 2 and 3) for esat-6 products.
4.2.2 p ll08-tP A  and pWR510-tPA vaccinia insertion plasmids
In order to minimise the cloning requirements for rVV-tPA-insert constructs, two generic 
insertion plasmids, pi 108-tPA and pWR510-tPA, were prepared Figures 2.2 (pi 108) and
2.3 (pWR510) show the plasmid constructs with and without the tPA region. In each case, 
the multiple cloning site (MCS) is shown Following insertion of tPA, both constructs lose 
their original MCS and share the MCS included in the tPA insert downstream from the 
signal sequence.
4.2.2.1 C Construction o f p i  108-tPA
The protocol was followed as described in Section 2.11.1.2. Figure 4.5a shows both 
oligonucleotides before and after hybridisation In addition, the right hand gel shows 
prepared vector in the penultimate (//«wHI/Klenow filled) and final stage o f manipulation 
(A’coRI cut) prior to cloning. The ligation then required cloning of the blunt/AcoRI tPA 
fragment into the BamHl, Klenow-filled, EcoRl cut vector.
An initial experiment produced only re-ligated vector (data not shown) Therefore, a second 
experiment was performed using a //»/»dill digested ligation mix This site is present in the 
vector, but absent in the tPA construct (Figure 2 2). Five clones were selected and 
recombinants were screened using ////»dill digestion Figure 4 5b shows that clones 1 3 and 
14  were not cut with this enzyme, consistent with successful recombination This was 
verified using BamHl and Nhe I digestion of the clone 1.3 and the vector as shown in Figure 
4 5c The HamH\ digest demonstrated presence of this site, as for pi 108-tPA This site 
would be absent from re-ligated vector lacking its MCS (a potential outcome following
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Table ref. 
no.
Plasmid name Unique
identifier
Origin of insert 
(primer pair code)
#1 p1108 P18 n/a
#2 p1108-85A P 7 PCR (03/04)’
#3 p1108-85B P 1 PCR (07/08)
#4 p1108-85C P 2 PCR (11/12)
#5 p1108-ESAT-6 P 8 PCR (19/20)
#6 p1108-tPA P 12 hybridised oligo's
#7 p1108-tPA-85A P 13 PCR (03/04)*
#8 p1108-tPA-85B P 14 PCR (07/08)
#9 p1108-tPA-85C P 15 PCR (11/12)
#10 p1108-tPA-ESAT-6 P 16 PCR (19/20)
#11 pWR510 P 19 n/a
#12 pWR510-85A P 21 sub-cloned from P13
#13 PWR510-85B P 17 PCR (16/22)
#14 pWR-510-85C P 4 PCR (21/10)
#15 pWR510-ESATdel-6 P5 PCR (17/18)
#16 PWR510-ESAT-6 P 23 sub-cloned from P16
#17 pWR510-tPA P 6 hybridised oligo's
#18 pWR510-tPA-85A P 20 sub-cloned from P13
#19 pWR510-tPA-85B P 9 PCR (16/22)
#20 pWR510-tPA-85C P 10 PCR (21/10)
#21 p W R 510-t PA-ESAT del-6 P11 PCR (17/18)
#22 p W R 510-t PA-ESAT-6 P 22 sub-cloned from P16
Table 4.1 Plasmids used in rVV construction and transcription/translation studies
*=PCR insert generated using Taq polymerase All others reactions used Pfu polymerase 
Unique identifier code numbered chronologically according to date o f construction, 
P=plasmid del=frameshift close to 5' end o f t-sal-6. n/a=not applicable
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Figure 4.5 Construction and verification of pllOK-tPA
a)i Agarose gel electrophoresis of tPA sense and antisense oligonucleotides (OLI-1 and 
OLI-2). ii Electrophoresis of the insert and vector prior to cloning: lane l=hybridised 
oligonucleotide pair (the tPA insert), lane 2=Smal digested, then Klenow filled pi 108 and 
lane 3=Smal cut, Klenow filled, then EcoK\ digested pi 108 (the fully cut vector), b) After 
cloning tPA into p 1108, plasmid preparations of 5 transformants (1.1 to 1.5) were picked 
and subjected to Hindlll digestion (+) or left uncut (-). Clones 1.3 and 1.4 show loss of the 
Hind\\\ site consistent with recombination, c) Clone 1.3 shows preservation of the Bamtil 
site and addition of a second Nhe\ site consistent with the predicted banding pattern for 
pi 108-tPA. X= lamda EcoRMHiruMU  digest marker. MW=l(X)bp molecular weight marker.
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negative selection in favour of those constructs lacking a ///«dill site). Further support for 
p 1108-tPA comes from the Nhel digest which demonstrated introduction of a second site 
(predicted from the tPA MCS), resulting in a fragment of -1250 bp
4.2.2.2 Construction o f  p  WR510-tPA
pWR510-tPA cloning was more straightforward and involved direct cloning of the tPA 
insert into Swal cut/EcoRl cut vector (see Figure 4 6a). Three transformants were picked 
and all clones demonstrated loss of the SacW site, present in the vector MCS, and 
introduction of a Smal site, present in the tPA MCS, consistent with recombination (see 
Figure 4.6b and map in Figure 2.3).
The MTB genes were subsequently cloned into pWR510-tPA (see below). By using sites 
on either side of the tPA coding region (iVal and Nhel), further evidence was provided for 
successful tPA recombination (see Figure 4 6c and map in Figure 2.3).
4.2.3 Gene cloning
Sixteen constructs were planned This included all four genes in each of the four insertion 
plasmids, pi 108 and pWR510, both with and without tPA Directional sticky-ended cloning 
was employed, as described in Section 2.11.2
4.2.3.1 A cloning example using standard methods
Following PCR amplification of five 100 pi identical reactions, the entire volume was 
electrophoresed and the band cut out. Figure 4 7a shows three such examples. Following 
electroelution, double enzyme digestion and a phenol/chloroform purification step, adequate 
yields of insert were demonstrated for 07/08 and 11/12 products, but no signal was seen for 
the 09/10 product, probably due to loss of the pellet (Figure 4 7b). This figure also shows 
the cut and phenol/chloroform purified vectors In this case, S5h and S5c were cloned into 
pi 108 Figure 4 7c shows a HamHl/EcoRl digest of 10 clones from the 85c ligation, six of 
which showed presence of a band consistent with successful recombination A similar result 
was achieved for H5h (data not shown).
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Figure 4.6 Construction and verification of pWR510-tPA
a) pWR510 was initially digested with Sw«I (middle lane) followed by £ cy>RI (right hand 
lane). The tPA insert was then cloned into the Swal/Ec^RI-digested pWR510, three clones 
were picked and plasmids prepared, b) Two single enzyme plasmid digests were per­
formed and the results were consistent with successful construction of p\VR510-tPA for 
all three clones (SacII is present in pWR510 only and Smal is present in pWR510-tPA 
only), c) Three MTB genes were cloned into pWR510-tPA and subjected to both Nhel/ 
EcoRl (N/E) and Sw«I/£cy>RI (S/E) double digestion. The banding pattern was consistent 
with correct cloning. (Furthest right hand lane=pWR510 digested with NheMEcoRY).
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Figure 4.7 Preparation of three Ag85 inserts and the construction of p ll08-85C
a) Three Ag85 PCR-generated gene inserts were purified using agarose gel electrophore­
sis. The primer pairs used for amplification o f the inserts were: 07/08 (85b for pi 108), 09/ 
10 (85c for pWR5IO) and 11/12 (85c for pi 108). h) Lanes 2-4 represent the gel- and 
phenol/chloroform-purified PCR products from a) which were then double enzyme di­
gested and phenol chloroform extracted prior to cloning. Lanes 5 and 6 represent simi­
larly prepared pi 108 and pWR510 vectors, c) Lanes 2-11 are BamHMEcoKX digested 
clones following transformation with the pi 108-85C ligation mix (primer pair 11/12). 
Lane 12 is BamWVEcoKi digested pi 108 alone. Lane 13 is an H5c PCR product acting as 
a positive control. A^lamda EcoRVHin&lU digest marker, M W= 100 bp mol. weight marker.
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4.2.3.2 Microcon membrane filtration - a means to enhance cloning efficiency 
Micron membrane filtration was employed as a means to desalt both vector and insert prior 
to ligation It also provided concentrated DNA suitable for cloning and separated the vector 
and insert from the unwanted sticky ended oligonucleotide fragments produced following 
restriction digestion. In addition, inserts were tested for both the removal of enzyme 
(Micropure EZ) and the extraction of DNA from agarose (Micropure). Figure 4 8a shows 
the membrane filtration system with the insert for enzyme removal and Figure 4.8b shows 
a gel documentation image of Micropure inserts containing ethidium bromide stained gel 
fragments.
High yields of concentrated, salt-reduced, cut vector and insert were obtained. For example, 
the gel shown in Figure 4 8a demonstrates excellent yields of fully prepared insert in a final 
volume of between 10-15 pi, thus giving a working concentration of between -50-500 
ng/pil.
However, the same success was not achieved with the agarose gel Micropure insert 
(Amicon), a system designed to separate DNA from agarose without the need for 
electroelution or a resin-binding technique Figure 4 8b shows very high signals at the gel 
purification step (left-hand gel) However, following the recommended spin time, the yields 
w ere poor (lanes 3 and 5), with much of the DNA remaining in a slurry above the 
membrane A subsequent spin resulted in a similar yield, but prolonged spinning resulted in 
a loss of membrane integrity and loss of DNA
4.2.3.3 PCR screening o f recombinant clones
Initially PCR screening of clones was performed as described in Section 2.11.2.3. Once 
colonies had grown overnight, this screening technique simply required a single colony pick 
as template and a standard small volume PCR was carried out Thus, results could be 
obtained within half a day. For example, Figure 4 9 shows results o f PCR screening for each 
o f the genes cloned into pWR510. Efficient recombination was achieved for three of the 
genes, as evidenced by clear signals of the appropriate molecular weight for S5b, S5c and 
esat-6, but not S5a.
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Figure 4.8 Use of Microcon spin columns to enhance plasm id cloning efficiency
a) This shows a Microcon spin column with an additional Micropure EZ plastic insert for 
removal of restriction enzymes. The column will remove small oligonucleotide fragments, 
perform a buffer exchange and concentrate the insert or plasmid prior to ligation. The 
agarose gel shows the yield obtained from a 500 pi volume of PCR-generated inserts 
following gel- and phenol/chloroform-purification, enzyme digestion and spin column 
purification of 85a (~800ng final DNA yield) and esat-6 (-3.8 pg final DNA yield), b) An 
assessment of the Microcon gel purification system was also carried out. Bands from 
preparatory gels for 85a and esat-6 PCR (left hand gel) were cut out and transferred to 
Microcon Micropure plastic inserts, (i) and (ii) (right hand gel). These were centrifuged 
according to the Amicon protocol. However, a gel slurry, containing most of the DNA, 
remained above the membrane, with only a fraction passing through for use (lanes 3 and 
5). Lancs 2 and 4 represent further DNA eluted from slurry following a second centrifuga­
tion. MW=1()() bp molecular weight marker. X=lamda EcoRI/Z/mdlll digest marker.
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Figure 4.9 PCR Screening of pWR510 clones
Successful recombinants were identified using a PCR screening technique. Bacterial 
colonies were picked for each of four ligation/transformation reactions, where pWR510 
was used as the vector and one of the four MTB genes was used as the insert. The agarose 
gels show the PCR products obtained following screening of ten pWR510 recombinant 
clones (lanes 2-11) for each of the four genes. The PCR template was whole E. coli (a 
‘toothpickfuF) and the primers were those used for generation of the insert. MW=100 bp 
molecular weight marker.
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4.2.3.4 Highly efficient cloning obviates the need fo r  PCR screening
From the PCR screening results, it was noted that using the optimised cloning strategy 
resulted in an 'all-or-nothing' phenomenon i.e. either the cloning was highly efficient with 
most clones containing inserts or the cloning failed with most clones not containing inserts. 
Therefore, subsequent experiments omitted PCR screening o f recombinants and plasmids 
Minipreps were performed selecting three to five transformants per ligation. Results of this 
strategy are demonstrated in Figure 4.10. Here, gels a and b show 100% efficiency for four 
PCR-generated inserts cloned into pi 108 and pi 108-tPA (all transformants selected are 
shown). Gels c and d represent four subcloning experiments Genes 85a and esat-6 were cut 
from p i 108-tPA and cloned into pWR510 and pWR510-tPA on a NheVEcoRX fragment. 
Again, 100% efficiency was achieved for all 20 clones
4.2.3.5 Clones constructed
Using the PCR-generated inserts, successful cloning was achieved for 14 of the 16 proposed 
constructs, although two of the 14 were subsequently found to contain errors (see below). 
Several attempts at cloning PCR-generated 85a into pWR510 or pWR510-tPA were 
unsuccessful Amplification o f 85a had been successfully achieved using either the primer 
pair 01/02 (Xbal in upper primer, Taq protocol, see Figure 4 4b) or the primer pair 13/02 
(NheI in upper primer, Pfu amplified, see Figure 4 2a) and adequate yields o f Microcon 
membrane-filtered cut inserts were obtained in both cases (20 ng/pl). However, clones 
screened for recombination were repeatedly negative (Figure 4.9a for 01/02, data not shown 
for 13/02).
Subsequently, two errors were noted in primers 06 (85b lower primer) and 17 (esat-6 upper 
primer) (see notes column, Table 2.3). In both cases, a frame shift had been introduced in 
error Therefore, 85b was re-amplified using primer pair 16/22 and this product successfully 
cloned into the pWR510 plasmids The pWR510 constructs with esat-6 and 85a were 
obtained by subcloning from pi 108-tPA constructs as described above (Section 4 2.3.4, 
Figure 4 10).
Details o f plasmid recombinants are summarised in Table 4 1. All of these plasmids were 
utilised in further experiments, such as rVV construction and/or in vitro 
transcription/translation. In order to improve purity, medium scale plasmid preparations 
(Midiprep, Promega) were performed, followed by an additional phenol/chloroform
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Figure 4.10 Plasmid cloning efficiency
Agarose gel electrophoresis showing double enzyme digests of transformants selected 
from four PCR cloning experiments and four subcloning experiments. These demonstrate 
100% recombination efficiency, based on the random selection of between 3 to 5 clones 
per ligation/transformation experiment. Images a) & b) show PCR-generated pi 108 clones 
digested with BhamHl and EcoRI. a) Lanes 2-5 = pi 108-85A, lanes 6-8 = pi 108-ESAT-6. 
b) Lanes 2-4 = pi 108-tPA-85C, lanes 5-7 = pi 108-tPA-ESAT-6. Images c) & d) show 
pWR510 subclones digested with Nhe\ and EcoRI. c) Lanes 2-6 = pWR510-85A, lanes 9- 
13 = pWR510-tPA-85A, lanes 7 and 14 = pi 108-tPA-85A (positive control), d) Lanes 2-6 
pWR510-ESAT-6, lanes 9-13 = pWR510-tPA-ESAT-6, lanes 7 and 14 = pi 108-tPA-ESAT- 
6 (positive control). MW=1()0 bp molecular weight marker.
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purification step and Microcon buffer exchange and the stock concentration was adjusted 
to 1 pg/pl. Figure 4.11 shows an example of BamHVEcoKl digested Midipreps.
4.2.4 Sequencing PCR clones
Following construction, all PCR clones were sequenced across the cloning site to confirm 
identity of the insert (carried out by Dr J McFadden's laboratory, University o f Surrey prior 
to sequencer being available locally). These data also confirmed the correct cloning and 
sequence of tPA in the two tPA vector derivatives (four forward runs for p 1108-tPA and 
three forward runs for pWR510-tPA) (sequence data not shown). Subsequently, a selection 
o f PCR clones were sequenced in more detail using both forward and reverse sequencing 
primers at LSHTM. These included pi 108-tP A constructs for all four genes and pWR510- 
tPA-85C. No errors were identified in any of the constructs.
4.2.5 Generation of rVV
rVV construction was performed as described in Section 2.15. Eighteen rVV were made 
using all the plasmids listed in Table 2.1 except #12, #15, #17 and #20. All the rVV were 
constructed simultaneously. Thus, a complete set of eight rVV, both with and without the 
signal sequence, was prepared for genes under the control o f  the p7.5 promoter Four 
functional rVV were prepared for use in the vaccinia/T7 hybrid system (85B and 85C 
constructs), plus two non-functional ESAT-6 constructs.
4.2.6 Verification of rVV construction using PCR
4.2.6.1 Purified r W  genome required for PCR
As described in the literature (Pasamontes et al. 1991), several attempts were made to verify 
rVV construction using PCR templates taken directly from the rVV-infected cell lysates. A 
variety of primers were tried including: 23/24 (pWR510), 25/26 (within the tPA region) and 
28/29 (Ik homology), but no signals were identified (see Table 2.4 for primer details). 
Therefore, genomic preparations were prepared for each of the rVV as described in Section 
2.161.1. Using these purified templates, PCR amplification was then demonstrable
4.2.6.2 Assessment o f  flanking and tPA primers fo r  verifying rVV recombination 
Figure 4 12 shows the result o f testing a variety of primer pair combinations for their ability 
to verify vaccinia recombination Details o f the primers and their predicted product size is 
given in Table 2 4 Products of PCR reactions were run in pairs, the rVV genomic
Figure 4.11 Double digest o f purified ‘M idiprep’ pi 108-tPA-constructs
Following identification of plasmid recombinants, a single clone was selected for each of 
the generated gene/vector combinations. Medium scale plasmid preparations (Midiprep, 
Promega) were performed and the products were subjected to phenol/chloroform and spin 
column purification. These highly purified plasmid preparations were used for sequencing 
and vaccinia recombination. The agarose gel shows an example of four constructs, pi 108- 
tPA-85A, -85B, -85C and -ESAT-6, each digested with Bam\\\ and £coRI. MW=100 bp 
molecular weight marker.
508F & tPAR (23/26; 508F & TKR (23/29)
P6 V6 P19 P6 V6 P 19
Figure 4.12 Identification of primers suitable for verification o f rVV
PCR was used to verify successful integration of the gene inserts into wild-type vaccinia. 
Purified genomic DNA, derived from rVV-infected cell lysates, was used as the PCR 
template and a variety of primer pairs were assessed for their ability to amplify across the 
cloning site (applicable for all constructs) and also from within the tPA region (constructs 
with tPA). The genomic preparation of an rVV was denoted as V plus digit and the corre­
sponding plasmid was used as a positive control (P plus digit)(see table 4.1 for details). 
Primer abbreviations arc coded by the names of the homologous region: 510=pWR510, 
l()8=pl 108, tPA=tPA region and TK=thymidine kinase. K & R=forward and reverse prim­
ers. The primer unique identifier is given in brackets (see table 2.4). * = 27/26
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preparation (coded V + unique identifier) and the corresponding insertion plasmid (P + 
unique identifier), acting as a positive control eg. V10=rVVT7-tPA-85C and 
P10=pWR510-tPA-85C (see Tables 2.4 and 4.1). As an additional control, an appropriate 
non-recombinant plasmid (pi 108 or pWR510) was also included for each o f  the primer pairs 
tested.
Figure 4 .12a shows discrete strong signals for both plasmid and rVV template reactions. 
This primer pair, 23/24, flanks the cloning site of pWR510. The tPA forward and reverse 
primer pair, 25/26, was equally effective (Figure 4 .12c). However, this pair also resulted in 
mispriming with the control plasmids lacking tPA, producing a band of ~ 1.5 kb (the product 
size is demonstrated in Figure 4.13a(ii) lanes 10 and 11). The same false positive result was 
also seen in other primer pair combinations which used the tPA antisense primer (Figure 
4 12 b and e). This would suggest binding of this primer to the other strand within the tkL 
region, as the same size product seen for both pWR510 and pi 108
Other primer pair combinations showed variable efficacy Of interest, combinations which 
included the TKR antisense primer would amplify a product from plasmid but not rVV (see 
Figure 4 .12b(ii), e(i) and f.
4.2.6.3 PCR verification o f r W -tPA and r W - T7 constructs
Following the identification of the best primer pairs for verifying recombination, all rVV 
were tested for tPA insertion and a pWR510 background Evidence for successful 
recombination (for the PCR positive constructs) was supported by a signal of the correct 
molecular weight in all the rVV-tPA constructs and none of the rVV lacking this region 
(Figure 4 13a). Furthermore, using the pWR510 primer pair, 23/24, PCR signals o f the 
predicted molecular weight were seen for all the rVVT7 constructs and their corresponding 
plasmids and none of the rVVp7.5 constructs (Figure 4.13b). This confirmed insertion of 
a fragment of the correct molecular weight in all the T7 constructs
4.2.6.4 l Jse o f  cloning primers to verify rVV
In addition to the tPA and flanking primer pairs described above, the cloning primers were 
also used to verily vaccinia recombination These data are shown in Figure 4.14, where 
evidence for recombination exists for most, but not all of the constructs Signals were absent 
for rVVp7.5-85B and rVVp7 5-ESAT-6 and their plasmid controls (Figure 4 14a, lanes
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Figure 4.13 PCR verification o f rVV using tPA internal primers and pWR510 
flanking primers
a) All the rVV were assessed for the integration of tPA, as indicated by a PCR signal 
using the primer pair, 25/26. A signal of the correct size was obtained in: i lanes 6, 9-13; 
and, ii lanes 2-4, 8 and 9. These signals corresponded with the predicted pattern for all the 
rVV-tPA constructs and none o f the rVV lacking tPA. b) PCR using the primer pair 23/24 
which flanks the pWR510 coding region. This demonstrated amplification of: i all the 
pWR510-derived constructs and, ii none of the pi 108-derived consructs (lanes 2-11). In 
addition, no signal was achieved if the PCR template was non-purified cell lysate (ii lane 
12, rVVT7-tPA-85C) rather than the genomic preparation from the same rVV (i lane 7). 
Lane 13 shows the positive control, where pWR51() was used as the PCR template. 
MW=1(K) bp molecular weight marker.
b MWV7V13P7 V1 V14V17V9 P1 V2 V15 V4V10 P10
900 bp
300 bp
MW V8 V16 V5 V11 P8
Figure 4.14 PCR verification of rVV using cloning primers
I n  o r d e r  t o  v e r i f y  i n t e g r a t io n  o f  t h e  g e n e  in s e r t s ,  P C R  w a s  p e r f o r m e d  u s in g  t h e  s a m e  c l o n i n g  p r im e r s  u s e d  t o  g e n e r a te  th e  in s e r t s .  P u r i f i e d  g e n o m ic  
p r e p a r a t io n s  o f  r V V - i n f e c t e d  c e l l  ly s a t e s  w e r e  u s e d  a s  t e m p la t e ,  e x c e p t  i n  o n e  c a s e  ( t o p  l e f t  h a n d  g e l ,  la n e  V l L )  w h e r e  th e  u n p u r i f i e d  c e l l  ly s a t e  w a s  u s e d .  
G r o u p s  o f  g e ls  r e p r e s e n t  t w o  r e p l i c a t e  e x p e r im e n t s ,  a) &  b ) . S ig n a ls  o f  t h e  p r e d ic t e d  s iz e  w e r e  o b t a in e d  f o r  a l l  c o n s t r u c t s ,  i n  a t  le a s t  o n e  o f  t h e  t w o  
e x p e r im e n t s ,  e x c e p t  f o r :  V 1 4  ( p i  1 0 8 - d e r iv e d  r V V - t P A - 8 5 B )  a n d  V 2  ( p i  1 0 8 - d e r iv e d  r V V - 8 5 C ) .  T a b le  4 .1  g i v e s  d e t a i l s  o f  t h e  c o n s t r u c t  n u m b e r  c o d e .  T h e  
t y p e  o f  c o n s t r u c t  u s e d  a s  P C R  t e m p la t e s  a re  in d i c a t e d  a s :  V  =  g e n o m ic  D N A  f r o m  r V V - i n f e c t e d  c e l l  ly s a t e s  a n d  P  =  p la s m id  t e m p la t e .  M W = 1 0 0  b p  
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12-15) and was only weakly discernable for rVVp7.5-85C (lane 6). Figure 4 .14b shows a 
repeat PCR for all the rVV grouped according to gene and each with a plasmid control for 
size comparison A signal of the correct size was seen in all cases except rVVp7.5-tPA-85B 
(lane 6) and rVVp7.5-85C (lane 10).
4.2.6.5 Identification offlanking primers for p i  108 and rW p7.5 constructs
Initially, no sequencing data was available downstream of the pi 108 MCS (Dr Mike 
Mackett, personal communication) Following construction of the pi 108-gene recombinants 
and sequencing the 3' end of the sense strand, a primer was selected (PR10840R, Table 2.1). 
In combination with PR10827F, this primer pair readily amplified all inserts in both pi 108- 
derived rVV and the corresponding plasmids (Figure 4.15). Thus, these data taken together 
provide evidence for successful gene integration into vaccinia in all cases
4.3 DISCUSSION
Twenty plasmids were prepared using pi 108 and pWR510 vectors A second generation of 
eighteen rVV were constructed The desired goals of Ag85 and esat-6 gene integration, tPA 
signal sequence insertion and gene integration under the T7 promoter were achieved in all 
possible combinations, except for the rVVT7-85A and rVVT7-ESAT-6 constructs. 
However, a variety of methodological issues arose during the different stages of 
development These are discussed by summarising the achievements, pitfalls and mistakes 
experienced
4.3.1 Achievements
4.3.1.1 ( 'lotting primers
The computer programme-generated primer predictions produced strong signals in all PCR 
reactions enabling the use o f I fit polymerase in all but one case, 85a into pi 108, for which 
laq  polymerase was used The inclusion of restriction sites and manipulation o f the start or 
stop codon was successful The only insert which could not be cloned was 85a into 
pWR510. The reasons for this are unclear Where PCR clones were not obtained (four 
pWR5IO constructs), subcloning from pi 108-tPA-85A and -ESAT-6 was possible due to 
the presence of both HamHl and Nhe\ sites in the tPA MCS.
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Figure 4.15 PCR verification of p ll08-derived  rVV
A primer pair flanking the cloning site was used to verify vaccinia recombination. The 
PCR templates were: the genomic preparation of a pi 108-derived rVV-infected TK-143 
cells (V) paired next to the corresponding p i 108 plasmid recombinant (P), with each plas­
mid acting as a positive control for the rVV. tPA- = no signal sequence, tPA+ = signal 
sequence present. Left hand lanes=100 bp molecular weight marker.
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4.3.1.2 p i  108-tPA andpWR510-tPA
Construction of the tPA insertion plasmids was achieved and sequence fidelity was 
confirmed This provided useful generic constructs with a MCS permitting relatively simple 
sticky or blunt-ended cloning This was not only useful for this study, but would also be of 
benefit for those wanting to create rVV-tPA fusions.
4.3.1.3 High cloning efficiency and membrane filtration
All inserts were readily cloned into their respective insertion plasmids with very high 
recombination efficiencies, reaching 100% for the final 8 ligations In part, this was 
facilitated by the cloning strategy which used membrane filtration with reduction in the salt 
content and the unwanted sticky-ended fragments following digestion The high 
recombination efficiency permitted omission o f PCR screening of bacterial colonies and 
selection of as little as three transformants for each ligation reaction. For the subcloning 
experiment, membrane filtration avoided the use of a phenol/chloroform purification step 
of cut insert following electroelution from the cut gel slice. Instead, the -500 pi volume was 
washed and concentrated (a 30m procedure). In addition, the cut vector was processed 
using the Micropure EZ insert (enzyme removal) and membrane filtration From four 
ligations, all 20 clones selected contained a correct insert However, no direct comparison 
of efficiency between phenol/chloroform purification and the Microcon system was made 
and the high cloning efficiency may have been due to other factors. Importantly, the 
Microcon system avoids some phenol/chloroform steps, thus improving safety and reducing 
processing time.
4.3.1.4 ( Construction o f rVV and PC'R verification
Construction o f 18 rVV was achieved Primer design and assessment of PCR verification 
produced clear results for primer pairs flanking the cloning sites of both pWR510-derived 
and pi 108-derived rVV, as well as for tPA-containing rVV Additional, but incomplete 
evidence was provided using the cloning primers Without sequencing data, none of these 
PCR data provide absolute proof o f correct gene integration. Flanking primers merely 
indicate that a correctly sized fragment has been cloned Cloning primers could potentially 
'verify' any PCR insert generated by the same primer pair e g the product of mispriming 
from the original BlueScribe vector carrying the gene. However, all plasmid clones were 
sequenced prior to vaccinia recombination, making this very unlikely. An alternative 
approach would have been to use a primer pair amplifying an internal region within each
gene, perhaps selected to distinguish the different Ag85 genes In addition, a combination 
o f flanking primers and internal primers might have permitted successful nested PCR and 
obviated the need for preparation of rVV DNA, a purification step required in this study but 
not by others (Pasamontes et al 1991).
4.3.2 Pitfalls and mistakes
4.3.2.1 Xbal in the forward primer
Xbal was chosen as the selected site for the upper primer in several cases (01, 05 and 09). 
The programme gave higher scores for these choices as compared with the equivalent 
primer with a Nhe\ site Whilst this produced a compatible sticky end for cloning into 
pWR510, the Nhe\ site would then have been lost, making subsequent recombination more 
difficult to verify and losing the ability to sub-clone. In the final event, none of these primers 
were used for plasmid construction.
4.3.2.2 Errors in primer design
Two errors were introduced into primers 06 and 17 at the time of their design. This was 
discovered early on in the case of the 85b PCR product and the mistake rectified. However, 
the error in primer 17 was only identified following rVVT7-ESAT-6 construction (during 
the alignment of sequence runs) In retrospect, a computer-generated plasmid sequence and 
protein translation would have identified this problem prior to primer purchase.
4.3.2.3 A need for early sequencing o f  clones
Two PCR clones used Taq polymerase-generated inserts (pi 108-85A constructs). Given the 
relatively lower fidelity of this enzyme, these clones should have been fully sequenced as 
soon as possible after construction Ideally, the same is also true for the /'/»/-generated PCR 
products, although the risk of misincorporation is much less This would identify sequence 
or cloning errors and permit early correction In addition, rVV which do not appear to 
express could be further explored without the worry of a potential PCR misincorporation 
error From a practical perspective at the time of the cloning, no automated sequencer was 
available in our institute All plasmids were sent away, but because of the relatively high 
expense, only sequencing across the cloning site was performed Manual sequencing o f  so 
many clones would have been very time consuming At a later date when an automated 
sequencer was available on site, eight plasmids were sequenced in both directions with no
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evidence of misincorporation (the two '/¿/¿/-generated clones, all the four pi 108-tPA clones 
and the two tPA-85C clones).
4.3.2.4 Subcloning rather than PCR cloning
Whilst Pfu polymerase generates inserts with a relatively low chance of misincorporation, 
th is chance is still significantly greater than subcloning a fully sequenced insert. In 
retrospect, a more efficient cloning strategy would have been construction of all four p 1108- 
tPA-gene constructs with full sequencing of these, followed by subcloning into pi 108, 
pW R510 and pWR510-tPA However, construction of pi 108-tPA took a relatively long 
time and the other reagents were fully prepared and ready for use (cut vectors and cut PCR 
inserts). Therefore, the construction o f PCR clones was chosen. However, despite the lack 
o f  availability o f pi 108-tPA early in the cloning experiments, subcloning could still have 
been performed from pi 108 to pi 108-tPA and likewise, for pWR510 to pWR510-tPA, thus 
limiting the number of clones requiring sequence verification.
4.4  CONCLUSION
Twenty insertion plasmids were constructed from vectors pi 108 and pWR510, using both 
PCR and subcloning Two of these, pi 108-tPA and pWR510-tPA represent generic vaccinia 
insertion plasmids for rVV expression of genes, fused downstream from the eukaryotic tPA 
signal sequence and under the control o f either p7.5 or T7 promoters. Sixteen of the 
plasmids plus the two vectors were used to construct eighteen rVV. The remaining four 
pW R510 plasmids (85a and esat-6 with and without tPA) were prepared for in vitro 
transcription/translation experiments All PCR clones were sequenced across the cloning site 
and eight were sequenced in both directions Successful integration of tPA and MTB genes 
into vaccinia was confirmed using a variety of flanking, tPA and cloning primers
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5.1 INTRODUCTION
The construction of the rVV, as described in Chapter 4, was apparently successful, judged 
at a DNA level. However, it was important to assess the expression o f  the recombinant 
antigens before the rVV could be used in immunological assays. This chapter describes the 
results of two methods used to assess protein expression from both rVV and plasmid 
constructs. For rVV expression, virally-infected cell lysates were subjected to 
immunoblotting using both dot and Western blotting techniques. In vitro 
transcription/translation was employed using the pWR510 constructs containing MTB genes 
under the control of the T7 promoter. This cell free system permitted further protein analysis 
using constructs with different mycobacterial genes, both with and without the signal 
sequence. In addition, protein expression for rVV-ESAT-6 constructs was demonstrated by 
collaborators using a newly developed capture ELISA. In chapter 6, the results of 
immunofluorescence are shown in order to demonstrate recombinant protein expression in 
rVV-infected cultured human macrophages which were used as CTL target cells.
5.1.1 Immunoblotting
Immunoblotting represents one of three common means to detect recombinant protein 
(Mackett, 1995). Whilst immunofluorescence staining o f cells infected with rVV represents 
a straightforward and fast method, it would not have permitted assessment of molecular 
weight differences or multiple bands resulting from post-translational modification. Size 
resolution and a high degree of sensitivity are possible with immunoprécipitation However, 
no metabolically-labelled culture filtrate protein positive control was available.
In these experiments, the Amersham ECL chemiluminescent protocol was used in all cases, 
as described in Section 2.16.3. A preliminary experiment compared diaminobenzidine (DAB, 
Sigma) staining and the chemiluminescence protocol; each utilised the same secondary 
antibody conjugated to horse radish peroxidase The DAB readout was less sensitive (data 
not shown) and was not employed in further experiments.
5.1.2 In vitro coupled T7 transcription/translation
The bacteriophage T7 promoter is particularly powerful, resulting in very high levels of 
expression in many systems (Moss et al 1990) Section 1.6.7 discusses this in more detail 
with particular reference to two systems the vaccinia/T7 hybrid system and in vitro cell free 
transcription/translation. This study utilised both methods in order to address two questions:
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Was the failure to observe rVV-ESAT-6 expression under p7.5 was due to low rather than 
absent protein expression? and; What was the effect of a eukaryotic signal sequence in a cell 
free system? The construction of rVV encoding MTB secreted proteins under the T7 
promoter (designated rVVpT7 constructs) would help assess absent versus low-level 
expression of protein. In  vitro transcription/translation using the pWR510 constructs would 
allow dissection of protein properties by comparing the impact of the signal sequence using 
the system both with and without microsomal membranes. Additional fractionation of the 
microsome reaction products into membrane-associated protein and protein in the 
supernatant would provide further evidence for post-translational modification. Thus, the 
pWR510 constructs were able to serve a dual function, as insertion plasmids for 
homologous recombination, and as templates for cell free protein expression.
5.2 RESULTS
5.2.1 Immunoblotting of rVV-Ag proteins
In order to identify proteins of the Ag85 complex, dot blot and Western blot experiments 
were performed using two mAbs, TD-17 and TD-32 (Table 2.5). Results from the latter 
mAb produced an identical signal pattern but of lower intensity. Most o f these data are not 
shown. Later in the project a further polyclonal antibody became available and was used to 
probe the same virally-infected cell lysates. For the purpose of comparison, blots using both 
the mAb, TD-17 and the polyclonal antibody, K92, are shown in the same figure.
5.2.1.1 Dot blotting o f rVV-AgS5 infected cell lysates
Twofold dilutions o f  rVV-Ag85-infected cell lysates were directly dotted onto a 
nitrocellulose membrane, dried and probed with mAb TD-17 using the protocol described 
in Sections 2 16 3.6-7 MTB culture filtrate (CF) was used as a positive control and rVV- 
tPA alone was used as a negative control. For comparison, a similar experiment was 
performed for the 85B constructs using the polyclonal antibody, K92. The results are shown 
in Figure 5.1. As well as the positive control, specific signals were detected for all 85 A and 
85B constructs, but not for 85C. Furthermore, in all cases where a specific signal was 
detected, the intensity was greater for tPA fusion protein than the corresponding non-tPA 
recombinant protein For mAb TD-17 and 85A, the addition of tPA accounted for 
approximately an eightfold increase With the same antibody, for 85B, the signal was 
approximately 2-4 fold greater However, with the polyclonal antibody, the tPA-85B signal 
was approximately 8-16 fold greater than 85B alone
150
a £
85A
tPA-85A
85B
tPA-85B
85C
tPA-85C 
tPA alone
culture filtrate
b
85B
tPA-85B
tPA alone
<z? <V ¿b <5^  K-
<o
Figure 5.1 Dot blots o f rVV-infected cell lysates probed for Ag85
rVV-Ag85 infected cell lysates and M. tuberculosis culture filtrate (CF) were dotted in 1 
|il aliquots onto nitrocellulose membrane, in twofold serial dilutions and probed using: a) 
mAbTD-17; or b) rabbit polyclonal anti-MPT59 (Ag85) antisera. The signal was created 
using peroxidase-conjugated secondary antibody and chemiluminescence (ECL, 
Amersham).
Chapter 5 Antigen 8 5  and ESAT-6 protein expression 151
5.2.1.2 Western blotting using the mAb TD-17
Using the same protein samples as used for dot blotting, Western blotting was performed 
with 15 pi of protein loaded per well. The initial data, using the mAb, is demonstrated in 
Figure 5.2a(i). This shows strong single bands for both rW -85A  and tPA-85A. Three bands 
of lower intensity are seen in the rVV-tPA-85B lane and a very strong signal from the CF 
positive control. The 85A band is in keeping with the predicted 32 kDa size. Only an 
approximate comparison can be made with the positive control in this blot (the signal is too 
strong for clear comparison), but equivalent molecular size is clearer in a similar experiment 
shown in Figure 5.2b(i) The band seen in rVV-tPA-85A is of a larger size than would be 
predicted, given that it encodes only a further 21 residues. The same is certainly true for 
tPA-85B which, in native mycobacterial form, is only 30 kDa in size (as the mature protein 
found in culture filtrate).
An underexposed Western blot containing the same protein was probed with the mAb, TD- 
32. Whilst a lower signal was apparent, the results illustrated in Figure 5.2a(ii) demonstrate 
two discrete bands in the CF control, consistent with the two dominant 85A and 85B 
proteins in mycobacterial CF (32 kDa and 30 kDa respectively)
A repeat Western blot was performed using the same protein concentration in each lane (the 
samples were previously equilibrated for concentration) This demonstrated the same 
banding pattern as seen in Figure 5.2a(i) (data not shown). In addition, both a short and long 
exposure were performed (Figure 5.2b). These demonstrated that all the 85A and 85B 
recombinants produced a signal indicating expression This included rVV-85B (without tPA) 
not seen in the previous Western blot Even in the over-exposed autoradiograph, there was 
still no evidence for 85C expression
5.2.1.3 Western blotting using the polyclonal antibtxly K92
When the polyclonal antibody became available, the Western blotting experiment was 
repeated using the same protein samples and K92 antibody. The result is shown in Figure 
5 3a For comparison, a detail from Figure 5.2a (the same Western blot probed with mAb 
TD-17) is given below (Figure 5.3b) Using the polyclonal sera, signals from the rVV-85B 
constructs were now similar to the rVV-85A constructs. As with the mAb probe, three 
higher molecular weight bands were noted for rVV-tPA-85B The presence o f multiple 
bands of a higher molecular weight than expected suggested post-translational modification
Figure 5.2 Western blots of rW-infected cell lysates probed for Ag85 using two monoclonal antibodies
a)i 10 pi o f  c e l l  l y s a t e  p e r  la n e  w a s  r u n  o n  SDS-PAGE, b lo t t e d  o n t o  n i t r o c e l l u lo s e  m e m b r a n e ,  p r o b e d  w i t h  m A b T D - 1 7  a n d  th e  s ig n a l  d e te c te d  
u s in g  c h e m i lu m in e s c e n c e ,  ii T h i s  is  a  d e t a i l  s h o w i n g  t h e  o n l y  s ig n a l  p r e s e n t  o n  a n  id e n t i c a l  b l o t  t o  a)i e x c e p t  t h a t  i n  t h i s  c a s e  i t  w a s  p r o b e d  w i t h  
m A b  T D - 3 2 .  N o t e  th e  d o u b le  b a n d  in  t h e  C F  la n e .  b)i & ii T h e s e  im a g e s  s h o w  t h e  s a m e  e x p e r im e n t  a s  a)i, b u t  in c lu d e  d i f f e r e n t  a u t o r a d io g r a p h ic  
e x p o s u r e s  o f  t h e  s a m e  b l o t ,  i A b r i e f  4 5 s  e x p o s u r e  a n d  ii a  p r o lo n g e d  1 5 m  e x p o s u r e .
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Figure 5.3 Western blots of rVV-infected cell lysates probed for Ag85 with polyclonal 
and monoclonal antibodies
rVV-Ag85 infected cell lysates (10 pi loaded per lane; lanes 1-8) and M. tuberculosis 
culture filtrate ( 1 pi loaded; lane 9) were run on SDS-PAGE, transferred to nitrocellulose 
membranes and probed using: a) rabbit polyclonal antiserum - K92; or b) mAb TD-17. 
The signal was created using peroxidase-conjugated secondary antibodies and 
chemiluminescence (ECL, Amersham).
of the recombinant protein. Further evidence for this is provided below. As for the mAb 
Western blot, no signal was seen for the 85C constructs.
5.2.1.4 Western blotting using immune sera fro m  Ag85 DNA vaccinated mice
In order to identify possible 85C expression, several mouse polyclonal sera were used in 
Western blotting studies. These were derived from mice vaccinated with a variety of Ag85 
DNA constructs including 85C. Previous work by K. Huygen had demonstrated that the 
85C construct was immunogenic along with the other DNA constructs (personal 
communication) (Huygen et al. 1996). Attempts at dot blotting with these sera was 
unsuccessful, the background being too high to distinguish a specific signal except for the 
CF positive control (Figure 5 4a). However, a Western blot probed with serum from a 
mouse vaccinated with 85A DNA showed a strong signal for 85A, tPA-85A and CF (Figure 
5 4b). Serum from a mouse vaccinated with 85B DNA produced a weak signal of the 
correct size for the CF control only (Figure 5 5a). For anti-85C, amongst non-specific 
binding, there were signals consistent with identification of 85A, tPA-85A, 85B, tPA-85B 
and CF, but not 85C (Figure 5.5b). A further serum sample came from a mouse vaccinated 
with all three DNA constructs (labelled anti-85A-C). Probing with this serum produced a 
pattern similar to the anti-85C blot (Figure 5.5c). It would be tempting to believe that the 
signal in the 85C lane, of about the correct size, might suggest the presence of this protein. 
However, similar signals were also evident in the negative controls
5.2.1.5 Evidence for glycosylation o f rW -tPA -85B
The previous Western blots identified three discrete bands for rVV-tPA-85B suggesting 
three possible glycoforms of the same protein. In order to confirm that these were 
glycoforms, N-glycosidase digestion of cell lysates were performed for this construct and 
85B without tPA (Section 2.16.3 8) Figure 5.6 shows a Western blot of digested and 
undigested cell lysates, probed with the polyclonal antibody, K92 Lanes 1 and 2 show that 
the enzyme had no effect on the non-tPA construct However, for tPA-85B, all three bands 
were lost following N-glycosidase digestion and were replaced with two further bands. The 
lower molecular weight band could represent non-glycosylated tPA-85B and the higher 
molecular weight band, a glycoform not digested with this enzyme
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Figure 5.4 Immunohlots probed with serum from a mouse immunised with 
an Ag85A DNA vaccine
a) A dot blot showing 1 fil aliquots of rVV-infected cell lysates tested neat and in a 
series o f twofold dilutions and probed with serum from a mouse previously vacci­
nated with a DNA vaccine encoding the tPA-Ag85A sequence, b) A Western blot 
using the same cell lysates (10 pi loaded per lane) and antibody probe.
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Figure 5.5 Western blots probed with serum samples from mice immunised with 
one or multiple Ag85 DNA vaccines
rVV-Ag85 cell lysates were subjected to Western blot analysis using three different serum 
samples from individual mice immunised with either: a) a DNA vaccine encoding the 
tPA-85B sequence (top image); b) a DNA vaccine encoding the tPA-85C sequence (middle 
image); and c) three DNA vaccinesencoding the IPA-85A, (PA-85B and tPA-85C sequences 
respectively (lower image).
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Figure 5.6 Western blot of N-glycosidase digested rVV-Ag85B lysates
Cell lysates, previously infected with rVV-Ag85B (lanes 1 and 2) or rVV-tPA-Ag85B 
(lanes 3 and 4), were digested (lanes 2 and 4) or mock digested (lanes 1 and 3) with N- 
glycosidase and then probed using a rabbit polyclonal anti-Ag85 antisera (K92). The detail 
shows shows an enlarged version of the CF lane from a replicate experiment where the 
signal for the Ag85 complex is more distinct (indicated by the arrow head). CF=A/. tuber­
culosis culture filtrate (positive control).
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5.2.1.6 85B expression using the T7 promoter and comparison with the p7.5 
promoter constructs
Of the four rVVpT7 constructs encoding 85b and 85c both with and without tPA, 
immunoblot signals were identified for the 85B constructs only. As for the rVVp7.5 
constructs, the addition o f tPA enhanced expression, as shown using dot blotting (Figure 
5.7a. In addition, a Western blot also showed a similar banding pattern to the rVVp7.5- 
generated protein (Figure 5.7b). Despite replicate experiments and careful attention to 
quantifying the viral titres, there was no evidence for enhanced expression using the T7 
vaccinia hybrid system (Figure 5.7a).
5.2.1.7 Second generation rW -ESA T-6 constructs
Cell lysates derived from p i 108-derived rVV-ESAT-6 and rVV-tPA-ESAT-6 constructs 
were probed with the mAb HYB 76-8 in both dot and Western blot experiments. SDS- 
PAGE gels were run using reducing and non-reducing conditions An alternative HYB 76 
mAb clone, HYB 76-13, was also used for immunoblotting. Despite the development of the 
tPA-ESAT-6 fusion, immunoblotting failed to detect a positive signal. The following year. 
Prof. M Harboe's group in the University of Oslo, Norway, developed a capture ELISA, 
utilising the original mAb, HYB 76-8, in the first layer, the test reagent in the second layer 
and a polyclonal anti-peptide antibody in the third layer (see below for description. Section 
5.3.2.3). They assessed rVV-ESAT-6 cell lysates from this study using their capture ELISA 
and demonstrated high level protein expression for rVV-tPA-ESAT-6 (Harboe et al. 1997). 
Protein expression was also seen for rVV-ESAT-6, but at a much lower level These results 
are summarised in Figure 5.8, which was kindly provided by Prof. M. Harboe.
5.2.2 In  v itr o  coupled T7 transcription/translation
5.2.2.1 7ranscription/translation without microsomes
Following subcloning of genes 85a and esat-6 from the appropriate pi 108-tPA plasmids, 
a full set o f pWR510 constructs were available for in vitro transcription/translation 
experiments (Section 2.11.3.3). Half a microgram of purified plasmid was added per 
reaction tube along with the other appropriate reagents, minus microsomes Metabolic 
labelling was performed using ” S methionine Further details of the methodology are 
described in Section 2.17 Figure 5.9 shows results from three separate experiments 
represented in the autoradiographs labelled 'a', 'b' and 'c'). Figure 5.9a shows metabolically-
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Figure 5.7 Immunoblots o f rVV-85B-infected cell lysates - p7.5 versus T7 promoter
a) rVV-85B infected cell lysates were prepared using constructs utilising the T7 promoter 
(pWR510-derived) and the p7.5 promoter (pi 108-derived). Protein samples were dotted 
using 1 pi aliquots, both neat and in a series of twofold dilutions. The membrane was then 
probed with a rabbit polyclonal antibody (K92). b) The Western blot shows rVV-85B 
infected cell lysates (p7.5 promoter constructs in lanes 1 and 3, T7 promoter constructs in 
the two far right lanes) also probed with K92. A similar banding pattern was produced 
irrespective of the promoter. Different protein concentrations were used, therefore no 
quantitative comparison can be made. Unlabelled lanes represent data from a separate 
experiment. CF=MTB culture filtrate.
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Figure 5.8 Capture ELISA for ESAT-6
Protein was obtained from rVV-infected cell lysates (this study) and MTB CF (ST-CF from 
the Statens Seruminstitut, Copenhagen) In Oslo, protein quantification was performed using 
the same technique for all samples (BCA protein assay reagent. Pierce Chemical Comp., 
Rockford, IL, US). Serial dilutions of protein were then assayed for ESAT-6 using a 
capture ELISA and the OD4"' measured (Harboe et al 1997).
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Figure 5.9 In vitro coupled T7 transcription/t ranslat ion of Ag8S and esat-6 genes in 
the absence of microsomes
Transcription/translation was performed using the pWR510 constructs (genes under control 
of the T7 promoter) in a single step microfuge tube reaction. This resulted in V,S methionine- 
labelled protein products. These products were then resolved using SDS-PAGE and the 
signal recorded using autoradiography. a)Thc figure shows products from all the pWR510 
constructs, b) A detail of a second experiment showing degradation of 85C (third lane 
from the left), c) A detail taken from a third experiment showing the size difference be­
tween ESAT-6 and tPA-ESAT-6.
labelled protein products for the whole set of pWR510 constructs. Signals o f the correct 
molecular weight were seen in all lanes except that containing the tPA-85C reaction. Here, 
there was a slight increase in signal at the gel front, as compared with the two negative 
controls (empty vector or pWR510-tPA alone). This suggested the possibility of protein 
degradation However, the background was relatively high, making overall interpretation 
difficult In a previous experiment using the same reaction conditions (which included 85B 
and 85C constructs only), no signal from the tPA-85C reaction was seen (Figure 5.9b). In 
this case, the 85C only lane showed a signal of the correct molecular weight, plus a stronger 
signal which had run with the dye front Again, this result supported the possibility o f  the 
85C protein being unstable and prone to degradation in this system
As would be predicted, the presence or absence of tPA resulted in an appropriate difference 
in molecular weight This was seen for 85 A (Figure 5.9a), 85B in two separate experiments 
(Figure 5.9a and 5.9b) and ESAT-6 in one of two experiments (Figure 5.9c). In the other 
ESAT-6 experiment, no apparent difference was seen in the reaction products (Figure 5.9a) 
due to over-running of the gel.
5.2.2.2 Transcription/translation in the presence o f microsomes
In order to assess the influence of the signal sequence, canine pancreatic microsomes were 
included in further reactions Ultracentrifugation of the reaction products permitted 
comparison o f membrane-associated protein (the pellet) and non-membrane associated 
protein (the supernatant) (see Section 2.17 2). In addition, further comparisons were made 
between reaction products with and without microsomes. The results of these experiments 
are shown in Figures 5.10a(85A), 5.10b (85B and tPA alone) and 5.1 la (ESAT-6 and tPA 
alone).
The figures demonstrate two key features associated with the tPA constructs. These are 
described below.
1) tPA leads to the association of protein with microsomal membrane 
For the membrane-associated fraction (the pellet), the intensity of the band was greater for 
those constructs which encoded the tPA signal sequence as compared to the same gene 
product without tPA (see lanes 3 and 6 for Figures 5.10a, 5.10b and 5.11 a). This is 
particularly clear
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85A constructs
tPA - - - + + +
microsomes - + + - + +
fraction na s/n pellet na s/n pellet
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tPA
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85B constructs tPA alone construct
+++i1i +++
+ + - + + + +
na s/n pellet na s/n pellet na s/n pellet
Figure 5.10 I n  vitro coupled T7 transcription/translation of 8 5a  and 85 b  genes
with the addition of microsomes - the effect of the tPA signal sequence
Reactions were performed with (+) and without (-) canine pancreatic microsomes. Those 
reactions in which microsomes were included were subject to ultracentrifugation in order 
to fractionate the protein products into membrane-associated (pellet) and non-membrane- 
associated (s/n). a) The products from pWR510-85A and -tPA-85A constructs, b) The 
products from pWR510-85B, -1PA-85B and -tPA constructs alone. tPA present= (+) and 
tPA absent= (-). s/n=supernatant and na=not applicable.
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Figure 5.11 I n  vitro  coupled T7 transcription/translation of esa t-6  and A g 8 5  
genes with the addition o f  microsomes
a) Reactions were performed using pW R510-ESAT-6 constructs both with (+) and without 
tPA (-). The pWR510-tPA construct was used as a negative control. Canine pancreatic 
microsomes were added in half of the reactions and the products of these reactions were 
fractionated into membrane-associated (pellet) and non-membrane-associated (s/n).
b) Products from reactions using the 85A, 85B and tPA constructs were run on a larger gel 
format in order to improve size resolution. Microsomes were included in all of these 
reactions. s/n=supernatant and na=not applicable.
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in the autoradiograph in Figure 5.11b, where the products of 85A and 85B from the 
microsome experiment were run in the same gel.
In addition, the relative proportion of product found in the pellet versus the supernatant 
varied according to the presence o f the tPA signal sequence. There was a general trend in 
favour of a stronger signal occurring with the supernatant fraction for non-tPA constructs 
and a stronger signal occurring with the membrane fraction for tPA constructs. This 
provided evidence for membrane-binding o f tPA constructs to the microsomes. Good 
examples of this are shown in Figure 5.11b in: (i) 85A (no tPA) where there is no signal with 
the membrane fraction (lanes 1 and 2) and (ii) 85B (with tPA) where there is no signal with 
the supernatant fraction (lanes 7 and 8). This comparison could not be made for esat-6, 
owing to the high background in the low molecular weight region of supernatant fraction. 
In contrast to the predicted pattern, the 85B (no tPA) reaction showed a definite signal with 
the membrane fraction However, there was no increase in molecular weight unlike the 
relevant tPA counterpart (see below).
2) Evidence in favour of tPA-associated post-translational modification 
In the case of the tPA constructs, but not those lacking the signal sequence, there was an 
increase in molecular weight for membrane-associated proteins (see lane 8, Figure 5.11a) 
and lanes 4 and 8, 5.11b), as compared with either the supernatant fraction or the products 
from the reactions not including microsomes This provides evidence in support of post- 
translational modification In addition, two bands were noted for 85A (with tPA) in the 
supernatant fraction (lane 3, Figure 5.11b). The lower molecular weight band corresponded 
to the predicted product size (similar to 85A (no tPA) and was smaller in size than the 
glycosylated 85A (tPA)). The higher molecular weight band migrated a shorter distance than 
the tPA membrane-associated product (lanes 3 versus 4). Possible reasons for this are 
discussed below (Section 5.3.1.3).
5.3 DISCUSSION
Following the failure to observe protein expression from the first rVV construct (pSCl 1- 
derived rVV-ESAT-6, chapter 3), three strategies to enhance expression were pursued the 
addition of alternative genes (Ag85 genes), the use of the T7 promoter and the addition of 
a signal sequence The following section discusses the achievements, failures and validity 
of these strategies
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5.3.1 Ag85 protein expression
In contrast to the pSCll-derived rVV-ESAT-6 immunoblots shown in chapter 3, 85A and 
85B rVV-encoded proteins were readily identified Immunoblotting demonstrated 
expression using two different monoclonal antibodies (TD-17 and TD-24), a rabbit 
polyclonal antibody (K92) and serum samples from mice vaccinated with Ag85 DNA 
constructs Furthermore, integrity of the coding region was supported by in vitro coupled 
T7 transcription/translation for all of the genes, except for the 85C construct with tPA.
5.3.1.1 Monoclonal immunoblotting o f  85A and 85B
As would be expected, the banding pattern was similar for all blots, irrespective of the 
antibody probe used. However, different antibodies produced marked differences in signal 
intensity, a feature most pronounced when comparing the mAb, TD-17, with the polyclonal 
antibody, K92 (Figure 5.3).
In the early part o f the study, only mAbs TD-17 and TD-24 were available. According to 
a previous study, native 85A, 85B and 85C were each recognised by these monoclonal 
antibodies with a similar degree of antibody reactivity (Drowart et al. 1992). However, in 
this study, TD-24 was unable to identify rVV-encoded 85B (data not shown) and TD-17 
could only recognise protein from the rVV-85B constructs following prolonged 
autoradiographic exposure (Figure 5.2b). Three possible explanations were considered: (i) 
only small amounts of recombinant 85B were made; (ii) the mAbs recognised native 85B 
more readily than the recombinant counterpart (perhaps due to a structural difference or 
post-translational modification); and (iii) despite the previous report, the mAbs recognise 
85B less clearly than 85A Figure 5 2a(ii) shows a Western blot probed with mAb TD-24, 
which included an MTB CF control lane This mAb was able to identify two bands in the 
MTB CF lane, a more intense 30 kDa band (consistent with native 85B) and a less intense 
32 kDa band (consistent with 85A). This finding is consistent with the fact that 85B is 
known to predominate in MTB CF (Drowart et al 1992) and suggests that mAb TD-17 can 
recognise 85B, at least in its native secreted form An argument against the first explanation 
(less recombinant 85B as compared with 85A), comes from the dot blot experiments These 
showed no difference in levels o f expression for either of the proteins with and without tPA 
(Figure 5 I and two repeat dot blots, data not shown). Thus, it was proposed that the 
pattern of mAb recognition o f 85A and 85B may have been due to conformational or
glycosylation differences. This could also explain the disparity between dot blots 
(undenatured protein) and Western blots (protein subjected to SDS-PAGE).
5.3.1.2 Recombinant 85C expressed in mammalian cells - problems o f
glycosylation
Given the difficulty with mAb recognition o f  85B, it was proposed that glycosylation might 
account for the failure to identify rVV-derived 85C. In support of this hypothesis, the 
existing mAbs were generated using the native mycobacterial Ag85 proteins. Whilst 
evidence exists for glycosylation o f other secreted mycobacterial proteins such as the 19 
kDa and 45 kDa MTB proteins (Garbe et al 1993; Dobos et al. 1995), there has been no 
data to suggest glycosylation of native Ag85 proteins (Dr C. Abou-Zeid, personal 
communication). If these Ag85 proteins were to be expressed in a eukaryotic system, they 
could be subject to post-translational modification. From sequence data, potential 
glycosylation sites for N-linked glycans include -Asn-Xaa-Ser/Thr- (where Xaa is any 
residue) and for O-linked glycans, Pro/Ser/Thr-rich regions (Carlsson, 1993). In the case of 
Ag85 complex proteins, the number of theoretical sites is high for 85C (seven N-linked 
sites), low for 85A (one N-linked site) and somewhere between for 85B (four N-linked 
sites). Thus, eukaryotic expression, using systems such as transfected cells, DNA 
vaccination or rVV, could give rise to glycosylated products that may not exist when 
derived from mycobacteria. This would be particularly true for those proteins which include 
a eukaryotic signal sequence This would facilitate translocation into the endoplasmic 
reticulum and progression through the Golgi system
The problem of glycosylated protein recognition was noted using recombinant Ag85 
expressed in transfected eukaryotic cells (Dr M Liu, Third International Conference on the 
Pathogenesis of Mycobacterial Infections, Stockholm, June 1996) Probing for recombinant 
Ag85 proteins using the available mAbs produced a strong signal for 85A, a weaker one for 
85B and an absent one for 85C. However, recombinant 85C was subsequently identified 
using serum from 85C DNA vaccinated mice or polyclonal antibody serum Moreover, a 
high degree of glycosylation was noted with this particular protein, as demonstrated by 
graded deglycosylation In this study, a similar pattern of mAb reactivity was noted for the 
three rVV-generated Ag85 proteins, a strong signal for 85A, a weak one for 85B and an 
absent signal for 85C. Therefore, sera from Ag85 DNA vaccinated mice were obtained in 
order to probe rVV-Ag85 Western blots. Both 85A and 85B were recognised with a
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banding pattern not dissimilar to that obtained with the mAb TD-17. Unlike Ag85 from 
transfected cells, 85C was not identified (Figures 5.4 and 5.5). At a later date, the same 
proteins were probed with the rabbit polyclonal antibody, K92. This demonstrated 
recombinant products from both 85A and 85B constructs, but again no signal from 85C was 
obtained (Figure 5.3a).
5.3.1.3 Evidence for glycosylation o f  rW -Ag85  - immunoblotting and in vitro 
transcription/translation
Western blotting of the rVV Ag85 constructs showed multiple bands for both tPA-85 A (two 
bands) and tPA-85B (three bands) (Figure 5.3). The molecular weight for these antibody- 
reactive targets is greater than would be predicted from their amino acid sequences This 
suggests post-translational modification and that each band represents a different glycoform 
of the same protein
Evidence in support of glycosylation comes from the constructs incorporating the tPA signal 
sequence. Firstly, N-glycosidase treatment of rVV-encoded tPA-85B resulted in the 
replacement of the three higher molecular weight bands with two bands of lower molecular 
weight This is consistent with partial deglycosylation (Figure 5.6). Secondly, the addition 
of microsomes to the in vitro transcription/translation expression system resulted in products 
of larger molecular weight and, in most cases, these were associated with the membrane 
fraction (Figure 5 10 and 5.11). There was no evidence in favour o f glycosylation for the 
non-tPA constructs
Using the in vitro transcription/translation system with microsomes, an interesting finding 
was noted with the tPA-85A construct. Two strong, discrete signals were noted in the 
supernatant fraction. The low molecular weight band was consistent with unmodified 
protein. The second band was of a higher molecular weight than the membrane-associated 
fraction from the same reaction (Figure 5.1 lb) One could explain this finding in terms of 
the degree of glycosylation, with a more fully glycosylated product being 'secreted' back into 
the supernatant However, further work would be required to confirm this explanation
5.3.1.4 Protein expression using the T7 as compared to the p7.5 promoter 
rVVpT7 constructs included the 85b and 85c genes both with and without tPA. Similarly 
to the rVVp7.5 constructs, only 85B was identified and expression was greater for tPA-85B
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than for 85B alone In addition, the same banding pattern was noted for these constructs. 
Surprisingly, levels of protein expression were less than for the early/late promoter (Figure 
5.7). This is in stark contrast to the reported literature which states that a 10-50 fold 
increase in protein expression can be obtained using the T7 promoter. Indeed, in one case, 
the foreign gene product accounted for 10% o f  the total cell protein (Elroy-Stein et al 
1989). Possible explanations for the failure to  elicit high protein levels using the T7 
promoter include: (i) inaccurate quantification o f  viral titres, thus limiting the proportion of 
cells which are dually infected (a pre-requisite for recombinant protein expression); (ii) a 
problem with the r W  encoding T7 polymerase (vTF7-3); and (iii) a problem with the rVV 
encoding the foreign genes under the T7 promoter. In order to reduce the possibility of 
inaccurate viral titres, a fresh stock of vTF7-3 was made and the pfu/ml re-assessed In 
addition, the rVVpT7-Ag85 constructs were also re-titred The second stock o f vTF7-3 was 
taken from the laboratory of Dr U Gompels, LSHTM, and was known to work in 
conjunction with plasmids containing human herpes virus-6 genes (Dr R Anderson, personal 
communication). Despite these measures, no difference in expression was noted The third 
potential problem could be due to the transfer plasmid, pWR510 In theory, this plasmid 
contains the necessary elements for high level protein expression: the T7 promoter, the 
encephalomyocarditis untranslated 5' leader (an internal ribosomal entry site permitting cap- 
independent translation) and the T7 transcription terminator However, no quantitative data 
has been published concerning pWR510-derived rVV, as compared with other rVV using 
vaccinia promoters In addition, a mutation within one of the elements responsible for high 
level expression might have occurred
It was not relevant to pursue the problems encountered with this system A key reason for 
utilising the T7 promoter was to identify recombinant protein which was undetectable using 
the p7.5 promoter However, 85A and 85B proteins were readily identified using the 
vaccinia promoter and 85C was not detected using either o f the promoters
5.3.2 ESAT-6 protein expression
5.3.2.1 tPA and T7 strategies
In the second generation of rVV, an ESAT-6 construct was made to include the tPA signal 
sequence It was hoped that addition of this region would stabilise the protein, allow 
translocation into a membrane compartment and permit a readout using the available mAb 
Despite these measures, no signal was identified In addition, the rVVpT7-ESAT-6
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constructs were non-functional due to a cloning error (see Section 4.3.2.2), preventing 
assessment of expression using the vaccinia/T7 hybrid system. This latter problem could 
have been addressed, if the frameshift error found in the initial PCR-generated pWR510- 
ESAT-6 and -tPA-ESAT-6 had been corrected by subcloning the gene from pi 108-tPA- 
ESAT-6. However, construction o f  further rVV-ESAT-6 did not seem appropriate, as the 
T7 system had failed to produce a high level of expression for the 85B constructs.
5.3.2.2 In vitro transcription/translation - evidence fo r  glycosylation o f  
tPA-ESAT-6
Strong signals of the correct molecular weight were seen with the sub-cloned pWR510- 
ESAT-6 constructs (see Table 4.1, plasmids P23 and P22) demonstrating integrity of the 
open reading frame (Figure 5.9a and 5.9c). Truncated products were noted using the initial 
PCR constructs, pWR510-ES AT del-6 (P5) and pWR510-tPA-ESATdel-6 (PI 1), consistent 
with premature stop codons introduced by a frame shift (data not shown) Following the 
addition of microsomes, there was strong evidence for post-translational modification of 
ESAT-6 (Figure 5.11a). In lane 6, the membrane-associated tPA-ESAT-6 fraction, two 
bands are present, a faint band of lower molecular weight comparable with the 'no 
microsomes' tPA-ESAT-6 reaction and a stronger band of higher molecular weight 
Unfortunately, the background signal obliterated the signal from the supernatant fraction. 
However, one might predict that the band would correspond to the 'no microsome' lane
There are two potential N-glycosylation sites on ESAT-6. Studies of native ESAT-6, using 
a glycan-protein double binding system, showed no evidence of glycosylation (Sorensen et 
al. 1995). It is tempting to speculate that failure to identify rVV-encoded tPA-ESAT-6 
might have been due to the presence of a glycan interfering with antibody binding However, 
it would also be necessary to suggest that the non-tPA ESAT-6 was either rapidly degraded 
or also glycosylated (not suggested from the in vitro transcription/translation data) This 
hypothesis could be verified, either by deglycosylation of the rVV-tPA-ESAT-6 cell lysate, 
as described in Section 2.16.3.8 (plus additional enzymes if required), or using an alternative 
antibody probe which was not available at the time this work was carried out.
5.3.2.3 Capture ELISA fo r  ESA T-6
Given the potential value of ESAT-6 as a key candidate antigen for the development o f a 
sub-unit vaccine. Prof M Harboe and colleagues, in Oslo, developed a quantitative assay
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for identification of recombinant ESAT-6 (see Section 5.2.1.7) (Harboe et al. 1997) In 
addition to the mAb HYB 76-8 (first layer), this assay made use of a polyclonal anti-peptide 
antibody (third layer). This latter reagent was identified by predicting candidate B cell 
epitopes from an ESAT-6 hydrophilicity plot. Three candidate peptides were selected from 
outward facing, hydrophilic regions of the molecule which would be expected to contain 
surface-exposed areas of the polypeptide chain with likely B cell epitopes These were 
synthesized, linked to keyhole limpet haemocyanin and used repeatedly to immunise rabbits 
The immune sera were then tested for reactivity against the immunising peptide and 
ESAT-6. A 23mer peptide, p40-62, was particularly effective and this was used in the final 
assay The capture ELISA was then able to quantitate both native and recombinant ESAT-6 
from different sources, including rW -ESAT-6 cell lysates obtained from this study. A very 
high level of ESAT-6 was identified from rVV-tPA-ESAT-6. A much more modest but 
definite signal was identified from rVV-ESAT-6 without the signal sequence (Figure 5 8) 
(Harboe et al. 1997). This result is somewhat surprising, as the initial capture antibody, 
HYB 76-8, was the same mAb used in the immunoblotting experiments performed in this 
study, where no signal was identified This result could be explained in two ways: (i) the 
capture ELISA is more sensitive than the immunoblotting; or (ii) the binding of HYB 76-8 
to rVV-generated ESAT-6 may behave differently in the ELISA, as compared with the 
immunoblot assay. In the former, the mAb is bound to plastic and the antigen is in liquid 
phase, in the latter, the converse is true, with the denatured antigen bound to nitrocellulose 
membrane and the mAb in solution The first explanation is unlikely as the chemiluminescent 
protocol used for immunoblotting permitted detection of ESAT-6 from 100-fold diluted 
MTB CF (estimated sensitivity of s 1.6 ng, see Figure 3.9), as compared with undiluted total 
protein rVV cell lysates In the ELISA, the concentration of ESAT-6 in the MTB culture 
filtrate was only ~15-fold greater than the rVV-tPA-ESAT-6 cell lysate (see Figure 5.8).
5.4 CO N CLU SIO N
Following the failure to identify ESAT-6 from the first rVV, a second generation o f  rVV 
were constructed Two of the three strategies to obtain rVV expression of MTB secreted 
proteins were successful The introduction of the Ag85 genes under the control o f the 
vaccinia early/late p7.5 promoter resulted in readily identifiable expression of both 85 A and 
85B Construction of a signal sequence fusion further facilitated expression of both o f  these 
proteins Whilst immunoblotting failed to identify rVV expression of ESAT-6, a capture 
ELISA showed clear expression of this protein with a particularly strong signal obtained
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from the tPA fusion The addition of this tPA signal sequence led to  microsomal membrane 
association and post-translational glycosylation for 85A, 85B and ESAT-6, as evidenced by 
in vitro coupled T7 transcription/translation. Further evidence was provided by successfi.il 
N-deglycosylation of three 85B glycoforms seen in rVV-tPA-85B. The third strategy 
employing the T7 promoter was unsuccessful. The results from the ESAT-6 capture ELISA 
suggested that failure to detect this recombinant protein by immunoblotting may have been 
due to denaturation of a conformational epitope recognised by the mAb rather than the 
lower sensitivity of Western blotting
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6.1 INTRODUCTION
The purpose of rW-Ag85 and -ESAT-6 construction was to assess both human CD8+ CTL 
function and vaccine efficacy in murine protection models. This chapter describes the 
preliminary data towards achieving these goals. The first part o f  the chapter covers human 
CTL. These assays were performed as part of this study using live BCG as a means to 
restimulate CTL. In addition, parallel CTL assays were performed by others in Prof A. Hill's 
laboratory, Institute of Molecular Medicine, Oxford using a different system (peptide 
restimulation of CTL).
Murine immunological studies were performed in Dr K. Huygen's laboratory, Pasteur 
Institute, Brussels (using the rVV Ag85 constructs) and in D r P. Andersen's laboratory, 
Statens Seruminstitut, Copenhagen (using the rVV ESAT-6 constructs). In addition to the 
CTL experiments performed in this study (Sections 6.2.1 and 6.2.2), this chapter discusses 
data from the three collaborating laboratories (Section 6.2.3 and 6.2.4) in order to show the 
functional application of the constructs.
6.1.1 Human CTL work
An increasing body of evidence has favoured a role for MHC class I-restricted T cells in 
protective immunity (Section 1.3.2) No mycobacterial antigens are known to be recognised 
by this population of cells, although there is indirect evidence in favour of Ag85 recognition 
(Rees et al. 1988; Manca et al. 1991). This laboratory had previously developed a system 
for stimulating human CD8+ CTL from TB patients and BCG vaccinees, using live BCG 
(Turner and Dockrell, 1996). As ESAT-6 is absent from BCG (Harboe et al 1996) and 
Ag85A is the most abundant of the three Ag85 proteins in BCG CF (Drowart et al 1992), 
the rVV-Ag85A constructs were selected as the initial recombinants for infection of the 
CTL target cells The levels of protein expression were higher for rVV-tPA-Ag85A, as 
compared with the same construct lacking the signal sequence However, from a theoretical 
perspective, the recombinant protein lacking the signal sequence would be more prone to 
cytoplasmic degradation, resulting in more efficient MHC class I processing and 
presentation to CD8+ CTL. Therefore, it was thought appropriate to assess both rVV- 
Ag85A constructs, with and without the tPA leader sequence.
In this study, live BCG was used to restimulate CTL derived from BCG vaccinated healthy 
donors and rVV-Ag85A constructs were used to infect autologous cultured macrophage
target cells in a standard 6 hour 51Cr release CTL assay. In preparation for assessing 
ESAT-6 specific CTL, several strategies were pursued to restimulate this sub-population. 
These included culture of M. marinum (MM) and verification of ESAT-6 expression and 
coating 1 pm latex beads with soluble antigen containing ESAT-6 (ST-CF from the Statens 
Seruminstitut, Copenhagen). It was intended that re-stimulating CTL with either live MM 
or antigen-coated beads, would lead to expansion of a putative ESAT-6 CTL population 
Previous data demonstrated that ESAT-6 was only expressed by a few mycobacteria 
including the highly pathogenic M  tuberculosis complex species and the less pathogenic 
MM (Sorensen et al. 1995). This suggested the possibility of using MM, a Category II 
organism requiring less stringent safety precautions during the seven day T cell 
restimulation. Evidence existed for increased class I processing of both MTB and BCG 
antigens when macrophages were infected with live rather than dead organisms (Mazzaccaro 
et al 1996; Turner and Dockrell, 1996) It seemed reasonable to assume that MM would 
behave in a similar manner, particularly as this organism behaves in a similar way to MTB 
with respect to  its cellular trafficking - avoidance of the host cell endocytic pathway and 
prevention o f phagosomal acidification (Barker et al 1997). An alternative strategy was to 
use antigen-coated beads (discussed in Section 1.3.2.7). Class I processing of antigen coated 
to latex beads had been demonstrated for ovalbumin (Kovacsovics Bankowski et al 1993; 
Harding and Song, 1994). Therefore, CF samples containing ESAT-6 were covalently linked 
to latex beads for restimulation of putative ESAT-6 specific CTL.
In Oxford, collaborators carried out peptide restimulation of putative CTL derived from TB 
patients and healthy controls They used a panel of ESAT-6 and Ag85 peptides congruent 
with HLA class I allele-specific motifs rVV-ESAT-6 made in this study was used to 
demonstrate that peptide-stimulated CD8+ T cell clones recognised target cells which 
endogenously processed whole recombinant antigen as well as peptide-pulsed target cells
6.1.2 M ouse immunology - background
Collaborators in Brussels and Copenhagen each made use of established murine models of 
mycobacterial infection In Brussels, a BCG infection model had been established to assess 
the cytokine response from immune spleen cells to recall antigens such as BCG, PPD and 
Ag85A (Huygen et al 1992). Previously, in the same laboratory, Ag85 DNA vaccinated 
mice had been assessed for humoral and T cell responses following immunisation In 
addition, protection was measured using an intravenous BCG challenge of 2 x 106 CFU,
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given 3-10 weeks after the last vaccination. Protective efficacy was measured according to 
the reduction in CFU counts of spleen and lung homogenates, taken at several time points 
post-challenge (Huygen et al 1996). In Copenhagen, a similar protection model was used 
The main differences between the two models were that the Copenhagen group: (i) 
challenged with a lower dose of mycobacteria (5 x 104 CFU); (ii) challenged with virulent 
MTB (H37Rv) in some cases; and (iii) gave immunised mice a prolonged rest (at least 12 
weeks) prior to challenge (Andersen, 1994). This latter issue of resting the immunised mice 
permitted a clearer distinction between protection afforded at the time of (or shortly after) 
the primary immune response, as compared with longer-lived protection mediated by 
immunological memory. Neither group has used aerosolised challenge with live 
mycobacteria Both the Pasteur Institute, Brussels and the Statens Seruminstitut were 
provided with cushion-purified rVV for the mouse protection studies
6.2  RESULTS
Sections 6.2.1 and 6 2.2 include human CTL work performed in this study Sections 6.2.3 
and 6.2.4 represent work performed by collaborators who have kindly given permission to 
present the human peptide-stimulated CTL data and murine immunology Although these 
latter data were not generated in this study, their inclusion shows the functional application 
o f  rVV and permits further discussion
6.2.1 Human CTL - a whole antigen approach
6.2.1.1 Is rW -encoded AgX5A expressed in 7 day cull tired primary human 
macrophages?
Clear evidence for expression of rVV-Ag85, 85B and ESAT-6 had been demonstrated in 
infected TK-143 cells (Section 5 4) However, the same expression is not necessarily true 
for rVV infection of primary human macrophages, the cells used as CTL targets in this 
laboratory (Turner and Dockrell, 1996) Broder and colleagues had previously demonstrated 
that not all rVV recombinant proteins were expressed in human seven day cultured 
macrophages (1994) Recombinant protein was expressed only when the foreign gene was 
under the control of an early but not a late promoter Importantly, with respect to the 
rVVpT7 constructs developed in this study, the researchers noted that primary cultured 
macrophages permitted high level expression using the vaccinia/T7 hybrid system, in 
contrast to absent expression with late promoters
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In theory, the early component of the p7.5 promoter should permit rVV expression in 
infected macrophages. This was confirmed using an immunofluorescence technique, as 
described in Section 2.16.4. Figure 6.1 shows immunofluorescence of rVV-infected primary 
human macrophages. rW-tPA-Ag85A expression was compared with rVV-tPA alone The 
propidium iodide stain shows the macrophage nuclei (blue fluorescence) indicating all the 
macrophages present in the field The green signal represents binding of FITC-coupled 
secondary antibody to the anti-Ag85 mAb, TD-17, indicating expression of Ag85A. No 
fluorescence was seen in the negative control (rVV-tPA infected macrophages). A clear 
signal was present in the rVV-tPA-Ag85 infected macrophages The fluorescence was 
suggestive of a cytoplasmic distribution, with a few additional punctate areas of increased 
signal, perhaps representing accumulation of Ag85A following translocation into a vacuolar 
compartment Approximately 25% of the macrophages showed immunofluorescence using 
a moi o f 25:1 (not shown in figure) No difference in signal was noted using rVV-Ag85A 
without the tPA signal sequence (data not shown).
6.2.1.2 Macrophage infection with two different hatches o f BCG
Our laboratory had previously noted a batch to batch variation between different cultures 
of BCG in their ability to activate CD8+ T cells These cultures had been derived from the 
same source (freeze-dried BCG Glaxo, Evans Medical) and cultured under the same 
conditions (grown in Middlebrook 7H9/OADC and harvested during log phase growth) For 
example, others in our laboratory had previously grown up and assessed two batches o f 
BCG: JT96023 (6.1 x 107CFU/ml) and JT96010 (7.7 x 108 CFU/ml). In this study they are 
designated as batch-1 and batch-2 respectively Under similar experimental conditions, each 
batch was used to stimulate PBMC from BCG vaccinees. Activated CD8+ T cells (CD25+) 
and CTL readouts gave a different pattern of results for each batch, as measured by flow 
cytometry and the MCr release assay; batch-1 required approximately a log1() lower moi to 
achieve a similar CTL assay result (J. Turner, personal communication) As it was possible 
that the differences observed reflected batch variation in bacterial viability, this issue was 
assessed as described below
Mycobacterial CFU counts were repeated using randomly selected frozen aliquots of BCG 
(Section 2.182.1) For batch-2, an average of two experiments showed just over half a log 
decrease in CFU as compared with the initial count following culture (7.7 x 10* CFU/ml in 
May 1996 fell to 1.6 x 10* CFU/ml in November 1996) This was consistent with a similar
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Figure 6.1 Immunofluorescence of rVV-infected macrophages
Top images: rVV-tPA-Ag8SA infection. Bottom images: rVV-tPA infection 
a) & c) show staining of macrophage nuclei with DAP1. 
h) & d) show immunofluorescence of rVV-infected macrophages using the 
Ag85-specific mAh, TD-17 and a FITC-conjugatcd secondary antibody.
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fall in viability over time previously noted for batch-1 BCG (Dr J. Turner, personal 
communication).
Both batches of BCG were used in an overnight infection of seven day primary human 
macrophage cultures, as described in Section 2.18.2.2. The tissue culture eight chamber 
slide system permitted infection of the same macrophage monolayer using the two batches 
ofBCG, each at four different moi's (25:1, 5:1, 1:1 and 0.2:1). Following methanol fixation, 
the upper 'chamber' section was removed from the glass slide and the infected macrophage 
monolayer was stained using the Ziehl-Neelsen (ZN) stain. This permitted uniform staining 
of the entire monolayer The two batches of BCG-infected macrophages were assessed 
using light microscopy. In the case of the 5:1 moi, batch-1 BCG was taken up by virtually 
all of the macrophages whilst batch-2 BCG was identified in only approximately 50% of 
macrophages. Figure 6.2 shows both batches ofBCG following macrophages infection (moi 
5 :1) and ZN staining. The morphological appearance and cellular distribution of the two 
batches ofBCG was different Infection with batch-1 BCG showed fragmented bacilli, with 
variable uptake of the acid fast stain Moreover, the bacilli were fairly evenly distributed 
throughout each cell In contrast, batch-2 BCG infection showed the bacilli to be more 
localised to one region within the cell Furthermore, the evidence for 'cording' (the formation 
of cord-like structures as a consequence of cord factors (Besra and Chatterjee, 1994) was 
seen more clearly In addition, acid fast staining of batch-2 bacilli was both more intense and 
homogenous with less overall fragmentation
6.2.1.3 CTL assay - optimisation o f B('(i moi o f macrophages
A CTL assay was employed in order to identify BCG-stimulated human CTL from BCG 
vaccinees BCG batch-1 and -2 were utilised in separate CTL experiments Batch-1 had 
previously been optimised by Dr J Turner who had identified the ideal moi required for 
effector cell restimulation which was either 0.2 or I bacillus:macrophage and for target cell 
infection was 1 bacillus:macrophage Similar optimisation experiments using batch-1 BCG 
were repeated in order to demonstrate reproducibility of the assay for use in this study The 
MCr-release assay results obtained using batch-1 BCG-stimulated CTL derived from two 
healthy BCG vaccinees are shown in Figure 6 3 In this experiment, a single moi for effector 
restimulation and target infection was selected (1:1 for each subject). This was based on 
previous data (Turner and Dockrell, 1996). Following one week of in vitro BCG- 
stimulation, the effector cells were added at three effector target ratios: 25:1, 5:1
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Figure 6.2 Ziehl-Neelsen staining of BCG-infected macrophages using two 
different batches of BCG
Two batches o f BCG were used to infect macrophages at four moi's (25:1, 5:1, 1:1 and 
0 2:1) Following overnight incubation with BCG, the macrophages were fixed and stained 
using the Ziehl-Neelsen technique The figure shows photographs o f macrophages infected 
with one of the BCG batches (batch-1 top photograph, batch-2 bottom photograph), using 
an moi of 5:1 in each case Photographs were taken under the x40 objective
CTL #BCG-1
30 0 % /
target infection 
(effectontarget ratio)
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Figure 6.3 MCr release CTL assays using BCG-stimulated PBMC as efTector cells and BCG-infected macrophages as target cells
CTL assays were performed using BCG-infected PBMC derived from two healthy, BCG vaccinated, PPD skin-test positive donors Effector cells were 
generated, using 7 days of in vitro restimulation of CTL with live BCG (batch-1) at a moi of 1:1 Autologous macrophage targets were infected with 
BCG (moi of 1 1) and a standard 6 hour 5lCr release assay was performed Three effector target ratios were assessed (25:1, 5:1 and 1:1) for'no Ag' 
targets and 'BCG-infected' targets
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and 1:1 (see Section 2.18.1 for methodology). Specific lysis varied from 12-26% for all 
target cells pulsed with BCG and was less than 10% for all the 'no Ag' target cells. An 
effectortarget ratio dose effect was observed for BCG-pulsed target cells for the assay #1. 
This was less apparent for assay #2. The converse was true for the 'no Ag' control target 
cells where an effector target ratio dose effect was observed in #2. This latter dose effect 
could be attributed to non-specific killing from lymphocyte-activated killer (LAK) cells. The 
supply of batch-1 BCG was limited, and therefore further optimisation experiments using 
batch-2 BCG were performed The data generated produced results which conflicted with 
the optimum moi's of batch-1 BCG These data suggested that using batch-2 BCG either a 
target cell moi o f  5:1 or 25:1 was required (see below). Whilst the higher moi produced 
marked specific lysis on occasions, this was not reliable and in some cases, a moi o f 25:1 
resulted in significant macrophage death (data not shown) Thus, subsequent experiments 
using batch-2 BCG, moi's o f 1:1 for effector stimulation and 5:1 for target cell infection 
were selected
6.2.1.4 rW -tPA-Ag85A infection o f  target macrophages
Sixteen CTL assays were performed, usually in pairs PBMC were derived from healthy 
BCG vaccinees who were known to be PPD skin test positive. Constructs expressing 
Ag85A (with and without the signal sequence) were used to infect target cells at either a 
single moi (25:1) o r a  range o f moi's (25:1, 5:1 and 1:1). A 'no Ag' negative control and a 
BCG-infected positive control were included in every case CTL assays were considered to 
have yielded significant results only when the negative control was less than 10% specific 
lysis and the positive control greater than 10% specific lysis Results failing to meet these 
criteria were disregarded Data which generated negative specific lysis results were treated 
as a zero result (i.e where the background isotope release from macrophages was greater 
than the isotope release from macrophages with effectors - see equation in Section 2.18.1). 
This applied to some of the negative controls and in the data presented, was never greater 
than -10% If the criteria was met for the positive and negative controls, then the 
experimental arms were deemed to show specific lysis if the lysis was above 10%. O f the 
sixteen CTL assays performed, four assays fulfilled the criteria for positive CTL induction 
Figure 6 4 demonstrates two assays comparing rVV-tPA-Ag85A-infected target cells with 
the rVV negative control Specific lysis of Ag85A expressing target cells was 22 and 11% 
respectively, whilst both the rVV negative controls were under 5%. In addition, the assay, 
CTL #4, showed a moi dose effect for the BCG positive control
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Figure 6.4 CTL assays using rVV-infected macrophage target cells
CTL assays were performed using PBMC from two healthy BCG-vaccinated subjects. BCG was used to restimulate CTL using a moi of 1:1. rVV 
was used to infect macrophage targets BCG infected macrophage targets were used as a positive control. Both assays show a comparison between 
an rW  expressing Ag85A and an rW  control lacking the gene insert (rWtarget moi of 25:1). In CTL #4, a series of fivefold BCGtarget moi's were 
selected (25:1, 5:1, 1 1, 0.2:1) to identify the best moi for the positive control (BCG-infected targets) and to demonstrate a dose effect
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In order to ascertain the optimum rW:macrophage moi, a subsequent experiment compared 
three rW : macrophage ratios: 25:1, 5:1 and 1:1. This is shown in Figure 6.5 where specific 
lysis was seen for rVV-tPA-Ag85A moi's of 25:1 and 5:1 but not 1:1. The rVV negative 
controls were all under 5%. A fourth CTL assay showed a similar trend, but whilst specific 
lysis for rVV-tPA-Ag85A was 22%, the rVV control was 12% (data not shown).
The remaining CTL assays showed either high background 'specific lysis' (4 subjects) and/or 
the positive control was below the threshold of 10% (9 subjects) (data not shown) These 
assays included comparisons between tPA-Ag85A and Ag85A alone. Therefore, no 
conclusions could be made concerning a possible difference between the constructs.
6.2.2 Alternative strategies for in vitro human CTL restimulation
If a whole antigen approach was going to be employed for restimulation of CD8+ CTL, 
BCG could not be used for ESAT-6 detection, as discussed above. MTB could potentially 
stimulate ESAT-6 specific CTL, but several practical reasons and health and safety issues 
prevented these experiments from being carried out in the time available for the study 
Therefore, two alternative approaches were developed with a view to restimulating putative 
low-precursor frequency CTL specific for ESAT-6.
6.2.2.1 M. marinum - a Category II organism that expresses ESA T-6
In order to confirm that M. marinum expressed ESAT-6, both MTB and M. marinum CF 
were prepared as described in Section 2.3.3.2. A single culture of MTB was prepared by 
growing the bacteria in Middlebrook 7H9/OADC medium. Several cultures of MM were 
prepared, which included growth in 7H9/OADC, 7H9/ADC and Sauton's media Figure 6 6 
shows dot and Western blots of different types of CF: (i) MM CF generated in this study 
(grown in 7H9 medium plus either OADC or ADC supplement or Sauton's medium); (ii) 
MTB CF from Copenhagen (grown in Sauton's medium); (iii) BCG CF from Brussels (two 
batches grown in Sauton's medium) The immunoblots were probed with the ESAT-6 
specific mAb, 76-8 In Figure 6 6a, the dot blot demonstrates a signal for all samples of CF, 
except MM grown in 7H9/OADC medium The same negative result was true for MTB CF 
grown in 7H9 with the same supplement (data not shown). The intensity o f  the signal was 
similar for all three organisms A second batch of MM CF (MM 2) was prepared and the 
organism was ZN-stained which confirmed the presence of acid fast bacilli A Western blot 
was performed (Figure 6 6b). This demonstrated a band of the correct molecular
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Figure 6.5 CTL assay using rVV-infected macrophage targets at a range of moi's
PBMC from a healthy BCG vaccinee were restimulated with BCG to induce rVV-Ag85- 
specificCTL Macrophage targets were infected rVV-tPA-85A (abbreviated to rVV-85A) 
or rVV-tPA lacking the gene insert, using three moi's (25:1,5:1, 1:1) Additional targets 
were either mock infected or infected with BCG alone (moi 5:1) and a standard 6 hour MCr 
release assay was performed
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Figure 6.6 Immunoblots o f MM, BCG and MTB CF probed for ESAT-6
A variety o f CF preparations from 3 different mycobacteria grown in different media 
were subjected to dot and Western blot analysis using the ESAT-6-specific mAb, 
HYB76-8. The samples were derived from M. marinum (MM) grown in Sauton’s 
medium (MM-Sauton), MM grown in 7H9 medium with OADC supplement (2 batches: 
MM1- & MM2-OADC); MM grown in 7H9 with ADC supplement (MM-ADC); BCG 
grown in 7H9/OADC (two batches: BCGl & BCG2); and MTB grown in 7H9/OADC. 
a) A dot blot showing I pi aliquots of neat CF ( 1 mg/ml) and a series of twofold dilu­
tions. b) Two exposures of the same Western blot showing ESAT-6 reactivity (6 kD 
bands) and additional ‘cross-reactive’ bands. The far right lane (MM mix) was loaded 
with an equal mix of MM 1-OADC and MM-Sauton.
weight for MTB CF (Sauton's-derived) and MM CF (Sauton's-derived), bu t not for M. 
marinum grown in 7H9/OADC (MM 1 and MM 2). Furthermore, one o f  the OADC 
containing CF samples was able to inhibit the signal of MM CF (Sauton's-derived) when 
loaded as a 50% mix, as shown in the last lane (MM mix), although the signal did become 
apparent after a prolonged (15m) autoradiographic exposure (lower image). The Western 
blot also confirmed that the dot blot signal seen with BCG CF was not ESAT-6, but due to 
cross-reactivity with other secreted proteins including the 30-32 kDa proteins (Harboe et 
al 1996). This experiment confirmed the finding of others, that MM expresses a protein 
with a molecular weight consistent with ESAT-6. Furthermore, using the ECL Western 
blotting system, growth of MM using OADC (but not ADC) supplement inhibited the signal 
A similar pattern was observed with MTB CF The key differences between the supplements 
are the presence of both oleic acid and catalase in OADC Further experiments, not 
appropriate for this study, would be required to elucidate the mechanism o f  loss of signal
6.2.2.2 Using CF-coated latex beads
One micron beads were coated with MTB CF (Copenhagen batch). The protocol entailed 
covalent linking of the CF proteins to 1 pm carboxylated beads as described in Section 
2.18.3.1. Coated beads were added, in three different amounts (40, 4 and 0 4 pi), to a seven 
day macrophage culture. Following an overnight incubation, the cells w ere fixed with 
acetone and stained using the K92 polyclonal antibody, an HRP-antibody conjugate 
secondary antibody and DAB (Section 2.18 3.2). No specific signal for MTB CF was 
detected as compared with BSA-coated beads However, of the three quantities tested, the 
lowest amount (0.4 pi) provided ample uptake by all macrophages. Indeed, the macrophages 
incubated with 40 pi were stuffed with beads and markedly damaged (data not shown).
Using the CTL 51Cr release assay protocol, the lowest concentration of beads was selected 
to restimulate effector T cells and/or pulse macrophage target cells Positive controls 
included live BCG, and negative controls included BSA-coated beads These controls were 
used to pulse target cells and restimulate the effector cells Microscopy of bead-restimulated 
PBMC suggested clonal expansion by day seven of the assay However, in this single assay, 
the controls were unsuccessful and the results could not be interpreted
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6.2.3 CTL using a peptide approach
An alternative approach to using whole antigen or organisms to restimulate CTL is the use 
of peptides. The advantages and disadvantages of this are discussed in Section 3.3.22. This 
strategy was pursued by Lalvani and colleagues (1997) in Prof A. Hill's laboratory in 
Oxford This group had a similar interest in both Ag85 proteins and ESAT-6 and a 
collaborative link was established, enabling the exchange of reagents. In particular, rVV- 
tPA-ESAT-6 was given to Prof Hill's group so they could assess the efficacy of peptide- 
induced CTL recognition of endogenously processed whole recombinant antigen.
In order to restimulate CTL, they scanned the sequences of ESAT-6 and Ag85 proteins for 
allele-specific peptide motifs for the HLA class I types -A2, -B7, -B8, -B35 and -B53. These 
alleles were selected on the grounds that they occurred with reasonable frequency in the 
study population In all, 49 peptides were identified, synthesized and sorted into pools 
according to their HLA class I allele The peptide pools were then used to restimulate 
PBMC derived from patients with active TB, treated TB patients and healthy controls The 
in vitro expanded T cell populations were then used in two assays to assess function: (i) a 
highly sensitive ELISPOT technique for detecting IFN-y from single cells (Miyahira et al. 
1995); and (ii) a 5 hour 51Cr release CTL assay.
The Oxford group identified tw o ESAT-6 CD8+ T cell epitopes from a panel of seven 
peptides. In contrast, no Ag85 CD8+ epitopes were identified from a possible 42 peptides. 
Whilst in vitro stimulation induced clonal expansion of putative anti-Ag85 CTL, the short 
term cell lines were all of the CD4+ T cell phenotype Interestingly, some of these nonomer 
peptides elicited an IFN-y response from uncultured CD4+ T cells (Lalvani A, Brookes R, 
Wilkinson RJ, Pasvol G, Hill AVS, unpublished data).
One of the ESAT-6 CD8+ peptides, ES12, was further characterised using a E S 12-specific 
CD8+ clone HLA class I restriction was formally demonstrated by comparing matched and 
mismatched EBV-transformed B cell lines (BCL), pre-pulsed with ES12 using the ELISPOT 
assay In order to show that the ES 12-specific clones could recognise endogenously- 
processed whole ESAT-6 protein, autologous BCL were infected with rVV-tPA-ESAT-6 
or a control rVV lacking the ESAT-6 coding sequence Using both the ELISPOT and CTL 
assay, the clones only recognised rVV-ESAT-6-infected BCL (Lalvani et al. 1997).
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6.2.4 Murine immunisation using rVV-Ag85 and rVV-ESAT-6 constructs
r W  generated in this study have been used to immunise mice in laboratories in Brussels and 
Copenhagen The key preliminary data come from the Brussels group and these are 
discussed below.
6.2.4.1 Spleen cell IL-2 and IFN-g secretion following rW -Ag85 immunisation
In Brussels, all the rVV-Ag85 constructs and a 'no antigen' control were used to immunise 
female C57BL/6 mice using 107 pfu given by the intravenous route. At 30 days, spleens 
were harvested from two mice per group. Spleen cells were cultured at 4 x 106 cells/ml in 
round-bottomed 96 well plates using 180 pi of cells (7.2 x 105) plus 20 pi of antigen (5 
pg/ml). The antigen consisted of the three Ag85 complex proteins (85A, 85B and 85C) 
purified from M. bovis BCG culture filtrate (De Bruyn et al. 1987). Supernatants from three 
wells were collected and pooled after 24h for an IL-2 assay and 72h for an IFN-y assay. 
Cytokines were measured using two bioassays: (i) IL-2 by CTLL-2 cell proliferation; and 
(ii) IFN-y by the CPE reduction assay of vesicular stomatitis virus on mouse L929 cells 
(Huygen et al. 1992) The IL-2 assay had a sensitivity of 10 pg/ml (10 000 cpm = 150 
pg/ml) and the IFN-y assay had a sensitivity of 110 pg/ml (Log, I = 220 pg/ml, Log22 = 440 
pg/ml etc).
Figure 6 7 shows the results of both IL-2 and IFN-y secretion from mouse immune spleen 
cells in response to the recall antigen The different rVV immunisation groups are 
represented along the X-axis and include all rVV-Ag85 constructs with and without the 
signal sequence. A clear pattern was apparent Strong cytokine responses were induced from 
spleen cells of mice previously immunised with rVV-tPA-85A and -tPA-85B for both IFN-y 
and IL-2. In contrast, weaker responses were obtained from the corresponding non-tPA 
constructs, rVV-85A and rVV-85B However, standard deviations were too large to 
confirm a definite biological effect induced by the constructs lacking the signal sequence, 
except for IL-2 production in the rVV-85B immunised mice The rVV-85C constructs failed 
to induce any detectable immune response using this system Dr K Huygen's group also 
measured antibody responses which showed a similar pattern, with higher titres for tPA than 
non-tPA Ag85A and 85B constructs (data not shown).
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Figure 6.7 C ytokine secretion from spleen cells derived from rVV-immunised mice
IL-2 and Il'N-y secretion by immune spleen cells in response to Ag85 recall antigen Each 
bar represents the mean cytokine bioassay readout (± l s.d.) from two B6 rVV- 
immunised mice, 30 days post infection. The IL-2 readout represents 150 pg/ml per 
10 (XX) cpm (CTLL-2 proliferation) The IFN-y readout represents 220 pg/ml for Log,I 
(CPE reduction assay) Open bars rVV with no signal sequence, grey bars rVV with 
signal sequence
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6.2.4.2 rW-ESA T-6 immunisation
Dr P Andersen's laboratory in Copenhagen immunised mice using a different immunisation 
protocol As an initial experiment, they selected a lower dose of rVV (106 pfu per mouse), 
given intravenously on two occasions, one month apart. Four groups of female C57BL/6 
mice were compared: rVV-tPA-ESAT-6, rVV-tPA-85B, rVV-tPA and non-immunised 
mice. They failed to identify an immune response or protective efficacy using rVV-tPA- 
ESAT-6. rW-tPA-85B showed raised IFN-y responses but only a slight protective efficacy 
(0.3 log reduction in MTB CFU counts from lung and spleen organ homogenate as 
compared with the negative control). However, this was a single set of experiments in which 
there had been problems with high backgrounds from the cells from non-immunised control 
mice (Ms L. Brandt, personal communication). These experiments are being repeated using 
a higher immunisation dose of 107 pfu per mouse
6.3 DISCUSSION
Data from three sets of experiments showed successful application of the rVV generated in 
this study First, PBMC derived from healthy BCG vaccinees could be restimulated with live 
BCG to induce specific CTL recognition of rVV-tPA-Ag85A infected macrophage target 
cells. Second, PBMC derived from TB patients could be restimulated with an MHC class 
I allele-specific ESAT-6 peptide to induce a CD8+, MHC class I-restricted T cell clone with 
the capacity to produce IFN-y and lyse rVV-tPA-ESAT-6 infected B cell lines Third, a 
single intravenous immunisation of female C57BL/6 mice with rVV-tPA-85A and tPA-85B 
was able to induce IL-2 and IFN-y cytokine production from spleen cells in response to 
purified Ag85 proteins These data will be discussed in terms o f their completeness, possible 
interpretation and the need for additional experiments
6.3.1 BCG restimulation of CTL
One quarter of the CTL assays performed suggested that CTL from BCG-vaccinated healthy 
donors could recognise rVV-encoded Ag85 in a specific way However, the data described 
in Section 6 2.1 represents only preliminary work using this approach The time limitations 
of the study prevented further delineation Additional data was required to both confirm the 
finding and identify the cell population(s) responsible These issues are as follows
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6 .3 .1 .1  The n e e d  to  c o n tr o l  f o r  n o n -sp e c if ic  ly s is
The initial assays, employing the positive BCG control only, showed a dose effect by varying 
the effector target ratio (Figure 6.3). A different dose effect was demonstrated in CTL #4  
(Figure 6.4) and CTL #8 (Figure 6.5), where the moi was varied for BCG and rVV 
respectively Whilst this provides support for the target cell lysis being dependent on both 
the type and quantity of antigen, it is not conclusive. One might argue that these particular 
antigens (BCG and rVV-tPA-Ag85A) could render the target cells more prone to non­
specific killing This issue should be addressed by including effectors stimulated with an 
irrelevant antigen and including rVV-infected target cells with a construct expressing a 
larger protein than the tPA signal sequence alone construct e g rVV-P-gal or rVV-MOMP 
If the HLA type of the subject were known, use of an appropriate peptide for PBMC 
restimulation and a rVV-flu construct for target infection would represent an effective 
control.
6 .3 .1 .2  R e p r o d u c ib il i ty  o f  C T L
Where specific CTL was seen, the assay should be repeated using PBMC from the same 
subject. Whilst CTL may change during the course of active disease such as patients 
undergoing treatment (analogous with a mouse model of infection (Orme, 1987)), one 
would expect that a healthy BCG vaccinee population, would have a similar CTL pre-cursor 
frequency from one point in time to another Thus, the result should be reproducible
6 .3 .1 .3  E ffe c t  o f  v a ry in g  e f fe c to r :  ta r g e t  r a t io s
Given the variability encountered in the results, with only 25% of assays yielding adequate 
control responses, further evidence is required to support that the data yielding a positive 
result represented a true biological effect rather than one that might have occurred by 
chance For example, the data shown in Figure 6 4, if taken alone, could represent two 
apparently successful assays among many not displaying this trend Demonstration of a dose 
effect using two or more effector target ratios (depending on the number of lymphocytes 
available), would address this issue as provided in Figure 6.5.
6 .3 .1 .4  The r o le  o f  C D 4 + a n d  C D S  +■ T  c e l l  su b s e ts
The restimulated PBMC should be defined in terms of T cell subsets Work from others 
would suggest that a large proportion of activated T cells would be either CD4+ or CD8+ 
T cells (Turner and Dockrell, 1996) Purification of the restimulated T cells into CD4+ and
CD8+ T cell populations would permit assessment of the relative contribution made by each 
o f these groups in the CTL assay. Once CD8+ CTL had been demonstrated, it would be 
appropriate to demonstrate that they were MHC class I-restricted, either by using blocking 
antibody or mismatching target cells. This approach had already been pursued in our 
laboratory by others using live and dead BCG and PPD for both T cell restimulation and 
target cell pulsing These experiments had confirmed that these antigens induced cytotoxic 
CD8+ T cells, but had failed to prove that these CD8+ CTL were MHC class I restricted 
(Turner and Dockrell, 1996).
6.3.2 Peptide restimulation of CTL and M HC class I restriction
6 .3 .2 .1  The va lu e  o f  a  d e f in e d  C D 8 +  T  c e l l  l ig a n d
Proof that human CD8+ CTL are MHC class I restricted can be better addressed by 
developing T cell lines or clones which recognise known target cells This was achieved by 
Prof A Hill's group using peptide prediction to identify potential CD8+ T cell epitopes. The 
advantages of this system are twofold. The specific T cell ligand (peptide/HLA allele) is 
known, allowing molecularly defined manipulation of the system to show both peptide and 
MHC class 1 specificity In addition, from a practical perspective, use of non-physiological 
APC's (EBV-transformed B cell lines) and T cell lines permits repeated assessment under 
a variety of assay conditions e g  ELISPOT, CTL with varying E:T ratios and mismatching 
target cells
The group in Oxford were able to demonstrate clearly that CD8+ MHC class I-restricted 
T cell lines could be raised using a predicted ESAT-6 peptide, ESI2. These cells possessed 
IFN-y secreting and CTL function They recognised endogenously processed rVV-encoded 
ESAT-6. Furthermore, using the very sensitive ELISPOT assay, the peptide was able to 
induce IFN-y production from unstimulated T cells taken straight from the TB patient from 
which the clone had been derived The latter experiment showed that the pre-cursor 
frequency was sufficiently high to suggest biological relevance
6 .3 .2 .2  The b io lo g ic a l  r e le v a n c e  o f  a  p e p t id e  sy s te m  ?
A key problem with this peptide approach is that it represents a self-selecting system If 
these data were taken alone, it would be difficult to interpret the biological importance of 
the CD8+ T cells in their role in immunity against MTB Because MHC class I peptides 
were chosen to restimulate T cells, with the addition of IL-7 and IL-2, using repeated
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rounds of stimulation, there is a possibility of expanding T cell lines which may not be of 
biological relevance. IL-7 is known to facilitate the induction of primary CTL in PBMC 
derived from humans naive to the antigen (Plebanski et al 1995). Furthermore, this study 
identified CD8+ CTL in only a small proportion of TB patients, despite the fact that high 
levels o f T cell reactivity (proliferation and cytokine responses) had been identified using 
PBMC from TB patients in response to the whole ESAT-6 and Ag85 antigens (Huygen et 
al 1988; Boesen et al. 1995). This disparity may reflect the limitations o f testing for CTL 
reactivity using only a few single peptides. Lalvani and colleagues (1997) screened only a 
few of over 1000 potential protein targets However, the study represents the first time that 
human IFN-y secreting CD8+ T cells, specific for an immunodominant MTB protein, have 
been shown to be MHC class I restricted
It would be useful to develop a system where CD8+ CTL could be restimulated using whole 
antigen(s) or organism This would increase the possibility of inducing a wider range of CTL 
which would be in proportion to  the degree of antigen processing and presentation and 
independent of peptide prediction (Sadovnikova et al 1994) This will be discussed in 
chapter 7.
6.3.3 Mouse immunisation
6 .3 .3 .1  C y to k in e  r e s p o n s e s  f r o m  im m u n e  s p le e n  c e l l s
Dr K Huygen's group were able to  demonstrate high levels of IFN-y and IL-2 secretion from 
spleen cells derived from rVV-tPA-Ag85A and rVV-tPA-Ag85B immunised mice in 
response to purified Ag85 complex proteins The cytokine secretion was either less or no 
better than background for mice immunised with constructs without the signal sequence 
(Figure 6.5) This trend reflected the pattern of expression seen using immunoblotting o f 
Ag85 proteins (Figures 5.1 and 5.2) and a capture ELISA for ESAT-6 (Figure 5.7). It 
would be a mistake to interpret these data as suggesting that recombinant protein without 
the signal sequence is less immunogenic, as only one aspect of the immune response was 
assessed It is likely that this difference reflects the preferential MHC class II processing o f 
recombinant antigen within a vacuolar compartment and perhaps secreted in non-degraded 
form for further presentation by professional APCs However, recombinant protein without 
the signal sequence may be more efficiently presented with MHC class I, analogous to signal 
sequence deletions of influenza nucleoprotein or haemagglutinin (Townsend et al 1988). 
This hypothesis was not addressed in this study. In Prof A Hill's group, the rVV-tPA-
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ESAT-6 construct was very efficiently recognised by the T cell clone, so it is unlikely that 
they would identify a difference between this construct and rVV-ESAT-6 alone.
6.3.3.2 A potential poxvirus vaccine?
From the perspective of a potential vaccine, the constructs with tPA would seem to be more 
promising Firstly, the preliminary cytokine data suggested that they induced a definite Thl 
response which was stronger than without tPA, an essential component of protective 
immunity (Orme et al 1993) Furthermore, DNA vaccination data has suggested that the 
plasmids which included tPA were more immunogenic (Huygen et al 1996).
However, numerous studies have been able to immunise mice and detect strong cytokine 
responses using different immunogens given with a variety of antigen carriers (Silva and 
Lowrie, 1994; Baumgart et al 1996; Huygen et al. 1996; Lindblad et al. 1997) The key 
issue is whether the r W  can induce long-lived protective immunity in the available models, 
particularly in response to low dose aerosolised challenge with MTB The laboratories in 
Brussels and Copenhagen are currently assessing protection, using MTB intravenous 
challenge (and also BCG challenge in Brussels) These data will give an early indication as 
to whether a poxvirus may represent a suitable vehicle for a future TB vaccine.
6.4 CONCLUSION
Functional application o f r W  expressing Ag85 and ESAT-6 secreted proteins of MTB was 
demonstrated in three separate laboratories In this laboratory, rVV-tPA-85A was used to 
infect human macrophage target cells in a MCr release CTL assay Preliminary data showed 
that these target cells were specifically lysed using BCG-restimulated whole PBMC from 
BCG vaccinees From the laboratory o f A Hill, Institute for Molecular Medicine, Oxford, 
an MHC class I restricted CD8+ T cell clone and short term T cell lines were raised from 
TB patients using a predicted peptide, ESI2, from ESAT-6. These T cells were able to 
produce IFN-y and lyse peptide-pulsed or rVV-tPA-ESAT-6 infected B cell line target cells 
From the laboratory of K Huygen, Pasteur Institute, Brussels, rVV-tPA-85A and rVV-tPA- 
85B were able to immunise mice and produce IFN-y and IL-2 responses following in vitro 
challenge of immune spleen cells with purified Ag85 proteins Mouse protection studies, 
which are in progress, will show whether these rVV can induce protective immunity against 
BCG and MTB infection
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7.1 IMPORTANCE OF THIS STUDY
Tuberculosis is a disease o f superlatives Mycobacterium tuberculosis causes more deaths 
annually than any other infectious agent Globally, it is the major pathogen associated with 
HIV disease (Fine and Rodrigues, 1990; Bloom and Murray, 1992) The vaccine, BCG, has 
been given to more people than any other vaccine. Coverage now is approximately 85% of 
the world's population. Whilst BCG confers clear benefit against disseminated childhood 
tuberculosis, efficacy against the predominant adult pulmonary disease has varied widely in 
different clinical trials (Fine and Rodrigues, 1990) Curiously, protection induced by BCG 
appears to be better, the further one is from the equator (Fine and Rodrigues, 1990). Indeed, 
in large studies in India and Malawi, BCG was ineffective as a vaccine against pulmonary 
tuberculosis ("The Tuberculosis Prevention Trial", 1980; Ponnighaus et al 1992). Given that 
tuberculosis trials are both costly and time consuming, there is a need to identify a 
short-term surrogate marker of potential efficacy, the current Mantoux or Heaf tests, based 
on skin test hypersensitivity, do not reflect protection (Fine et al 1994). Alternative vaccine 
and diagnostic strategies are therefore urgently required
Chapter 7 Final discussion 197
A sub-unit vaccine approach is attractive in terms of both quality control and safety. 
However, in order to pursue a rational design strategy, it is necessary to know the protective 
antigens and the  cellular components which are required for immunity (Malin and Young, 
1996). An increasing body of evidence supports an immunodominant role for M. 
tuberculosis secreted proteins in protection (Andersen et al. 1991; Orme et al. 1992; 
Horwitz et al. 1995), particularly Antigen 85A (Andersen et al 1992; Huygen et al 1994; 
Huygen et al. 1996), 85B (Andersen et al 1992; Horwitz et al 1995) and ESAT-6 
(Andersen and Heron, 1993; Sorensen et al. 1995). Secreted proteins have induced 
protective immunity in both mouse (Andersen, 1994) and guinea pig (Horwitz et al 1995) 
models. In addition, DNA vaccination with an Ag85A-encoding construct has induced 
protection to the  same order of magnitude as BCG (Huygen et al 1996).
The cellular components o f immunity include a key role for Thl-type CD4+ T cells and 
macrophages (Orme et al. 1993). However, other cell subsets may also be essential. 
Evidence in mouse gene knock-out models has implicated an additional requirement for 
class I-restricted T cell involvement (Flynn et al 1992; Ladel et al 1995) Direct evidence 
for murine CD8+ T CTL comes from immunisation of MHC class I congenic mice with 
BCG (Denis et al 1997). CD8+ T cells have been shown to be cytolytic, but they have also 
been shown to  release IFN-y, which also plays a role in protection (Carter and Dutton, 
1996) To dissect this problem, two groups studied the course of infection in perforin gene- 
knockout, and granzyme gene-knockout mice They showed no evidence for the importance 
of these mediators of CD8+ T cell lytic activity (Cooper et al 1997; Laochumroonvorapong 
et al 1997) This suggests that cytokine secretion may be the major protective mediator of 
CD8+ T cells
Mounting evidence exists for CD8+ T cell involvement in human immunity to tuberculosis 
In vitro studies have identified mycobacterial-specific human CD8+ T cells (Rees et al 
1988). Moreover, CD8+ CTL from BCG vaccinees (Turner and Dockrell, 1996) and 
tuberculosis patients (Turner, unpublished results) can be generated by restimulating 
peripheral blood mononuclear cells with live BCG These studies did not identify the MHC 
molecules responsible for antigen presentation Therefore, whilst classical class I MHC 
restriction seems likely, alternative ligand recognition, such as in association with CD1, 
could not be excluded In another study, CD8+ re-stimulation of CTL from TB patients has 
been achieved utilising a peptide approach. CD8+ T cell lines recognized both ESAT-6
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peptide and endogenously processed recombinant ESAT-6 expressed in vaccinia, in a class 
I restricted manner (Lalvani et al. 1997). Further evidence suggestive o f a role for CD8+ T 
cells comes from murine vaccination data using single mycobacterial antigen delivery 
systems, transfected tumour cells and DNA vaccination Both systems permitted class I, as 
well as class II, antigen processing (Silva and Lowrie, 1994; Huygen et al. 1996; Tascon et 
al 1996).
It is unclear how mycobacterial antigens enter the class I processing pathway. Possible 
explanations include escape of whole organisms into the cytosol (McDonough et al. 1993), 
regurgitation of processed antigen (Pfeifer et al 1993), or egress of soluble proteins through 
pores within the membrane of the TB phagosome (Mazzaccaro et al 1996). Evidence is 
accruing in favour o f the latter phenomenon Mazzaccaro and colleagues (1996) provide 
data to suggest that MTB releases mycobacterial proteins into the cytoplasm in a manner 
analogous to Listeria with TAP-dependent class I antigen processing. The same was true, 
to a lesser extent, with BCG This lends support for the hypothesis that BCG may fail to 
elicit protection in some cases due to inadequate induction of a CD8+ T cell response 
Overall, these studies suggest the need for an antigen delivery system capable of both class 
I and class II antigen processing for maximum protection Such a delivery system would 
have utility, both as a potential vaccine carrier and also as a tool to specifically address the 
role of MHC class I-restricted T cell responses. One such carrier includes the poxvirus 
family.
Vaccinia, the archetypal poxvirus, is a cytoplasmic vims and, in recombinant form, it permits 
both class I and class II processing o f antigen with good induction of CD4 and CD8 T cells 
(Tartaglia et al 1990). From a vaccination perspective, attenuated poxviruses, such as 
modified vaccinia vims Ankara (MVA), are safe in the immunocompromised host but 
remain highly immunogenic (Tartaglia et al 1990) These factors prompted us to make a 
panel of vaccinia recombinants (rVV) to express the immunodominant proteins of the 
Antigen 85 complex and ESAT-6. In order to enhance expression and improve 
immunogenicity, the signal sequence o f tissue plasminogen activator (tPA) was included as 
an N-terminus fusion and these constructs were compared with those expressing the mature 
protein alone
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7.2 KEY FINDINGS
This study describes the construction of rW  expressing M. tuberculosis Ag85 and ESAT-6 
proteins and their functional application, both as immunogens and tools to present processed 
antigen in the context of MHC class I. A marked enhancement of expression was noted 
using the heterologous eukaryotic signal sequence and, in the case of Ag85A and Ag85B, 
this was accompanied by enhanced in vivo cytokine responses to recall antigen (Huygen, 
unpublished results) The same feature was noted with rVV-ESAT-6 constructs where the 
quantity of recombinant protein was more than tenfold greater with tPA than without the 
signal sequence (Harboe et al. 1997). This enhanced secretion had been demonstrated 
previously in an in vitro HIV gpl60 expression system (Chapman et al. 1991). Furthermore, 
Ag85A, also used in this study, had been expressed previously in a transfected cell line, both 
with and without tPA. The presence of tPA led to the secretion of the protein into the 
culture media (Huygen et al 1996). In the same investigation, tPA was included in an 
Ag85A DNA construct for murine vaccination. This construct was able to confer protection 
in murine models to an order of magnitude similar to BCG, although there was no difference 
in protective efficacy between Ag85A constructs, both with and without tPA (Huygen and 
Content, unpublished results).
The present study was unable to show evidence o f  protein secretion for the rVV-tPA- 
Ag85A and -85B fusions Perhaps protein secretion occurred, but at a level undetectable 
using immunoblotting Alternatively, the signal sequence may have permitted translocation 
into a vacuolar compartment but been inadequate to permit trafficking to the cell surface for 
secretion into the extracellular environment There is strong evidence for membrane 
translocation and post-translational modification of rVV-tPA-85B, as three glycoforms were 
identified N-glycosylation was confirmed showing a reduction in molecular weight 
following N-glycosidase digestion of rVV-encoded tPA-85B but not 85B without tPA
Ag85C expression was not identified for either of the rVV constructs, despite testing with 
a variety of antibodies The available antibody probes were raised using native mycobacterial 
proteins and the possibility existed that these would fail to detect a heavily glycosylated 
eukaryotic cell-derived 85C protein Therefore, sera from mice immunised with Ag85 DNA 
constructs were used in further immunoblots. Serum samples were able to provide specific 
signals for rVV-encoded Ag85A and Ag85B proteins but not Ag85C. It is not clear why this 
was the case, as plasmid sequencing data confirmed PCR fidelity and T7 coupled in vitro
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transcription/translation of the same insert confirmed open reading frame integrity 
Interestingly, using this in vitro cell free system, 85C products appeared particularly unstable 
as compared with products from the other three genes
In terms o f cytokine responses, rVV-tPA-Ag85A and rVV-tPA-85B appeared to be the 
most immunogenic o f the constructs, as measured by IL-2 and IFN-y responses following 
in vitro stimulation o f immune splenocytes using purified Ag85 recall antigen (Huygen, 
unpublished results). This pattern paralleled the relative increase in expression when tPA 
was included in the constructs The enhanced immunogenicity could represent a quantitative 
difference reflecting the level of protein expression In addition, signal sequence-mediated 
translocation to a membrane compartment might also reduce degradation of recombinant 
antigen prior to uptake by professional antigen presenting cells.
In terms o f  a potential vehicle for TB vaccination, vaccinia holds the esteemed position of 
being the only vaccine to eradicate a global disease In addition, it has been used as a vector 
for expressing numerous foreign genes of human, animal, bacterial and viral origin (Tartaglia 
et al 1990). Animal vaccination has protected against a large number o f infections including 
influenza, herpes simplex, hepatitis B and rabies (Brochier et al 1990; Tartaglia et al 1990). 
Several MTB and M. leprae rW  have been made (Lyons et al 1990; Baumgart et al. 1996) 
and protection in a murine BCG model has been demonstrated (Baumgart et al. 1996). Wild 
type vaccinia recombinants could lead to an overwhelming disseminated viraemia in the 
immunocompromised host However, an attenuated poxvirus could be used as a human 
vaccine vehicle. The highly host-range restricted poxvirus, MVA, represents an attractive 
candidate It has a vaccination programme 'track record' for safety and immunogenicity and 
it is able to process antigen in the context of class I and induce CD8+ T cells as well as 
CD4+ T cells (Sutter et al 1994). In a recombinant form, it is immunogenic (Sutter et al 
1994)and its large size will permit expression o f multiple proteins including 
immunomodulatory molecules In addition, a number o f gene deletions have rendered it 
replication-defective in humans and given it a favourable safety and immunogenic profile 
(Blanchard et al 1997) Such recombinant constructs could also be used to restimulate 
CTL, without the MHC limitations imposed by a peptide or transfected cell line approach
This study has demonstrated high level expression of rVV-encoded Ag85A, Ag85B and 
ESAT-6 under a vaccinia early/late promoter with use of the tPA signal sequence. Following
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rVV-Ag85 immunisation o f  mice, IFN-y and IL-2 production from splenocytes was 
considerably greater for those animals vaccinated with the tPA constructs (Huygen, 
unpublished results) Further animal protection studies are under way. Poxvirus expression 
o f MTB secreted proteins therefore represents an attractive choice towards the rational 
design of an effective tuberculosis vaccine
7.3 FUTURE WORK
7.3.1 Outline
In order to investigate the potential of poxvirus constructs expressing M. tuberculosis 
proteins, a potential next step would be to construct a panel o f recombinant modified 
vaccinia virus Ankara (rMVA) to express immunoprotective secreted proteins of 
Mycobacterium tuberculosis (Antigens 85A and 85B and ESAT-6). These could then be 
used in a murine model o f tuberculosis to  assess: (i) the protective efficacy o f rMVA 
constructs compared with BCG, (ii) the ’booster' efficacy of rMVA constructs compared 
with BCG; and (iii) the potential correlates of protection such as cytotoxicity mediated by 
CTL and secretion of IFN-y
If rMVA constructs induced a significant degree of protection, then the system could be 
manipulated to address effects of: (i) different vaccination routes such as parenteral versus 
respiratory; (ii) multiple versus single gene insertions; (iii) the addition of rMVA-encoded 
cytokines such as IFN-y, granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
interleukin-12 (IL-12); and (iv) directing recombinant antigens to different cellular sites, 
such as to the cytoplasm or to  the membrane or inducing cellular secretion
It would also be interesting to compare the vaccine potential of rMVA with alternative 
delivery systems expressing the same antigens, such as DNA vaccination This would be 
feasible for both Ag85 and ESAT-6, as protection studies using DNA vaccination have 
already been carried out An additional advantage of rMVA would be its minimal lytic 
activity in vitro rVV derived from wild-type vaccinia are too lytic to be used to restimulate 
low precursor frequency CTL, and so the use of rMVA would provide a better tool for the 
identification o f biologically important CTL epitopes
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7.3.2 Initial phase
Development of first generation rMVA TB constructs
In order to develop first generation rMVA TB constructs, vaccinia transfer plasmids made 
in this study, could be utilized to construct rMVA-ESAT-6, -85A and -85B. These plasmids 
express Eco-gpt, permitting positive selection with MPA (Sutter et al 1994). Previously, 
rMVA construction utilized one of the strain's deletion loci. However, homologous 
recombination using thymidine kinase flanking homology is possible (Dr T. Blanchard, 
personal communication), thus permitting the use of transfer plasmids designed for wt VV 
(WR strain) Recombinant TB genes would be placed under the control of the vaccinia 
early/late promoter, p7 5. PCR could be used to confirm recombinants as specific primers 
and reactions have been previously optimised. Expression would be confirmed by 
immunoblotting using the already available mAbs rMVAs could also be designed to express 
a fusion of an Ag85 protein and ESAT-6 (Ag85-ESAT-6 fusion transfer plasmids could be 
constructed by sub-cloning from available constructs) Thus, a single construct could be 
used to vaccinate against two key immunoprotective antigens
Mouse TB protection model
In order to test rMVA recombinants, the mouse TB protection model could be used A 
potential initial screening protocol could include immunisation with 107 pfu intramuscularly 
o f rMVA or 5 x 104 CFU sub-cutaneously of BCG (Glaxo strain) into 6-8 week old 
C57BL/6J female mice A proportion of mice from each group could be challenged at 28 
days using 5 x 104 CFU intravenously of MTB H37Rv strain and the protective efficacy 
measured as reduction in CFU culturing spleen and lung homogenates on Middlebrook 
7H 11 media The remaining mice would provide material for immunological studies to 
assess CTL and cytokine production such as IFN-y These could be compared with 
protective efficacy data, in order to assist in the identification of'immunological correlates 
o f protection' Such studies could utilise single cell suspensions of spleen cells harvested 
from rMVA-vaccinated mice 4 weeks post-immunisation and be used in two ‘screening’ T 
cell assays
(1) CTL assay - cells would be re-stimulated with antigen and IL-2 (10 U/ml). rMVA would 
be used to infect target cells in a standard 5lCr release assay. CD4+ and CD8+ T cell sub­
populations could then be assessed.
(2) lh'N-(assay - cells would be stimulated with recall antigen (the corresponding native 
MTB antigen preparation) and supernatants harvested at appropriate time points Other
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supernatants could be stored for subsequent cytokine analysis (IL-4, IL-6, IL-10, TNF-" and 
GM-CSF) for favourable rMVA candidates.
7.3.3 Subsequent phase
Promising candidates - a similar or greater reduction in CFU count as compared with BCG 
Subsequent experiments would assess (1) vaccine dose, (2) route of vaccine administration 
(e g intranasal versus parenteral), (3) route of MTB challenge (aerosolised versus 
parenteral); (3) time of challenge increased from 28 to 70 days post immunisation (in order 
to avoid a non-specific anti-inflammatory effect induced following vaccination); (4) effects 
in alternative strains and species including outbred mice and guinea pigs; and (5) effect of 
priming mice with BCG, then comparing a 'booster' immunisation with rMVA as compared 
with BCG.
Second generation rMVA - rMVA-IFN-y and rMVA-lL-12
Recent studies using DNA vaccination have shown that an ovalbumin-IL-12 cytokine fusion 
construct produced better IFN-y and CTL responses (Maecker et al. 1997). Co-expression 
o f recombinant antigens with cytokines (IFN-y and IL-12) should skew the immune 
response in favour of a Thl profile thought to be important in immunity to TB Murine 
cytokine genes could be amplified using PCR from murine genomic template or plasmid (if 
available) and cloned under the control o f a different promoter, such as the strong synthetic 
early/late dsP promoter (Sutter et al 1994) The transfer plasmid would consist of a co­
expression cassette containing cytokine and antigen genes, flanked by viral genome 
homology plus a selectable marker (Eco-gpt or P-gal)
Additional strategies could be employed to further enhance rMVA immunogenicity. For 
example, multiple genes could be expressed in a single construct and compared with the first 
generation constructs Potential expression could include genes expressed under different 
promoters, or as a single open reading frame encoding a polyprotein One such likely 
candidate would express Ag85B, ESAT-6 and hsplO By this stage it is also likely that other 
immunoprotective antigens might have been identified Therefore, alternative genes thought 
to encode immunoprotective antigens could be included, such as other secreted proteins, 
heat shock proteins or novel proteins emerging from the MTB genome mapping project
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It would also be interesting to compare immunogenicity o f a model antigen expressed at 
different cellular sites (cytoplasmic, membrane and secreted). Transfer plasmids and wt rVV 
were prepared in this study for both cytoplasmic and secreted expression (with and without 
the tPA signal sequence). Membrane expression would entail construction of a fusion 
protein with antigen expression at the extracellular domain o f a transmembrane protein.
7.3.4 Potential long-term prospects
Should rMVA-TB constructs appear significantly immunogenic in the small animal models, 
candidate vaccine development could include: (i) re-construction with human cytokine genes 
(for cytokine-encoding rMVA); (ii) sub-human primate challenge (with the possibility of 
collaboration such as that in the Philippine facility (Walsh et al 1996); (iii) re-construction 
of successful rMVA up to GMP standards and (iv) phase I/II studies
7.4 CONCLUSION
This study has demonstrated high level expression of rVV-encoded Ag85A, Ag85B and 
ESAT-6 under a vaccinia early/late promoter with use of the tPA signal sequence In CTL 
experiments, rVV-tPA-Ag85A-infected macrophage target cells could be lysed specifically 
by BCG restimulated human CTL derived from healthy BCG vaccinees In addition, rVV- 
tPA-ESAT-6 represented a useful tool for the identification of human MHC class I- 
restricted, cytotoxic, IFN-y-producing, CD8+ T cells derived from patients with 
tuberculosis Following rVV-Ag85A and -Ag85B immunisation of mice, IFN-y and IL-2 
production from immune splenocytes was considerably greater for those animals vaccinated 
with the tPA constructs than those constructs lacking this signal sequence Poxvirus 
expression of MTB secreted proteins therefore represents an attractive choice towards the 
rational design o f an effective tuberculosis vaccine.
However, formidable problems will be faced in moving any vaccine from the laboratory into 
clinical trials. Whilst immunogenicity in animal models provides encouragement, it cannot 
be taken as a measure of protection in man Seventy years o f experience with BCG has 
shown the difficulty of evaluating a vaccine against tuberculosis Development of an 
improved TB vaccine presents a daunting task in the face o f our limited understanding of 
the organism’s virulence and the host’s immune response Given the superlative impact of 
tuberculosis, we cannot avoid this task In fact, we require superlative effort
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Appendix A
weight (g)
glucose 2
bovine serum 
albumin (BSA)
5
sodium chloride 0.85
water 100 ml final voi.
Table A .l ADC supplement
Table A.2 Sauton's media
Reagent Amount (g) to 
be dissolved in 
10 ml
Solvent Stock
concentration
Enzymes
inhibited
*
EDTA 2.92 g water 1 M metalloproteases
*
EGTA 3 80 g water 1 M metalloproteases
NEM 125 g water 1 M thiol proteases
Pepstatin 6.85 mg ethanol 1 mM aspartyl
proteases
PMSF 581 mg ethanol 0.33 M serine proteases
TPCK 352 mg ethanol 0.1 M serine, thiol 
proteases
Table A.3 Reagents used in protease inhibitor mix
EDTA=ethylene diamine tetraacetic acid, disodium salt, EGTA=ethylene glycol bis (2-amino 
ethyl ether) - N, N, N\ N'- tetraacetic acid; NEM=N-ethlymaleimide; PMSF=phenyl methyl 
sulphonyl fluoride; TPCK=N-tosylamide-L-phenylalanine chloromethyl ketone *=kept at 
pH 8 0 to maintain in solution
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Errata
pi 2 DAPI - 'cell nuclei' should read 'DNA'
pl2 dNTPs - 'deoxynucleotide' should read 'deoxynucleoside'
p i3 FCS - 'fetal'should read'foetal'
p 13 X - 'lamda' should read 'lambda'
p i8 line 28 - 'unequal-equal' should read 'unequal'
p23-24 bottom paragraph p23/top paragraph p24 - should read 'Initial work suggested that the 
terminal arabinose side-chains of M yco b a cteria  spp could lead to a difference in strain 
virulence. This was based on data suggesting that the virulent MTB Erdman strain 
contained a relatively inert LAM with mannose-capping (ManLAM). In contrast, the less 
virulent H37Ra strain contained LAM lacking this mannose-capping (Ara LAM) This 
latter form of LAM was thought to more readily induce inflammatory cytokines, such as 
TNF-a, permitting more rapid clearance o f the organism. However, subsequent data 
showed that LAM from the vaccine strain. M. hovis BCG. was also mannose-capped 
(Prinzis et al. 1993). 
p26 line 15 - 'units' should read 'unit' 
p27 line 15 - 'CD-1' should read 'CDI' 
p31 line 11 - 'was' should read 'were' 
p34 line 5 - 'by (Orme' should read 'by Orme' 
p35 line 25 - 'De et al' should read 'De Bruyn et al' 
p37 line 3 - 'ESAT6' should read 'ESAT-6', 
p37 line 17 - 'this protein' should read 'the ESAT-6 protein' 
p38 line 12 - omit '(Horwitz et al. 1995)' 
p41 line 7 - '(Smith. 1993)' should read '(Lane et al. 1969)'
p42 line 5 - 'to grow' in mammalian cell lines' should read 'to grow in many mammalian cell
lines'
p42 line 15. The sentence beginning 'Both IFN receptors . ' should read 'Both IFN receptors 
down-regulale immune responsiveness and the IFN-a/pR is associated ..' 
p48 line 6 - 'EcoRI' should read 'EcoKV 
p51 line 10 - insert comma after 'ESAT-6' 
p55 line 3 of bottom paragraph - omit 'required' 
p59 Table 2.2, row 9 - PRTK4294' should read 'PRTK429R' 
p60 line 11 - 'deoxynucleotide' should read 'deoxynucleoside' 
p60 second line from bottom - after '10 mCi/ml' should follow '(>1000 Ci/mmol)'; 
p60 bottom line - after '15 mCi/ml' should follow '(>1000 Ci/mmol)' 
p6l line 1 - after'1-5 nCi/ml' should follow '(200-900 Ci/g Cr)' 
p61 line 20 - 'lamda'should read'lambda'
Errata i n
p71 line 10 - 'glutamax 11' should read 'Glutamax I'
p79 line 15 - '50 ml' should read '50 pi'
p80 line 6 - should read 'MgCL'
p84 line 15 - 'protein gel electrophoresis' should read 'polyacrylamide gel electrophoresis'
p87 line 15 - 'Photographed' should read 'Photography'
p i00 line 7 - '4 examples' should read '3 examples'
p i06 line 24 - '(lowest dilution)' should read '(3 pg lane)'
pi 12 bottom line - the reference 'Mackett, 1995' should be replaced with 'Yuen and Moss, 
1987’.
pi 13 top line - the first sentence should be replaced with 'The details concerning the 7.5K. 
promoter have been identified previously (Cochran et al. 1985), including the 
transcriptional initiation site.' 
pi 17 bottom line - 'Tamron' should read 'Tamarron'
pi 18 line third from bottom - replace 'Mackett. 1995' reference with 'Elroy-Stein et al. 1989'
pl24 line 7 - 'Figure 4.2c' should read 'Figure 4.2bii'
p 136 line 14 - '# 12, # 15, # 17 and #20' should read '# 12, # 16, # 18 and #22'
p 139 line 7 - '23/24' should read '23/26'
p i39 line 16 - 'e(i) and f  should read 'e and f(i)'
p i49 line 1 - omit second 'was'
p i65 line 17 - 'lane 8' should read 'lane 6'
p i67 line 13 - '(where Xaa is any residue)' should read '(where Xaa is any residue except 
proline)'
p i76 line 22 - 'rVV-Ag85,' should read ’rVV-Ag85A,' 
pl89 line 5 - should read'IFN-y'
p 191 second line from bottom - 'was' should read 'were'
p209 should include the reference. 'Cochran MA. Puckett C and Moss B (1985) In vitro 
mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early 
and late regulatory signals. J. Virol. 54. 30-37.'
p214 should include the reference, 'Lane JM. Ruben FL, Neff JM and Millar JD (1969) 
Complications of smallpox vaccination. 1968. National Surv eillance in the United States 
N. Engl J  Med. 281, 1201-1208.'
p22() should include the reference. 'Prin/is S. Chatterjee D and Brennan PJ (1993) Structure 
and antigenicity of lipoarabinomannan from Mycobacterium bovis BCG. Gen. 
Microbiol. 139. 2649-2658.'
p223 omit second Townsend et al reference and change date on the first of these from ' 1988a' 
to '1988'
p224 should include the reference, 'Yuen L and Moss B (1987) Oligonucleotide sequence 
signalling transcriptional termination of vaccinia virus early genes Proc. N atl Acad Sci 
U. S. A 84. 6417-6421 '
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E S A T - 6  i s  a n  i m p o r t a n t  T - c e ll  a n t ig e n  r e c o g n iz e d  b y  p r o t e c t iv e  T  c e l l s  in  a n i m a l  m o d e ls  o f  in f e c t io n  w ith  
Mycobacterium tuberculosis. In  a n  e n z y m e - l in k e d  im m u n o s o r b e n t  a s s a y  ( E L I S A )  w i t h  o v e r la p p in g  p e p t id e s  
s p a n n i n g  t h e  s e q u e n c e  o f  E S A T - 6 ,  m o n o c lo n a l  a n t ib o d y  H Y B 7 6 - 8  r e a c t e d  w i t h  t w o  p e p t id e s  in  t h e  N - t e r m in a l  
r e g io n  o f  t h e  m o le c u le .  A s s a y s  w ith  s y n t h e t i c  t r u n c a t e d  p e p t id e s  a l lo w e d  a  p r e c i s e  m a p p in g  o f  t h e  e p i t o p e  to  
t h e  r e s i d u e s  E Q Q W N F A G I E A A A  a t  p o s i t i o n s  3  t o  1 5 . H y d r o p h i l i c i t y  p lo t s  r e v e a l e d  o n e  h y d r o p h i l ic  a r e a  a t  t h e  
N  t e r m in u s  a n d  t w o  a d d i t i o n a l  a r e a s  f u r t h e r  a l o n g  t h e  p o ly p e p t id e  c h a i n .  A n t i p e p t i d e  a n t ib o d ie s  w e r e  g e n e r ­
a t e d  b y  im m u n iz a t io n  w i t h  s y n t h e t i c  8 - m e r  p e p t id e s  c o r r e s p o n d in g  t o  t h e s e  t w o  r e g io n s  c o u p le d  to  k e y h o le  
l im p e t  h e m o c y a n in .  P r o l o n g e d  i m m u n i z a t i o n  w i t h  a  2 3 - m e r  p e p t id e  ( p o s i t i o n s  4 0  t o  6 2 )  r e s u l t e d  in  t h e  
f o r m a t io n  o f  a n t ib o d ie s  r e a c t i n g  w i t h  t h e  p e p t id e  a s  w e l l  a s  n a t iv e  E S A T - 6 .  A  d o u b le - a n t i b o d y  E L I S A  w a s  t h e n  
d e v e lo p e d  w it h  m o n o c l o n a l  a n t ib o d y  H Y B 7 6 - 8  a s  a  c a p t u r e  a n t ib o d y ,  a n t ig e n  f o r  t e s t in g  in  t h e  s e c o n d  la y e r ,  
a n d  a n t ip e p t id e  a n t ib o d y  in  t h e  t h ir d  l a y e r .  T h e  a s s a y  w a s  s u i t a b le  f o r  q u a n t i f i c a t i o n  o f  E S A T - 6  in  M. tuber­
culosis a n t ig e n  p r e p a r a t i o n s ,  s h o w in g  n o  r e a c t iv it y  w i t h  M. bovis B C G  T o k y o  c u l t u r e  f lu id ,  u s e d  a s  a  n e g a t iv e  
c o n t r o l ,  o r  w i t h  M P T 6 4  o r  a n t ig e n  8 5 B ,  p r e v io u s ly  s h o w n  to  c r o s s - r e a c t  w i t h  H Y B 7 6 - 8 .  T h is  c a p t u r e  E L I S A  
p e r m i t t e d  t h e  i d e n t i f i c a t io n  o f  E S A T - 6  e x p r e s s i o n  f r o m  v a c c in ia  v i r u s  c o n s t r u c t s  c o n t a in i n g  t h e  esat-6 g e n e ;  
t h i s  e x p r e s s io n  c o u ld  n o t  b e  id e n t i f ie d  b y  s t a n d a r d  i m m u n o b lo t t in g .
A key question in the development of new vaccines against 
tuberculosis is whether particular antigens of Mycobacterium 
tuberculosis are of major importance in the development of 
protective immunity.
Various techniques are used for the identification of protec­
tive antigens. In particular, we have studied the specificity of 
T-cell responses in a mouse model of memory immunity after 
infection with M. tuberculosis (1, 5). This system involves M. 
tuberculosis infection of C57BL/6J mice for 1 month, treatment 
with isoniazid and rifampin to clear the infection, and then 
resting for a longer period prior to  reinfection. Following M. 
tuberculosis reinfection, these memory immune mice develop a 
rapid and intense T-cell response which controls the infection. 
By testing individual fractions of a short-term culture filtrate 
(ST-CF) enriched in proteins actively secreted by M. tubercu­
losis (4), the protective T cells were found to exhibit a very 
restricted specificity. Two fractions (3 to 10 and 25 to 31 kDa) 
were strongly recognized and induced both marked prolifera­
tive responses and high levels of gamma interferon (IFN-y) 
release (5).
In the fraction containing 25- to  31-kDa proteins, the com­
ponents of the antigen 85 complex are major constituents (34, 
37). Among these, 85B has been demonstrated to induce pro­
liferation and high levels of IFN-y release in T-cell cultures 
from memory immune mice (1. 2). The 85A protein has pre­
viously been shown to induce IFN--y production in cultures of
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spleen cells from mice recently infected with M. tuberculosis 
(9). In agreement with this finding, antigen 85A has recently 
been shown to be protective in DNA vaccination (17).
In the second fraction, containing proteins ranging in mo­
lecular mass from 3 to  10 kDa, a protein with an apparent 
molecular mass of 6 kD a designated ESAT-6 (6-kDa early 
secretory antigenic target) was shown to possess the major 
activity (1). Overlapping peptides spanning the sequence of 
ESAT-6 have been used to map two T-cell epitopes on this 
molecule in mice. One epitope, recognized in the context of 
H-2hd, was located in the N-terminal part of the molecule; the 
other epitope, recognized in the context of H-2"k, covered 
amino acids 51 to 60 (7). The esat-6 gene, which lacks a signal 
sequence (1, 30), is present in M. tuberculosis and virulent 
Mycobacterium bovis but absent in the M. bovis BCG vaccine 
strain (16).
One possible avenue toward improved vaccines against tu ­
berculosis would therefore be recombinant live vaccine carriers 
such as BCG or attenuated vaccinia virus expressing ESAT-6 
(13. 25). Specific quantification of ESAT-6 expression in soni­
cates and culture fluids of recombinant microorganisms in 
which the esat-6 gene has been introduced is essential as part 
of the selection of candidate recombinant microorganisms for 
further vaccination experiments. The purpose of the present 
work was to characterize B-cell epitopes on the ESAT-6 mol­
ecule as a basis for the development of an enzyme-linked 
immunosorbent assay (ELISA) for its quantification.
MATERIALS ANI> METHODS
Hacteriul cultures and antigen preparations. M boxii BCG substrain Danish 
1331 was obtained from Statens Scruminslilut. Copenhagen. Denmark, and
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substrain Tokyo 172 was obtained from the National Institute of Health. Tokyo, 
lapan. and grown on Sauton medium. ST-CF, enriched in proteins actively 
secreted by M. tuberculosis H37Rv, was produced as described previously (3). 
Culture fluids. 3 to 5 weeks old from stationary cultures of M. tuberculosis H37Rv 
containing secreted proteins and only small amounts of cytosolic proteins re­
leased by bacterial lysis were prepared as described previously (27, 35).
Clinical isolates of M. tuberculosis were identified by standard diagnostic meth­
ods at the Mycobacteria Department. Statens Scruminstitut. grown on Ogawa 
slants or Lowcnstcin-Jcnscn medium, and then transferred to liquid Sauton 
medium for further cultivation.
Isolation of proteins. Proteins were isolated as described in detail previously, 
and then tested for homogeneity by sodium dodccyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). protein staining, and immunological techniques. 
MPT59 (85B) and MPT64 were purified from M. tuberculosis culture filtrate (27). 
The term MPB was introduced by Nagai ct al. (26) for the designation of a 
protein purified from M. bovis BCG. with a number denoting the relative mo­
bility in PAGE (7.7% polyacrylamide) at a running pH of 9.5. The corresponding 
term MPT is used to denote a protein isolated from M. tuberculosis. ESAT-6 was 
purified from 3- to 5-wcck-old culture filtrate of M. tuberculosis H37Rv (30).
Preparation and purification of recombinant ESAT-6. A synthetic DNA se­
quence (5-G CGA CAT CAC CAT CAC CAT CAC CAT CAC ATC GAG 
GGC A3' plus protruding 5' GATC overhangs), coding for a stretch of eight His 
residues followed by a factor Xa cleavage site, was inserted in the unique Bglll 
recognition site of the expression plasmid pGH433 (31). This generated plasmid 
pMCT6, in which the Bglll site downstream of the insert was maintained. The 
DNA sequence coding for the full-length ESAT-6 protein was PCR amplified 
from cloned M. tuberculosis genomic DNA with the primers 5'-GAAGATCTA 
TGACAGAGCAGCAGTGG (nucleotides 1 to 18 of the coding sequence with 
a Bglll site added upstream) and 5'-CCGCCATGGTAAACACGAGAAAGG 
GCG (nucleotides 67 to 84 after the stop codon, with a N col site added down­
stream) and inserted between the B glII and N col sites of pMCT6. The recom­
binant protein was produced in Escherichia coli XL1 blue and purified by metal 
ion affinity chromatography on a Ni* column esentially as described previously 
(32) but with phosphate buffers containing 8 M urea, which was removed after 
the purification.
Hvdrophilicitv plots. Hydrophilicity plots were prepared by the method of 
Kyte and Doolittle (21).
Synthesis of ESAT-6 peptides and generation of antibodies. Monoclonal an­
tibody (MAb) HYB76-8, reacting with ESAT-6, was obtained from purified 
protein derivative-immunized CF1 x BALB/c F, mice (20). The MAb (batch
0.5C8.025B3) was purified by affinity chromatography on protein A-Scpharosc 
CL-4B as specified by the manufacturer (Pharmacia Biotech. Uppsala. Sweden).
Eight overlapping 20- to 24-mcr peptides covering the amino acid sequence of 
ESAT-6 and a scries of truncated peptides in the residue 1 to 20 region from the 
N-tcrminal end were synthesized as described in detail previously (7). To pro­
duce antibodies to peptides from regions within the ESAT-6 molecule presumed 
to contain B-ccll epitopes, two 9-mcr peptides (DEGKQSLTK. positions 30 to 38 
(p30-38), and YQGVQQKWD, positions 51 to 59 (p51—59J) were obtained from 
McdProbe A/S. Oslo, Norway, as peptide amides, blocking the C-terminal car­
boxyl group of the peptide to more closely mimic the charge environment of the 
native protein. A cysteine residue was added at the N terminus, using a part of 
the peptide for coupling to keyhole limpet hemocyanin (KLH) as the carrier 
protein for immunization. The hcterobifunctional reagent m-malcimidobenzoyl- 
/V-hydroxysuccinimidc ester (MBS) was used for coupling by a two-step proce­
dure, first activating the carrier and then coupling the peptide (12, 19, 22). The 
rabbits were immunized by repeated subcutaneous injections of peptide coupled 
to KLH in an emulsion with incomplete Freund’s adjuvant at multiple sites by 
standard procedures (14). The same technique was used to generate antibodies 
against the 23-mcr peptide AAAWGGSGSEAYQGVQQKWDATA (p40-62). 
The rabbits were bled on the day before the first immunization, immediately 
before subsequent immunizations, or separately as indicated.
To obtain anti-p30-38 and anti-p51-59, 180 ^ g of coupled protein was used to 
immunize each rabbit on day 1 and 90 ¿¿g was used for each of the three 
subsequent immunizations 3, 5. and 9 weeks later. The rabbits were bled on day 
I and then 3, 7, 9. and 11 weeks later.
To obtain anti-p40-62, 830 p.g of protein was used to immunize each rabbit on 
day 1 and then 2. 9, and 13 weeks later. These animals were hied on day 1 and 
then 3. 9, 11, 13. 15. and 16 weeks later.
Polyvalent rabhit anti-BCG immunoglobulin was kindly provided by DAKO 
Immunoglobulins. Copenhagen, Denmark. Generation of polyvalent anti-M. tu ­
berculosis culture fluid and monospecific polyclonal rabbit antibodies to isolated 
mycobacterial proteins has been described previously (35).
SDS-PAGE with immunoblolling. SDS-PAGE was performed with the Phar­
macia system for horizontal electrophoresis in a Multifor II electrophoresis unit 
2117 (Pharmacia LKB Biotechnology AB. Uppsala. Sweden) with precast poly­
acrylamide gels. ExccIGcl SDS gradient 8-18 (Pharmacia). Samples (10 p.1) of 
the various culture filtrates containing 10 m-8 (°ial protein were applied in each 
lane Semidry Western blotting was performed with the model 2117-250 Nova- 
blot electrophoretic transfer kit (LKB. Bromma. Sweden) onto 0.2-fim-porc-sizc 
nitrocellulose membranes (Schleicher and Schull, Dassel. Germany). After elec­
trophoretic transfer, antigen bands were delected with horseradish peroxidase 
(HRP)-conjugated donkey anti-rahhil immunoglobulin (Amersham Interna­
tional pic. Little Chalfont, United Kingdom), with diaminobcnzidinc in 0.1 M 
sodium acetate buffer (pH 4.0) as the substrate.
ELISA technology. To test for antibody reactivity with synthetic peptides, the 
plates were coated with individual peptides by applying I fig of peptide per well 
in 100 ftl of phosphate-buffered saline (PBS) (pH 7.4), blocking with 5 mg of bovine 
scrum albumin per ml in PBS. For reactivity with MAb HYB76-8, detection was 
carried out with HRP-labellcd sheep anti-mouse immunoglobulin (Amersham); for 
reactivity with polyclonal rabbit anti-peptide antibodies, detection was carried 
out with HRP-labellcd donkey anti-rabbit immunoglobulin (Amersham).
Based on initial titer determination experiments outlined below, a double­
antibody ELISA was set up according to the principle described in detail previ­
ously (16, 36). Briefly, Immunoplalc MaxiSorp 96-wcll plates (no. 442404; 
NUNC, Roskilde, Denmark) were coated with 100 p.1 of purified MAb HYB76-8 
(500 fjLg/ml) diluted 1:200. Blocking was carried out with 5 mg of bovine scrum 
albumin per ml in PBS. The second layer contained serial twofold dilutions of the 
antigen to be tested (culture fluids, sonicates, or purified proteins) in the con­
centrations indicated. Dilutions of culture fluids of M. tuberculosis H37Rv and 
BCG Tokyo were included as positive and negative controls, respectively. The 
third layer contained polyclonal rabbit anti-p40-62 peptide at 1:200. The indi­
cator system consisted of HRP'conjugatcd donkey anti-rabbit immunoglobulin 
(Amersham) at 1:1,000. The substrate was 2,2'-azino-di-(3-cthylbenzthiazolinc- 
sulfonate (16)] (ABTS). The samples were washed four times between each step 
with PBS containing 0.1% Tween 20. All reaction mixtures were set up in triplicate, 
and the median values were used for recording and calculations. The results were 
read on an MR 7000 ELlSA reader (Dynatech Laboratories Inc., Chantilly, Va.).
rW expressing ESAT-6. Two recombinant vaccinia virus (rVV)-ESAT-6 se­
quences were constructed with the following foreign coding sequences; (i) esat-6 
alone or (ii) esat-6 fused downstream from a heterologous eukaryotic signal 
sequence, t p a , belonging to tissue plasminogen activator (tPA) (28). These were 
inserted into the nonessential thymidine kinase locus of wild-type VV (strain 
WR) with the transfer plasmids pi 108 and pSCll. These transfer plasmids 
included a cloning site for foreign sequence insertion under the vaccinia early/ 
late p7.5 promoter, flanking viral thymidine kinase sequence which permits 
homologous recombination and a selectable marker under a second VV pro­
moter, and the £. coli genes, gpt for pi 108 and lacZ for pSCll (23). For 
rVV-tPA—ESAT-6. pll08-tPA was constructed by cloning synthetic sense and 
antisense oligonucleotide strands (MWG Biotech, Ebersberg, Germany) encod­
ing the 21-amino-acid leader sequence of tPA and a multiple-cloning site con­
taining N h e I, Bam HI, Sm a I, and £coRI (24). An esat-6 coding sequence was 
inserted into both pi 108 and pll08-tPA on a B a m H l-E co R l PCR-gcneratcd 
fragment with restriction sites incorporated within the primers. Following con­
firmation of plasmid sequence fidelity, homologous recombination into VV was 
carried out as described elsewhere (23). Briefly, a near-confluent monolayer of 
TK-143 cells was infected with wild-type VV at a multiplicity of infection of 1:10. 
followed 1 h later by transfection with pi 108-ESAT-6 or pi 108-tPA-ESAT-6 with 
the cationic lipid transfection reagent N-(l-(2.3-dioleoyloxy)propyl]-/V.N.jV- 
trimcthylammonium mcthylsulfate (DOTAP; Bochringcr, Mannheim, Germa­
ny). Viral recombinants were selected with mycophcnolic acid (23), and three 
rounds of plaque purification were performed. rVV-ESAT-6 and rVV-tPA- 
ESAT-6 were verified with PCR primers both flanking the coding region and 
within it ( tp a and esat-6). A similar procedure was used with the pSCl 1 transfer 
plasmid, but in this case, recombinants were color selected with 5-bromo-4- 
chloro-3-indolyl-3-o-galactopyranoside (X-Gal; Sigma Chemical Co., St. Louis, 
Mo.). Protein cell lysates were obtained from rVV-infected TK-143 cells (mul­
tiplicity of infection, 30:1) 18 h postinfcction. The cells were lysed in 1 ml of 1% 
Nonidct-P-4() in 50 mM Tris (pH 8.0)-150 mM NaCI, representing 8 x 105 
cclls/ml. The cell lysates were assayed for their protein concentration with the 
bicinchoninic acid protein assay reagent (Pierce Chemical Co.. Rockford, III.) as 
specified by the manufacturer and stored at -70°C prior to use.
Southern blotting, RT-PCR, and Western blotting of rW-ESAT-6. Southern 
blotting of rVV-ESAT-6 genomic DNA was performed with a digoxigenin- 
labcllcd wholc-gcnc probe. Cell monolayers were infected with rVV-ESAT-6 
and rVV-p-galactosidasc (negative control), and genomic DNA was extracted by 
standard methods. Genomic and plasmid (pSCl l-ESAT-6 and pSCll alone) 
DNA were digested with EcoRI, resulting in a predicted 700-bp fragment incor­
porating esa t-6 . These digests were subjected to standard Southern blotting, and 
the signal was detected by a chemiluminescence method (Bochringer Mann­
heim) with an anti-digoxigenin alkaline phosphate-conjugate antibody. Lumigen 
purified protein derivative substrate, and a digoxigcnin-UTP-labcllcd esat-6 
whole-gene probe as specified by the manufacturer.
Reverse transcription-PCR (RT-PCR) was performed for recombinant esat-6 
transcripts. mRNA was purified from infected-cell lysates and reverse transcribed 
with Superscript (Life Technologies, Paisley, United Kingdom). r.«i/-6-spccific PCR 
primers were used to amplify a predicted 300-bp product. Given that the mRNA 
preparation would be contaminated with viral genomic DNA (VV is a cytoplas­
mic virus), the samples were treated with DNase (Life Technologies) before the 
RT step. Relevant controls included no RT step (both with and without DNase 
treatment), no DNase treatment, a plasmid incorporating esat-6 as a positive 
control, and cDNA from rVV lacking esat-6 as a negative control.
Western blotting was performed on rVV-infccted cell lysates. Samples were 
run on SDS-PAGE under both reducing and nonreducing conditions and with 
both large- and small-scale gel systems. Following protein transfer, the nitroccl-
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P e p t i d e S e q u e n c e R e a c t i v i t y
w i t h  H Y B 7 6 - 8
P I 1 - 2 0 M TEQ Q W N FA G  I  E A A A S A IQ G
P 2 1 2 - 3 5 E A A A S A IQ G N V T S IH S L L D E G K Q S ♦
P 3 2 2 - 4 5 V T S  IH S L L D E G K Q SL T K L A A A W G G -
P4 3 2 - 5 5 G K Q SL T K L A A A W G G SG SEA Y Q G V Q -
P 5 4 2 - 6 5 A W G G SG SEA Y Q G V Q Q K W D A TA TEL -
P 6 5 2 - 7 5 Q G V Q Q K W D A TA TELN N A LQ N LA R T -
P 7 6 2 - 8 5 A T E L N N A L Q N L A R T IS E A G Q A M A S -
P 8 7 2 - 9 5 L A R T IS E A G Q A M A S T E G N V T G M F A “
■f ♦ ♦ O . D .  i n E L I S A  > 0 . 9 0 0
♦ O . D .  0 . 1 0 0 - 0 . 2 0 0
- O . D .  < 0 . 1 0 0
FIG. 1. Reactivity of overlapping synthetic peptides derived from the se­
quence of ESAT-6 in ELISA.
lulose membrane was probed with HYB76-8 followed by HRP-conjugated sec­
ondary antibody (P260; Dako). The blotting procedure and signal detection were 
performed as specified for the enhanced chemiluminescence Western blotting 
detection system (Amersham).
RESULTS
Reactivity of MAb HYB76-8 with ESAT-6. MAb HYB76-8 
defines the ESAT-6 antigen (1, 16, 30). To precisely locate the 
epitope recognized by HYB76-8, a series of overlapping pep­
tides covering the sequence was tested in an ELISA. Figure 1 
shows the reactivity o f eight synthetic 20- to 24-mer peptides 
on the solid phase with MAb HYB76-8 diluted 1:100. Reac­
tivity is shown by +  +  + , +, and -  signs as indicators of the 
signal strength based on the optical densities (ODs) obtained 
on an ELISA plate in which the recorded peptides were tested 
simultaneously. S trong reactivity was observed with the pep­
tide corresponding to  residues 1 to 20 from the N-tcrminal 
end. Weaker but significant reactivity was observed with the 
peptide corresponding to residues 12 to 35, while the six re­
maining peptides showed no reactivity with HYB76-8.
For more precise localization of the reactive epitope, trun­
cated peptides were synthesized. The reactivities of 15 peptides 
are shown in Fig. 2. The peptide designation is indicated ac­
cording to the residues present.
Strong reactivity was observed with 10 of the peptides, with 
a striking decrease in ODs from peptide p3-15 to p3-14 (0.735 
and 0.062, respectively). The corresponding ODs for p3-15, 
p4-15, and p5-15 were 0.735, 0.049, and 0.039 respectively. 
These findings thus indicate a requirement of the 13 EQQWN- 
FAGIEAAA residues for full reactivity with MAb HYB76-8.
P e p t i d e S e q u e n c e R e a c t i v i t y  
w i t h  H Y B 7 6 - 8
p l - 2 0 M T E Q Q W N F A G  I E A A A S A IQ G ♦  ♦ ♦
p i  - 1 9 M T E Q Q W N F A G  I  E A A A S A  IQ
p i  - 1 8 M T E Q Q W N F A G  I  E A A A S A  I ♦  *  ♦
p 2  - 2 0 T E Q Q W N F A G I E A A A S A IQ G
p 3  -  2 0 E Q Q W N F A G IE A A A S  A I  QG
p 3  - 1 9 E Q Q W N F A G IE A A A S A IQ ♦  ♦ ♦
p 3  -  1 8 E Q Q W N F A G  I  E A A A S A  I
p 3  - 1 7 E Q Q W N F A G  I  E A A A S  A *  ♦ ♦
p 3  - 1 6 E Q Q W N F A G  I  E A A A S
p 3  - 1 5 rE Q Q W N F A G IE A A A l
p 3  - 1 4 E Q Q W N F A G  IE A A -
p 3  - 1 3 E Q Q W N F A G  I E A -
p 3  - 1 2 E Q Q W N F A G  I E -
p 4  -  1 5 Q Q W N F A G IE A A A -
p 5  - 1 5 Q W N F A G IE A A A
FIG. 2 Mapping of the HYB76-K-rcnclivc epit.ipc in ELISA through reac­
tion with synthetic peptides. The core peptide is honed.
H y d r o p h i l ic it y  p lo t  o f ES AT-6
R e s id u e  n u m b e r
FIG. 3. Hydrophilicity plot of ESAT-6. The hydrophilicity value at each point 
is the sum of the results for seven consecutive amino acids blotted at the middle 
residue. The horizontal bars indicate the positions of the synthetic peptides used 
for immunization.
This conclusion was supported by testing of eight additional 
peptides (p 3 -ll, p3-10, p4-14, p5-20, p5-14, p6-14, p7-14, 
and p8-14), which gave negative reactions with ODs of <0.050 
in plates in which a positive control with peptide p l-2 0  gave 
ODs of >0.850.
Reactivity of antipeptide antibodies with ESAT-6. Having 
established the location of the HYB76-8-reactive epitope, we 
continued our work to develop antibodies to other parts of the 
molecule. Figure 3 shows a hydrophilicity plot of ESAT-6. In 
addition to the N-terminal region, there are two other main 
hydrophilic areas which would be expected to contain surface- 
exposed areas of the polypeptide chain with B-cell epitopes. 
Consequently, two peptides, corresponding to positions 30 to 
38 and 51 to 59, were synthesized with a cysteine residue added 
at the N-terminal end for coupling to KLH as the carrier 
molecule for immunization. In three rabbits immunized with 
one of the peptides coupled to KLH, antibodies were rapidly 
formed and reacted with the corresponding free peptide bound 
on a solid phase in an ELISA; however, no reactivity was 
observed with the other peptide. Two weeks after the second 
immunization, the titer in an ELISA was >1:1,000 with ODs at 
a 1:100 dilution of >0.850 with the relevant peptide in five 
rabbits and <0.035 with the other peptide.
The anti-p30-38 antibody reacted significantly with three of 
the overlapping peptides of ESAT-6; the strongest reaction 
was with peptide P3 containing residues 22 to 45. The anti- 
p51-59 antibody reacted with the P4 and P5 peptides; the 
strongest reaction was observed with P4 containing residues 32 
to 55, as shown in Table 1. However, these antibodies did not
T A B L E  1. Reactivity o f  antibodies to synthetic peptides o f ESAT-6 
in ELISA
Peptide
OD values
Anti-p30-38“ Anti-p5l-59 Anti-p40-62
P I (1-20) 0.049* 0.040 0.059
P2 (12-35) 0.136 0.050 0.066
P3 (22—45) 0.499 0.040 0.043
P4 (32-55) 0.141 0.877 0.350
P5 (42-65) 0.049 0.688 1.147
P6 (52-75) 0.046 0.066 0.681
P7 (62-85) 0.029 0.030 0.049
PH (72-95) 0.033 0.030 0.047
rESAT-6 0.147 0.106 0.394
'* Each antiserum shown is representative for three rabbits immunized with 
each peptide.
'’The OD value recorded is for the second bleeding of each rabbit.
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FIG. 4. Reactivity of the anti-p40-62 antipeptide antibody with M. tubercu­
losis culture fluid in Western blotting. Lancs: 1, scrum obtained before immu­
nization; 2 to 4, serum obtained 3, 11, and 15 weeks, respectively, after immu­
nization; 5, reaction of MAb HYB76-8 with ESAT-6 for comparison. The 
positions of molecular mass markers are indicated at the left. The strong band at 
30 kDa represents the antigen 85 complex.
react with native ESAT-6 in Western blotting or in capture 
ELISA with HYB76-8 at the solid phase, M. tuberculosis cul­
ture fluid or rESAT-6 in the second layer, the antipeptide 
antibody in the third layer, and the standard detection system 
for binding of rabbit immunoglobulin.
We therefore continued by immunizing three rabbits with a 
longer peptide corresponding to  the extended hydrophilic re­
gion furthest from the HYB76-8 reactive epitope. A 23-mer 
peptide containing residues 40 to 62, containing the main hy­
drophilic region with neutral and hydrophobic residues on 
both sides, was selected. In ELISA with the peptide at the solid 
phase, significant antibody activity was demonstrated in serum 
taken 1 week after the second immunization. Reactivity in the 
ELISA with the overlapping peptides of ESAT-6 is shown 
for a representative antiserum  (K618) in Table 1, with max­
imal activity as would be expected against peptide P5. Sera 
from early bleedings were again without reactivity with na­
tive ESAT-6 in Western blotting experiments or the capture 
ELISA. The immunization was therefore continued, and in 
late bleedings the antibodies also reacted with native ESAT-6 
in Western blotting experiments, as shown in Fig. 4. In ELISA 
with rESAT-6 from E. coli at the solid phase, reactivity was low 
initially and markedly higher from the third bleeding onward; 
this is similar to the findings in Western blotting experiments. 
Figure 4 also illustrates the reactivity of rabbit serum obtained 
prior to immunization with several components of M. tubercu­
losis culture fluid, including the antigen 85 complex.
Double-antibody ELISA for quantification of ESAT-6. Hav­
ing obtained antibodies reacting with two different epitopes on 
ESAT-6, titer determinations were performed to obtain the 
optimal conditions for an ELISA. For MAb HYB76-8, we se­
lected a dilution (1:100) ensuring its presence in antibody ex­
cess in a reaction with M. tuberculosis culture fluids. Antigen 
preparations in the second layer were tested in twofold serial 
dilutions. Culture fluids and sonicates started at 4 p.g of total 
protein/wcll, isolated proteins tested for cross-reactivity in this 
system started at 4 p.g of protein/wcll, and purified rESAT-6 
started at 0.1 p.g/well. The anti-p40-62 antiserum was used as 
a 1:200 dilution to ensure a sufficient strength of this antibody 
while avoiding the effects of coexisting antibodies to proteins of 
the antigen 85 complex in normal rabbit sera (Fig. 4), which 
tend to give rise to unwanted signals when more concentrat­
ed scrum samples arc used. Typical results arc shown in Fig. 5.
M. tuberculosis H37Rv culture fluid gave a curve with a pla­
teau at the three initial dilutions with ODs of about 1.20 and 
then decreasing. The curve of rESAT-6 isolated from E. coli 
initially decreased slowly; this was followed by a portion of the 
curve with an angle similar to that of the M. tuberculosis culture 
fluid curve. BCG Tokyo culture fluid gave no OD signals above 
0.100 at any dilution, in agreement with the previous demon­
stration of the lack of this antigen in BCG. MAb HYB76-8 has 
previously (16) been demonstrated to cross-react with MPT64 
and the antigen 85 complex. Purified MPT64 gave an OD of 
0.093 at 4 p.g/well, and MPT59 (85B) gave a value of 0.084, 
both with entirely flat curves upon further dilution in the 
ELISA. The cross-reactivity of HYB76-8 thus had no signifi­
cant influence on the assay system developed.
Application of double-antibody ELISA to recombinant m i­
croorganisms. Three rVV-ESAT-6 constructs were made with 
pSCl 1 initially and then pi 108. pi 108 was used to  create rVV 
both with and without tPA. The two rVV constructs without 
tPA were ostensibly identical and included the sam e protein­
coding sequence and promoter. The latter construct was in­
cluded as a control for the pi 108-derived rVV-tPA-ESAT-6. 
Successful incorporation of esat-6 into VV was confirmed by 
plasmid sequencing and PCR (data not shown) or Southern 
blotting (Fig. 6A). This figure shows signals indicating esat-6 in 
both digested pSCl l-ESAT-6 and rVV-ESAT-6 and no signal 
for empty vector constructs. ESAT-6 transcription was also 
readily identified by RT-PCR (Fig. 6B). In this experiment, rel­
evant controls excluded the possibility of contamination from 
the viral genome acting as the template. Despite confirming 
sequence fidelity and the presence of mRNA. protein expres­
sion in immunoblotting could not be identified by Western 
blotting (Fig. 6C). This absence of signal was true for the three 
separate rVV constructs with MAb HYB76-8 at a  wide range 
of dilutions, blotting in the presence or absence of various block­
ing reagents, and the use of “preparatory" large-scale SDS- 
PAGE. ST-CF from M. tuberculosis was used as a positive 
control, and ESAT-6 was readily identified (Fig. 6C) in ST-CF 
diluted 1:100 containing approximately 10 to 100 ng of ESAT- 
6. Of note, nonspecific background was particularly appar­
ent in lane 1, which has a high protein content. However, the 
background was limited to the higher-molecular-mass p ro ­
teins and would not have interfered with a signal of 6 kDa.
Total-cell lysates (containing viral and cellular proteins) 
from rVV-infectcd cells were assessed by the capture ELISA;
ELISA lor ESAT-6
OO 405 IM
N a n o g ra m  p ro te in /w a ll
— O —  rCSAT 6
FIG. 5. Reactivity of M  tuberculosis culture fluid (M.lub. cf.) and purified 
recombinant ESAT-6 in the double-antibody ELISA, compared with BCG 
Tokyo culture fluid as negative control. The open circle indicates that corre­
sponding ODs were obtained with the isolated proteins MPTr>4 and MPTH5B 
(MPT5‘>).
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FIG. 6. (A) Southern blot of EcoRI-digesletJ plasmid and purified viral 
DNA. Lanes: 1, nonrecombinant insertion plasmid, pSCl 1; 2, pSCl Mi SAT-6, 3, 
rVV-p galactosidase; 4. rVV-ESAT-6. (B) RT-PCR of virally encoded ESAT-6 
transcripts. Lancs: 1, 100-bp pair molecular mass marker: 2, DNase-treated. RT 
step included: 3: DNase treated, no RT step; 4, no DNase, no RT step (con­
taminating viral DNA): 5, no DNase, no RT step. 6, plasmid containing o a t-0 
gene (positive control). (C) Western blot of rVV-infcclcd cell lysates in a large 
gel system with 285 pi of cell lysateAvell. Lanes: I, neat cell lysate; 2. diluted 1:2: 
3. 1:4; 4. Af. tuberculous culture filtrate (positive control).
twofold serially diluted samples were tested as illustrated in 
Fig. 7. The three rVV constructs illustrated were from mono- 
layers with similar confluence and rVV titers, and the highest 
concentration corresponded to lysates of 4 x  10 ' cells. The 
lysate of cells containing rVV-tPA-ESAT-6 gave a strong sig­
nal. Upon dilution, the curve showed an angle similar to that 
for M. tuberculosis culture fluid, requiring about a 20-fold- 
highcr total-protein content to give an ESAT-6 signal of sim­
ilar strength. Lack of tPA in the rVV-ESAT-6 construct did 
not affect viral replication, in -that PFU counts postinfection 
were similar for the two constructs. The construct containing 
esat-6 alone. rVV-ESAT-6, gave a considerably weaker signal, 
still considered positive, while the lysate of cells with empty 
vector gave a flat curve.
DISCUSSION
In the experiments involving ELISA with overlapping pep­
tides of the ESAT-6 sequence at the solid phase, the H YB76-8
reactive epitope was localized to the N-terminal part of the 
polypeptide chain (Fig. 1), with further localization to a core 
area with the EQQWNFAGIEAAA residues at positions 3 to 
15 by the use of synthetic truncated peptides from this region, 
as shown in Fig. 2.
Comparing the reactivity illustrated in these figures, a strik­
ing feature emerges: The C-terminal border of the epitope is 
revealed by the striking difference in HYB76-8 reactivity with 
peptides p3-15 and p3-14, giving ODs in the ELISA of 0.735 
and 0.062, respectively. In assays with the overlapping pep­
tides, the ODs for peptides PI, P2, and P3 were 0.918, 0.186, 
and 0.009, respectively, thus showing a positive reaction with 
peptide P2 containing only four residues of the core epitope, 
EAAA. This indicates a striking influence of further flanking 
residues in the P2 peptide for maintenance of reactivity with 
MAb HYB76-8.
The mapping of the HYB76-8-reactive epitope to residues 3 
to  15 corresponds exactly to the previous mapping of T-cell- 
reactive epitopes on this molecule in mice by Brandt et al. (7). 
Two T-cell epitopes, recognized in the context of different H-2 
types, were defined. In BALB/c (H-2?) and C57BLV6j (,H-2b) 
mice, only the N-terminal peptide 1 of nine overlapping pep­
tides covering the ESAT-6 sequence reacted with T cells re­
covered during recall of immunity to M. tuberculosis. Mapping 
with truncated synthetic peptides in C57BL/6j mice showed a 
slight variation in different test systems, defining the epitope to 
a 13-amino-acid core sequence corresponding to residues 3 to 
15 in tests of IFN-y release upon stimulation of T cells from 
memory immune mice.
This localization of reactivity was observed in only two of the 
six inbred strains tested, and we note that MAb HYB76-8 was 
generated in CF1 x  BALB/c F, mice (20) expressing H -21. 
Following infection with M. tuberculosis (8) or M. bovis BCG 
(18), formation of antibody to components of mycobacterial 
sonicates and culture fluids varies markedly, depending on the 
genes in the major histocompatibility complex. Additional work is 
needed to see whether B-ccll epitope localization on a single pro­
tein, like ESAT-6, will differ in different inbred mouse strains.
While B-cell epitopes in general correspond to surface-ex­
posed areas of the polypeptide chain and T-cell epitopes de­
pend on antigen processing and presentation by the major 
histocompatibility complex, it is well established that areas of 
polypeptide chains may overlap with regard to the presence of 
B- and T-cell epitopes. Regarding mycobacterial proteins, this 
feature has been demonstrated in several instances. In the 
M. tuberculosis 16-kDa antigen, two linear B-cell epitopes at
OO 40S nm
N a n o g ra m  p ro te m /w e il
■ ■■ rVV-lPA
FIC». 7. Reactivity of douhic-antihody ELISA for ESAT-6 with rVV. M.tub 
cf„ M tuberculosis culture fluid.
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p31-40 and p61-70 were demonstrated in mice (33), while 
three T-cell epitopes, one of them at p21-40, were demonstrat­
ed in human T-ccll responses ( II ) . A significant overlap of B- 
and T-cell epitopes has been demonstrated in the 19-kDa lipo­
protein (6). Overlapping B-cell and T-cell epitopes were dem­
onstrated regarding reactivity with the 65-kDa heat shock pro­
tein in cells obtained from patients with Behcet’s disease (10). 
Pollock et al. (29) have demonstrated two T-cell epitopes, at 
positions 118 to 135 and 174 to 194 with numbering starting at 
Met 1 of the signal peptide, on the secreted MPB70 protein 
using cells from cattle infected with M. bovis. One of these, at 
the C-terminal end of the polypeptide chain, overlaps the B- 
cell epitope at position 174 to 190, reacting with the monoclo­
nal antibody 1-1D (38). Billman-Jacobe et al. (6a) demon­
strated another T-cell epitope on MPB70, at positions 103 to 
113, overlapping the MAb 1-5C reactive epitope at positions 
109 to 118 (38).
Reaction of our initial antipeptide antibodies with the pep­
tide used for immunization without reactivity with the native 
ESAT-6 molecule is a well-known feature of antipeptide anti­
bodies. W hen a longer peptide corresponding to the extended 
hydrophilic region of ESAT-6 was used, the fine specificity of 
the antipeptide antibodies changed upon extended immuniza­
tion, and reactivity with native ESAT-6 was obtained, permit­
ting the establishment of a double-antibody ELISA and giving 
a strong signal with M. tuberculosis H37Rv culture fluid. BCG 
Tokyo culture fluid was considered a particularly suitable neg­
ative control, containing proteins of the antigen 85 complex as 
well as large amounts of MPB64 (15), which was previously 
demonstrated to cross-react with HYB76-8 (16). Its signal was 
sufficiently low, giving a flat curve as illustrated in Fig. 5, thus 
demonstrating a marked difference in reactivity with respect to 
M. tuberculosis and BCG.
Observing the strong signal obtained in the double-antibody 
ELISA with lysates of cells containing rVV-tPA-ESAT-6 (Fig. 
7), it was surprising to obtain no signal in Western blotting with 
MAb HYB76-8 on the same lysates, as shown in Fig. 6C. This 
observation is probably explained by the tendency of MAbs to 
depend strongly on the three-dimensional structure of the an­
tigen and its reactive epitope while polyclonal antibodies are 
less sensitive in this regard.
A variety of M. tuberculosis preparations are being tested. 
ST-CF (3) gives a good signal, albeit somewhat weaker than 
that o f culture fluids obtained from longer-lasting stationary- 
phase cultures of M. tuberculosis like the 4-wcek culture shown 
in Fig. 5. Culture fluids from 10 clinical isolates of M. tubercu­
losis gave strong signals, with all but one being stronger than 
those o f the ST-CF preparations. In M. tuberculosis sonicates, 
a positive signal was obtained although it varied in strength. 
This corresponds to the dem onstration of ESAT-6 in culture 
fluid as well as cytosol of M. tuberculosis by Sorensen et al. 
(30). A  thorough investigation o f culture fluids and soni­
cates o f  washed M. tuberculosis cells obtained from individual 
cultures is needed for further characterization of the release of 
the ESAT-6 protein from the mycobacterial cell (35).
Furthermore, the assay will be valuable for the demonstra­
tion and quantification of ESAT-6 produced by various recom­
binant organisms like BCG, Mycobacterium sme^matis, and VV 
to select candidate vaccines for protection studies. Information 
on ESAT-6 expression in different constructs of the same car­
rier is readily obtained, as illustrated in Fig. 7. Quantitative 
information comparing the expression in different carriers is 
more uncertain, since the sensitivity of the assay may vary for 
recombinant ESAT-6 in different carriers and in relation to 
native ESAT-6 in M. tuberculosis.
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ABSTRACT Protective immunity to Mycobacterium tuber­
culosis is poorly understood, but mounting evidence, at least in 
animal models, implicates m ajor histocompatibility complex 
class I-restricted CD8* T cells as an essential component. By 
using a highly sensitive assay  for single cell interferon y  
release, we screened an a rra y  of M. tuberculosis antigen- 
derived peptides congruent with HLA class I allele-specific 
motifs. We identified CD8* T  cells specific for epitopes in the 
early secretory antigenic ta rg e t 6 during active tuberculosis, 
after clinical recovery and in healthy contacts. Unrestimu- 
lated cells exhibited peptide-specific interferon y  secretion, 
whereas lines or clones recognized endogenously processed 
antigen and showed cytolytic activity. These results provide 
direct evidence for the involvement of CD8+ cytotoxic T 
lymphocytes in host defense against M. tuberculosis in hum ans 
and support current a ttem pts to generate protective cytotoxic 
T lymphocyte responses against M. tuberculosis by vaccination.
Onc-third of the world's population is latently infected with 
Mycobacterium tuberculosis, which causes over 2 million deaths 
per year (1); more than any o ther single pathogen. The global 
resurgence of tuberculosis, together with the HIV pandemic 
and emerging multi-drug resistance, have heightened the need 
for an effective vaccine suitable for use in immunocompro­
mised individuals. The curren t live attenuated vaccine. Bacille 
Calmettc-Guerin (BCG), has variable and limited efficacy in 
tuberculosis-endemic regions (2). Knowledge of protective 
immune responses in tuberculosis is incomplete. Delayed type 
hypersensitivity, mediated by cytokine-secreting CD4* T  cells, 
contributes to both pathogenesis and protection. However, 
delayed type hypersensitivity, as measured by tuberculin skin 
testing, does not correlate w ith the partial protection induced 
by BCG vaccination, implicating another component o f cell- 
mediated immunity (2). C D 8 " , as well as CD4* T cells are a 
feature of the tuberculous granuloma. Recent evidence from 
murine models points to a protective role for CD8* T  cells in 
M. tuberculosis infection (3 -6 ) . However, major histocompat­
ibility complex (MHC) class I-restrictcd CD8* T cells specific 
l for M. tuberculosis have not hitherto been found in humans.
although BCG-specific CD 8* T cell responses of undefined 
antigen specificity have been reported (7). Low frequencies of 
MHC class l-rcstricted M. tuberculosis-specific CDS* cytotoxic 
T lymphocytes (CTL) below the limits of detection of standard 
assays may have impeded their detection; we have adopted a 
novel, sensitive approach to  identify such cells.
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Two secreted antigens of M. tuberculosis, early secretory 
antigenic target 6 (ESAT-6) and the Antigen 85 complex, were 
studied because secreted antigens arc implicated as targets of 
protective immune responses (8) and are more likely to access 
the host cell cytdsol and hence the MHC class I antigen 
processing pathway. These antigens are the target of protective 
immune responses in mice (9, 10). ESAT-6 (6kD a) is virtually 
specific for M. tuberculosis complex; the gene is present in all 
isolates of M. tuberculosis and virulent Mycobacterium bovis but 
is absent from all strains of BCG examined (11). The 30-32- 
kDa Antigen 85 complex consists of 3 homologous proteins, A. 
B, and C, which constitute 30% of M. tuberculosis culture 
filtrate (12) and elicit strong CD4* T  cell responses in tuber­
culin skin test-positive subjects (13).
The sequences of ESAT-6 and antigens 85A, 85B, and 85C 
were scanned with allele-specific peptide motifs for the HLA 
class I types HLA-A2, HLA-B7, HLA-B8, HLA-B35, HLA- 
B52, and HLA-B53, all of which were present in the study 
population. A total of 49 peptides congruent with these motifs 
were synthesized (Table 1). These candidate epitopes were 
then sorted into pools according to HLA class I alleles and 
used to stimulate peripheral blood mononuclear cells (PB- 
MCs) from subjects with the corresponding HLA class I allele. 
In virro-expanded populations of peptide-specific T cells were 
then detected with two different assays of effector function. In 
a preliminary study using the standard 5,Cr release CTL assay 
we detected low levels of lytic activity against some peptide 
pools, but responses from the few remaining cells were too 
weak to define epitopes. We therefore adapted a more sensi­
tive enzyme-linked immunospot (ELISPOT) technique for 
detecting single cell interferon y  (IFN-y) secretion. We cali­
brated this assay against the 51Cr release CTL assay and found 
it an order of magnitude more sensitive for detecting low 
numbers of cultured human CD8* peptide-specific T  cells 
(14).
Thirty-nine adults were studied using the more sensitive 
ELISPOT assay. These included patients representing the full 
clinical spectrum of active tuberculosis (pulmonary, lymphad­
enitis, and extrapulmonary). as well as healthy contacts.
M A TE R IA L S  AND M ETH O D S
Subjects. Thirty-nine adult patients and contacts with suit­
able HLA haplotypcs were studied. Most subjects originated
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Table I. Peptides from ESAT-6 
HLA class I
allele Peptide motif Peptide Sequence Position
HLA-A2 -L/l/M...... V/L/l ES8 GIEAAASAI 10-18
ES9 AIOGNVTSI 17-25
ES 10 LLDEGKQSL 28-36
ESI 1 ELNNALONL 64-72
ES 13 AMASTEGNV 82-90
HLA-B8 -K-K—L/l ES7 EGKQSLTKL 31-39
HLA-B52 -O---- l/V ES12 LQNLARTI 69-76
We searched for 8-, 9-, or 10-residue sequences from ESAT-6, which 
were congruent with the peptide motifs of the HLA class I alleles -A2. 
-B7, -B8, -B35. -B52. and -B53. Sequences congruent with the peptide 
motifs for HLA-A2, HLA-B8, and HLA-B52 were identified; these 
peptides were synthesized and arc displayed. No sequences congruent 
with HLA-B7, HLA-B35, and HLA-B53 were present in ESAT-6 and, 
thus, no peptides were synthesized for these HLA class I alleles. 
Peptides were sorted into pools that were used form vitro restimulation 
of donor PBMCs. Peptides found to be CDS'  epitopes are shown in 
boldface. Similarly, 42 peptides were synthesized based on the se­
quences of antigens 85A and 85C. No CDS * epitopes were identified 
among these and the peptides are not shown.
from the Indian subcontinent, Africa, or northern Europe. The 
number of patients with different clinical types of disease, as 
well as the number of healthy contacts, are listed in Table 2. 
Most subjects were tuberculin skin test positive. All contacts, 
except one who was not tested, had a positive Heaf test of grade 
2 or more. All patients had at least 5 mm of cutaneous 
induration in response to intradermal injection with 1 tuber­
culin unit of purified protein derivative, except four who were 
not tested and four who were negative (three with old, inactive 
pulmonary tuberculosis and one with active miliary disease). 
The distribution of each of the 6 HLA class I alleles for which 
we tested peptide pools was as follows: HLA-A2 was present 
in 26 subjects, HLA-B8 in 7 subjects, HLA-B7 in 6 subjects, 
HLA-B35 in 2 subjects, HLA-B52 in 2 subjects, and HLA-B53 
in 2 subjects.
Each subject was tested against the peptide pool (or pools if 
the subject had more than one suitable HLA class I allele) once 
only. Repeat blood samples were obtained and further testing 
carried out only if the donor had responded on the first 
occasion.
Diagnosis of Tuberculosis in Patients NPH54 and NPH97.
NPH54 was diagnosed with tuberculosis on the basis of clinical 
symptoms, acute erythema nodosum and mediastinal lymph- 
adenopathy. Tuberculin skin test showed 25 mm induration 48 
hr after intradermal injection of 1 tuberculin unit of purified 
protein derivative. In addition, a very high antibody titer of > 
1/6,250 in response to the 16 kDa antigen of M. tuberculosis, 
helped to confirm active infection (15). For NPH97, the 
tuberculin skin test was positive and culture of a proximal 
phalangeal bone biopsy of the affected hand on Lowenstein- 
Jcnscn medium grew M. tuberculosis.
Tissue Typing. Subjects were HLA typed serologically. 
NPH54, NPH97, WB, Akiba, and PG were additionally typed
Table 2. Numbers of healthy contacts and patients with different 
types of clinical disease ~ -
Clinical phenotype Subjects, n
Pulmonary (active) 8
Pulmonary (inactive) 6
Pleural 2
Lymphadenitis 4
Ostcoarticular 5
Miliary I
Gastrointestinal I
Epididymo-urchilis I
Healthy contacts II
by amplification refractory mutation system (A RM S)-PCR 
using sequence-specific oligonucleotide primers (16).
Peptide Synthesis. Peptides were synthesized on solid phase 
on a synthesizer (Zinsser, Frankfurt) using fluorenylmethoxy- 
carbonyl chemistry. Purity was confirmed by HPLC.
ELISPOT Assay for IFN-y. Ninety-six-well polyvinylidene 
difluoride (PVDF)-backed plates (Millipore) precoated with 
the anti-IFN-y mAh I-D1K at 15 pg/ml (M ABTECH, Stock­
holm) were washed with RPMI medium 1640 and blocked with 
RIO for 1 hr at room temperature. Short-term cell lines 
(STCLs), CTL lines, or clones were washed two tim es in RPMI 
medium 1640. resuspended in RIO. and dispensed at known 
input cell numbers per well in duplicate wells. Peptide was 
added either directly to the supernatant at a final concentra­
tion of 2 p.M (free peptide) or presented on a Bcell line (BCL). 
prepulsed with 10 p.M peptide for 1 hr at 37*C, and then 
washed three times in RIO. Plates were incubated fo r 12 hr at 
37°C, in 5% CC>2/95% air. After »ashing six tim es with 
phosphate buffered saline (PBS)/0.05% Tween 20 to  remove 
cells, plates were incubated for 3 hr with the second biotin­
ylated an ti-IF N -y  mAh 7 -B 6-l-b io tin  at 1 /ig /m l 
(MABTECH). A further wash, as above, was followed by 
incubation with a 1:1,000 dilution of streptavidin-alkaline 
phosphatase conjugate for 2 hr. After another wash, chromo- 
genic alkaline phosphatase substrate (Bio-Rad) was added to 
the wells, and 30 min later plates were washed with tap  water. 
After drying, spot-forming cells (SFC) were counted  under 
x20 magnification. For ex vivo ELISPOT assays, 500,000 
freshly isolated uncultured PBMCs were used per well. Re­
sponses were considered significant if a minimum o f  10 SFCs 
were present per well and, additionally, this num ber was at 
least twice that in control wells.
Generation of CD8* T Cell Lines. STCLs were generated as 
described (17). Briefly, PBMCs separated from whole blood 
were prepulsed with 30-50 jzM peptide for 1 hr in a  cell pellet 
and then diluted up to I X I lf  cells/ml in RPMI m edium  1640 
supplemented with 10% pooled heat-inactivated human AB 
serum (R10) and 25 ng/ml rhIL-7 (R & D Systems), and 
seeded at 200 /xl per well in a U-bottomed 96-well plate. 
Lymphocult-T ( Biotest, Dreicch. Germany) was added  to 10% 
of each well at regular intervals. STCLs were assayed at day 14. 
Lines 3-9, 3-10, and 3-20 were generated from individual 
STCLs by two rounds of restimulation (on days 14 an d  21) with 
autologous peptide-pulsed irradiated BCL at a 1:3 feeder:re- 
sponder ratio. Line 4-1 was generated by pooling four ES12- 
specific STCLs (originally established with CD4-depleted PB­
MCs), followed by rcstimulation with peptide-pulsed autolo­
gous BCL.
Generation of CDS* T Cell Clones. Enumeration of IFN-y 
SFCs after CD4 and CD8 depletions indicated th a t the fre­
quency of CD8* ES12-specific T cells in NPH54-derived 
monospecific lines 3-9 and 3-20 was 1:44 and 1:67 CD8* T 
cells, respectively. This indicated that for T cells seeded  at one 
cell per well, 1.5-2.3 specific clones should be generated per 
100 wells seeded. This quantitative data guided o u r  cloning 
procedure: for each line, 240 wells were seeded at o n e  cell per 
well (following CD4 depletion). Cloning mix consisted of 
three-way mixed lymphocyte reaction. 10% Lymphocult-T, 
phytohcmagglutinin at I fxg/ml. and ESI2-pulsed autologous 
irradiated washed BCL, with a total of 100,000 feeders per 
well. Clones were screened in ELISPOT assays and three 
ES12-specific clones were subsequently recovered from line 
3-9 and two from line 3-20. Clones were m aintained by 
peptide-pulsed autologous irradiated BCL restimulation and 
supplementation with 10% Lvmphocult-T and rhIL-7 at 25 
ng/ml.
5lCr Release Cytotoxicity Assays. Standard chrom ium  re­
lease assays were performed as described (18). In brief, BCLs 
were labeled with 100 mCi "C r (Amersham), washed in RPMI 
medium 1640. and then pulsed with peptide as above and
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plated out at 5,000 cells per well. C T L , R IO , or 5%  T r ito n  
X - I0 0  w ere added. Test wells were in d u p lica te , other wells in 
quadruplicate. Plates were incubated fo r 5 h r  at 37”C , in 5 %  
C 0 2 /9 5 %  a ir  and harvested supernatant read  on filte rm ats in 
an L K B  1205 beta-plate scintillation co u n te r (W a llac , G a ith ­
ersburg, M D ) .  Background 5lC r release was less than 2 0 % . 
Percent lysis was calculated from  the fo rm u la  100 X ( E  — 
M ) / ( T  -  M ) .  where E  is the experim ental release, M  is the  
spontaneous release, and T  is the m axim al release.
Specific C e ll Depletions. C D 4 *  and C D 8 *  T  cells w ere  
depleted by 30-m in incubation w ith a n t i -C D 4  or a n ti-C D 8  
mAbs conjugated to ferrous beads, D Y N A B E A D S  M -4 5 0 .  
(D yn a l, O s lo ) in 500 *¿1 o f R 1 0  on ice. F o llo w in g  dilution o f  up  
to 5 ml in R 1 0 , the conjugate-coated cells w e re  removed by a 
magnetic fie ld . C D 8"' T  cell depletions w ere  highly effective  
and were not toxic, because there was no detectab le  loss o f  
viab ility  in the depleted population and responses o f antigen  
85-specific C D 4 *  T  cell lines were u na ffected  by depletion.
R ecom binant Vaccin ia V iru s  C o nstru ction . Construction o f  
the r V V  is described in detail elsewhere (re f.  19; and A .S .M .,  
unpublished w ork). In  brief, the am p lific a tio n  product o f  the  
E S A T -6  gene obtained by P C R  using the plasm id tem pla te  
p A A 2 4 9  (P . Andersen, Staatens S e ru m in stitu t, C o p en h a­
gen-5, D e n m a rk ) was cloned into plasmid p i  10 8 -tP A  to create  
p i 1 0 8 -tP A -E S A T -6 . Hom ologous reco m b in atio n  into the thy­
m idine kinase locus o f vaccinia strain W R  w ith  cationic lip id  
transfection was follow ed by selection o f  r V V  using m ycophe- 
nolic acid. A  second negative control r V V  was also constructed  
by using p i  108 minus the coding sequence. Recom binants  
w ere verified  by sequencing and expression co n firm e d  by P C R  
and capture E L IS A  (M .  H arb oe, unp ublished w ork).
R E S U L T S
Id en tifica tio n  o f ESAT-6-Specific  E ffe c to r T  Cells D ire c t  
fro m  P e rip h era l Blood. Tw o  C D 8 *  epitopes in  E S A T -6  w ere  
identified. T h e  T  cells from  donor N P H 5 4 , w h o  had tubercu­
lous m ediastinal lym phadenitis, recognized peptides c o rre ­
sponding to  both o f these epitopes. U n c u ltu re d  PB M C s iso­
lated at the tim e o f the diagnosis fro m  N P H 5 4 , who has 
H L A -B 5 2  and H L A -A 2 .0 1 , secreted IF N --y  in  response to  an 
E S A T -6 -d e rived peptide pool for these class I alleles in an e x  
v iv o  E L IS P O T  assay. The mean num ber o f  IF N -y  SFC s  
enum erated  from  5 x 105 P B M C s in dup licate  wells was 19 fo r  
the E S A T -6  peptides com pared w ith 2 in the co n tro l wells w ith  
no peptide. A  subsequent assay tested freshly isolated P B M C s  
against each o f the individual peptides w ith in  the responding  
pools; IF N - y  SFCs were detected in response to  peptides E S I 2 
and ES13, whose sequences are congruent w ith  the H L A -B 5 2  
and H L A -A 2 .0 1  peptide motifs, respectively. T h e  frequency o f  
ES12- and ES13-specific IF N - y  SFCs is o f  th e  same order o f  
m agnitude as SFCs for H L A -A 2 .0 1 -re s tric te d  in fluenza m atrix  
epitope M l  5 8 -6 6  (Fig. I A ) .  U n restim ulatcd  P B M C s fro m  a 
second don or, N P H 97 , w ith  tuberculous osteom yelitis, also 
recognized the ES12 peptide. This patient a lso  has H L A -B 5 2  
and H L A -A 2 .0 1 , and the magnitude o f th e  ES12-spccific  
response was sim ilar to the response to the H L A -A 2 -re s tr ic te d  
in fluenza m atrix epitope. Single cell IF N - y  release by freshly  
isolated T  cells in these short' 12-hr e x  v iv o  assays, em ploying  
no stimulus other than cognate peptide, indicates that these 
cells arc highly likely to be circulating activated effector T  cells 
(14 ).
ES A T-6 Epitope-Specific T  Cells Are C D S * .  E S I 2-specific T  
cell lines w ere generated fro m  N P H 5 4  and N P H 9 7  P B M C s. 
D epic tion  experim ents dem onstrated that the ES I2-spccific  T  
cells are C D 8 *  (F ig . IB ). S im ilar dep letion  studies on E S 13- 
specific S T C L s  from  donor W B , a healthy co n tac t w ith H L A -  
A 2 .0 I ,  con firm ed  that these E S I 3-specific T  cells are also 
C D 8 ’ (F ig . 1C). C D 4-dcp!cted  E S I3 -s p e c ific  STCLs fro m  
donor N P H 4 3 , a patient w ith  lym phaden itis  (class I H L A
A
4 0
Flu m atrix ESI 2 ESI 3 No peptid.
B
5 0 0  T
C D 4 -d e p le te d  C D 8 -d e p le te d
c
2 5
C D 4 -d « p l* t« d  C D 8 -d « p le te d
F ig . 1. (A )  Enumeration of circulating peptide-specific effectors
from the peripheral blood of NPH54 (H L A  class I haplotype: HLA- 
A2.01, H LA-A68; HLA-B52. HLA-B38). The sequences of peptides 
ES12 and ES13 are congruent with the peptide motifs of HLA-B52 and 
HLA-A2.01, respectively. The frequency of ES12-specific effectors 
during active tuberculosis (1:23.000) is slightly less than the frequency 
of effectors specific for the HLA-A2-rcstricted epitope in influenza 
virus M l 58-66 (1:14,000). Activated effectors specific for ES13. an 
HLA-A2-restricted epitope, are also evident, but at a lower frequency 
(1:50,000). Freshly isolated PBMCs (500.000) were seeded in duplicate 
wells and peptide added to a final concentration of 2 ¿aM  in a 12-hr ex 
vivo ELISPO T assay for IFN-y. ( B ) ES12-spccific IF N -y  secreting T  
cells are CD S*. Enumeration of IF N -y  SFCs in a 12-hr ELISPO T assay 
for IF N -y  with cell line 3 20 from donor NPH54 was performed and 
is shown. After depletion of C D 4* or CDS* cells, 20,000 cells were 
added to each of a pair of duplicate wells and peptide ES12 was added 
to a final concentration of 2 /xM: the mean number of SFCs is shown. 
No SFCs were observed in the absence of peptide. C D S* cell depletion 
completely abrogates the response. Similar results were obtained with 
cell line 3-9. (C )  ES13-specific IF N -y  release by an STCL raised 
against ES13 with PBMCs from donor WB; a healthy contact with 
H L A  haplotype H L A -A 2. HLA-A1; HLA-B7, H LA -B 8 After mag 
nctic depletion of C D 4 * or CDS * cells, 20,000 cells were added to each 
of a pair of duplicate wells in a 12-hr ELISPO T assay and peptide 
added at 2 ¿tM to the supernatant. The mean number o f IFN -y  SFCs 
for each pair of wells is shown.
haplotype: H L A -A 2 .0 1 ,  H L A - A 29; H L A -B 7 . and H L A -B 5 I) ,  
recognized p ep tid e  presented through H L A -A 2 .0 1  on ES13- 
prepulsed H L A - A 2.01 -matched heterologous B C L . Ninety- 
eight IF N -y  S F C s  were enum erated in response to the E S I 3- 
pulsed B C L, com pared  with 48 IF N - y  SFCs for the unpulsed 
control B C L; the high backgrounds are probably due to
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alloresponse (13). Responses to  E S I3 were transient and often  
undetectable in P B M C s fro m  subsequent b lood samples drawn  
la te r in the course o f therapy, thus precluding comprehensive  
analysis o f this epitope.
N o  C D 8 *  epitopes were identified am ong any o f the 42 
peptides from antigens 85A , 85B , or 85C. D espite  stim ulation  
in  v i tro  w ith nonam er peptides, the resultant S T C L s  were all 
C D 4 * .  Interestingly, certain peptides elicited IF N - y  secretion  
by freshly isolated uncultured C D 4 *  cells in 12-hr ex  v iv o  
E L IS P O T  assays (A .L ., R .B ., R .J.W ., G .P ., and A .V .S .H .,  
unpublished data.)
ESI 2-Specific CD8+ T Cells Are MHC Class I-Restricted 
and Recognize Endogenously Processed Antigen. T h e epitope  
E S I 2 was further characterized w ith E S I 2-specific lines and  
clones. T  cell recognition o f peptide had until now  relied on  
presentation o f ES12 on autologous cells by adding free  
peptide to the E L IS P O T  assay supernatant. T o  dem onstrate  
H L A  class I restriction, ES12 peptide was presented to clones 
w ith  ES12-prepulsed B C L m atched or m ism atched at B52; 
only H LA -B 52-m atched  ES12-prepulsed B C L  w ere recog­
nized by cells pooled from  clones 3—1, 3 -1 5 , and 3 -9 8  (Fig . 2 A ) .  
ES12-specific lines raised fro m  N P H 9 7 ’s P B M C s were sim i­
larly confirm ed to be H L A -B 5 2  restricted (d a ta  not shown).
T o  show that the ES12-specific C D 8 *  T  cell clones w ere  
capable o f recognizing endogenously processed antigen, au­
tologous BC L, infected w ith  vaccinia virus recom binant for  
E S A T -6  ( rV V -E S A T -6 )  o r a control lacking the E S A T -6  
sequence, were used to stim ulate  cytokine release. O n ly  clones 
3 -1 , 3 -1 5 , and 3 -9 8  incubated w ith  the E S A T -6  recom binant 
vaccinia-infected B C L-secreted  IF N -y  in the E L IS P O T  assay 
(F ig . 2 B ).
M . tu b e rc u lo s is  Antigen-Specific CDS * T Cells Are Cytolytic.
By using a sensitive m easurem ent o f cytokine release, we 
characterized C D 8 *  T  cells specific for ES12. W e  now re ­
tu rned  to conventional 51C r release assays to  test w hether these 
cells w ere also capable o f ly tic  activity. Th is  was confirm ed  
over a broad range o f  e ffecto r: target ratios fo r C D 8 *  T  cell 
lines from  both N P H 5 4  and N P H 9 7  using E S I2 -p u lscd  h eter­
ologous H L A -B 52-m atched  B C L  as targets (F ig . 3 -4  and B ) .  
Peptide-specific lysis was detectable even w hen the peptide  
prepulse concentration was titra te d  as low as 1 n M  (data not 
show n). Finally, to establish w hether ES12-specific C T L  could  
also k ill targets expressing endogenously processed antigen, we 
dem onstrated H L A -B 52-res tric ted  lysis o f heterologous H L A -  
B52-m atched targets infected w ith  rV V -E S A T -6  (F ig . 3C ).
DISCUSSION
W e have identified C D 8 *  H L A  class I-restric ted  T  cells 
specific for epitopes in the M . tu b e rc u lo s is  p rote in  E S A T -6  in 
4 o f  39 infected individuals. This is almost certainly an 
underestim ate o f the actual prevalence o f M . tu b e rc u lo s is -  
s p e c i f ic  C D 8 *  C T L  in in fected  individuals fo r the follow ing  
reasons. First, we lim ited th e  search to epitopes restricted 
through six H L A  class I a lleles. S econd,-o f the very large  
num ber of antigens secreted by M . tu b e rc u lo s is , we studied only  
two. A n d  third, M . tu b e r c u lo s is - s p e c if ic  C D S *  C T L  are more 
like ly  to be found in dra in in g  lymph nodes or at the site o f  
infection rather than in the peripheral .circulation. N everth e­
less, the frequencies o f c irculating E S A T-6-spccific  effectors in 
the peripheral blood o f N P H 5 4  approximates to that for an 
in fluen za virus epitope (F ig . 1-4). This relatively high fre ­
quency o f C T L  effectors specific for a single bacterial epitope  
is com parable to  that found in malaria, a protozoal disease, 
w here there is substantial ind irec t evidence for a protective  
role for P lu s m o d iu m  f a l c ip a r u m -specific C T L  (18 , 20, 21). 
E S A T-6-spccific  effectors am ong uncultured PB M C s w ere  
detectable in the e x  v ivo  E L IS P O T  assay in N P H 5 4  w ith  
tuberculous lym phadenitis an d  in N P H 9 7  w ith  tuberculous 
osteomyelitis. For the com m on H L A  class I a lle le , H L A -A 2 .
A
F ig . 2. ( A ) Photomicrograph showing peptide-specific HLA-B52- 
restricted IF N -y  release by ES12-specific CDS'  clones derived from 
donor NPH54. Cells from clones 3 -1 , 3-15, and 3-98 were pooled and 
assayed against unpulsed (first pair o f wells in a and b), and ES12- 
pulsed (second pair of wells in a and b ) . HLA-B52-mismatched (-4) and 
matched {B ) target BCLs. The mismatched BCL is PG: HLA-A2.01. 
HLA-A3; HLA-B7, HLA-B51 and is shown in A. The matched BCL, 
a homozygous typing line, is Akiba: HLA-A24; HLA-B52. and is 
shown in B. Assays were performed in duplicate wells with 5.000 T  cells 
and 50.000 B cells per well. Only the pair of duplicate wells with 
ES12-pu!sed HLA-B52-matchcd targets are positive; the spots arc so 
numerous that they appear confluent. (B )  Photomicrograph showing 
IFN-y release by ES12-specific C D S ' clone 3-15 of donor NPH54. in 
response to autologous BCL infected with vaccinia virus recombinant 
for the gene encoding ESAT-6 (rV V-ES A T-6). The negative control 
is the left-hand well, using autologous BCL infected with rV V  control. 
BCL were infected the night before with the respective recombinant 
viruses at a multiplicity of infection (m.o.i) of 7 plaque-forming units 
per cell in serum-free medium; after 9« min. cells were diluted up to 
I million/ml in R10 and incubated overnight. Infected BCL ( lOO.OtX)) 
were then added to each well along with 5,000 cloned T  cells. The 
photomicrograph shows the result with clone 3-15, giving in excess of 
450 SFCs. The results with the other two clones, 3-1 and 3-98, were 
so strongly positive that the spots were confluent. (x 2 0 .)
the num ber o f subjects studied is sufficient to  perm it a 
prelim inary comparison o f the prevalence o f responders be­
tween the different clinical subgroups. For donors w ith H L A -  
A 2 , ES I3-specific IF N -y  secretion in freshly isolated PBMCs  
or STCLs was observed in 1 o f  7 healthy contacts and 2 o f 3 
patients w ith  lymphadenitis, but in none of 12 patients with 
other more disseminated forms o f  disease (pulm onary, pleural, 
and gastrointestinal). This d istribution  o f responses suggests 
that responses to E S A T -6  may be associated w ith  an immune 
response capable o f contain ing M  tu b e rc u lo s is , but larger 
numbers o f subjects w ill be req u ired  to establish this.
The E L IS P O T  assay for IF N - y  release may measure an 
effector function o f more protective relevance than the " C r  
release cytotoxicity assay. IF N - y ,  a potent activator o f mac­
rophages, is essential for resistance to M . tu b e rc u lo s is  infection 
in mice (22. 23), whereas recent studies in p erfo rin  gene and 
Fas receptor gene knockout m ice indicate that the lytic activity 
o f C D S * T  cells is not requ ired  to control viru lent M.
274 Immunology: Lalvani et al. Proc. Natl. Acad. Sci. USA 95 (1998)
A
■  E S I2 -pulsed targets  
□  Unpulsed targets
4
1 00  to  1 10 to  1 1 to  1
E ffector:Target Ratio
30 to 1 10 to 1 3 to 1 1 to 1
E ffector:Target Ratio
c
•s>-_j I
*  rW -E S A T  6-infected targets  
□  rW -contro l-in fected  targets
- n  ■
2 0  to  1 7 to  1
Effector: Target Ratio
F ig . 3. (A )  ES12-spccific cytolytic activity of CTL line 4-1 from
donor NPH54 in a 5 hr 5,C r release cytotoxicity assay. Peptide-specific 
lysis titrated downwards with diminishing effector-to-targct cell ratio, 
and nonspecific lysis of unpulsed targets was less than 5% . Target cells 
were heterologous HLA-B52-matched BCL (homozygous typing line, 
Akiba: HLA-A24; HLA-B52, as in Fig. 2/4), prepulsed with 10 /xM 
ESI 2. (B ) ESI 2-specific cytolytic activity of a CTL line from donor 
NPH97 in a 5 hr 5,Cr release cytotoxicity assay. The CTL line was 
generated by restimulation of 14-day STCLs (cultured as described in 
M aterials a n d  M ethods) with ES12-pulsed, washed, irradiated autolo­
gous BCL. Peptide-specific lysis titrated downwards with each 3-fold 
diminution in effector-to-target cell ratio, and nonspecific lysis of 
unpulsed targets was less than 5% . Target cells were heterologous 
HLA-B52-matched BCL (A kiba) as in Fig. 2/4, prepulsed with 10 /xM 
E S I2. (C ) Lysis of HLA-B52-matchcd heterologous targets (Akiba 
BCL) expressing endogenously processed ESAT-6. Targets were in­
fected with rVV-ESAT-6 and rVV-control as in Fig. 2B  and were 
labeled with 5,Cr the following day. C TL line 4-1 raised against E S I2 
specifically lysed the rVV-ESAT-6-infccted targets; lysis of rVV- 
control-infcctcd targets was below 10%.
tu b e rc u lo s is  infection (2 4 ). M oreover, humans homozygous for 
a point m utation in the IF N - y  receptor 1 gene, in whom cell 
surface expression o f this receptor is absent, are highly sus­
ceptib le to fata l dissem inated mycobacterial infection (25), 
and human T  cell-derived IF N - y  has recently been reported to 
inh ib it the in tracellu lar g row th  o f  M . tu b e rc u lo s is
C D 8 *  C T L-d erivcd  I F N - y  may be especially im portant both 
fo r cells lacking M H C  class I I  molecules, c.g., in the lung (26)
Zhang. M., Gong, J.. Lin. Y.. Boylcn, C. T. & Barnes, P. F. American 
Association of Immunologists Joint Meeting, June 2-6 , 1996. New 
Orleans, LA.
and fo r  macrophages w here mycobacteria can evade recogni­
tion  d u rin g  chronic infection by sequestering th e ir  antigens 
aw ay fro m  sensitized C D 4 + T  cells (27 ). M o reo ver, infection 
o f m u r in e  macrophage cell lines w ith  live M . tu b e rc u lo s is  has 
re c e n tly  been shown to dow n-regulatc M H C  class I I  expression 
w h ile  sim ultaneously enhancing the presentation o f  exogenous 
so lub le  antigen through the M H C  class I antigen processing 
p a th w a y  (28).
T h e  observation that E S I 2-specific T  cell lines and clones 
reco g n ize  target cells infected w ith  vaccinia virus recombinant 
fo r E S A T -6  indicates that this antigen can be endogenous!) 
processed through the M H C  class I antigen processing path­
w ay, resulting in the presentation o f the epitope E S I 2 through 
H L A -B 5 2 .  Because responses to the M . tu b e r c u lo s is - s p c c i fk  
p e p tid e  ES12 w ere elic ited  fro m  freshly isolated, unrestimu- 
la ted  lym phocytes in an e x  v iv o  assay, C D 8 + T  cells must have 
been prim e d  through recognition o f processed antigen in  vivo. 
T h is  study thus'p ro vides evidence that in hum ans an M. 
tu b e r c u lo s is  antigen is naturally processed in  v iv o  through the 
M H C  class I pathway leading to the induction o f  M H C  class 
I-re s tr ic te d  effector T  cells. F urther support comes from  
p re lim in a ry  data showing that hum an m acrophages infected 
w ith  M . tu b e rc u lo s is  in  v itro  are recognized by ES12-spccific. 
H L A -B 5 2 -re s tr ic te d  C T L  that suppress m ycobacterial growth 
(R .B . ,  e t  a l ., unpublished data).
M u r in e  models, including studies w ith ^ -m ic ro g lo b u lin  
gene knockout m ice (3 ),  T A P -1  null m utant m ice (28 ), and 
a d o p tiv e  transfer experim ents w ith  HSP-65 im m un ized mice 
(4 )  sho w  that C D 8 *  C T L  are essential for protection  against 
M . tu b e r c u lo s is  infection. C D 8 + T  cells also constitute a crucial 
e ffe c to r  mechanism in the protective im m unity con ferred  by 
D N A  vaccination against tuberculosis (9, 29). It  has therefore 
been im p o rtan t to  establish w hether M H C  class I-restricted  
C D 8 ^  C T L  play a role in M . tu b e rc u lo s is  infection in humans, 
for, i f  so, their induction could guide the ra tio n a l design ol 
su b u n it vaccines. H o w ever, it has proved very d ifficu lt to 
id e n t ify  these cells in humans (7, 30). Indeed, the recent 
id e n tific a tio n  o f hum an C D  1-restricted C D 8 *  T  cells specific 
for M . tu b e rc u lo s is  nonpeptide antigens has led to  the sugges­
tion  th a t disruption o f  C D l-m e d ia te d  antigen presentation  
m ay a c c o u n t fo r  the  e n h an ced  s u s c e p tib ility  o f  /32- 
m icro g lo b u lin  gene knockout mice to M . tu b e r c u lo s is  infection 
(3 1 ). H ow ever, this study demonstrates the presence o f clas­
sical M H C  class I-restric ted  C D 8 + C T L  specific for an M. 
tu b e r c u lo s is  protein antigen in infected individuals. These cells 
c irc u la te  at a relatively high frequency in peripheral blood and 
fresh ly  isolated, unrestim ulated cells rapidly display effector 
fu n c tio n  w ithin 12 hr o f antigen contact. In duction  o f M H C  
class I-restric ted  peptide-specific C D 8 4 C T L  w ith  new gener­
a tio n  C T L -in d u c in g  vaccines is now feasible. T h e  phenotype 
and specific ity o f the cells identified here not o n ly  endorses 
e ffo rts  to  develop C T L -in d u c in g  vaccines against tuberculosis 
but a lso  supports the candidacy o f  E S A T -6  as a com ponent of 
such vaccines.
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